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Abstract
With an ageing population on the increase, there is a growing need for more effective treatments
to enhance the quality of life of patients. Biomaterials employed in such treatments are there-
fore required to last longer and function more effectively. A biomaterial of particular interest is
polymethyl methacrylate (PMMA) bone cement, which is widely employed in joint replacement
surgery. Although this replacement procedure reduces pain and restores joint function, it is
associated with a failure rate of approximately 10% after 15 years usually as a consequence of
cement functional deterioration. Failure usually requires a complicated revision surgery, which
is a burden on both the patient and health care services. This study has therefore applied novel
interdisciplinary approaches to the design of PMMA bone cements in an effort to reduce failure
in cemented joint replacements.
Failure of PMMA bone cements has been previously linked to agglomerations of the radiopacifier
employed, which create stress concentrations and initiate cracks. A model cement was there-
fore developed, with compositional, mechanical, fatigue and rheological properties similar to
commercial cements, which enabled two novel radiopacifiers to be tested (anatase TiO2 and
yttria-stabilised ZrO2). Regardless of the material employed, agglomerations of the radiopaci-
fiers were found to be a significant problem. Silane treating the radiopacifiers enhanced their
dispersion, improving the mechanical and fatigue properties of the cement. Furthermore, anatase
TiO2 and silane-treated anatase TiO2 were found to induce hydroxylapatite mineralisation in
vitro and enhance the adhesion of MC3T3-E1 osteoblast precursor cells on the surface of the
cement. The silane treatment however, was found to decrease the rate of osteoblast proliferation.
Ageing effects and moisture uptake in PMMA bone cements were also examined as cement
is known to fail predominantly after long periods of use. Ageing cements in isotonic fluid re-
sulted in a maximum moisture uptake of approximately 2%w/w, which was found to induce
structural changes over time and caused degradation in the mechanical properties of the cement,
potentially contributing to cement failure.
A major obstacle with joint replacements is the likelihood of post-operative infections. In an
attempt to prevent this, many commercial cements incorporate large amounts of powdered an-
tibiotic to achieve a local therapeutic release. The powdered antibiotic was found to be poorly
dispersed and resulted in an uncontrolled initial release from surface agglomerations within the
first 6 hours, with potentially sub-inhibitory resistance-inducing levels thereafter. Furthermore,
only a small percentage (2-9%) of the antibiotic was released, the commercial cements demon-
strated poor bacterial inhibition and incorporating powdered antibiotics was detrimental to the
mechanical and fatigue performance of the cement. To overcome these limitations a novel de-
livery system was developed based on drug-entrapped liposome vesicles. A block co-polymer
coating was applied to phospholipid liposomes (100nm diameter) to achieve a uniform dispersion
in a commercial bone cement (Palacos R). When antibiotic-loaded liposomes (gentamicin sul-
phate) were dispersed in the cement, greater levels of antibiotic were released in a more prolonged
manner, with enhanced antimicrobial, mechanical, fracture toughness and fatigue properties.
Techniques from a variety of disciplines were employed in this study and this inter-disciplinary
approach has allowed many features of PMMA bone cement to be investigated. The experiments
have offered an insight into cement failure while novel techniques and formulations have been
developed, which have the potential to reduce failure and infection in cemented implants and
may have wider application in a variety of biomaterials.
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Chapter 1
Introduction
1.1 Ageing population
Recent advances in health care have led to an increase in the average life expectancy of
populations. The increase in life expectancy has resulted in an increase in the number
of elderly people in the country and an ageing population which has considerable conse-
quences for public services. It is estimated that around 10 million people in the UK are
over 65 years old. This is expected to increase by 5.5 million in 20 years time and double
to around 19 million by 2050. Currently one-in-six of the UK population is aged 65 and
over and this is expected to become one-in-four by 20501. This dramatic increase in the
elderly population poses significant problems, one of which is the ability of health care and
health care technology to keep up with the number of ageing citizens requiring treatment.
Furthermore recent data has shown that in 2007/08, the NHS expenditure was on average
almost double for retired households (£5,200) when compared to non-retired households
(£2,800) as elderly patients require more treatment due to health deterioration1.
Joint related problems are one of the most common reported in elderly patients. As a
person ages, bone mass is lost and the bones begin to lose calcium and other minerals.
The range of motion becomes limited and the amount of fluid around the joints decreases,
causing the the cartilage to gradually erode. Minerals may also begin to deposit in and
around certain joints (calcification)2. Almost all elderly people experience joint changes,
ranging from minor stiffness to severe arthritis. In severe cases, the loss of joint function
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or pain may require surgical intervention and artificial joints. In England and Wales in
2009 alone, there were approximately 150,000 hip and knee replacement surgeries carried
out, with patients having an average age of around 70 years3.
1.2 Clinical conditions
The main clinical condition requiring surgical intervention and the use of artificial joints
is osteoarthritis3. Osteoarthritis is a degenerative joint disease and is the most common
joint disorder in the world5. Degradation of articular cartilage and changes to subchondral
bone (as shown in Figure 1.1) results in joint pain and stiffness.
Currently, treatment for arthritis is limited to drug therapies, physical therapies and
surgery. Drug and physical therapies may help overcome symptoms of osteoarthritis such
as pain, swelling and stiffness; however as the disease progresses, patient quality of life is
reduced and joint replacement surgery is required.
Inflammatory arthritis, such as rheumatoid arthritis involves the inflammation of articulat-
ing joints. In rheumatoid arthritis the synovium, a soft tissue found between articulating
Figure 1.1: Osteoarthritis of the knee joint4
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joints, becomes inflamed causing the patient to experience reduced joint function and
pain6. Treatment options are similar to osteoarthritis, however drug therapies are more
effective as anti-inflammatory medications can be used to suppress symptoms. Therefore
a significantly smaller percentage of hip and knee replacements are carried out as a result
of inflammatory arthritis3. Similarly, osteonecrosis (death of bone), trauma (physiologi-
cal injury) and infection account for only a small percentage of joint replacements when
compared to osteoarthritis.
1.3 Biomaterials
The treatment of many clinical conditions, such as those discussed would not be possible
without the development of biomaterials. Biomaterials are materials intended to interact
with biological systems to treat, augment, or replace any tissue, organ or function of the
body7. The applications of biomaterials are vast and include joint and limb replacements,
artificial arteries and skin, contact lenses and dentures. Biomaterials can be classified into
three groups: inert materials, which elicit no or minimal tissue response; active materials,
which encourage bonding to surrounding tissue and degradable and resorbable materials,
which over time either dissolve or are broken down in the body. A requirement for all
biomaterials is that they do not elicit an adverse reaction when implanted in the body.
A variety of biomaterials are currently used, these include: metallic biomaterials, which
are used for load bearing applications; ceramic biomaterials, due to their hardness and
wear resistance and polymeric biomaterials, which are used for their flexibility and low
friction properties. Other biomaterials are used as they induce biological responses from
the surrounding tissue, such as hydroxylapatite which promotes bone growth.
A biomaterial of particular interest is poly(methyl methacrylate) (PMMA). PMMA-based
biomaterials have been developed for joint arthroplasty, cranioplasty, vertebroplasty and
3
Chapter 1. Introduction
dentistry8. PMMA can be formulated as a self-setting mixture, it can be combined with
other materials to form a composite and it can be formulated to have a range of viscous
properties. This makes PMMA a versatile biomaterial with a variety of applications. As a
significant problem with the ageing population is joint degradation, this thesis will focus
on the biomaterial PMMA, which is extensively employed in hip and knee replacements.
1.4 Cemented and cementless joint replacements
Total knee and hip replacements remain the most effective treatment for severe degener-
ative joint conditions such as osteoarthritis. There are currently two forms of total joint
replacements: cemented, which use PMMA bone cement and cementless, which use coated
implants.
In cemented total joint replacements the diseased or damaged joint is completely removed
and a cavity is drilled into the bone. The cavity is then filled with PMMA bone cement
and the implant, usually metallic, is inserted and positioned whilst the cement sets. Ce-
mentless total joint replacements follow a similar procedure however, the implant is placed
directly in contact with the bone without the presence of a polymeric cement.
In the UK, bone cement has been used since the late 1950s when Sir John Charnley first
used PMMA for a hip replacement3, 9. In the United States, the use of cement for securing
joint replacements is less favoured as the American Food and Drug Administration (FDA)
did not approve PMMA for use in surgery until much later10,11. The Swedish Hip Reg-
istry annual report for 2010 demonstrated that approximately 70% of all hip replacements
in Sweden used bone cement12 . Furthermore, in the UK, cementless replacements were
found to have a higher failure rate for both hip and knee replacements as will be discussed
later3. In terms of intra-operative incidents, cementless hip replacement surgeries had 510
incidents (out of a total of 27,492 surgeries) whilst cemented hip replacement surgeries
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were reported to have only 252 intra-operative incidents reported (out of a total of 23,414
surgeries). Therefore for hip replacements, cementless implants reported approximately
double the number of intra-operative incidents when compared to cemented hip implants.
With this in mind, cemented techniques, which utilise PMMA, are still considered the
best option.
The three main functions of PMMA in a total joint replacement are to secure the implant in
place; transfer stresses and strains from the implant to the bone and prevent post-surgical
infections if antibiotics are incorporated, as shown in Figure 1.2. The Young’s modulus
of cancellous bone is approximately 0.5 to 1GPa, rising to 10 to 15GPa for cortical bone
compared to approximately 200GPa for metallic implants13. This difference in modulus
may result in poor stress transfer between the implant and bone and may be damaging
under high impact loads. Bone cement, with a Young’s modulus of approximately 2GPa,
assists in transferring some of the stresses between the implant and bone, reducing the
likelihood of bone damage.
Figure 1.2: Cemented total hip replacements
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Although bone cements have been used in joint replacements since the late 1950’s, the
failure mechanisms are still not fully understood. With cemented implant revision rates
stated to be approximately 10% after 10 years14, understanding why bone cement fails
is of clinical relevance and is the first step to reducing revision rates. Once the cause of
failure is identified, improvements to the current bone cement systems can then be made
to help reduce failure rates. With novel materials and drug delivery systems constantly
being developed, there is an opportunity to improve some aspects of bone cements such
as mechanical, fatigue, bone growth and anti-microbial properties. If successful these
novel formulations may benefit future patients by reducing failure rates and therefore the
number of revision surgeries.
1.5 Revision surgery
Revision surgeries are those which are performed as a result of implant failure. Revision
surgeries take longer to perform, the prostheses are more expensive and the patient’s hos-
pital stay is prolonged, incurring higher costs for hospitals15, 16. Furthermore, revision
surgery is more complex than primary surgery and there is a higher risk of failure and
poorer prognosis associated with it15, 17. This is as a result of soft tissue and bone defects
being present and the implant requiring removal, making the surgery technically challeng-
ing. Studies have shown that the cost of revision surgeries are substantially greater than
for primary surgeries as highlighted in a recent review by Vanhegan et al.18. In the year
2000 in the UK, the total cost associated with revision surgery of the hip and knee carried
out by the National Health Service (NHS) exceeded £60 million19. On average in 2007,
Trusts were reimbursed between £6000 and £12000 per revision procedure depending on
the expected costs associated with the procedure20. The National Joint Registry (NJR)
for England and Wales declared that in 2008, around 10,000 revision surgeries were carried
out in the UK for both hip and knee replacements and this increased to around 12,000
in 20093, 21. This is as a result of the number of joint replacement surgeries increasing
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annually, highlighting the need for improvements in the materials and techniques used. It
is also clear that revision procedures incur high costs, are less profitable for hospitals and
subject patients to multiple high-risk surgeries and therefore there is a need to avoid them.
The aim of this study was to investigate the properties of current commercially avail-
able cements and potential methods to improve them. The ageing and moisture uptake
of commercial cements were also investigated to obtain a better understanding of how the
cement properties change in vivo over time. A review of previous studies and published
literature was carried out to understand what has already been attempted and helped to
form the basis of experimental work.
Although previous studies have already attempted to address several of the problems
associated with PMMA bone cements, as will be discussed later, there is a need for a
novel approach to this problem. Biomaterials that can interact with the surrounding tis-
sue in a beneficial way whilst mechanically performing to a required standard are essential.
In order to achieve this, the current problem requires a multidisciplinary approach, com-
bining expertise from multiple scientific fields.
The first half of this thesis will look at the literature on bone cements, how it fails and ages
and novel materials that can be used to prevent cement failure. The use of a silane-treated
TiO2 radiopacifier is particularly interesting due to its ability to encourage bone growth.
The second half of this thesis will focus more on the pharmaceutical and drug delivery
aspects of bone cements by investigating the behaviour of commercially available antibi-
otic bone cements and also by developing and testing a completely novel drug delivery
system. This novel system employs liposomes, which improve the release and toughness
of the cement. This system has the exciting potential to reduce failure in cemented joint
replacements, by delivering synergistic antibiotic combinations and osteogenic material.
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1.6 Background on PMMA bone cements
1.6.1 History of bone cements
Acrylic acid was first discovered in 1843, which led to the subsequent formulation of
methacrylic acid in 186522. When reacted with methanol, methacrylic acid forms methyl
methacrylate, the basis for the polymer polymethyl methacrylate (PMMA). It was not
until 1877 that the polymerisation from methyl methacrylate to PMMA was discovered
by Fittig and Paul23 . The synthesis and further development of acrylates was carried out
by Otto Ro¨hm, which led to the patenting of PMMA as Plexiglas in 1928 and the forma-
tion of the company Ro¨hm and Hass11,24. In 1936 it was found that mixing fine ground
PMMA particles with a liquid monomer resulted in a dough-like substance24 and in the
same year PMMA was used as a dental implant for the first time8. The first reported use
of PMMA for a medical purpose was to fix cranial defects in monkeys in 193824, which
was shortly followed by fixing cranial defects in humans in 194125. In 1943 the company
Degussa and Kulzer developed a method of cold curing the polymer using a co-initiator
(tertiary aromatic amines) as opposed to curing under heat24, 26.
The Judet brothers were the first to employ PMMA in arthroplastic surgery in the 1950s
when they created PMMA femoral heads27. This however, was unsuccessful due to biocom-
patibility and mechanical reasons24. In 1953 PMMA was utilised as a grout to improve
the fixation of implants to bone28 and this was later followed by Sir John Charnley in
1958 who successfully anchored a femoral head prosthesis in the femur with the use of
auto-polymerizing PMMA9. This resulted in the development of a completely novel sur-
gical technique whereby acetabular and femoral implants could be secured to bone using
PMMA during hip replacements29. Antibiotic loading of the cement with gentamicin,
penicillin, erythromycin soon followed, with gentamicin still incorporated in bone cements
today30.
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It is estimated that in the year 2000, around 1 million orthopaedic implants were secured
with bone cement worldwide and more recent datum has shown that the total number of
cemented hip and knee replacements in England and Wales in 2009 was around 84,000
(not accounting for revision surgeries and hybrid implants)21. This highlights the large
role that bone cement plays in orthopaedic surgery and how an improvement to the current
system could have a significant impact on the quality of life of thousands of patients.
1.6.2 Poly(methyl methacrylate)
Commercial poly(methyl methacrylate) (PMMA) bone cement is made up of two parts,
a liquid component and a powder component, which when mixed undergoes free radical
polymerisation to form polymer chains. In commercially available PMMA bone cements,
the liquid component comprises of methyl methacrylate (MMA, a monomer as shown in
Figure 1.3), N,N-Dimethyl-p-Toluidine (DMPT, an activator) and a small amount of hy-
droquinone, which prevents the monomer from polymerising during storage. The powder
component consists of polymethyl methacrylate polymer particles (Figure 1.4), barium
sulphate (BaSO4) or zirconium dioxide (ZrO2) (a radiopaque agent for viewing under X-
ray imaging) and benzoyl peroxide (BPO, an initiator for the polymerisation reaction)31.
Depending on the manufacturer of the bone cement, the composition and quantities of
these materials can vary as can the powder to liquid ratio as shown in Table 1.132.
Figure 1.3: Methyl methacrylate monomer
Figure 1.4: Poly(methyl methacrylate) polymer
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Table 1.1: Composition of commercially available PMMA bone cements
Cemex Cemex Cemex Cemex CMW1 CMW3 Palacos Simplex Zimmer
Isoplastic(a) RX(b) XL
Gun
1310/S
R(c) P(d)
Hi-
fatigue(e)
Liquid component / g 13.30 13.30 18.33 22.00 18.37 17.90 18.78 20.00 20.00
Methyl Methacrylate
99.10 99.10 98.20 98.20 99.18 97.49 97.98 97.50 99.35
/ %w/w
N-N Dimethyl-p-Toluidine
0.90 0.90 1.80 1.80 0.82 2.51 2.02 2.50 0.65
/ %w/w
Hydroquinone
75.00 75.00 75.00 75.00 25.00 25.00 60.00 80.00 60.00
/ ppm
Powder Component / g 40.00 40.00 50.00 60.00 39.99 37.00 40.00 40.00 40.85
Polymethyl Methacrylate
84.30 88.27 85.00 85.00 88.84 87.03 84.50 88.50 86.90
/ %w/w
Barium Sulphate
13.00 9.00 12.00 12.00 9.10 10.81 - 10.00 -
/ %w/w
Benzoyl Peroxide
2.70 2.73 3.00 3.00 2.05 2.16 0.50 1.50 0.86
/ %w/w
Zirconia
- - - - - - 15.00 - 12.24
/ %w/w
Powder : Liquid ratio 3.01 3.01 2.73 2.73 2.18 2.07 2.13 2.00 2.04
Note: (a) - High viscosity, (b) - Low viscosity, (c) - Poly(methyl methacrylate/methyl acrylate), (d) - 73.5%w/w poly(methyl
methacrylate)/styrene co-polymer, 15.0%w/w pre-polymerised PMMA and (e) - MMA Styrene
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The four main stages in the preparation of surgical bone cements are: mixing of the pow-
der and liquid components, a short waiting period, handing/application of the cement and
setting of the cement. Each stage has a different time duration which can vary according
to cement manufacturer’s specifications.
PMMA bone cements undergo free radical polymerisation. Free radical polymerisation
is essentially an addition polymerisation reaction and occurs in three stages: initiation,
propagation and termination. The ability of bone cement to undergo such a process allows
it to be self curing.
Initiation
The initiation involves the formation of benzoyl peroxide free radicals which are created
from the reaction between benzoyl peroxide and a tertiary amine, in this case DMPT
(Figure 1.5). The benzoyloxide radical carries an unpaired electron in the outer shell,
which results in high reactivity with the monomer molecules25.
Figure 1.5: Benzoyloxide radical formation
11
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When the benzoyloxide radical reacts with the monomer (MMA), a primary radical is
formed (Figure 1.6). This primary radical acts as an active centre, allowing the reaction
to propagate.
Figure 1.6: Primary free radical formation
Propagation
As described, the primary radical acts as an active centre and reacts with MMA molecules.
After it attaches itself to an MMA molecule, it reacts with other MMA molecules, elongat-
ing the polymer chain as shown in Figure 1.7. With each addition of an MMA molecule,
energy is released and this gives the reaction its exothermic properties.
Figure 1.7: Free radical propagation
12
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Termination
The polymerisation reaction is known to terminate by two mechanisms, either by com-
bination or by disproportionation. The combination mechanism occurs when two active
centres with unpaired electrons of growing chains react with one another to form a single
bond, pairing up electrons and terminating chain propagation (Figure 1.8).
Figure 1.8: Free radical termination by combination
Disproportionation involves the unpaired electron of the radical removing not only an elec-
tron from another growing chain, but a hydrogen ion as well (Figure 1.9). This terminates
the chain propagation as the first chain now has no unpaired electrons and the end carbon
now shares a stable eight electrons.
Figure 1.9: Free radical termination by disproportionation
13
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1.6.3 Implant technique
The method of mixing and inserting bone cements into a patient varies according to the
cement manufacturer and the surgeon’s preference. Currently, methods of mixing include
hand, vacuum and centrifuge mixing. Hand mixing simply involves placing both the pow-
der and liquid component in a plastic bowl and mixing with a spatula for a specified
amount of time. This is the simplest method, however studies have shown that pores de-
velop due to entrapped air, potentially weakening the cement33–35. This will be discussed
later in further detail. The majority of surgeons have adopted newer generation mixing
techniques such as vacuum mixing as the standard mixing method. A reduced pressure
during mixing (ranging from -39kPa to -86kPa) creates a vacuum which removes air, re-
ducing airborne vapours during surgery and also alters the porosity of the final cement
mixture. Mixing under a vacuum, as demonstrated in a study by Bettencourt et al.36,
significantly decreases the amount of residual monomer released from the cement when
compared to manual mixing. This may also benefit the patient in terms of toxicity. Cen-
trifuge mixing involves mixing the powder and liquid component at high rotary speeds
(up to 3000rpm). Centrifuge and vacuum mixing are considered second generation mixing
methods and studies tend to place both of them at the same level in terms of porosity and
mechanical properties. The effect of mixing method on the performance of bone cements
is the subject of much debate and will be discussed in more detail later in this chapter.
Once mixed, the cement is then inserted into the patient. Depending on the viscosity
of the cement being used, this can be achieved by injection or manual handling. Bone
cement can be injected either through a fine needle, usually with low viscosity cements
for vertebroplasty, or using a cement gun system. For the cement gun system, the mixed
cement is either poured into a cartridge or the cement is mixed within the cartridge, which
14
Chapter 1. Introduction
Figure 1.10: Typical cement gun system37
is then attached to a pressure gun system as shown in Figure 1.10. This system applies
pressure to the mixture and extrudes the cement out of an orifice into the bone cavity.
The other method involves the surgeon manually applying the cement to the required area
and applying pressure via digitation to compact it.
The setting of current commercially available cements tends to take place in four steps:
mixing, waiting, handling and application/setting. Generally, mixing should take no longer
than 1 minute, after which a dough-like mass will form. This mass will remain of dough-like
consistency for up to a maximum of 4-5 minutes so the waiting period after mixing should
not exceed 1 minute. This waiting period allows the PMMA beads to soak up the MMA
monomer and polymerization to commence. The cement is then applied as previously
discussed. For standard cements this period is between 5 to 8 minutes, allowing the
surgeon time to carefully apply the cement, followed by the implant (ensuring the correct
positioning) and also allows the surgeon to remove any excess cement while it is still soft.
The cement then hardens and sets over 2-3 minutes, securing the implant in place. For
the majority of cements, this entire process does not take more than 15 minutes, which
is sufficient for the surgeon to successfully complete the procedure whilst minimising the
risks associated with lengthy surgeries. Figure 1.11 shows the recommended setting times
for several commercially available cements.
15
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Figure 1.11: Recommended setting times at 23◦C for commercially available cements
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1.6.4 Surgical complications
Although surgical complications account for a small percentage of failure rates in total joint
replacements, they are of great concern as they greatly impact morbidity and mortality
rates. As previously discussed, bone cement cures slowly to allow surgeons to correctly
align the implant, however if the surgeon does not achieve this in time, the cement must
be removed and the procedure repeated. A malaligned total knee or hip replacement can
greatly affect the functionality of the implant and may subject the cement to abnormal
stresses and strains which may lead to premature cement failure. In order to repeat the
procedure, more bone must be removed, which is not desirable, to accommodate for the
new cement. Proper surgical training may help reduce the likelihood of such an event
occurring. Other complications may also arise as a consequence of introducing a foreign
material into the human body or as a result of the procedure itself. It has been observed
that a drop in blood pressure immediately after implantation of PMMA bone cement oc-
curs for up to five minutes38. Initially bone cement was thought to be the cause of this with
authors blaming the exothermic curing temperatures39 or leaching monomer40. Bright et
al.41 found however that the hypotensive effects of MMA only occurred in animals at
MMA concentrations around tenfold of those found to occur in humans during surgery.
Furthermore Homsby et al.42 found no statistical correlation between MMA concentra-
tions and pressure drop and death in animals was found to occur only with hundredfold
concentrations of MMA. Although the initiator (DMPT) is known to be toxic, Shlag et
al.43 demonstrated that the initiator is totally depleted during the polymerisation of bone
cement.
Cemented joint replacements have been shown to carry higher risks of embolisms over
cementless joint replacements44. Cardiac arrest during joint replacement surgery has also
been well documented24,38. This condition is known as “cardiac arrest syndrome” and in
most cases is manageable with resuscitation but is not always reversible, leading to mortal-
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ity, as a number of cases have reported24 . Autopsy of some of these cases showed extensive
pulmonary fat embolisms had developed and in some cases cancellous bone fragments and
even bone cement were present in the fat embolisms45. These develop as manipulation
of the bone cavity increases the intramedullary pressure and fat, bone marrow and air
embolises into the venous system and to the lung. This can in turn lead to acute hy-
potension and, as reported in some cases, even cardiac arrest. Parvizi et al.45 conducted
a large retrospective study on hip surgeries (38,488 patients) and found the mortality
rate to be around 0.06%. Patients with fractured femoral necks where found to be at a
particularly higher risk (0.18%) as were patients with pertrochanteric fracture (1.6%). A
separate study by Leidinger et al.46 on a smaller cohort of patients (150 patients) also
found mortality rates of patients with femoral neck fractures to be much higher at 8%.
Elective total hip replacement surgery however, is generally rated as having a risk well
below 0.1%24. This is due to the novel techniques employed during surgery to reduce the
likelihood of embolisms forming such as the use of pulsatile jet-lavage on the bone canal
during surgery and continuous echocardiographic monitoring intraoperatively. Further-
more identifying high risk patients in which morbidity and mortality can be minimized
by using uncemented replacements is possible and should be carried out prior to surgery47.
According to the 2009 annual report from the National Joint Registry for England and
Wales, less than 1% intra-operative incidents occurred for all hip and knee replacements21.
As previously discussed, for hip replacements, cementless implants accounted for twice
the number of intra-operative incidents when compared to cemented implants. For intra-
operative cemented hip implant incidents, 20% were pelvic penetrations, 19% were trochanteric
fractures (as shown in Figure 1.12), calcar cracks accounted for 14%, 3% were shaft frac-
tures and 2% were shaft penetrations21. Penetration related cases in cement implants
may be as a result of excess cement causing discomfort to the patient, whilst cracks and
fractures are most likely caused by the removal or drilling of bone during surgery.
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Figure 1.12: Common hip fractures in untoward intra-operative incidents48
Untoward intra-operative events in knee replacements were found to be greater in ce-
mented cases (440) than in uncemented cases (12), however this figure reflects the high
number of cemented surgeries carried out on knee replacements (60,882) when compared
to uncemented surgeries (4,445). Intra-operative incidents for cemented knee replacements
in 2009 were found to be as a result of fracture (20%), ligament injury (9%) and patellar
tendon avulsion (6%)21. Again, fracture of the bone may have resulted due to drilling
and removal of the articulating joint, whilst ligament injury and patellar tendon rupture
is most likely caused by surgical errors. It should be noted that complicated revision
surgeries tend to employ cemented techniques due to the simplicity of the procedure and
the lower likelihood of untoward intra-operative events.
1.6.5 Failure rates
In order to understand the current problems of PMMA bone cements and to highlight
the need for improvements, it is essential to analyse recent data on the failure rates of
cemented implants. In orthopaedics, the two most discussed and popular surgeries that
use PMMA bone cement are total hip and knee replacements. By focusing primarily on
these two procedures, a good representation of the overall performance of bone cements
in orthopaedics can be obtained. The following information has been reproduced from
the National Joint Registry’s (NJR) annual report for 201021. The NJR was set up by
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the Department of Health and Welsh Assembly Government to collect information and
monitor the performance of all hip, knee and ankle replacements in England and Wales.
In 2009 there were 72,432 hip replacement surgeries in England and Wales. Of these
surgeries, 90% (65,229 surgeries) were primary procedures and 10% (7,203 surgeries) were
revision procedures. This signifies an estimated 10% failure rate for all hip replacements.
Within primary hip replacement surgeries, 36% (23,414 surgeries) were cemented, with
the remainder being either cementless, hybrid (or not classified) or resurfacing proce-
dures. Therefore, even with the introduction of novel technology such as cementless and
hydbrid implants, over one third of all hip replacements in England and Wales still use
PMMA bone cement.
When comparing cemented and cementless hip implants between the 1st April 2003 and
the 31st December 2009, cemented hip implants (99,359 cases) had a failure rate of 0.6%
after one year, 1.4% after three years and 2.0% after five years. Cementless hip replace-
ments (62,937 cases) were found to have higher failure rates, with 1.3% after one year,
2.5% after three years and 3.4% after five years. Therefore, even with the introduction
of novel cementless hip implants, it is clear that cemented hip implants perform better
clinically over time. Over a 10 year study, other sources have found cemented hip replace-
ments to fail at a higher rate of approximately 10%14.
The main reasons for hip revision surgeries in England and Wales in 2009 were found to
be aseptic loosening (49%, 3,524 surgeries), lysis (14%, 999 surgeries) and infection (14%,
1,020 surgeries). This agrees with a significant amount of published literature which states
aseptic loosening to be the main cause of implant failure11, 14, 49, 50.
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For total knee replacements in 2009 (77,545 total surgeries), 94% were primary procedures
(72,980 surgeries) and out of these procedures 79% were cemented (60,882 surgeries). This
shows cemented techniques to be more popular in knee replacements, possibly related to
their lower failure rate. 6% of the total surgeries were for revision purposes (4,565 surg-
eries), again caused mainly by aseptic loosening 35% (1,554), followed by infection 23%
(1,026) and lysis 10% (448). When compared to hip replacements, the failure rate seems to
be less, possibly due to the loading conditions of the cement. In total knee replacements it
is thought that the majority of loading occurs in compression whereas in hip replacements
the femoral stem is thought to apply more bending and tensile stresses on the cement.
Between 1st April 2003 and 31st December 2009 the failure rates for cemented knee re-
placements were 0.6% after one year, 2.1% after three years and 3.0% after five years.
Cementless knee replacements on the other hand experienced a 0.7% failure rate after one
year, 2.7% after three years and 3.7% after five years. Again, cemented knee replacements
outperform uncemented implants after the first 5 years. Although the failure rate after 5
years for cemented knee replacements is higher than hip replacements, other studies have
shown the overall failure rate after 10 years to be around 5%, half that of hip replace-
ments51.
Although this data highlights important information on the clinical use and success of
cemented implants in orthopaedics, further analysis of published studies and literature is
required to better understand the failure mechanisms in PMMA bone cement. Bone ce-
ments have been used since the late 1950’s and the literature on the subject is considerable
and a complete review of the literature on the matter would be difficult to achieve. By
necessity, therefore, this section will pay particular attention to the causes of failure and
those methods that have already been employed in an attempt to reduce this failure. The
test methods reported in the literature will also be summarised.
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1.6.6 Failure of PMMA bone cement
Aseptic loosening is known to be the main cause of failure for cemented orthopaedic
implants. The cement surrounding the prosthesis fractures and fails, which results in
the loosening of the implant. The reason for the cement failure is widely disputed and
substantial research has been carried out to better understand it.
Fatigue
As previously discussed, the rate of failure in cemented hip and knee replacements after 1
year is less than 1% and this increases to a much higher rate of 5% and 10% for cemented
knee and hip replacements respectively after 10 years. These figures help in understanding
the failure mechanism of cement. As failure rates increase dramatically after long-term
usage, it is suspected that fatigue plays a role in the fracture and eventual failure of
PMMA bone cements32. Cement fatigue is either thought to be a primary event, directly
contributing to implant loosening (Topoleski et al.52 and Culleton et al.53) or a secondary
event preceded by other failure phenomena, such as debonding at the cement-implant
interface (Jasty et al.54). Cracks in the cement are thought to initiate at voids, pores,
agglomerations, imperfections, damaged areas, areas of concentrated stress or due to ce-
ment shrinkage during polymerisation. Loading and unloading of the cement can cause
these cracks to grow and coalesce over prolonged periods of time, gradually weakening the
cement until failure of the implant occurs. This causes the cement to fail at stresses below
its yield strength. This concept has been investigated using fatigue testing methods and a
variety of different loading simulations with varying loads, frequencies and environments.
Overloads
The forces applied to bone cement in vivo vary significantly depending on the activity un-
dertaken. For example, standing, walking, stair climbing, standing from a seated position
and other activities will generate widely varying forces and stresses in the cement55, and
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these variations have a significant effect on crack propagation in PMMA56, 57. Therefore
to model such activity, overloads can be applied.
An overload is a force of greater magnitude than that which is being applied. Evans
et al.58 studied the effects of loading regimes on crack formation and found that overloads
in PMMA at low crack growth rates actually had a retarding effect on crack growth. The
overloads were thought to slow crack growth by plastic deformation due to crazing or shear
yielding ahead of the crack tip. This resulted in either blunting the crack tip, releasing
stresses, plastically inducing crack closure or changing the path of the crack itself. With
a more complex, commercially available cement however the results were not as clear,
demonstrating that cement composition is vital to preventing fatigue failure. Overall it
was found that overloads could decrease crack growth by a factor of 2 or increase it by a
factor of 658. Further studies into overloads showed that overloads at a certain ratio above
the baseline load accelerate cracks by overcoming microstructural obstacles. The retarda-
tion of crack growth by overloads can be explained by the main crack re-directing itself
to smaller secondary cracks and defects ahead of it33. The formation and accumulation of
crazes at low stress intensities ahead of the crack tip however can be extremely damaging
when an overload is applied. If the overload is large enough, it can cause the crazes to
coalesce and induce a burst in crack growth which may lead to the eventual failure of
PMMA below the expected threshold33, 59. As overloads and constant loading/unloading
commonly occurs during long-term in vivo use of cemented implants, it is difficult to avoid
this problem. Therefore to overcome this inevitable problem, some form of toughening is
required which will absorb energy at the crack tip. This may be achieved by changes in
the composition and microstructure of the cement.
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Porosity
Porosity is widely discussed in the failure of bone cements and is caused by entrapped
air during the mixing process, evaporating monomer and cement shrinkage34,60–62. Fig-
ure 1.13 shows a pore in PMMA bone cement.
Figure 1.13: Scanning electron microscopy image of a pore in PMMA bone cement
As previously discussed, the method of mixing has been found to greatly affect the poros-
ity of the cement, however the effect this has on the mechanical and fatigue properties are
still debated. Some authors have claimed that pores decrease fatigue life by decreasing the
load bearing area, which increases nominal stresses and creates stress concentrations33–35.
Nevertheless, pores are also known to be beneficial for drug delivery, bone ingrowth and
are thought to have a blunting effect on cracks by forming microcracks ahead of the crack
tip63, 64. This can force large cracks to change direction or branch out into smaller cracks
and can induce a greater amount of plastic deformation in the cement which requires a
higher amount of energy for the crack to propagate. Other authors claim that the size
of pores and the distance between them has a greater effect on fatigue life. It was found
using both experimental and analytical methods that fatigue life is reduced with larger
pores as the maximum principal stresses occur around the equator of the pore. This causes
larger pores to initiate failure cracks as well as speed up the crack growth rate around
them59, 60, 65. The effect of this is further increased as the distance between the pores is
reduced60, 63, 65. It was found that a 2mm pore is equally as damaging as two 1mm pores
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in close proximity as pores can link up to act as a larger void63. This can be mathe-
matically predicted using the theory of critical distances which implies that if pores are
sufficiently far apart they act as single entities and do not interact. A recent finite element
and micro-CT study by Coultrup et al.66 also hypothesised that the damage accumula-
tion process is most affected by larger pores, followed by smaller pores and radiopacifier
agglomerations. Smaller pores however, have been found to be insufficient in initiating
cracks by themselves60. They are also thought to help reduce polymerisation shrinkage,
reducing the likelihood of residual stress-induced cracks61.
It is clear that porosity affects the in vivo performance of bone cement and therefore
the mixing technique employed plays a vital role in reducing failure rates. Newer gener-
ation mixing techniques such as vacuum mixing and centrifugation are reported to have
improved the survival rate of bone cements by altering the porosity67, 68. As previously
discussed, vacuum mixing employs a reduced pressure (-39kPa to -86kPa) which helps
to remove some of the air during the mixing process. This system has been shown in a
study by Hansen et al.69, to increase the peak setting temperature of the cement. Reduced
oxygen levels are thought to initially inhibit the chemical reaction, resulting in a greater
number of free radicals reacting at the final polymerisation stage over a shorter period
of time. Vacuum mixing also reduces porosity to a certain extent as well as the residual
monomer as the vacuum removes any evaporated methyl methacrylate60, 70. Other authors
have found however, that the vacuum mixing systems used do not give significantly differ-
ent results to hand mixed samples34, 71–76. This is due to the weak vacuum not significantly
reducing porosity. It was also found that altering the level of the vacuum pressure has an
effect on the fatigue life of samples71, 77. Therefore with newer mixing systems, it is the
type of porosity created that changes, rather than the amount of pores76. It is thought
that vacuum mixing creates fewer but larger pores whilst hand mixing creates smaller
clusters of pores, which when grouped together are thought to initiate failure59, 61, 63. A
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study comparing laboratory fatigue tests and finite element models has shown that in
laboratory tests, pores tend to act as sites for crack initiations whilst in simulations crack
initiation is governed by local stress singularities. This would explain why modern mixing
techniques have failed to demonstrate improvements clinically78.
Pelletier et al.79 has shown that mixing temperature also affects porosity as cooler tem-
peratures (20◦C) resulted in smaller pores around the outside of samples, warmer temper-
atures (50◦C) resulted in larger pores nearer to the centre, which interestingly gave better
mechanical properties. Walker et al.80 has shown that reducing the temperature to 4◦C
decreases the overall porosity. Altering the mixing temperature however is known to affect
the setting/handling time and temperature. Cooling the powder and liquid prior to mixing
was found to increase the handling time and decrease the peak setting temperature, as
demonstrated by Li et al.81. Preheating the femoral stem of the implant is a technique that
has been investigated and it was found to reduce porosity at the cement-metal interface
as the cement would set faster closer to the stem81.
Radiopacifiers
Radiopacifiers in PMMA bone cements can be used to observe the location and penetration
of the cement in a non-invasive manner. When implant failure occurs in vivo it is essential
to assess the cause of failure using non-invasive techniques such as X-ray imaging. This
provides the surgeon with the necessary information to prepare and perform the appropri-
ate procedure to correct the problem. This also reduces the number and length of risky
surgeries the patient will have to undergo. To assess whether cement failure has occurred
the cement itself must be visible under X-rays. As PMMA is considered radiolucent, it
is essential to incorporate inorganic particles which will attenuate the X-rays sufficiently
to view cracks and fractures in the cement. As previously outlined, commercial cements
tend to use either BaSO4 or ZrO2 in the powder component at percentages of 8-15%w/w
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(Table 1.1)25, 32, 82. It has been speculated that these micron-sized particles contribute to
cement failure. A recent study by Baleani et al.83 has shown that the addition of 10%
BaSO4 to plain PMMA lowered the endurance limit and fracture toughness of the mate-
rial by 13% but also decreased the crack growth rate by up to 66%. A similar study by
Ginebra et al.82 found that BaSO4 decreased the tensile strength, did not affect fracture
toughness but improved crack propagation resistance whilst ZrO2 was found to improve
all three. A review by Lewis et al.84 on the fatigue performance of acrylic bone cements
has highlighted the positive effect radiopacifiers can have on the fatigue life of cements
drawing on 5 different studies85–90. Similar conclusions were drawn from these studies
with regards to crack propagation. It is hypothesised that inorganic filler particles retard
crack propagation by redirecting and deviating the crack tip. Other studies however have
shown agglomerations of the radiopacifier (both BaSO4 and ZrO2) to be detrimental to the
fatigue life of the cement. The agglomerations (as shown in Figure 1.1424) act as sites for
crack initiation and debonding of the radiopacifier from the PMMA matrix was also found
to cause defects35, 66, 91–95. An analytical study using stress analysis and fracture mechan-
ics techniques by Evans et al.60 also found that stress concentrations from small spherical
voids such as pores are too small to account for crack initiation and therefore cracks must
be initiated at additional stress raisers such as radiopacifier particles. A similar study
by Janssen et al.78 comparing laboratory tests and finite element models has drawn a
similar conclusion. Furthermore in static tests, the radiopacifier may act as inclusions,
Figure 1.14: SEM of a BaSO4 agglomeration in PMMA bone cement
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weakening the matrix. Therefore, although radiopacifiers have been found to reduce crack
propagation, they are also thought to be the cause of crack initiation. Similarities can be
drawn between pores and radiopacifier particles. It seems under stress, agglomerations
of radiopacifier particles act in the same way as large pores, initiating cracks. Similarly,
well-dispersed radiopacifier particles may act in the same way as small pores, retarding
crack propagation. Further problems have also been linked to radiopacifiers in terms of
tribology and biology. It is thought that released radiopacifier particles can be abrasive,
causing damage to articulating surfaces as well as enhancing macrophage-osteoclast differ-
entiation, contributing to bone resorption and aseptic loosening96–99. It is clear however
that several characteristics of the radiopacifier play a vital role on the performance and
success of the cement. These are the size, morphology, dispersion, adhesion to the polymer
matrix and the material properties of the filler particle itself.
Polymerisation temperature
PMMA bone cement undergoes an exothermic free radical polymerisation reaction as pre-
viously discussed. The conversion from MMA to PMMA comes with a breakdown of
covalent bonds which releases 52kJ per mole of MMA24. This results in heat being pro-
duced at approximately 1.4 to 1.7×108J/m3 25. The heat is produced rapidly and peaks
over a short period of time. This heat has been previously thought to cause thermal necro-
sis of the bone due to temperatures exceeding 50◦C, which may consequently cause aseptic
loosening of the implant100, 101. In vitro studies have shown that the maximum temper-
atures achieved in models of cemented hip replacements were approximately 70◦C102–104.
These studies have also found that higher monomer to polymer ratios and thicker cement
mantles increase the amount of heat produced103. Finite element studies by Hansen et
al.105 on the cement-implant interface have found maximum temperatures achieved during
the curing of cement to be around 53◦C, however peak temperatures found in vitro do
not necessarily correspond with temperatures reached in vivo. Clinical tests have shown
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significantly lower intra operative peak temperatures ranging from 40 to 46◦C, with the
higher limit only reached when a thickness of 3mm or greater without cancellous inter-
digitation occurs24. Similar in vivo setting temperatures have been found in several other
studies. A recent review by Whitehouse et al.11 has summarised these findings. Reckling
et al.106 found a mean maximum temperature of 48◦C whilst temperatures in excess of
56◦C have been recorded for periods of two to three minutes in a study by Harving et
al.107. The reasons for the lower in vivo maximum temperatures are due to thinner layers
of cement (3-5mm), blood circulation and heat dissipation to the prosthesis and to the
surrounding tissue24, 108. The temperature at which necrosis of cells occurs has also been
well documented. Moritz and Henriques109 suggested that a temperature of 55◦C for 30
seconds was sufficient to cause necrosis of epithelial cells. At lower temperatures however,
the time for necrosis was much greater (five hours at 45◦C). Lundskog et al.110 found bone
cells had a lower threshold, 30 seconds at 50◦C, and the regenerative capacity of bone was
only compromised at temperatures above 70◦C. Using vital microscopy, Eriksson et al.111
found evidence of widespread tissue damage in rabbit bone after one minute at 50◦C,
however a previous animal study by Lindner et al.112 indicated that there is no change in
bone regeneration following the use of bone cement. From these studies it is clear that al-
though the high setting temperatures of bone cements are a concern in terms of necrosis of
tissue, it appears it does not significantly contribute to the aseptic loosening of cemented
implants due to lower in vivo setting temperatures and the regenerative nature of bone.
Shrinkage stresses
As well as high setting temperatures, PMMA bone cement shrinks during curing. During
the polymerisation reaction of MMA, many short MMA monomer molecules combine to
form a few long polymer molecules. This conversion from monomer to polymer comes with
a reduction in volume. When polymerising pure MMA, a large volume shrinkage of 21%
is observed24, the process is very time consuming and the exothermic temperature is not
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controlled. To overcome these problems, pre-polymerised beads of PMMA are employed
in bone cement, which allows the amount of MMA employed to be halved. This reduces
the volumetric shrinkage to 6-7% and possibly less depending on to the level of porosity
in the cement. Volumetric shrinkage is also compensated via the uptake of water in vivo.
Nevertheless, the volumetric shrinkage experienced combined with a high exothermic set-
ting temperature can induce stresses, sufficient to initiate cracks in the cement.
Several studies have been conducted investigating the shrinkage of acrylic cement around
hip replacement stems and it was found that cracks originated from the inner surface of
the cement mantle, suggesting that they were caused by hoop stresses as a consequence
of shrinkage of the cement during polymerisation54, 113, 114. A theoretical model using
thick-walled cylinder theory further confirms that stresses during curing are sufficient to
initiate cracks prior to functional loading. The same study also demonstrated that pores
are capable of expanding in order to reduce shrinkage stresses within the bulk of the ce-
ment therefore preventing crack initiation. Experimental studies quantified these residual
stresses to be between 4 and 10MPa within the cement mantle115,116. Using acoustic emis-
sion techniques, Roques et al.115 found partial relaxation of these stresses to occur due to
cracking and sliding mechanisms at the cement-implant interface during curing. Two stud-
ies, one using an acoustic emission technique combined with micro-computed tomography
(Mavrogado et al.62) and the other using experimental and computer models (Lennon et
al.116) found that thermal contraction due to the peak exothermic temperature played a
larger role in cement damage than volumetric shrinkage alone. From this information it
can be deduced that shrinkage as a result of high setting temperatures contributes to crack
initiation and aseptic loosening to a greater extend than bone necrosis. Increased porosity
may help reduce these stresses, however porosity can be detrimental to the mechanical
performance of the cement. The exothermic nature of PMMA allows it to be self-curing,
making its application simpler during surgery. Therefore, little can be done to completely
30
Chapter 1. Introduction
remove both the heat from curing and shrinkage stresses. Manipulating porosity to benefit
both shrinkage stresses and mechanical properties would be difficult to achieve. Therefore,
slight changes in the composition of PMMA bone cements may provide greater benefits
to both shrinkage stresses and mechanical properties.
Sterilization
As with any implant used in the human body, bone cements must be sterilized before being
introduced into the body. This process will remove microbial contamination in the cement
and help prevent bacterial infection in vivo. Sterilization and packaging of the cement com-
ponents is carried out by the manufacturer to ensure maintenance of the sterility of the
product between the manufacturing location and the operating theatre. The monomer,
MMA is typically sterilized using membrane filtration68. For the powder component, two
techniques are used, gamma irradiation or ethylene oxide sterilization. Both of these tech-
niques have their respective advantages and disadvantages. Gamma irradiation has a high
penetration depth which allows the material to be sterilized in its final packaging whilst
ethylene oxide gas is an effective surface sterilant. Gamma irradiation however, has been
known to affect molecular weight and cause free radical generation, which is harmful to
the body. Furthermore these free radicals may interact with the benzoyloxide radical and
affect the polymerisation process of PMMA. Ethylene oxide on the other hand does not
have a high penetration depth and produces toxic by-products so the material must also
be desorbed after sterilization24.
Several studies have been conducted on the effects that the sterilization technique has
on the properties of PMMA bone cements. Overall it was found that gamma steriliza-
tion lowered the molecular weight of PMMA powder when compared to ethylene oxide
sterilization as a result of chain scission24, 68, 117–119. This in turn had a detrimental effect
on the fatigue performance and fracture resistance of the cement68, 117, 119. The reduc-
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tion in molecular weight on the static properties of PMMA are not as obvious. Certain
authors have claimed to have observed a reduction in tensile strength, Young’s modulus
and strain-to-failure as well as changes in setting properties as a consequence of molecular
weight reductions24,119, whilst other authors found there to be no significant effect on
quasi-static properties, such as bending and compression117, 118. It was also highlighted
by Graham et al.68 that the porosity of the final mixture due to the mixing technique
employed had a larger effect on the mechanical properties than the sterilization method.
Developments in novel sterilization techniques may benefit bone cements in the future,
however at present it is a vital method for preventing bacterial-related surgical complica-
tions. The effectiveness of these techniques, although disadvantageous at times, is reflected
upon in the low number of septic loosening cases for cemented implants. In 2009, it was
reported that in England and Wales, only 14% of hip revision surgeries were due to infec-
tion, whilst 49% were due to aseptic loosening. Similarly 35% of knee revision surgeries
were required due to aseptic loosening and to a lesser extent 23% due to septic loosening21.
Although fewer cases of septic loosening are reported, there is still a need to implement
added measures to prevent it such as the use of local antibiotic delivery systems in bone
cements as will be discussed in detail later.
Composition
Table 1.1 summarizes the different compositions of several commercially available bone
cements. These formulations have been optimised throughout the years to give the best
performance in vivo. As previously described, changes in the radiopacifier used and the
molecular weight of the polymer will have a significant effect on the setting and mechanical
properties of bone cements. Different manufacturers have taken different approaches to
their formulations. For example Cemex has a much higher powder to liquid ratio (≃3),
which the company (Tecres) claims to reduce the polymerization heat, the amount of
residual monomer that the patient is subjected to and the shrinkage stresses37. Cemex
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has also a lower amount of toxic N,N-Dimethyl-p-Toluidine (DMPT) and a higher amount
of benzoyl peroxide (BPO). Palacos R has a lower powder to liquid ratio (≃2) and a
higher DMPT content with lower amounts of BPO. Palacos also has a copolymer (methyl
acrylate) and ZrO2 as a radiopacifier in an effort to improve the mechanical properties of
the cement as well as a small amount of chlorophyll to give the cement enhanced visibility
during surgery. Heraeus claims that Palacos has “half the risk of revision after 10 years
compared to other cements”, “very high visibility” and “excellent fatigue strength”120.
Two compositional changes of interest are the initiator/activator ratio and the monomer/
polymer ratio. As previously discussed the initiator (BPO) reacts with the activator
(DMPT) to give a benzoyloxide radical which reacts with MMA to polymerise into PMMA.
DMPT is toxic and therefore a lower level is favoured to prevent toxicity problems. In
order for the MMA to self polymerise however, sufficient benzoyloxide radicals must be
produced, therefore a high BPO to DMPT ratio is also favoured, as is a lower amount of
MMA to reduce the amount of residual monomer. Studies have shown that more MMA
results in higher setting temperatures103,121–124. These studies also showed that the BPO
and DMPT concentrations are proportional to the maximum curing temperatures and
inversely proportional to setting times124–126. A separate study by Noble et al.127 how-
ever has revealed that different formulations of cement only affect the duration of the
heat generation as opposed to the quantity of heat generated. Therefore increasing the
amount of initiator and activator increases the rate at which the cement cures which in
turn makes the curing parameters (temperature and time) less favourable. In terms of
mechanical properties, it was found that decreasing the powder to liquid ratio by intro-
ducing more MMA results in a reduction in compressive strength128, 129. A recent study
carried out at the Cardiff School of Engineering has led to similar conclusions130. There
was no correlation in terms of maximum temperature between the powder to liquid ratio,
however more monomer was found to increase the setting time and decrease the compres-
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sive strength of the cement. Altering the initiator to activator ratio also did not change
the maximum setting temperature, however lowering the BPO to DMPT ratio resulted in
a stiffer cement with higher compressive strength. Cement manufacturers have attempted
to have a low powder to liquid ratio to prevent reductions in compressive strength but also
enough monomer to allow the surgeon sufficient working time. The initiator/activator and
the monomer/polymer ratios have been carefully optimised by manufacturers for specific
purposes. Changing the initiation chemistry of PMMA bone cements improve some prop-
erties of the cement, however detrimental effects on other properties are likely to occur in
the process.
Interfaces
In cemented implants there are two interfaces of interest where potential failure can cause
implant loosening. These are the cement-metal interface and the cement-bone interface.
The former bond arises as a result of direct contact between the cement and the metal-
lic implant. This bond primarily develops from hydrogen bonds between the superficial
metal oxide layer and PMMA. Macro and micro-retention can also be achieved as a result
of surface roughness131. As water diffuses through cracks and is absorbed in the cement,
this interface is subjected to hydrolysis which over time decreases its mechanical stability.
This was further demonstrated by Ahmed et al.132 as samples immersed in saline over
time showed significant reductions in bond strength. A study by Davies et al.133 has de-
veloped a technique to monitor debonding in vitro using acoustic emissions in conjunction
with ultrasound. From this study it was found that cracks in the cement and around the
implant stem caused loosening of the implant, whilst cement without cracks maintained a
good bond with the implant, however it was not deduced if the cracking originated from
the cement itself or as a consequence of the debonding. To overcome hydrolytic debond-
ing, implant coatings have been developed using polymers, silica and/or silane coatings
which so far have proved to be successful131, 132, 134, however it is postulated that improv-
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ing this bond may increase the stresses transferred to the weaker cement-bone interface135.
Although the cement-metal interface is important, the cement-bone interface has been
more widely researched and discussed in publications. It is believed that the cement-bone
interface is more prone to failure due to biological processes and micro-structural fea-
tures. Acoustic emission techniques and computer tomography showed that damage was
initiated at this interface and was found to be related to stress-raising micro-structural
features in the cement. These features were as a result of irregularities in the geometry of
the bone, creating recesses and notches filled with cement, as outlined by Leung et al.136.
Furthermore an ideal cement thickness of 1.0-1.5mm has been recommended by Terrier et
al.137 as too thin a cement layer will not support loads and too thick a cement layer will
not elastically deform, subsequently increasing interfacial stresses and micromotion at the
cement-bone interface. An animal study by Radin et al.138 using sheep has demonstrated
failure at the cement-bone interface to be more prevalent and most likely caused by a
decreased torsional rigidity. A more biological approach to the cement-bone interface fail-
ure, taken by Goldring et al.139, showed retrievals from aseptically failed hip replacements
contained synovial-like tissue with the capacity to generate prostaglandin E2 and collage-
nase which can cause progressive bone lysis and resorption. Separate studies also found
a similar membranous tissue or osteoid lining to occur in loosened implants140, 141. These
studies also detected cement particles and debris such as radiopacifier particles in the bone
surrounding the implant. Particles released by the cement and implant may therefore con-
tribute to loosening after extended periods of time, as certain amounts of bone resorption
and macrophagic reactions were found to occur even in successful implants142.
The technique used to apply bone cement was also found to affect cement penetration
into bone and therefore affects the cement-bone interface as well. As outlined, bone ce-
ment can be introduced using a cement gun or manually using a “finger packing” method.
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Studies have been conducted that have looked at the cement penetration of these two
techniques. It was found that the use of a cement gun over finger packing resulted in
higher pressures which in turn resulted in greater interdigitation of the cement into the
cancellous bone143,144. This allows the cement to interlock with the pores of the bone
and anchor itself more effectively. Nevertheless the same studies found there were no ad-
vantages in terms of mechanical and fatigue properties by employing one system over the
other. Another study by Leung et al.136 found that interdigitation of cement with bone
initiated damage by creating high levels of stress at the interface causing the cement to
fracture. Furthermore concerns were also brought up as high levels of cement penetration
may cause bone necrosis due to high curing temperatures. An in vitro study by Klein
et al.145 which pressurized test samples during curing found that increased pressure does
in fact increase ultimate strength to a value similar to that of vacuum mixed cement but
found there to be no difference in tensile properties and porosity. A separate study by
Askew et al.146 also highlights the fact that although cement penetration into bone may
be beneficial, the strength of the fixation will always be limited by the intrinsic strength
of the bone.
From these studies it seems that cement-metal interface failure tends to be mechanically
and chemically induced whilst failure of the cement-bone interface tends to be induced by
wear and debris particles as well as mechanically and biologically induced. Greater cement
penetration into bone may not improve the cement-bone interface strength. Therefore
changes to bone cement which can improve the biological and mechanical interactions be-
tween these interfaces and strengthen the bonds between them may prove more successful
in reducing implant failure rates. For the cement-metal interface a mechanically stronger
bond that resists hydrolytic degradation is required, whilst for the cement-bone interface,
reduction of debris particles and bone growth and osseointegration into the cement as
opposed to interdigitation would be beneficial.
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Ageing
The final topic on cement failure involves the ageing of PMMA. As previously described,
failure rates dramatically increase 5 years after surgery, demonstrating how bone cement
tends to fail as a result of fatigue and ageing. Bone cement must function in the harsh
environment of the human body and over time, water, higher temperatures and cells cause
the cement to degrade, changing many of its properties. Although current commercially
available cements must possess certain mechanical properties to pass standards, over time
these properties can deteriorate in vivo. Recent studies have found that ageing in vivo and
in simulated physiological conditions resulted in a reduction in mechanical properties. It
was found that mechanical properties increased during the first week due to polymerization
and formation of interpenetrating molecular networks, after which a decrease was observed
due to the plasticising effect of water uptake147. Testing in dry conditions, as dictated
by standards, was found to always give higher values for mechanical properties which
increased over time as the cement was found to polymerise over a period of 5 years50.
The plasticising effect of water also increased the creep rate of bone cements. Conditions
which increase plasticisation (longer ageing, higher temperatures and stresses) were found
to increase creep rates up to a maximum temperature of 40◦C, above which the effects were
diminished due to increased molecular mobility in the material148. Ageing of bone cements
not only affected mechanical properties, but it was also found to affect the structure and
surface properties of the cement. Cement retrievals from hip replacements were found to
have a decrease in molecular weight and scission-based degradation was found to occur over
long periods of time, changing the actual structure of the PMMA molecule, as described
in a study by Hughes et al.149. Bettencourt et al.150 showed that biological fluids cause
hydrolysis of the PMMA ester groups, not only changing the composition of the cement
but also the wettability of its surface. which may play a role in the loosening of the
implant.
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1.6.7 Novel Formulations
Having examined some of the causes of failure in PMMA bone cements, focus will now be
placed on techniques that have been used in an attempt to overcome some of the problems
previously highlighted.
Boneloc cement
To overcome the problem of high setting temperatures causing bone necrosis, Bone-
loc cement (Biomet Inc., Indiana, USA) was developed. Boneloc replaced half of the
MMA content in the liquid component of the cement with n-decylmethacrylate isobornyl-
methacrylate, changed the activator to a mixture of adihydroxypropyl-p-toluidine and
DMPT and added butyl-methacrylate-MMA co-polymers to the powder component of the
cement151. This resulted in a 20◦C to 33◦C reduction in setting temperature when com-
pared to other vacuum mixed cements but unfortunately, the changes had a detrimental
effect on clinical results. Aseptic loosening rates were increased to 34% after three years152.
This was due to a significantly lower glass transition temperature which meant the cement
satisfied the standard tests at room temperature, but in vivo at 37◦C, the cement had
unacceptably high levels of stress relaxation and creep leading to clinical failure151.
Two-solution cements
Two-solution type cement mixtures are currently being developed in an attempt to over-
come problems associated with porosity and inhomogeneities. These systems involve dis-
persing PMMA powder and an activator in MMA in one part and in the second part
dispersing PMMA powder and an initiator in MMA. A study by Hasenwinkel et al.153
looking at the effect of BPO and DMPT content on the properties of these two-solution
cements found that setting times, setting temperature and maximum strains were within
the range of commercial cements and an increase in flexural strength and modulus by
54% and 43% respectively was experienced. A later study by the same author showed the
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fracture toughness and fatigue strength were comparable to a commercial cement, how-
ever these experiments did not employ radiopacifiers154. A separate study by Rodrigues
et al.155 showed that the addition of zirconia to the two-solution cement increased its
viscosity and also affected its mechanical properties, acting as a reinforcing phase when
cross-linked PMMA spheres were added. Furthermore the amount of MMA used is much
larger than in conventional cements, meaning more residual monomer will be present in
the patient after surgery154. The storage of MMA containing BPO over long periods of
time is also a topic of concern as spontaneous polymerisation over time will limit the shelf
life of two-solution cements. A study found that shelf life was very much temperature
dependant and storage at 4◦C yielded a shelf life of approximately 12 months whilst shelf
life at 70◦C resulted in setting of the cement in 5-7 minutes. Higher levels of initiator con-
centrations also shortened the shelf life, as demonstrated by Shim et al.156. Changing the
polymerisation chemistry of bone cement systems and altering the state of its components
may successfully overcome problems such as porosity and high setting temperatures. In
doing so however, unwanted problems that are less well understood than the current prob-
lems with traditional bone cement systems may develop. The unsatisfactory failure rates
of Boneloc and potential future problems of two-solution cements make changes such as
these very high risk. Therefore it may be better to modify only slightly current cement for-
mulations by introducing novel materials as opposed to developing a completely different
system. Slight modifications to the current cement system would be simpler to implement
in an industrial scale and less likely to cause problems that have not been experienced
before.
Copolymers
An example of this is the recent use of methylacrylate (MA), butylmethacrylate (BMA)
and styrene copolymers in commercial bone cements in order to improve mechanical and
fatigue properties. MA is a small molecule with a low glass transition temperature (6◦C)
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that makes the cement more hydrophilic and flexible resulting in a higher failure strain, a
relatively low compressive strength and a relatively higher strength and failure strain in
tension. Therefore MA makes the cement less brittle and less susceptible to stress risers
like pores. BMA has a much higher molecular weight than MMA and the addition of a
small amount of BMA gives the PMMA powder a more porous and open structure. This
may improve the bond between polymer chains, which will entangle with the outer surface
of the PMMA beads. BMA also has a low glass transition temperature (20◦C) and adding
a small percentage of BMA to the powder component (≤5%w/w but preferably ≤1%w/w)
is claimed to result in enhanced fatigue strength157. Styrene copolymers on the other
hand are more hydrophobic with a higher glass transition temperature (120◦C) and so the
time and energy needed to make a homogeneous mixture will be longer than MMA-MA,
MMA-BMA mixtures. It is thought that the addition of styrene to PMMA bone cements
is beneficial to the fatigue strength, however little datum is published on this matter24.
Cross-linking agents
A similar approach to copolymers involves the use of cross-linking agents. Cross-linking
agents are thought to strengthen polymers by linking polymer chains together via covalent
bonds. This process may strengthen the material however, chain mobility is reduced,
making the polymer rigid and more prone to brittle failure. A study by Deb et al.158
looking at different cross-linking agents in bone cement found that small amounts of cross-
linking was beneficial to reducing creep and improving mechanical properties in bone
cement, however too much cross-linking was detrimental to the cement. The same author
also found that the use of these agents improves the bond between the polymer matrix
and radiopacifier particles and improves tensile strength159. Similarly a study by Nien et
al.160 implementing poly(methylmethacrylate-acrylic acid sodium salt) into bone cements
found that too much cross-linking agent was detrimental to the mechanical properties
and another study found cross-linking monomers to improve mechanical properties only
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when used in conjunction with glass fibre161, 162. It seems as though small amounts of
cross-linking agents improves mechanical properties by improving the bond between filler
particles and the PMMA matrix. The biocompatibility of cross-linking agents is also
questioned and further research is required in this field before such materials can be
implemented in bone cements.
Plasticisers
Plasticisers function in the opposite way to cross-linkers. They work by sitting between
polymer chains, spacing them apart, increasing the free volume and allowing for greater
chain mobility. This decreases the glass transition temperature of polymers and makes
them softer and more ductile. Citrate esters were tested in pure PMMA and found to lower
the glass transition temperature, tensile strength and Young’s modulus. The percentage
elongation also increased dramatically after 20%w/w plasticiser was used163. When added
to bone cement at up to 12%w/w, castor oil plasticiser was found to decrease yield strength
from 88 to 15 MPa, Young’s modulus from 1500 to 446 MPa and maximum polymerization
temperature from 41.3 to 25.6◦C, without affecting the setting time. Castor oil also
interfered with the polymerization reaction and had a negative effect on cell viability, as
demonstrated by Lopez et al.164. Similarly, Lam et al.165 found reductions in modulus
and compressive strength to occur when linoleic acid coated strontium was added to bone
cements. Although plasticisers may be of use in vertebroplasties where a lower modulus
cement is favourable to prevent brittle failure and damage to vertebral discs, in total
joint replacements the reduction in mechanical properties may lead to early failure of
the implant. Lowering of the glass transition temperature may also result in high levels
of creep at in vivo temperatures, which can again may lead to premature failure of the
cement. Furthermore as previously described, water uptake has a plasticising effect on
PMMA over time and therefore synthetic plasticisers may not be required to achieve a
more ductile material. The disadvantages outlined, coupled with lack of information on
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the biocompatibility of plasticisers currently rules out the viability of this option.
Rubber Particles
Having eliminated the use of plasticisers in PMMA for total joint replacements, there
is still a need to reduce brittle failure in bone cements. In an effort to achieve this,
several authors have attempted to modify PMMA with rubber particles in order to achieve
higher levels of toughness. Several studies have found that using rubber particles in
PMMA improves the overall fracture toughness of the cement166–168. Cho et al.169 found
that toughening in three-point bending occurred as a result of crazing and under impact
shear yielding was induced by cavitation of the rubber particles. Further investigation
into using poly-(n-butyl acrylate) for toughening either as a particle or in a core-shell
configuration with PMMA showed that both methods work equally well. It was also found
that at low strain rates the interfacial adhesion between the rubber particle and PMMA
matrix is sufficient to induce matrix deformation whilst at high strain rates failure at the
interface of the rubber particle and PMMA occurs166. A similar study by Lalande et al.168
using PMMA-b-polybutylacrylate triblock copolymers also showed high impact stresses to
induce brittle failure associated with increased localization of the crack tip deformation.
Rubber toughening appears to be an effective method of retarding fatigue failure in bone
cements under low strain conditions, however at higher strain rates improved adhesion
between the particle and the PMMA matrix is required to prevent brittle failure.
Iodine-based radiopacifiers
Another area of recent interest is the use of iodine-based radiopacifiers to replace con-
ventional powdered radiopacifiers such as BaSO4 and ZrO2. As previously identified,
conventional radiopacifiers have been associated with many problems, even failure of bone
cements. The use of a liquid radiopacifier may overcome such problems. A study by
Artola et al.170 using 4-iodophenol methacrylate (IPMA) instead of BaSO4 found that
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15%v/v in the liquid component gave similar radiopacity as 10%w/w BaSO4 as shown
in Figure 1.15. Furthermore there was no change in glass transition temperature and
there was enhanced compressive strength, tensile strength, and elastic modulus170. The
same author also investigated adding 5%v/v 2-[2’,3’,5’-triiodobenzoyl] ethyl methacry-
late (TIBMA) and 3,5-diiodine salicylic methacrylate (DISMA) to the liquid component
of bone cement and found that the mechanical properties were better than those of the
BaSO4 containing cement. The radiopacity was found to be comparable with BaSO4 and
all samples showed good biocompatibility171. Lewis et al.172 investigated using an iodine-
containing copolymer in the powder component of bone cement and found similar results,
stating iodine-based cements are a viable candidate cement for arthroplasties. Closer ex-
amination of this study however, found that the mean fatigue life of the iodine-containing
cement is lower, there is no significant difference in work to fracture and fracture tough-
ness and the iodine-based cement had higher variability (larger standard deviations). A
study by Manero et al.173 looking at fatigue crack propagation of three iodine-containing
cements (IPMA, TIBMA and DISMA) in comparison with conventional BaSO4 cement
found that the BaSO4 cement demonstrated the best performance in terms of fatigue
crack propagation, then the iodine-based cements followed by radiolucent cement. There-
fore although iodine-based cements may provide enhanced static mechanical properties
Figure 1.15: X-ray of iodine-based bone cements170
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over conventional cements, they do not perform better in terms of crack propagation.
This may be due to the fact that iodine-based radiopacifers cannot redirect crack tips like
conventional radiopacifier particles. Also this technique has not been commercialised due
to the risks associated with iodine allergies in patients24.
Fibre reinforcement
Different studies have taken a similar approach to improving bone cements by adding
novel materials to improve certain properties. A commercial example is the use of ZrO2
to replace BaSO4. ZrO2 has been widely used for dental cements due to its mechanical
properties and is also employed in Palacos bone cement for that same reason. Further
research into ZrO2 by Kotha et al.
174 found that the use ZrO2 fibres instead of particles
further improves the ultimate strength and fracture toughness of cements. Similarly, when
PMMA fibres were added to pure PMMA in a study by Gilbert et al.175, improvements
in tensile, fracture toughness and fatigue properties were observed. The biocompatibility
of fibres however and the effect they may have on the human body is still disputed.
Improving bone growth
Other novel materials such as strontium oxide (SrO) for improving bone growth into the
cement have been investigated and suggested for total joint replacements by Lewis et
al.176. Replacing BaSO4 with SrO however, results in higher hardness values, a greater
elastic modulus and a lower mean fatigue life. When discussing bone growth, the use of
hydroxylapatite (HA) is well documented as it is widely used as a material for bone repair.
The addition of HA to PMMA by Tihan et al.177 was found to increase the hydrophilicity
and water absorption of PMMA and as a result, leads to good cell growth, proliferation and
viability on the material. The addition of HA to PMMA however, has been documented to
reduce mechanical properties and increase water absorption which may accelerate ageing
or hydrolytic degradation mechanisms178, 179. Sodium fluoride, which is also thought to
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promote bone growth, has also been tested by Minari et al.88 in cements with BaSO4
but did not show significantly different mechanical properties or increased radiopacity
and its effect on bone growth in cements is yet to be tested. Although improving bone
growth properties would be beneficial to the long-term performance of bone cements, it
is vital for the novel materials to not reduce the mechanical and fatigue properties of
the cement. Other cement types such as calcium phosphate and apatite based cements
promote bone growth well, however do not have sufficient mechanical properties for load
bearing applications such as joint arthroplasty. The use of titanium dioxide (TiO2) as a
radiopacifier may provide a solution to this problem. Titanium is the main material of
hip and knee replacements due to its good biocompatibility, mechanical properties and its
ability to bond with bone. A recent study by Fukuda et al.180 using rutile TiO2 in bone
cement found it to have high levels of osteoconductivity and good mechanical properties.
A separate study by Chou et al.178 however showed TiO2 to decrease the strain at break
and the flexural strength, which was due to agglomerations of TiO2 and brittle failure.
Chemical coatings
Gillani et al.181 investigated the functionalisation of ZrO2 and BaSO4 using a silane cou-
pling agent and found that cements with unfunctionalised radiopacifiers exhibited brittle
failure whilst functionalised radiopacifiers exhibited plastic failure modes. This was due
to a stronger bond forming between the radiopacifier and the polymer which under stress
induced plastic deformation of the polymer matrix as opposed to separation of the ra-
diopacifier from the matrix, which can initiate cracks and brittle failure. Cement adhesion
to the metallic implant is usually not desirable in joint replacements as hip replacements
with polished, tapered stems have been shown to have a lower failure rate when compared
to hip replacements with roughened stems. It is thought that the polished stem, under
load, can loosen and wedge itself deeper in the cement, whilst roughened stems create
wear debris which may contribute to the loosening of the implant. Nevertheless, several
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studies have been carried out investigating the use of chemical coatings to enhance the
bond strength between bone cement and the metallic implant in an effort to prevent excess
movement of the implant. Coating of cobalt-chrome alloy implants with a silane was found
to significantly improve their bond strength with PMMA bone cement, as demonstrated
by Yerby et al.134. The same silane was added to the monomer of PMMA in a separate
study by Gbureck et al.182 and the bond strength between the titanium implant and the
bone cement was assessed. It was found that the mechanical properties of the cement
itself were not altered by the addition of the silane, the cement-metal interface was more
hydrolysis resistant and the bond strength between the metal and PMMA was significantly
improved. Furthermore Miyazaki et al.183 observed accelerated apatite formation on the
surface of bone cements using the same silane in conjunction with calcium chloride. It
was found that the silanol group (Si-OH), provided by the silane after hydrolysis, induced
apatite formation as well as a dissolution of calcium ions (Ca2+) from the material. A
similar chemical known as Span 60, which forms a bond with the hydroxyl group of TiO2
in the same way a silane does, was found to improve the dispersion of TiO2 particles, in-
creasing its hydrophobicity and reducing agglomerations, as demonstrated by Li et al.184.
As the surface of radiopacifier particles tend to have high surface energies and are highly
hydrophilic, the coating of the surface using a hydrophobic and low surface energy silane
coupling agent may also offer improved dispersion characteristics which will reduce ag-
glomerations185. Although the biocompatibility of silanes is questioned, the use of small
amounts as coatings for radiopacifier particles may not have a detrimental effect on cells.
The use of silanes, coupled with a novel bioactive material such as TiO2 may improve
bone growth, bonding to the metallic implant, dispersion of the radiopacifier particles and
as a result of this, improve mechanical and fatigue properties and the long-term success
of cemented implants.
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Nanoparticles
With the recent development of nanotechnology, there has been a great deal of inter-
est in using such technology to improve bone cements. Current radiopacifiers used are
in the range of 1-3µm, which when poorly dispersed can lead to 50-200µm agglomer-
ates. Several studies using nano-particle radiopacifiers found that agglomerations were
reduced, mechanical and fatigue properties were improved, osteoblast adhesion was im-
proved, decreases in curing temperatures were experienced and increases in radiopacity
occured186–188. Due to the size of the radiopacifier nanoparticles, cell and tissue inter-
actions must be investigated to ensure nano-sized particles released from the cement do
not have a detrimental effect on the surrounding tissue and patient’s well being. A study
by Hill et al.49 using nano-calcium carbonate (CaCO3), which is known to be biocom-
patible, in bone cements found that energy to maximum load, elastic modulus, bending
strength and bending modulus were improved by the addition of less than 1%w/w. Coat-
ing the nano-CaCO3 with sodium citrate to improve dispersion also increased the energy
to maximum load and elastic modulus but had a detrimental effect on bending proper-
ties. The cement used to achieve these results however, did not contain any radiopacifier
particles and the study focused only on mechanical properties as opposed to fatigue and
cytocompatibility tests.
Nanotubes
The development of super strong carbon nanotubes, which exhibit extremely high tensile
strength and modulus has been of great interest to material scientists for many years. The
ability of nanotubes to undergo plastic deformation under excessive tensile strain makes
it applicable to countless materials including PMMA bone cement. Carbon nanotubes,
although strong in tension are not as strong in compression, bending and torsion as they
tend to buckle. Nevertheless, it was found that nano-tubes enhanced the mechanical and
fatigue properties of bone cement both in tension and compression189, 190. Furthermore, the
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addition of multi-walled carbon nanotubes was found to reduce the setting temperature
due to the good thermal conductivity of the nanotubes. Carbon nanotubes were also
found to improve the mechanical properties by retarding crack growth by a bridging effect
in the crack, normal to the direction of crack growth. Agglomerations of the multi-
walled nanotubes were also found to occur, but this was dependant upon the method used
to incorporate the nanotubes into the cement, as outlined by Ormsby et al.191, 192. A
biological study by Usui et al.193 on the effects of multi-walled carbon nanotubes found
that they “induce little local inflammatory reaction, show high bone-tissue compatibility,
permit bone repair, become integrated into new bone, and accelerate bone formation”.
Nanotubes therefore offer an exciting new approach to improving bone cements, however
there is speculation regarding its biocompatibility and as this technology is still under
development, the costs of manufacturing nanotubes are relatively high, making its use in
bone cements not economically viable. Nevertheless, as more efficient production methods
are being developed, the use of nanotubes in orthopaedics is very likely as they become
more economically viable.
1.6.8 Drug delivery systems and antibiotics
Powdered gentamicin
Powdered antibiotics, such gentamicin sulphate, have been employed in PMMA bone ce-
ments in an effort to prevent septic loosening of the implant. This technique is currently
under much debate due to the fear of resistant bacteria becoming established and the
effect of gentamicin on the mechanical and fatigue properties of the cement. Gentamicin
is generally added to the powder component of the cement in doses of 0.5-1g of gentamicin
sulphate powder per 40g of cement. Dunne et al.194, 195 showed that the addition of 1-4g
of gentamicin resulted in a significant decrease in compressive and bending strength. Like-
wise an earlier study by Lautenschlager et al.196 investigating the addition of gentamicin
to Simplex P bone cement found the antibiotic to cause gradual, proportional decreases
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in compressive and tensile strengths. The amount of antibiotic released was also found
to increase with increased dosage, however the majority of the gentamicin release occured
within the first 6 hours in a “burst” type mode194, 195, 197. When testing on Staphylococ-
cus spp. clinical isolates the increased release initially reduced the amount of bacterial
colonisation but at 72 hours there was no beneficial effect as biofilms formed regardless of
gentamicin release194, 195. Separate studies obtained similar results and conclusions demon-
strate that the use of gentamicin sulphate powder in bone cements does not completely
inhibit the formation of infectious biofilms198,199. Furthermore there have been studies
that showed the antibiotic to have a detrimental effect on the fatigue life of cements194, 200.
In contrast other studies have found that there was no significant difference in terms of
fatigue performance201, 202. It has been shown that the porosity and therefore the mixing
method also plays a role on the elution of antibiotics as vacuum and hand mixing have
been found to affect gentamicin release203, 204. In general the manual addition of gentam-
icin in-situ prior to surgery is not recommended due to a lack of homogeneity achieved in
the mixing200, but this is also disputed205.
Gentamicin solution
To overcome the problem of dispersion and homogeneity of antibiotic-loaded cements as
well as to reduce costs, gentamicin solution has been tested and was found to have good
release characteristics, but was also found to reduce the mechanical properties signifi-
cantly206, 207. This may be due to the phase separation of the two liquids occurring as
MMA is hydrophobic, not mixing well with water-based gentamicin solutions, creating
large voids in the cement upon polymerisation. To overcome this, Miller et al.208 tested
employing emulsifiers with liquid gentamicin in bone cement but found little success in
terms of mechanical performance. The use of gentamicin solution with vancomycin also
yielded positive results in terms of antibiotic release but poor mechanical properties, as
demonstrated by Hsieh et al.209.
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Alternative therapeutic agents
Different antibiotics in a powdered form such as vancomycin have also been tested in bone
cements, either alone or in conjunction with other antibiotics. Laine et al.210 demon-
strated the use of powdered vancomycin in PMMA had a similar effect as gentamicin,
as a reduction in mechanical strength was observed regardless of mixing method. When
employed in conjunction with gentamicin loaded cements, vancomycin was found to re-
duce the compressive strength and porosity of the cement but maintained a compressive
strength above the minimum values required by ISO standards (70MPa). Furthermore the
combination of gentamicin and vancomycin was found to inhibit the growth of more strains
whilst gentamicin alone selected for methicillin-resistant Staphylococcus aureus211, 212. An-
other therapeutic agent tested in bone cements is chitosan, however this has met with little
success. It was found that chitosan did not have any antimicrobial benefit or benefit to
the gentamicin release. Setting properties were also altered and a detrimental effect on
the mechanical properties of the cement over time was observed213–215. Fusidic acid and
clindamycin was also tested in combination with gentamicin in bone cements in a study by
Neut et al.216. It was found that fusidic acid in combination with gentamicin was effective
against a higher number of clinical isolates when compared to gentamicin and gentamicin
with clindamycin, however mechanical properties are yet to be assessed216. The addition
of lactose to gentamicin was found to increase the amount of antibiotic released but also
increased porosity which reduced mechanical properties217, 218. It appears that the addi-
tion of other therapeutic agents to bone cement either in conjunction with gentamicin or
by itself, can improve the antimicrobial efficacy of the cement, however the changes in
mechanical properties experienced are not beneficial to the long-term success of the im-
plant. Therefore a different approach such as redesigning the delivery system may prove
more effective in preventing implant infections whilst preserving mechanical and fatigue
performance.
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Silver nanoparticles
An example of a different antimicrobial system in PMMA is the recent use of silver
nanoparticles. Silver has a wide spectrum antimicrobial activity, however due to the
cytotoxicity of silver salts it is unsuitable for continuous clinical use. Silver nanoparticles
however may overcome this issue. When introduced in PMMA, silver nanoparticles were
found to have high antibacterial efficacy even against methicillin-resistant Staphylococcus
epidermidis (MRSE) and methicillin-resistant Staphylococcus aureus (MRSA)219, 220. Also
the in vitro cytotoxicity of silver nanoparticle containing bone cement was not significantly
different from plain bone cement220. A recent animal study by Moojen et al.221 however
showed that silver bone cement was not effective in preventing methicillin-sensitive staphy-
lococcal infections in vivo as the antimicrobial effect is only exhibited at the cement surface
rather than the surrounding tissue. This may be due to the fact the silver nanoparticles
are not released from the cement into the surrounding fluid and tissue like antibiotics.
Also results on mechanical and fatigue properties of silver bone cements are yet to be
published.
1.7 Test methods
1.7.1 Test parameters
From the reviewed literature it is clear that a wide range of different test methods have
been applied to assess different properties of PMMA bone cements. The properties tested
have been categorized into static, dynamic, crack growth, fracture toughness, viscoelastic
and rheological tests in a review by Saha et al.222. These properties can be altered by many
factors, including: the preparation method, the composition/additives used in the cement,
the sterilization techniques employed, the porosity of the cement and the storage/ageing
conditions. Furthermore parameters such as test temperature, environment, specimen
preparation method and strain/loading rates also affect the results obtained.
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1.7.2 Standard tests
To prevent test parameters from affecting results, the majority of reported tests are per-
formed according to guidelines published by the International Organization for Standard-
ization (ISO) and the American Society for Testing and Materials (ASTM). The standards
used for PMMA bone cements are either the “ISO5833:2002 Implants for surgery - Acrylic
resin cements” standard223 or the “ASTM F451-08 Standard Specification for Acrylic Bone
Cement” standard224. The ISO5833 guidelines have established minimum requirements
that all novel cements must achieve, as shown in Table 1.2.
Table 1.2: ISO5833 Requirements for acrylic resin cements
Parameter Requirement
Maximum setting Average / ◦C 90
temperature Maximum deviation / ◦C ± 5
Doughing time
Average / min ≤ 5
Maximum deviation / min ± 1.5
Setting time / min 3 to 15
Compressive strength / MPa ≥ 70
Bending modulus / MPa ≥ 1800
Bending strength / MPa ≥ 50
ISO5833 also specifies procedures for establishing setting, compression and flexural prop-
erties. ASTM F451 is similar to the ISO standard, however uses tensile tests as opposed
to flexural tests. These standards also specify the required conditioning of samples prior
to testing and the strain rates that must be applied during testing as static properties of
bone cement have been found to be affected by these parameters222. The availability of
such standards has made the comparison of bone cement properties across different studies
possible. From three separate studies that have used the standards, the average values
for static properties of polymerised commercial bone cements were found to be: 35.3MPa
tensile strength, 64.2MPa bending strength, 93.0MPa compressive strength and 2552MPa
bending modulus24, 25, 74, 222.
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1.7.3 Alternative tests
PMMA bone cement is subjected to complex loading in vivo, however the standards do not
fully establish how the cement will perform in vivo. Several different methods are used in
the literature that have been developed to better understand bone cement properties.
These include: hardness92,225, fatigue32, 74, crack propagation33, 58, 173, 226, 227 , fracture
toughness74, 228, 229, creep230–234 and stress relaxation tests235–238. The use of rheomet-
ric testing to understand the rheological and setting properties of bone cement have also
been outlined74, 239–244. Similarly methods to investigate the molecular structure of bone
cements have also been developed24,50, 148–150, 245. The radiopacity, porosity and cracking
of cements has been investigated using X-ray imaging62,79, 136, 170, 246 ; and the bone growth
properties of novel cement formulations have been investigated using simulated body flu-
ids247–253, cell culture methods254–256 and animal trials138, 180, 257, 258 . The antibiotic release
from bone cements is of great interest and has been studied using HPLC and chemical as-
say methods195, 213, 217, 259 as well as mathematical methods.197 Similarly the effectiveness
of the antibiotic release on different strains of bacteria has also been investigated203, 216, 220 .
Some of the methods listed have been used throughout this thesis and will be discussed in
more detail in subsequent chapters. The effectiveness of the methods used and the results
obtained will also be discussed and compared to previous studies.
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General Methods
This chapter will refer to some of the common methods that have been used to test the
different properties of bone cements throughout this thesis. Later chapters will refer back
to these methods to reduce repetition. Test methods that are specific to certain chapters
will be described in detail in the appropriate chapter.
2.1 Mixing bone cements
As previously stated, PMMA bone cement is composed of a liquid and powder compo-
nent which when mixed undergoes free radical polymerisation to form a rigid polymer.
When preparing commercially available bone cement, mixing was carried out according
to the manufacturer’s instructions. When preparing the authors own formulation of bone
cement, the ISO 5833:2002 (Implants for surgery - Acrylic resin cements) standard223 was
used as a guideline. All the contents of the cement were stored at room temperature in
the dark and conditioned at 23◦C for 2 hours prior to mixing. Each material of the pow-
der component was put through a 35 mesh sieve (0.5mm opening) before being carefully
weighed out to an accuracy of ±0.01g and mixed together thoroughly. Seperately each
chemical of the liquid component was weighed out and mixed together. Both components
were then introduced into a clean polypropylene bowl and hand mixed at approximately
1Hz with a polypropylene spatula for 1 minute. The cement was then applied into a mould
or appropriate container.
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Moulds were prepared out of polytetrafluoroethylene (PTFE) in order to make uniform
samples with specific dimensions. PTFE was chosen as it does not adhere to or react with
bone cement, it can withstand the setting temperatures, allows for the easy removal of
samples and has no leachables. The cement was mixed as previously specified and poured
into the mould. The mould was then clamped with two steel endplates covered with PTFE
film at either end. After 10 minutes, the samples were pushed out of the mould using a
steel removal rod and allowed to cure at 23◦C for 24±2 hours. After 24 hours the samples
were sanded down to the correct dimensions using 320 grit silicon carbide paper.
2.2 Setting properties
Measurements and calculations for the setting properties were carried out according to the
ISO5833:2002 standard using a high density polyethylene mould and a K-type wire ther-
mocouple connected to a Picotech ADC11 Data Logger. The ambient temperature was
recorded prior to mixing and 25g of cement was prepared. Recording of the temperature
and time commenced as soon as the liquid came into contact with the powder. Tempera-
tures were recorded to an accuracy of ±0.5◦C. The setting temperature was calculated as
shown in Equation 2.1 and the setting time (tset) was defined as the time when the setting
temperature was reached (Tset).
Tset =
Tmax + Tamb
2
(2.1)
Where:
Tset is the setting temperature
Tmax is the maximum temperature reached during curing
Tamb is the recorded ambient temperature prior to mixing
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2.3 Mechanical properties
2.3.1 Compressive strength
Compressive strength was determined as specified in the ISO 5833:2002 standard223.
Cylindrical bone cement samples were prepared with 12±0.1mm length and 6±0.1mm di-
ameter (Figure 2.1(a)). Prior to loading, the dimensions of the samples were recorded to an
accuracy of ±0.01mm. Each individual sample was then loaded incrementally in compres-
sion using a Zwick Roell ProLine table-top Z050/Z100 materials testing machine (Zwick
Testing Machines Ltd., Herefordshire, UK) at a constant cross-head speed of 20mm/min.
Load and displacement was recorded and loading was stopped when failure occurred or
the upper yield point had been passed.
To calculate the compressive strength (σc) in MPa, Fmax, the load to cause fracture,
the 2% offset load or the upper yield point load (whichever occurred first, in N) was di-
vided by the original cross-sectional area (in mm2) of the sample as shown in Equation 2.2.
An average of five samples were used.
σc =
Fmax
cross sectional area
(2.2)
(a) Compression test (b) Bending test (c) Fracture toughness test
Figure 2.1: ISO5833 and ISO13586 tests
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2.3.2 Bending modulus and strength
Bending modulus and strength was determined as specified in the ISO 5833:2002 stan-
dard223. Rectangular bone cement samples were prepared with a length of 75±0.1mm,
width of 10±0.1mm and thickness of 3.3±0.1mm (Figure 2.1(b)). Prior to loading, the
width and thickness of the samples were noted to an accuracy of ±0.01mm. A four-point
bending test rig was used with a distance between the outer loading points of 60±1mm
and a distance between the inner loading points of 20±1mm (Figure 2.1(b)). Each indi-
vidual sample was carefully placed in the centre of the four-point bending rig and loaded
incrementally using a Zwick Roell ProLine table-top Z050/Z100 materials testing machine
at a constant cross-head speed of 5mm/min. Displacement as a function of applied force
was recorded. Loading was stopped when failure of the specimen occurred.
Equation 2.3 was used to calculate the bending modulus and Equation 2.4 was used
to calculate the bending strength of each sample. Five samples were used to obtain an
average bending modulus and bending strength for each group.
Eb =
∆Fa
4fbh3
(3l2 − 4a2) (2.3)
B =
3Ffracta
bh2
(2.4)
Where:
f is the difference between the deflections at 15N and 50N in mm
b is the average width of the specimen in mm
h is the average thickness of the specimen in mm
l is the distance between the outer loading points (60mm)
∆F is the load range (50N - 15N)
a is the distance between the inner and outer loading points (20mm)
Ffract Force at fracture in N
a is the distance between the inner and outer loading points (20mm)
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2.4 Fracture toughness tests
The ISO13586:2000 Plastics - Determination of fracture toughness (GIC and KIC) - Linear
elastic fracture mechanics (LEFM) approach standard was used to determine the fracture
toughness of samples228. This was similar to the bending tests, but with a sharp chevron
notch (roughly 4.5-5.5mm) through the centre of the sample, created using a sharp razor
blade. Prior to loading in three-point bending (Figure 2.1(c)) using a Zwick Roell ProLine
table-top Z050/Z100 materials testing machine, a Pye Scientific travelling microscope (Pye
Scientific, Cambridge, UK) was used to measure the length of the crack and the width
and length of each sample was measured using a Vernier caliper. The results from five
samples for each group were recorded to obtain an average.
Determination of the load at crack growth initiation (FQ)
A tangent to the load displacement curve of a specimen was drawn to determine the initial
stiffness (S). This stiffness was then reduced by 5% and a line from the zero-point was
drawn. If the maximum of the load displacement curve fell between the two lines drawn,
then FQ was equal to Fmax. If the second line (stiffness reduced by 5%) intersects with
the load curve before the maximum then the point of intersection (F5) was considered to
be FQ. The conditions of linear elastic fracture mechanics (LEFM) were met when:
Fmax
F5
≤ 1.1
Calculating the critical stress intensity factor (KIC)
The critical stress intensity factor (KIC) was calculated using Equation 2.5 which used
the load (FQ) at crack growth initiation and the original crack length (a).
KIC = f
FQ
H
√
w
(2.5)
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Where:
FQ is the load at crack growth initiation in N
H is the thickness of the specimen in m
w is the width of the specimen in m
a is the crack length in m
f is the geometry calibration factor (retrieved from Annex A of the BS ISO
13586:2000)
Validity of results
Equations 2.6 and 2.7 were used to check the accuracy of the results obtained. If the
value for Estiff was 15% larger than Efract then KIC and GIC was checked for errors or
the test was carried out again.
Estiff =
2f2φS
H
(2.6)
Efract =
K2IC
GIC
(2.7)
Where:
E is the modulus of elasticity in Pa
H is the thickness of the specimen in m
S is the stiffness of the specimen in Pa
φ is the energy calibration factor (retrieved from Annex A of the BS ISO
13586:2000)
f(a/w) is the geometry calibration factor (retrieved from Annex A of the BS ISO
13586:2000)
KIC is the critical stress intensity factor MPam
1/2
GIC is the critical energy release rate Nm
−1
2.5 Fatigue testing
For fatigue testing, the ISO15850:2002260 (Plastics - Determination of tension-tension fa-
tigue crack propagation) and ASTM E399261 standards were used as guidelines. Fatigue
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tests were conducted at 37◦C using an Instron environmental chamber (Instron SFL, Bris-
tol, UK) and a 5kN Dartec servohydraulic testing machine with an MTS FlexTest GT
controller (MTS, Minnesota, USA). Circular disc compact tension samples were prepared
according to Section 2.1 with a diameter of 27mm and thickness of 9mm with two drilled
5mm holes (as shown in Figure 2.2(a)). A chevron notch (roughly 5mm in length) was cut
into the sample to ensure symmetric crack growth using a modified mictrotome. Sample
dimensions were measured using a travelling microscope (Pye Scientific, Cambridge, UK)
as shown in Figure 2.2(b). Symmetric loading was applied using the drilled oversized holes
allowing the loading pins to rotate without friction. Krak gages (KG-A10, Hartrun Cor-
poration, Minnesota, USA) were attached to the samples (Figure 2.2(b)) and connected to
a constant current supply and amplifier built and designed by Evans et al.58 to measure
crack lengths with an accuracy of ±0.001mm even at low crack growth rates. Prior to
testing, samples were conditioned for 2 months to ensure their material properties had
stabilised.
(a) Sample dimensions (b) Sample measurements
Figure 2.2: CT fatigue testing samples
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Samples were cyclically tested in load control with a sine wave at 5Hz between 70N and
7N (or 100N and 10N for Palacos cements) (R-ratio of 0.1) allowing for measurements
of crack growth rates through stress intensities of 0.3 to 0.8MPam1/2 as the crack grows
through the length of the sample. Prior to loading, samples were subjected to a pre-
cracking procedure to ensure a steady crack growth rate of 10−9m/cycle to begin with.
For precracking, a high cyclic load of 235N at 5Hz was applied and reduced by no more
than 20% after 0.2mm of crack growth until the test loads were reached (70N for Cemex
and 100N for Palacos cements). 5Hz was selected as it represents a loading cycle between
walking (1Hz) and running (20Hz) and also allows for a faster testing time when compared
to the standard walking load cycle (1Hz).
The crack length and number of cycles was measured during loading. The crack growth
rate (da/dN) was then calculated from this data every 0.2mm. Similarly the corresponding
stress intensity factor range (∆K) for each sample and crack length (ranging from 6-12mm,
in steps of 0.2mm) was calculated using Equation 2.8.
∆K =
(Pmax − Pmin)
b
√
W
× (2 + α)
(1− α)3/2 (0.76 + 4.8α − 11.58α
2 + 11.43α3 − 4.08α4) (2.8)
Where:
∆K is the stress intensity factor range in MPam1/2
Pmax is the maximum load in N
Pmin is the minimum load in N
Y is the stress intensity factor function
b is the sample thickness in m
α is a/W and is greater than 0.2
a is the crack length from centre point of the holes to the tip of the krak gage
in m
W is the width of the specimen from centre point of the holes to the bottom
of the specimen in m
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Two samples were tested to obtain an average plot of crack growth rate (da/dN) as a
function of the stress intensity factor range (∆K) on a logarithmic scale. A linear regression
was used to fit the data and the Paris Law was then applied to give the constants ‘A’ and
‘m’ (as shown in Equation 2.9)262. ‘A’ represents the intercept at the da/dN axis when
∆K=1 and therefore is the crack growth rate at 1MPam1/2; and ‘m’ is the slope, which
is a measure of the crack acceleration as it increases in length. Therefore a more fatigue
resistant cement would have a reduction in both ‘A’ and ‘m’ material constants.
da
dN
= A∆Km (2.9)
Where:
da/dn is the crack growth rate (y-axis) in m/cycle
∆K is stress intensity factor range in MPam1/2
A is the y-intercept at x=1 (∆K=1MPam1/2)
m is slope of the linear regression
2.6 Vickers hardness tests
Disc shaped samples with a 10mm diameter, a 2mm height were prepared and the surfaces
polished with a 4000 grit silicon carbide paper. Samples were then tested for hardness
under the ISO6507-2 standard263 for Vickers hardness testing. Five small indentations,
1mm apart and from the edges of the sample, were put on both sides of each sample using a
Zwick 3212 indenter (Zwick Testing Machines Ltd., Herefordshire, UK) fitted with a 136◦
square-based pyramid diamond indenter to obtain a mean hardness value. Indentations
that occurred near to or on pores were disregarded and repeated. The load was set at 200g
and was held for 10 seconds after initial contact with the sample. For each indentation a
travelling microscope was used to measure the two diagonal lengths from which a mean
value was obtained. Using Equation 2.10 the hardness values for each sample in Kg/mm2
were calculated, where ‘F’ is the load in Kg (0.2), ‘Ai’ is the area of the indentation and
‘d’ is the mean diagonal length of the indentation in mm.
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Hardness(HV ) =
F
Ai
= F/
d2
2sin(136◦/2)
≃ 1.854 F
d2
(2.10)
2.7 Glass transition temperature
A Rheometric Scientific V500 (TA Instruments Ltd., Elstree, UK) testing machine was
used to determine the glass transition temperature of samples by dynamic mechanical
analysis. Small matchstick like samples were used with a length of roughly 30mm, width
of 2-3mm and a height of 1-2mm. Samples were loaded sinusoidally at a frequency of 1Hz
in a dual cantilever configuration as the sample was heated from 35◦C to 200◦C at a rate
of 10◦C/min. The applied stress and strain was measured as shown in Figure 2.3.
Figure 2.3: Stress (σ) and strain (ε) during a dynamic mechanical analysis
The phase lag (δ) between the stress and strain was measured and the storage modulus
(E’) and loss modulus (E”) was calculated using Equations 2.11 and 2.12 respectively.
E′ =
σ
ε
cosδ (2.11)
E′′ =
σ
ε
sinδ (2.12)
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From this the complex viscosity in the form of tanδ was calculated as shown in Equa-
tion 2.13. For perfectly elastic materials, tanδ=0 and for perfectly viscous materials
tan δ=∞. Tan δ was therefore plotted against temperature and the temperature at which
tan δ was at its maximum was considered to be the glass transition temperature. Five
samples were tested to obtain a mean value for glass transition temperatures.
tanδ =
E′
E′′
(2.13)
2.8 Scanning electron microscopy
Throughout the course of this study, scanning electron microscopy (SEM) was employed
to study surfaces of samples to assess fractures and porosity. Prior to imaging with an
EBT1 Scanning Electron Microscope (SEM Tech Ltd, Southampton, UK) at 15KeV, the
samples were gold coated using an E65x sputter coater (Emitech,Kent, UK).
2.9 Statistical analysis
An analysis of variance (ANOVA) was carried out to establish significant differences be-
tween groups of samples using the data analysis package in Excel (Microsoft, Reading,
UK). Significance between groups was defined as those with a calculated p-value of less
than 0.05.
65

Chapter 3
Mechanical properties of
commercial cements and the
development of a standardised model
of cement
3.1 Introduction
In order to improve current bone cement performance, novel materials must be tested in
a standardised formulation. Commercial cements come premixed as separate powder and
liquid components (as discussed in Chapter 1), modifying the composition of a commer-
cial cement is thus very difficult. Commercial cements also vary in formulation and as a
result, propriety products have many different properties, making unpredictable the effect
of compositional change.
The approach undertaken was to develop a simple model cement with a similar composi-
tion and similar properties to commercial cements. By doing so, it was possible to change
individual components of the model cement to investigate the effect of those changes.
Static mechanical tests, as outlined by the ISO5833 standard for acrylic-based cements,
falls short in predicting clinical success. Therefore, research studies have introduced alter-
native tests in an attempt to create more accurate predictability for clinical application.
This chapter establishes a series of tests, mechanical and physical, by which formulation
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performance can be analysed. By studying the formulations of several commercial cements
(Table 1.1) and using average quantities for each ingredient, a basic model cement was de-
veloped and tested. Two different commercially available cements were also tested and the
results defined a target performance range that the model cement would have to achieve.
The failure mechanisms of the commercial cements tested were also investigated to provide
an insight into potential areas that could be improved. The properties of the commercial
cements obtained in this chapter were used in subsequent chapters for comparison with
novel formulations.
3.1.1 Failure modes and toughening in polymers
When a polymer is subjected to high stresses, crack growth may be initiated by the fracture
of covalent bonds or the breaking of weaker van der Waal forces. It has been suggested
that the polymer fracture process can be simplified into 3 steps264:
1. The excitation of bonds under the action of an applied stress
2. The scission of the excited, over-stressed bonds by thermal fluctuations
3. The formation of small microcracks in crazes which coalesce to form larger cracks
Furthermore propagation of cracks can be classified into three different modes as shown
in Figure 3.1. Mode I represents crack growth due to tensile stresses perpendicular to the
plane of the crack; mode II represents a sliding mode due to in-plane shear and mode III
represents a tearing mode caused by out-of-plane shear. Crack propagation may occur as
a result of a combination of these three modes.
Figure 3.1: Crack propagation modes265
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During these fracture processes, there is a degree of shear yielding which consists of a
change in shape without a significant change in volume. This viscoelastic and plastic
energy dissipating process is localised and usually occurs in the vicinity of the crack
tip. In order to prevent crack propagation it is essential to incorporate energy absorbing
mechanisms from many sites rather than a few, which increases the overall volume of
the polymer and blunts the crack. Crazing, shear deformation and crack pinning are
forms of energy absorbing mechanisms which naturally occur in polymers under load.
When such mechanisms are not present, brittle fracture tends to occur. To promote
these mechanisms throughout the bulk of the material and to improve the mechanical
properties of the polymer, additional particles can be incorporated. This second phase
can be rubber particles, which is known as rubber toughening or rigid-particle fillers with
a higher stiffness than the polymer.
Crazing
Crazes are a network of small, fine cracks which are initiated when an applied tensile
stress causes microvoids to nucleate at points of high stress concentrations created by
scratches, flaws or molecular heterogeneities. This usually occurs ahead of the crack tip
and creates fibrils of plastically deformed, oriented polymeric material spanning the craze
(Figure 3.2(a)). Crazing is a cavitation process and unlike shear yielding, it occurs with
an increase in volume.
(a) Crazing (b) Shear Bands (c) Crack Pinning
Figure 3.2: Crack blunting mechanisms in polymers266–268
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Although considerable plastic deformation and local energy adsorption are involved in
craze initiation, growth and breakdown, this is highly localised to a small volume. If sta-
ble crazes can be initiated in a larger volume, it may lead to a tough and ductile material
response.
Using transmission electron microscopy (TEM) on high-impact polystyrene, it has been
proven that craze growth occurs by meniscus instability269, 270. In this mechanism, yielded
polymer particles at the concave air/polymer interface break off and produce new craze
matter (Figure 3.3). As crazes grow and coalesce, they gradually break down into a crack.
If the applied stress is parallel to the orientation of the craze however, then crack initiation
can be inhibited and will only occur at much higher stress levels264.
Figure 3.3: Craze formation. (a) Side view of the craze tip; (b)-(d) sections through the
midline of the craze showing the craze advance by meniscus instability270
Shear deformation
Shear deformation consists of a change in shape without a significant change in volume.
It is important because it is the factor that limits the strength of the polymer if brittle
fracture is supressed. Shear yielding in the form of micro-shear bands also plays a key
role in crack initiation and even brittle crack propagation in polymers usually involves
localised viscoelastic and plastic energy dissipation in the crack tip vicinity.
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Large plastic shear deformations result in the formation of shear bands (Figure 3.2(b)), a
lens-like region, roughly 45◦ to the applied force. When both crazes and shear bands are
present in a polymer, one of the following may take place:
1. The shear band may terminate the craze when grown into the craze tip.
2. When a growing craze meets a pre-existing shear band, no termination takes place,
rather crack nucleation begins.
If upon crack extension only highly localised shear deformations occur around the crack
tip, then the material will generally exhibit a brittle fracture at a low stress intensity since
plastic deformation is confined to a small volume of polymer264.
Crack pinning
The inclusion of particles into a polymer matrix allows for crack pinning to occur. This
is when a crack grows from particle to particle, bowing between each one as shown in
Figure 3.2(c). This bowing shape results in a new fracture being formed and a longer
distance for the crack to grow. This in turn results in more energy dissipated at the crack
tip and thus retardation of the crack. For this mechanism to work effectively, the particles
must be spaced an optimum distance apart264.
Crack branching and deviation
The formation of microcracks ahead of the crack tip also plays a role in the toughening
of materials. Microcracks located in the vicinity of the crack tip may cause the main
crack to change direction or branch out into smaller cracks in order to coalesce with the
microcrack. This deviation or branching of the main crack requires a greater amount
of energy to propagate the crack and reduces the stress intensity at the main crack tip.
Microcrack formation also requires the utilisation of energy and the creation of multiple
microcracks requires a substantial increase in the amount of work required for the crack
to advance.
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3.1.2 Fracture mechanics theory
It has long been understood that the theoretical strength of a material is much greater
than the apparent strength due to the presence of flaws in the microstructure of the
material. Fracture mechanics is a method that can account for such flaws and can be used
to investigate how cracks will propagate through a material. Analysis of stresses at the
crack tip can be used to predict the potential for crack growth and therefore failure60.
Using conservation of energy arguments and the crack tip stress analysis developed by
Inglis271, Griffith272 developed an equation in the 1920’s to derive the tensile strength
of a brittle material with crack-like flaws (Equation 3.1), where the stress to fracture is
dependant upon the length of the crack and the surface energy as the crack propagates
through the material. σf is the stress to fracture, a is the length of the crack, γs is
the surface energy and E is the Young’s modulus. The underlying assumptions in this
equation are that all the energy required to generate a new crack surface is accounted for
by the surface energy and that fracture occurs when the rate of energy supplied to the
body exceeds that dissipated through crack advance.
σf =
2
pi
(
√
E
γsa
) (3.1)
Griffith discovered that a high stress concentration is necessary for crack propagation to
occur, however energy is also required to break intermolecular bonds within the material
to generate cracks272. Such energy was found to come from stored strain energy in the
material around the crack60, 262. This equation was further developed to take into account
the irreversible effects of plastic flow at the crack tip and resulted in a single property
called work of fracture (energy required per unit area of a new crack) which takes into
account all the forces involved in crack growth. This value is then compared to the rate
at which strain energy is released (G) and if the work of fracture is less than G, then the
crack will propagate.
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Another approach carried out by Irwin et al.274 studied the stress intensity just beyond
the crack tip as theoretically the stress at the tip itself is infinite. These stresses were
investigated using polar coordinates, which led to a simple relationship whereby all stresses
beyond the crack tip were found to be proportional to the term σ
√
pia. This led to the
stress intensity (K) being defined as Equation 3.2, whereby if the critical value of K
(fracture toughness) is reached, the crack will propagate. A shape correction factor (Y)
can be added to this equation to account for different loading methods, geometries and
proximity to external boundaries60, 262. This equation is the basis for those described in
Sections 2.4 and 2.5.
K = Y σ
√
pia (3.2)
When this theory is applied to crack growth tests as described in Section 2.5, it is possible
to obtain an accurate measure of the fatigue endurance of a material. The characteristic
shape of the results obtained is shown in Figure 3.4 where: region I represents crack initia-
Figure 3.4: Characteristic crack propagation results, reproduced from Motarjemi et al.273
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tion after the critical stress intensity factor threshold is reached; region II represents stable
crack propagation and region III represents unstable crack growth followed by fracture273.
As previously described, the Paris Law can be applied to region II in order to describe a
material’s crack propagation properties.
3.2 Methods
3.2.1 Materials
Cemex Isoplastic was obtained from Tecres (Sommacampagna, Italy) and Palacos R was
provided by Heraeus (Newbury, UK). Methyl methacrylate with 75ppm hydroquinone, N-
N dimethyl-p-toluidine and benzoyl peroxide were purchased from Sigma Aldrich (Gilling-
ham, UK); polymethyl methacrylate powder with a methylacrylate copolymer (Colacryl
TS1713) was provided by Lucite International UK (Southampton, UK); and barium sul-
phate was obtained from Fisher Scientific UK (Leicestershire, UK). The composition of
the commercial cements are shown in Table 3.1 along with the formulation for the model
cement. This formulation was developed by averaging compositional values from a wide
range of different cement brands as shown in Table 1.1.
Table 3.1: Composition of the model cement and the commercial cements used
Cemex Palacos Model
Isoplastic R Cement
Liquid component / g 13.30 18.78 16.93
Methyl Methacrylate / %w/w 99.10 97.98 98.50
N-N Dimethyl-p-Toluidine / %w/w 0.90 2.02 1.50
Hydroquinone / ppm 75.00 60.00 75.00
Powder Component / g 40.00 40.00 40.00
Polymethyl Methacrylate / %w/w 84.30 84.50 88.30
Barium Sulphate / %w/w 13.00 - 10.00
Benzoyl Peroxide / %w/w 2.70 0.50 1.70
Zirconia / %w/w - 15.00 -
Powder : Liquid ratio 3.01 2.13 2.36
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3.2.2 Mechanical testing
Compression and bending samples were prepared and tested according to Sections 2.1,
2.3.1 and 2.3.2.
3.2.3 Setting properties
The setting temperature and time was measured as detailed in Section 2.2. This ensured
the model bone cement tested was not significantly different from commercially available
cements.
3.2.4 Fracture toughness
The fracture toughness of each cement was tested as specified in Section 2.4.
3.2.5 Fatigue testing
Fatigue tests were carried out as described in Section 2.5 under load control to determine
any differences in fatigue properties between commercial cements and the model cement.
3.2.6 SEM images
SEM images of the fracture surfaces of fatigue samples were assessed as described in
Section 2.8 and the morphology of Palacos R and Cemex powders were also observed.
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3.3 Results
3.3.1 Setting properties
Figure 3.5 and Table 3.2 show the setting profiles and setting properties respectively for
Palacos R, Cemex and the model cement. Cemex Isoplastic took the longest time to set
and had the lowest maximum setting temperature whilst Palacos R set the quickest and
had the highest maximum setting temperature. The model cement was found to set in
a time between that of Palacos R and Cemex and also with an intermediate maximum
setting temperature.
Figure 3.5: Setting profiles of commercial bone cements and the model cement
Table 3.2: Setting properties of commercial bone cements and the model cement
Setting time
(tset) / s
Setting
temperature
(Tset) /
◦ C
Maximum
temperature
(Tmax) /
◦ C
Cemex 738 46.5 69.8
Palacos R 479 52.1 78.5
Model cement 665 49.2 76.2
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3.3.2 Mechanical properties
Table 3.3 shows the compressive strength, bending modulus and bending strength of Pala-
cos R, Cemex and the model cement. Palacos R had significantly higher compressive
strength (ANOVA - p<0.05, p=4.99×10−05), bending modulus (p=0.02) and bending
strength (p=1.48×10−03) when compared to Cemex.
In terms of compressive strength there were significant differences between all three ce-
ments (p=8.59×10−06), however the model cement had a compressive strength halfway
between that of Palacos R and Cemex.
The bending modulus of the model cement was higher than both the commercial cements.
There was no significant difference between the model cement and Palacos R (p=0.11),
however the difference with Cemex was found to be significant (p=0.01).
In terms of bending strength, the model cement was found to be halfway between Palacos
R and Cemex. There was no significant difference in bending strength between the model
cement and Cemex (p=0.14) but Palacos R had a significantly higher bending strength
than the model cement (p=0.01). Overall with the exception of bending modulus, the
model cement formulation has demonstrated ideal mechanical properties, between what is
considered a “good” cement and a “poor” cement in terms of mechanical properties.
Table 3.3: Mechanical properties and fracture toughness of commercial and model cements
Compressive
strength (σ c)
/ MPa
Bending
modulus
(Eb) / MPa
Bending
strength (B) /
MPa
Fracture
toughness
(KIC) /
MPam1/2
Palacos R 104.6±2.6 3410±123 69.7±7.7 2.5±0.2
Cemex 85.2±4.2 3080±205 46.0±6.5 1.16±0.1
Model cement 95.5±2.67 3730±319 53.7±6.9 1.5±0.2
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3.3.3 Fracture toughness
Table 3.3 shows the results of the fracture toughness tests. Similar to the results of
the mechanical properties, Palacos R had significantly enhanced fracture toughness with a
higher critical stress intensity factor value than Cemex (p=5.81×10−07). All three cements
were found to be significantly different (p=2.54×10−07) but the model cement had a critical
stress intensity factor value between that of Palacos R and Cemex.
3.3.4 Fatigue
Using the Paris Law on the crack propagation data, two constants were obtained, con-
stant ‘A’ (crack growth at ∆K=1MPam1/2) and constant ‘m’ (crack growth rate as stress
intensity increases), as shown in Table 3.4. Palacos R demonstrated the best crack growth
resistance at ∆K=1MPam1/2. The model cement was found to have a value for constant
‘A’ between that of Palacos R and Cemex. For constant ‘m’ the model cement had a
lower value than the commercial cements, signifying less change in crack growth rate with
increased stress intensity. An ‘m’ value of 1 would mean crack growth rates for all stress
intensities are the same. From this data it is clear that Cemex also performs poorly in
fatigue.
Table 3.4: Fatigue constants of commercial and model cements
A m
Palacos R 3.73×10−07 4.65
Cemex 5.39×10−07 5.92
Model cement 4.83×10−07 3.73
Figure 3.6 shows the crack growth rates obtained for varying stress intensities for the
commercial and model cements. All three cements obtained similar crack growth rates
through the stress intensities tested. At lower crack growth rates the model cement per-
formed poorly in comparison to Cemex and Palacos R, however the slope of the model
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cement data is less steep, demonstrating less change in crack growth rate throughout the
range of stress intensities tested.
Figure 3.6: Crack propagation of commercial bone cements and the model cement
3.3.5 SEM images
Figure 3.7 shows scanning electron microscopy images of the fatigue fracture surfaces of
Palacos R, Cemex and the model cement. Palacos R and Cemex bone cement fracture
surfaces were found to have significantly more pores (which appear as dark circles) than the
model cement. PMMA beads were not visible in the fracture surfaces of Palacos R, whilst
in the Cemex and the model bone cement, PMMA beads were observed as light grey circles
in the SEM images. Closer inspection of the fracture surfaces revealed that Palacos R and
the model cement had a greater amount of small cracks whilst Cemex appeared to have
fewer but larger cracks. The fracture surface of Palacos R also shows shear deformation
as a large shear band is visible on the fracture surface. As previously described this shear
band appears to have terminated several crazes, acting as a toughening mechanism.
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(a) Palacos R ×13 (b) Palacos R ×70
(c) Cemex ×13 (d) Cemex ×70
(e) Model cement ×13 (f) Model cement ×70
Figure 3.7: SEM images of the fracture surfaces of fatigue samples for (a-b) Palacos R,
(c-d) Cemex and (e-f) the model cement - Red arrows indicate the location of PMMA
beads, green arrows indicate radiopacifier particles, blue arrows indicate pores and voids,
yellow arrows indicate the edges of shear bands and white arrows indicate microcracks
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The morphology of the powders differed, as shown in Figure 3.8, whereby Palacos beads
were clearly separated whilst Cemex beads are fused together. Both cements however had
similar PMMA bead sizes (≃50µm) and were found to have accumulated radiopacifier
particles on the surface of the PMMA beads.
(a) Palacos R ×70 (b) Palacos R ×226
(c) Cemex ×70 (d) Cemex ×226
Figure 3.8: SEM images of the powder morphologies of (a-b) Palacos R and (c-d) Cemex
- Red arrows indicate PMMA beads and green arrows indicate radiopacifier particles
3.4 Discussion
Studying the effects that a change in formulation or the addition of a novel material will
have on the properties of PMMA bone cement is of great interest and essential for develop-
ing better cement formulations. Numerous studies have attempted to test novel materials
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in bone cements but few obtain results that can be compared with commercial cements
or truly test the effects of the novel material. For example Lewis et al.172 tested the
use of iodine-containing copolymers and compared it with conventional BaSO4 cement.
The BaSO4 containing cement was very similar in composition to the cement used in this
study and to other commercial cements, however it used butylmethacrylate (BMA) in the
liquid component, which is not generally employed in commercial cements. Furthermore
the iodine based cement had lower levels of PMMA, BPO and higher levels of MMA,
butylmethacrylate (BMA) and DMPT when compared to the BaSO4 cement employed.
Therefore improvements or changes to the properties of the iodine-based cement in com-
parison to the BaSO4 cement may be as a result of the different levels of polymer, initiator
or activator used and not as a direct result of the iodine radiopacifier. Gillani et al.181
used a liquid MMA to powder PMMA ratio of 5:1 (10g of MMA to 2g of PMMA) with 1g
of radiopacifier particles and the catalyst 1,1-Azobis(cyclo-hexanecarbonitrile) (0.05% by
mass of MMA) which was mixed in a 70◦C water bath. This composition bears no resem-
blance to commercial PMMA bone cements and the catalyst and the method of mixing
is not relevant to orthopaedic cements. Many other studies employ diverse compositions
or do not specify the cement compositions used82, 188, 275. Another study using strontia
(SrO) in Simplex P, prepared cements with an identical composition to Simplex P and
only altered the amount of SrO and BaSO4
176. This study proved to be more effective
in identifying key changes as a result of replacing BaSO4 with SrO, however the study
was limited to the Simplex P formulations only and although carefully and thoughtfully
prepared, the homogeneity of the mixtures obtained cannot be compared to industrial
preparations due to the mixing/sterilization techniques employed. The work presented in
this chapter attempted to create a model cement with similar properties to two PMMA
bone cements currently used in orthopaedics. The model cement is intended to allow for
novel materials to be tested in an unbiased way, whilst still providing results which may
be compared to commercial cements.
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The formulation of the model cement was selected as it incorporated characteristics of
many different commercial cements. For example, a poly(methyl methacrylate/methyl
acrylate) copolymer was used for the model cement as is employed in Palacos R. Similarly
a powder to liquid ratio between that of Palacos R and Cemex was used. BaSO4 was used
as the radiopacifier instead of ZrO2 as the majority of commercial cements use BaSO4.
Combining these specific attributes has resulted in a model cement with average properties
between what can be considered a mechanically “good” cement and a “poor” cement.
Palacos R was found to have a shorter setting time than Cemex in this study. This
does not correspond with the datum from the manufacturers which shows Palacos R to
have a longer setting time. This may be attributed to the methods employed by the man-
ufacturers to determine setting times. As claimed by Tecres, the setting temperature of
Cemex was much lower than Palacos R, due to the lower quantity of MMA employed.
The results for the mechanical properties obtained for Cemex and Palacos R correlate
well with results from previous literature74, 222. There was a positive correlation between
log ∆K and log da/dN for all fatigue results and the shape of the curves agrees with other
studies58,82. As demonstrated in the results, the copolymer used in Palacos R enhanced
bending and fatigue properties when compared to Cemex bone cement. As discussed in
Chapter 1 copolymers prevent brittle fracture and make the cement less susceptible to
stress raisers. This is clear in the model cement and Palacos R where many small cracks
or crazes were observed as opposed to Cemex where a few large cracks were seen, par-
ticularly around pores. The positive effect of copolymers is further highlighted by the
fact that both the model cement and Palacos R had better fatigue properties than Ce-
mex. This is as a result of crazing mechanisms in the bulk of the cement, encouraged
by the copolymer, which caused crack propagation to occur only at the higher levels of
stress. Shear bands were also visible on the fracture surface of Palacos R, demonstrat-
83
Chapter 3. Commercial and model cements
ing a further toughening mechanism. The lack of copolymer in Cemex may have created
stress concentrations around the pores, resulting in crack initiation and weakening of the
cement. The pores however, may have also caused crack pinning, blunting the crack tip
and retarding crack growth. Although the effect of these pores is not well understood
and there is a clear difference in porosity between the commercial and model cements,
studies have shown that small sub-millimeter spherical pores as seen in the images, do not
affect the fatigue behaviour of sharp notched specimens34 and are of limited significance
compared to other stress concentrations such as agglomerations of radiopacifier particles60.
Although the use of a copolymer appears to enhance the mechanical and fatigue per-
formance of the model cement and Palacos R, the use of BaSO4 as a radiopacifier in the
model cement seems to be a limiting factor on its performance. The use of BaSO4 coupled
with the same copolymer and a similar powder to liquid ratio as Palacos R did not yield
results comparable to Palacos R. Furthermore the use of copolymers can be detrimental
to the compressive strength of the cement, however Palacos R still achieved the highest
compressive strength. Therefore it can be speculated that the radiopacifier has a critical
effect on the properties of the cement and may be key to improving the cement. Several
other authors have reached similar conclusions82, 83, 91, 92, 95.
Another key parameter is the amount of MMA used. Palacos R had the greatest MMA
content and as a result had the highest setting temperature and shortest curing time.
Furthermore PMMA beads were not visible on the fracture surfaces of Palacos R whilst
they were clearly present in the model cement and Cemex fracture surfaces. It can be
speculated that the slightly higher amount of MMA used in Palacos R may lead to higher
levels of dissolution of PMMA beads in MMA during mixing and curing. As Cemex and
the model cement had less MMA, the PMMA beads were more visible. The presence
of BaSO4 around the PMMA may have also contributed to the enhanced visibility of the
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PMMA beads on the SEM images of the fracture surfaces. Although the size of the PMMA
beads were similar for both commercial cements, the morphology differed. This however,
did not affect the propagation of the crack as the fracture was found to grow through the
PMMA beads for both cements.
Overall the properties and characteristics of commercial cements have been investigated
and can be used for reference in future chapters and studies. Similarly a model cement
has been developed, which will allow for the effect of novel additives to be investigated.
3.5 Conclusions
A model cement with similar properties to both Palacos R and Cemex bone cement has
been successfully developed. Although not all properties were found to fall between the
values of the two commercial cements (bending modulus and ‘m’ constant for fatigue), the
majority of properties achieved the required criteria. Furthermore, fatigue fracture sur-
faces demonstrated the model cement to have attributes from both Palacos R and Cemex.
Therefore, the model cement is thought to represent effectively a wide range of properties
found in most commercial cements.
Several examples of toughening mechanisms were also observed on the fracture surfaces
of the commercial cements, proving such mechanisms are beneficial to the performance
of the cement. Having established that the radiopacifiers used can limit the performance
of a cement composition, it is now possible to use alternative radiopacifiers in the model
cement in an attempt to improve bone cement performance.
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Development of novel radiopacifiers
4.1 Introduction
Radiopacifiers such as barium sulphate (BaSO4) and zirconium dioxide (ZrO2) are incor-
porated into bone cements to permit the inspection of cement integrity non-invasively. It
is disputed whether such materials could have a detrimental effect on the performance
of the cement60, 66, 82, 83, 88, 91, 92, 95 . Titanium dioxide (TiO2) has the potential for use as
a radiopacifier because of its biocompatibility, capacity to attenuate X-rays as a solid
metal, and its ability to encourage bone growth276. The anatase form of TiO2 is of par-
ticular interest as several studies have shown it to be highly beneficial to bone growth
and osseointegration277–279. Yttria-stabilised ZrO2, which has a transformation toughen-
ing mechanism, and is used in ceramics, may also be a suitable radiopacifier. Following
on from the development of a model cement in Chapter 3, both can now be tested as
alternative radiopacifiers and this is considered in this chapter.
4.1.1 Radiopacifiers as functional fillers
The primary function of a radiopacifier in bone cement is to attenuate X-rays and allow
for the non-invasive inspection of the cement. The presence of these materials may also
enhance the stiffness and strength of the cement and therefore are thought to have a sec-
ondary function. Authors have reported a moderate increase in toughness when using
rigid-particles in polymers83, 173. Since rigid particles do not deform under stress it is
initially difficult to understand how rigid particles can contribute to an increase in tough-
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ness. It is hypothesised however, that the presence of rigid particles induces a toughening
mechanism in the polymer matrix. As described in Chapter 3, crack branching and crack
deviation also toughens materials and a dispersion of rigid particles can potentially induce
this behaviour. Bartczak et al.280 demonstrated that when the distance between rigid
particles is lower than a critical value, polymer crystallites orient preferentially on the
surface of those rigid particles, leading to higher levels of toughness. As the rigid particles
do not cavitate, debonding from the polymer matrix occurs. Debonding and stretching of
the polymer matrix requires high levels of energy which also makes the material tougher.
The degree of toughness is governed mainly by the adhesion between the rigid particle and
the polymer matrix and also the dispersion of the particles as agglomerations have been
known to act as points of high stress concentration.
4.1.2 Barium sulphate
Barium sulphate (BaSO4) is a radiopacifier commonly used in bone cements due to its
ability to effectively attenuate X-rays. BaSO4 is an insoluble salt used clinically as an
orally administered radioconstrast agent. Although barium itself is a toxic heavy metal,
the insolubility of BaSO4 prevents harmful amounts of the metal being absorbed and
allows for easy removal from the body. This makes BaSO4 non-toxic and biocompatible
for use in bone cement. Nevertheless, BaSO4 has been known to weaken bone cement,
particularly when agglomerated, as it may act in a similar way to a pore due to its low
mechanical strength and therefore present as a site for potential crack initiation94.
4.1.3 Zirconium dioxide
Zirconium dioxide (ZrO2, otherwise known as zirconia or zirconium oxide) is a material
commonly used in ceramics and polymers as a rigid-particle filler to help strengthen and
improve material properties. This arises from its high strength and toughness, chemical
and wear resistance, and the structural transformations ZrO2 undergoes during heating.
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When heated from room temperature to 950oC, ZrO2 adopts a monoclinic crystal structure
(Figure 4.1(a)). Above 950◦C it converts to tetragonal (Figure 4.1(b)) and later cubic
(Figure 4.1(c)), which is accompanied by a 1-4% volume reduction. Usually when cooled,
it returns to a monoclinic structure, however the addition of oxides (magnesium oxide
(MgO), yttrium oxide (Y2O3), calcium oxide (CaO) or cerium oxide (Ce2O3)) results in
a stable tetragonal state at room temperature. Each tetragonal ZrO2 precipitate is under
stress and full of strain energy. When a crack tip approaches the ZrO2 particle, it expands
and transforms back into the monoclinic phase, releasing energy and applying compression
to the crack tip. This mechanism is known as transformation toughening and triggers a
uniform distribution of low level internal strain within the bulk of the material. ZrO2 is
currently used in certain commercial bone cements, however the use of yttria-stabilised
ZrO2 as a radiopacifier has yet to be evaluated.
(a) Monoclinic (b) Tetragonal (c) Cubic
Figure 4.1: Crystal structures of ZrO2
4.1.4 Titanium dioxide
Titanium dioxide (TiO2, otherwise known as titania or titanium(IV) oxide) is a naturally
occuring oxide of titanium also used as a rigid-particle filler for its high refractive index,
electrical properties and mechanical properties. It is used in medical implants due to
its biocompatibility and ability to interact with bone. TiO2 is an inexpensive, non-toxic,
thermally-stable and photostable material. The surface of TiO2 itself is hydrophilic due to
the presence of a charged oxide layer which makes it suitable for surface treatments. When
used in polymers, changes to the material properties are dependent upon the composition,
size and concentration of the TiO2 particles.
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4.1.5 X-ray imaging
Incorporating radiopacifiers into bone cements allows X-ray imaging techniques to be car-
ried out to assess potential problems in vivo in a minimally invasive manner. Radiopacifiers
attenuate and absorb X-rays which produces an image according to the level of absorption
and attenuation that takes place. The ability of a radiopacifier to attenuate and absorb
X-rays is governed by its atomic number and density, which in turn affects what are
known as its mass attenuation coefficient and mass energy absorption coefficient281. The
mass attenuation coefficient is a measure of the total loss of X-ray intensity due to both
scattering and absorption, whereas the mass energy absorption coefficient is a measure of
loss of X-ray intensity caused by absorption only. Therefore using the mass attenuation
coefficient is more useful when studying the radiopacity of a material. Both coefficients
however are dependent upon the energy levels employed by the imaging equipment. This
is shown in Figures 4.2 and 4.3 for PMMA, barium, titanium and zirconium. Beyond
energy levels of around 15keV PMMA is no longer capable of attenuating or absorbing
X-rays, highlighting the need for a radiopacifier.
Figure 4.2: Attenuation spectra for Barium, Titanium, Zirconium and PMMA
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Figure 4.3: Absorption spectra for Barium, Titanium, Zirconium and PMMA
X-rays performed clinically employ an energy level of 70keV, 63mAs to minimise the ra-
diation dose given to a patient. Figure 4.2 can be used to deduce the mass attenuation
coefficient (µm) of a material at 70keV. For example, barium at 70keV has a mass attenu-
ation coefficient (µm) of approximately 10cm
2/g. This value multiplied by the density of
the material (ρ) provides the linear attenuation coefficient (µl). The negative exponential
function of the product of the linear attenuation coefficient (µl) and the thickness of the
sample (e) will provide a ratio of the X-ray intensity that will pass through the material
(I) from the original X-ray intensity transmitted (Io) as demonstrated in Equation 4.1. It
is therefore possible to theoretically deduce the intensity of X-rays that are transmitted
through certain materials. This provides a measure of how effectively a material attenuates
and absorbs X-rays282.
I
Io
= exp(−µle), µl = (µm)ρ (4.1)
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Table 4.1 shows the calculated I values for barium, titanium, zirconium and PMMA at
two different X-ray intensity settings. At a clinical setting (70keV) barium (I=1.3× 10−6)
will provide the best contrast and radiopacity followed by zirconium (I=36.4× 10−6), tita-
nium (I=7.9) and PMMA (I=60.7), which only attenuates around 20% of the transmitted
X-ray. At 35keV however, a setting which is employed for research and analytical pur-
poses, zirconium (I=2.0× 10−50) would perform best followed by barium (I=9.2× 10−10),
titanium (I=3.3× 10−6) and PMMA (I=25.5). This is a theoretical approximation which
assumes unit thickness for the material and only considers elemental materials as opposed
to compounds.
Table 4.1: Transmitted intensity values at varying energy levels
Material
Original
Intensity
(Io) /keV
Density
(ρ)
/gcm−1
Mass
attenuation
coefficient
(µ/ρ) /cm2/g
Linear
attenuation
coefficient (µ)
/cm−1
Material
thickness
(e) /cm
Transmitted
Intensity (I)
/keV
Barium
70
3.5
5.1 17.9
1
1.3× 10−06
35 6.9 24.4 9.2× 10−10
Titanium
70
4.5
0.5 2.3
1
7.9
35 3.6 16.2 3.3× 10−06
Zirconium
70
6.5
2.2 14.5
1
3.6× 10−05
35 18.1 118.0 2.0× 10−50
PMMA
70
1.18
0.2 0.2
1
60.7
35 0.3 0.3 25.5
4.1.6 Thermal conductivity and heat transfer
Metal oxides are known to enhance the thermal conductivity of polymers283–286. The use
of radiopaque agents with a high thermal conductivity (e.g. TiO2, Table 4.2) in PMMA
will result in an increase in the thermal conductivity of the polymer. If well-dispersed, the
radiopacifier may prevent areas of local heat concentration by spreading and dissipating
heat. This may result in lower setting temperatures and less heat induced stresses on the
cement.
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Table 4.2: Thermal conductivity and expansion of radiopacifier materials
Material
Thermal
conductivity /
W/mK
Coefficient of
thermal expansion /
K−1
aPMMA 0.17 - 0.19 70-77×10−6
bBaSO4 1.72 10×10−6
aZrO2 2.50 10×10−6
aTiO2 2.50-5.00 8-9×10−6
Note: Data obtained from (a) www.goodfellow.com and (b) Weidenfeller et al.286
After the peak setting temperature is reached, the bone cement cools and decreases in
volume. This is caused by the volumetric contraction of the polymer chains during poly-
merisation. When polymer molecules relax, shrinkage stresses can occur. The addition of
fillers helps to reduce shrinkage as they prevent the molecules from relaxing during cool-
ing287, 288. Filler particles also reduce shrinkage due to the significantly lower coefficient of
thermal expansion, which results in smaller volume changes with changing temperatures.
4.2 Methods
4.2.1 Materials
Anatase TiO2, yttria-stabilised ZrO2 , methyl methacrylate with 75ppm hydroquinone,
N-N dimethyl-p-toluidine and benzoyl peroxide were obtained from Sigma Aldrich (Gilling-
ham, UK) and BaSO4 was obtained from Fisher Scientific UK (Leicestershire, UK). Poly-
methyl methacrylate powder with a methylacrylate copolymer (Colacryl TS1713) was
provided by Lucite International UK (Southampton, UK).
4.2.2 Particle Sizing
The particle size distributions of BaSO4, anatase TiO2 and yttria-stabilised ZrO2 were
examined using a Malvern Mastersizer X (Malvern Instruments Ltd, Worcestershire, UK)
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attached to an ultrasonic bath mixer. A small sample of the radiopacifier was added
to deionised distilled water in the ultrasonic bath mixer. This disperses the particles,
preventing agglomeration in order to obtain accurate size readings. The solution was then
pumped into the Mastersizer X and the particle size distributions were obtained by laser
diffraction.
4.2.3 Mechanical testing
Compression, bending and fracture toughness samples were prepared and tested as stated
in Chapter 2. Data on the properties of commercial Cemex Isoplastic, Palacos R and the
model cement were used from Chapter 3. Model cement samples without any radiopaci-
fier (radiolucent) and model cement samples containing 5 to 25%w/w of the different
radiopacifiers (TiO2 and ZrO2, Table 4.3) were prepared and tested.
Table 4.3: Composition of tested bone cements
Radio
-lucent
Model
cement
5%
TiO2 or
ZrO2
10%
TiO2 or
ZrO2
15%
TiO2 or
ZrO2
20%
TiO2 or
ZrO2
25%
TiO2 or
ZrO2
Liquid component / g 16.93
Methyl Methacrylate
98.50
/ %w/w
N-N Dimethyl-p-Toluidine
1.50
/ %w/w
Hydroquinone
75.00
/ ppm
Powder Component / g 40.00
Polymethyl Methacrylate
98.30 88.30 93.30 88.30 83.30 78.30 73.30
/ %w/w
Barium sulphate
- 10.00 - - - - -
/ %w/w
Benzoyl Peroxide
1.70
/ %w/w
ZrO2 or TiO2 - - 5.00 10.00 15.00 20.00 25.00
/ %w/w
Powder : Liquid ratio 2.36
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4.2.4 Setting properties
Data from Chapter 3 on the setting time, setting temperature and maximum temperature
of commercial cements and the model cement were taken from Chapter 3. The radiolucent
model cement and model cement with 10%w/w TiO2 and 10%w/w ZrO2 were tested
according to Section 2.2.
4.2.5 Fracture toughness
Fracture toughness results for the commercial cements and the model cement were taken
from Chapter 3 and fracture toughness measurements were taken according to Section 2.4
for the model cement samples containing 0 to 25%w/w of the different radiopacifiers (TiO2
and ZrO2).
4.2.6 Fatigue testing
The fatigue properties of Cemex Isoplastic, Palacos R and the model cement have already
been determined in Chapter 3. The radiolucent model cement and model cement with
10%w/w TiO2 and 10%w/w ZrO2 were tested as described in Section 2.5. Two fatigue
samples for each cement type were tested.
4.2.7 SEM images
SEM images of the fracture surfaces of fatigue samples were taken to study surface rough-
ness and the presence of agglomerations, voids, pores and microstructure as described in
Section 2.8.
4.2.8 X-ray imaging
2±1mm thick by 10±1mm square samples of Cemex Isoplastic, Palacos R, the model
cement and model cement samples containing 0 to 25%w/w of the different radiopacifiers
(TiO2 and ZrO2) were prepared for the X-ray study. The dimensions were selected to
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represent the minimum cement mantle thickness usually found in vivo289. Two samples
for each test group were used and an energy level of 35keV, 150µA was employed in air.
Image analysis was carried out using ImageJ (National Institutes of Health, Maryland,
USA) to assess the optical density of samples in terms of average brightness of the image
picture elements (pixels). The results were obtained as mean grey values, ranging from
0 to 255, where 0 is black and 255 is white. A mean grey value of 255 would indicate
complete absorption of X-rays, whilst a value of 0 would indicate complete transmission.
4.3 Results
4.3.1 Particle size
Figure 4.4 shows the particle size distributions for the radiopacifiers tested. The median
diameters (D50) for BaSO4, TiO2 and ZrO2 were 2.72µm, 0.53µm and 0.74µm respectively.
Both TiO2 and ZrO2 had unimodal distributions whilst BaSO4 had a partially bimodal
distribution.
Figure 4.4: Particle size of BaSO4, TiO2 and ZrO2 in water
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4.3.2 Setting properties
Table 4.4 shows the setting properties of the commercial and novel bone cement formu-
lations. 10%w/w ZrO2 had the shortest setting time and highest setting and maximum
temperatures (similar to Palacos R), whilst Cemex had the longest setting time and lowest
setting and maximum temperatures. 10%w/w TiO2 and radiolucent cements had similar
setting properties and were found to have shorter setting times and higher temperatures
than the model cement.
Table 4.4: Setting properties of commercial bone cements, the model cement, radiolucent
cement and the cement with novel radiopacifiers
Setting time
(tset) / s
Setting
temperature
(Tset) /
◦C
Maximum
temperature
(Tmax) /
◦C
Cemex 738 46.5 69.8
Palacos R 479 52.1 78.5
Model cement 665 49.2 76.2
Radiolucent 615 51.4 81.6
10%w/w TiO2 631 52.9 82.1
10%w/w ZrO2 441 53.3 82.2
4.3.3 Mechanical properties
Compressive strength
Figure 4.5 shows the compressive strength for samples with varying amounts of TiO2 and
ZrO2. The model bone cement (with 10%w/w BaSO4) had a significantly higher compres-
sive strength over other formulations (ANOVA, p<0.05), whilst there were no significant
differences between Cemex bone cement and the different formulations (p=0.06). ZrO2
gave significantly higher values when compared with TiO2 at 5%w/w (p=7.52×10−05) and
15%w/w (p=0.03), however TiO2 was significantly stronger at 20%w/w (p=0.04). When
compared to radiolucent cement (0%w/w radiopacifier), 10%w/w (p=0.01) and 20%w/w
ZrO2 (p=0.01) and 20%w/w TiO2 (p=1.48×10−03) had significantly higher compressive
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Figure 4.5: Average compressive strength
strength, whilst the other formulations were found to have no significant difference. It
was expected that the compressive strength of bone cement would increase linearly with
increased radiopacifier content as the rigid particles would resist compression more effec-
tively. The results however, demonstrate that there is no linear relationship between the
percentage of TiO2 and ZrO2 in bone cement and compressive strength. Overall it can be
said that there were no improvements in compressive strength with the use of TiO2 and
ZrO2 as radiopacifiers when compared with BaSO4. Nevertheless, all cement formulations
were found to be above the ISO5833 minimum standard for compressive strength, demon-
strating that additives from 5%w/w to 25%w/w TiO2 and ZrO2 are suitable in terms of
compressive strength for bone cements.
Bending modulus and strength
Figures 4.6(a) and 4.6(b) show the bending modulus and bending strength respectively
for bone cements with varying amounts of TiO2 and ZrO2. There is a clear trend for both
TiO2 and ZrO2 where an increase in the percentage of radiopacifier used results in an in-
crease in bending modulus and a decrease in bending strength. TiO2 containing samples
had a significantly higher modulus after 10%w/w additive when compared to Cemex bone
cement (p<0.05). Bone cement with ZrO2 had a significantly higher modulus than Cemex
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(a) Bending modulus
(b) Bending strength
Figure 4.6: Average flexural properties
at 25%w/w (p=0.03). The addition of 5%w/w TiO2 or ZrO2 did not significantly affect
the bending modulus when compared to the radiolucent cement (0%w/w radiopacifier,
p=0.27 and p=1.00 respectively). The addition of 10%w/w or more TiO2 or ZrO2 sig-
nificantly increased the bending modulus (p<0.05). After 10%w/w or more radiopacifier,
TiO2 was found to have a significantly higher modulus than ZrO2 (p=3.31×10−03, p=0.04,
p=4.35×10−03 and p=0.01 for 10, 15, 20 and 25%w/w respectively).
Samples with no radiopacifier were found to have significantly higher bending strength
over Cemex (p=4.78×10−04), the model cement (p=2.54×10−04), cements with TiO2 and
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ZrO2 (p<0.05) and comparable bending strength to Palacos R. By adding only 5%w/w
TiO2 or ZrO2, a significant decrease in bending strength was observed (p=4.68×10−04
and p=1.10×10−03 respectively). Cemex was found to be significantly stronger when
compared to 25%w/w TiO2 samples (p=0.01) and the model cement was significantly
stronger than samples with 25%w/w TiO2 (p=0.03). Overall ZrO2 samples demonstrated
enhanced bending strength when compared with TiO2 as 15%w/w and 20%w/w ZrO2 was
significantly stronger than the same composition of TiO2 (p=7.73×10−03 and p=0.04 re-
spectively). All samples were found to have bending moduli above the ISO5833 minimum
requirement, however TiO2 and ZrO2 containing samples failed to meet the minimum
requirement of 50MPa for bending strength.
Fracture toughness
There was a gradual reduction in fracture toughness with increased TiO2 content in the
bone cement (Figure 4.7). This however does not occur with ZrO2 possibly as a result of
the toughening mechanism of yttria-stabilised ZrO2. When compared to Cemex in terms
of critical stress intensity factor, all TiO2 and ZrO2 samples showed significant (ANOVA,
p<0.05) improvements with the exception of 25%w/w formulations (p=0.33). There were
no significant differences between the model cement and samples containing TiO2 and
Figure 4.7: Average fracture toughness
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ZrO2 (p>0.05). When compared to radiolucent cement (0%w/w radiopacifier), all the
samples experienced a reduction in critical stress intensity factor, however the reduction
was only significant for 25%w/w ZrO2 (p=0.01) and 15%w/w or more TiO2 samples
(p=7.25×10−04, p=5.61×10−04 and p=4.67×10−04 for 15, 20 and 25%w/w respectively).
4.3.4 Fatigue
Figure 4.8 and Table 4.5 show the fatigue testing results and the analysis when the Paris
Law262 was applied to the data respectively. 10%w/w ZrO2 performed most poorly in
fatigue even though the yttria stabilisation should have enhanced its crack resistance.
The use of 10%w/w TiO2 also reduced the fatigue properties when compared to the model
cement and the commercial cements, however a moderate improvement was observed in
the ‘A’ coefficient when compared to radiolucent (0%w/w raciopacifier) cement. A great
deal of variance in crack growth per cycle for the 10%w/w TiO2 cement was observed
when compared to the model and commercial cements. This is shown in Table 4.5 by the
lower correlation coefficient when the Paris Law was applied.
Figure 4.8: Fatigue results for commercial, model and novel cements
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Table 4.5: Fatigue constants of commercial, model and novel cements, where ‘A’ is the
crack growth at ∆K=1MPam1/2 and ‘m’ is the slope of the data
A m
Correlation
coefficient
Palacos R 3.73×10−07 4.65 0.61
Cemex 5.39×10−07 5.92 0.82
Model cement 4.83×10−07 3.73 0.67
0%w/w radiopacifier 3.53×10−06 5.49 0.69
10%w/w TiO2 3.00×10−06 6.03 0.57
10%w/w ZrO2 6.92×10−05 6.88 0.73
4.3.5 SEM
Figure 4.9 shows large agglomerations of radiopacifiers. The agglomerations ranged from
20 to 200µm in length, up to a hundred times the size of the individual radiopacifier
particles. Agglomerations of this size were not expected, given the particle sizing results.
Surrounding the agglomerations were large voids, possibly caused by the absorption of
MMA monomer or caused by the deformation of the polymer matrix around the rigid
particle during fracture. Such void formation is expected to reduce the bending strength
and fracture toughness of the cement.
(a) 10%w/w BaSO4 (b) 10%w/w TiO2 (c) 10%w/w ZrO2
Figure 4.9: Void formation around agglomerations of radiopacifiers - Red arrows indicate
PMMA beads, green arrows indicate radiopacifier particle agglomerations, blue arrows
indicate pores and voids and white arrows indicate microcracks
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When comparing the different radiopaciers, BaSO4 samples were found to have rougher
fracture surfaces than TiO2 and ZrO2 samples (Figure 4.10). This demonstrates enhanced
crack resistance in BaSO4 samples, whilst TiO2 and ZrO2 samples were found to fracture
in a more brittle manner.
(a) 10%w/w BaSO4 (b) 10%w/w TiO2 (c) 10%w/w ZrO2
Figure 4.10: Surface roughness of fractures - Red arrows indicate PMMA beads, green
arrows indicate radiopacifier particle agglomerations, blue arrows indicate pores and voids
and white arrows indicate microcracks
4.3.6 Radiopacity
Figure 4.11 shows the calculated mean grey values for X-ray imaging at 35keV, 150µA. An
ANOVA (p<0.05) found that there were no significant differences between formulations
with 10%w/w or more radiopacifier and the commercially available and model cements
(p=0.15). There was however, a significant difference between the samples without any
Figure 4.11: Mean grey values of X-ray images
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radiopacifier (radiolucent) and all other cement samples (p<0.05). It was expected that
the radiolucent cement would produce lower grey values, demonstrating PMMA has a
natural opacity under X-ray imaging at 35keV. This may not be the case at higher clinical
settings (70keV).
4.4 Discussion
The use of radiopacifiers in PMMA bone cement is essential for the examination of cement
integrity in vivo, however the radiopacifier may have a possible effect on the mechanical
and fatigue performance of bone cement. BaSO4, which is widely utilised by bone cement
manufacturers, is known to agglomerate24 , in turn negatively affecting the performance
of the cement82–84. Anatase TiO2 and yttria-stabilised ZrO2 have been incorporated into
the model cement, developed in Chapter 3, in an effort to overcome the problems asso-
ciated with conventional bone cements. The use of TiO2 in orthopaedic implants is well
documented, however few studies have attempted to use powdered anatase TiO2 as a ra-
diopacifier in PMMA bone cement. On the contrary the use of ZrO2 in PMMA to improve
material properties is widely recognised in both bone and dental cements; the ZrO2 used in
this study was yttria-stabilised, which is claimed to benefit fracture toughness properties.
The particle size distributions of the anatase TiO2 and yttria-stabilised ZrO2 used were
found to be very similar whilst the results for the BaSO4 used in the model cement indicate
a larger particle size. It is possible that the larger particle size and bimodal distribution
experienced by the BaSO4 could be a result of agglomerating BaSO4 particles in distilled
water. The plateau experienced at lower particle sizes either indicate that the BaSO4 used
has a wide particle size distribution or simply that few non-agglomerated particles were
detected.
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The higher thermal conductivity of anatase TiO2 did not improve the setting properties
and heat dissipation of bone cement. This may be attributed to poor dispersion of the
radiopacifier or that the differences in thermal conductivity are not sufficient to induce im-
provements in the setting properties. Furthermore, the changes in thermal conductivity ob-
served in the literature correspond to higher levels of metal oxide fillers (≃40%w/w)283–286.
Chou et al.178 found the peak setting temperature of bone cement to reduce with increased
filler loading. It is possible that higher quantities of radiopacifier may be required before a
change is observed. Nevertheless the setting properties were changed when using 10%w/w
yttria-stabilised ZrO2. The properties were found to be similar to that of Palacos R,
which also uses ZrO2 as a radiopacifier. It is hypothesised that ZrO2 interacts with, and
affects, the polymerisation reaction of bone cement, however the mechanisms affecting the
reaction are not understood. It is speculated that the polymer orientates itself on the
surface of the ZrO2 particle when polymerising. If this is the case, the change in setting
properties observed may be linked to the specific surface properties, which are governed
by the surface oxides and crystal structure of ZrO2.
The increase in modulus that was experienced as a result of higher levels of radiopaci-
fier can be linked to the fact that stiffer particles have replaced a portion of the PMMA
powder in the compositions used. The results show that the amount of rigid particles used
is directly proportional to the final bending modulus obtained and in the case of TiO2,
inversely proportional to the bending strength. Therefore high percentages of TiO2 or
ZrO2 make bone cement more brittle. Similar studies by Fukuda et al.
178, 180, 290 found
the same trend. Values from these studies were much higher than the values obtained in
this study as the cement was different in composition to commercial cements as it had
significantly lower quantities of PMMA and the PMMA beads were a different size.
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It is speculated that poor adherence between the TiO2/ZrO2 particles and the polymer
matrix has caused the decrease in bending strength. The rigid particle filler can eas-
ily be detached under strain, creating microvoids between the particle and the polymer
matrix, weakening the cement. As discussed, the thermal coefficient of expansion of the
radiopacifiers used are significantly higher than that of PMMA. This may have induced
cracking and void formations as the PMMA expanded and contracted at a higher rate
than the radiopacifier, weakening the cement. Particle size has also been known to affect
flexural properties as larger particles are unable to deform and therefore create greater
stress concentrations. The reduction in strength of the novel formulations with increased
radiopacifier content may also be caused by agglomerations.
The anticipated transformation-toughening mechanism of yttria-stabilised ZrO2 did not
improve the fracture toughness of the cement. Again, this may be as a consequence of poor
dispersion and particle adhesion to the polymer matrix. Similarly, yttria-stabilised ZrO2
was expected to improve fatigue properties, however closer examination of the fracture
surfaces revealed highly agglomerated radiopacifier particles for both TiO2 and yttria-
stabilised ZrO2. In previous studies agglomerations of radiopacifiers have been found to
be detrimental to the fatigue life of bone cements35, 66, 91–95. Further, the addition of stiff
radiopacifiers appears to have made the cement fail in a more brittle manner.
In terms of radiopacity, in theory ZrO2 containing cements were expected to be the most
radiopaque at 35keV, but the differences observed were not significant. The theoretical
calculations only accounted for elemental metals and not compounds such as the metal
oxides used. The low percentages of radiopacifiers tested in PMMA would also make
subtle differences in the radiopacity of the various materials difficult to distinguish. It is
clear that in order to obtain similar radiopacity as the commercially available cements, a
minimum of 10%w/w anatase TiO2 or yttria-stabilised ZrO2 is required.
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4.5 Conclusions
Overall the the novel radiopacifiers tested did not improve the mechanical, fatigue and
setting properties of the model cement. Furthermore, certain properties were found to be
poorer when using high percentages of anatase TiO2 and yttria-stabilised ZrO2. 10%w/w
radiopacifier was found to provide sufficient radiopacity without significantly compromis-
ing many of the material properties.
Yttria-stabilised ZrO2 did not improve the fracture toughness or fatigue properties of
the cement and affected the setting properties. Anatase TiO2 had suitable setting proper-
ties, however it did not demonstrate any significant improvement in terms of mechanical
and fatigue properties. It should be recognised however, that anatase TiO2 still may have
potential as a radiopacifier due to its ability to enhance bone growth and osseointegration.
Further, it is clear that agglomerations and poor bonding of radiopacifier particles to the
polymer matrix are problems that must be overcome in order to improve the properties
of bone cement. A potential method to overcome these limiting features was investigated
in the following chapter.
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Chapter 5
Improving radiopacifier dispersion
and adhesion
5.1 Introduction
Radiopacifier agglomerations and poor adhesion between the radiopacifier particles and
the polymer matrix is suspected to weaken bone cement. To ensure that the radiopaci-
fier particles toughen the cement effectively, they must be well-dispersed throughout the
cement and must be sufficiently well bonded to the polymer matrix to induce toughening
mechanisms. The use of silane coupling agents may help achieve this.
Silane coupling agents (herein referred to as silanes) are solutions that have the abil-
ity to form durable bonds between organic and inorganic materials. These bonds modify
the wetting and adhesion characteristics of the substrate used (e.g. the radiopacifiers). In
general, silanes are composed of an organofunctional group, a linker, a silicon atom and a
hydrolyzable group as shown in Figure 5.1185.
Figure 5.1: Silane structure
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A silane couples to the substrate in four steps (Figure 5.2):
1. Hydrolysis of the 3 labile groups occurs.
2. Condensation to the oligomers follows.
3. Oligomers then hydrogen bond with hydroxyl groups on the substrate surface.
4. Finally during drying and/or curing, a covalent linkage is formed with the substrate
with concomitant loss of water.
Figure 5.2: Hydrolytic deposition of silanes
The latter 3 steps can occur simultaneously after the initial hydrolysis event. At the inter-
face there is usually only one bond from each silicon atom to the substrate surface. The R
group remains available for covalent reaction or physical interaction with other phases. It
should be noted that these steps represent hydrolytic deposition of silanes and therefore
water is required for the process to take place. Water may be added or may come from
the substrate surface or the surrounding atmosphere. The degree of polymerisation is de-
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termined by the amount of water available, the organic substituent and the concentration
of silicon atoms. Factors which may influence the effectiveness of silane coupling agents
include the concentration of surface hydroxyl groups; the type of surface hydroxyl groups;
the hydrolytic stability of the bond formed and the physical dimensions of the substrate
or substrate features.
The linker length of the silane also imposes a number of physical properties. If the linker
length is long, the functional group has greater mobility and extends farther from the
inorganic substrate. Furthermore a longer linker length will increase the distance between
adjacent particles improving dispersion characteristics.
TiO2 and ZrO2 have hydrolytically stable surface oxides, however the oxidised surface
has sufficient hydroxyl functionality to allow coupling by the hydrolytic deposition pro-
cess outlined.
A methacrylate based functional silane was selected for this study, methacryloxypropy-
ltrimethoxysilane (also known as 3-(trimethoxysilyl)propyl methacrylate); this has been
employed as a coating for implants in studies investigating the surface adhesion be-
tween bone cement and metallic implants134,291. The structure of methacryloxypropy-
ltrimethoxysilane is shown in Figure 5.3. As this particular silane has three carbon atoms
between the functional group and the silicon atom, it is a gamma substituted silane, which
is thermally stable up to 350◦C in the short term and 160◦C in the long term and there-
Figure 5.3: Methacryloxypropyl trimethoxysilane
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fore, the silane will not be affected by the exothermic polymerisation reaction of bone
cement and the temperatures experienced in-vivo. This particular silane has a toxicity
similar to that of MMA (LD50>3000mg/Kg) and will only be present in small quanti-
ties185. Therefore it should not significantly alter the toxicity of PMMA bone cements;
this will be investigated in Chapter 6.
5.2 Methods
5.2.1 Materials
Methacryloxypropyltrimethoxysilane, HPLC grade ethanol (≥99.8%), anatase TiO2, yttria-
stabilised ZrO2 , methyl methacrylate with 75ppm hydroquinone, N-N dimethyl-p-toluidine
and benzoyl peroxide were obtained from Sigma Aldrich (Gillingham, UK). Whatman
grade 6 filters (185mm diameter) were purchased from Fisher Scientific UK (Leicester-
shire, UK). Polymethyl methacrylate powder with a methylacrylate copolymer (Colacryl
TS1713) was provided by Lucite International UK (Southampton, UK).
The model cement formulation was used when making cement samples, however the
10%w/w BaSO4 was replaced with either 10%w/w silane-treated TiO2 or 10%w/w silane-
treated ZrO2. The silane-treated oxides were added to the liquid component of the ce-
ment (MMA) to improve dispersion. 10%w/w silane-treated radiopacifier was selected
as the results from the previous chapter show 10%w/w radiopacifier to provide sufficient
radiopacity without significantly compromising mechanical properties.
5.2.2 Silane treatment
The procedure used to treat the radiopacifier particles is based on industrial processes
used to coat metallic surfaces and glassware185, 292. The radiopacifiers treated with the
silane were anatase TiO2 and yttria-stabilised ZrO2.
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A 100mL solution of 95% ethanol, 5% distilled water was produced for 5g of radiopacifier
powder. Acetic acid was used to adjust the pH to 4.5-5.5. The silane (methacryloxypropy-
ltrimethoxysilane) was added at a 2%v/v concentration and allowed to hydrolyse at room
temperature for 5 minutes. The radiopacifier powder was added and the solution was
stirred using a magnetic stirrer for 24 hours. The solution was allowed to settle and the
upper clear layer decanted. The remaining solution was filtered through a funnel with a
Whatman grade 6 filter. The slurry was rinsed twice briefly with ethanol to remove any
excess unreacted silane before drying in an oven at 80◦C for 24 hours. Once dried the
powder was crushed using a pestle and mortar and put through a 30-mesh sieve followed
by a 300 mesh sieve to ensure a powder size of less that 50µm. The powder was then
dispersed in the liquid component of the cement (MMA).
5.2.3 FTIR of treated radiopacifiers
To characterise and assess the success of the treatment process, fourier transform infrared
spectroscopy (FTIR) was used. Potassium bromide (KBr) discs containing the radiopaci-
fier powders were prepared as described in Chapter 7 and the spectra obtained using a
Perkin Elmer Spectrum One FT-IR Spectrometer with FT-IR Spectrum software (Perkin
Elmer, Massachusetts, USA) at the Cardiff School of History, Archaeology and Religion.
TiO2, ZrO2, silane-treated TiO2, silane-treated ZrO2 and the silane alone were scanned
from 4000cm−1 to 450cm−1 at a resolution of 4cm−1.
5.2.4 Setting properties
The setting properties for commercial cements and model cements containing 10%w/w
TiO2 and 10%w/w ZrO2 were previously determined in Chapters 3 and 4. Setting prop-
erties for 10%w/w silane-treated TiO2 and 10%w/w silane-treated ZrO2 were measured
according to Section 2.2.
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5.2.5 Mechanical testing
Compression and bending test samples with 10%w/w silane-treated TiO2 and 10%w/w
silane-treated ZrO2 were prepared as described in Sections 2.3.1 and 2.3.2. Results were
taken from Chapters 3 and 4 for comparison.
5.2.6 Fracture toughness
Fracture toughness values for commercial cements, the model cement and cements con-
taining 10%w/w TiO2 and 10%w/w ZrO2 were previously determined in Chapters 3 and
4. Fracture toughness values for 10%w/w silane-treated TiO2 and 10%w/w silane-treated
ZrO2 were obtained as described in Section 2.4.
5.2.7 Fatigue
Fatigue tests were carried out as outlined in Section 2.5 for both silane-treated oxides.
Data for commercial cements, the model cement and cements containing 10%w/w TiO2
and 10%w/w ZrO2 were obtained from Chapters 3 and 4.
5.2.8 SEM images
SEM images for the fatigue samples were obtained as described in Section 2.8 in order to
study radiopacifier dispersion, voids, porosity and fracture characteristics. SEM images
of samples containing 10%w/w TiO2 and 10%w/w ZrO2 were taken from Chapter 4.
5.3 Results
5.3.1 FTIR analysis of treated radiopacifiers
Figure 5.4 shows the FTIR spectra for silane-treated TiO2 and ZrO2. Both radiopacifiers
appear to have been successfully treated as both oxide particle spectra were found to
contain similar peaks to the silane. The most prominent peaks were the C=O bond
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(a) Silane-TiO2
(b) Silane-ZrO2
Figure 5.4: FTIR of silane-treated radiopacifiers using KBr discs
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stretch at 1730cm−1, the C=C stretch at 1600cm−1, the C-O-C and CH3 peaks around
1300cm−1 and the two peaks at 1100cm−1 and 1200cm−1 associated with silicon. The
intensity of the silane-treated TiO2 was found to be greater than that obtained from the
silane-treated ZrO2. Both samples also show characteristics of their original untreated
material in the form of a small broad peak at around 1600cm−1 and a drop in intensity
for wavelength values below 900cm−1.
5.3.2 Setting properties
Table 5.1 shows the setting properties for the commercial bone cements, the model ce-
ment, radiolucent cement and the cement with treated and untreated novel radiopacifiers.
The cements containing silane-treated radiopacifiers gave similar results to the cements
with untreated radiopacifiers. A slight reduction in the setting temperature and maxi-
mum temperature was observed with the silane-treated 10%w/w TiO2 when compared to
10%w/w TiO2; whilst a significant reduction was observed when comparing silane-treated
10%w/w ZrO2 and 10%w/w ZrO2. A slight reduction in the setting time was observed
when silane-treated 10%w/w TiO2 was used and there was no significant change in setting
time for silane-treated 10%w/w ZrO2
Table 5.1: Setting properties of commercial bone cements, the model cement, radiolucent
cement and the cement with untreated and silane-treated novel radiopacifiers
Setting time
(tset) / s
Setting
temperature
(Tset) /
◦C
Maximum
temperature
(Tmax) /
◦C
Cemex 738 46.5 69.8
Palacos R 479 52.1 78.5
Model cement 665 49.2 76.2
Radiolucent 615 51.4 81.6
10%w/w TiO2 631 52.9 82.1
Silane-10%w/w TiO2 579 51.0 79.6
10%w/w ZrO2 441 53.28 82.2
Silane-10%w/w ZrO2 442 46.1 69.1
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5.3.3 Mechanical testing
Figure 5.5 shows the average compressive strength values for commercial cements, 10%w/w
TiO2 and ZrO2, and silane-treated 10%w/w TiO2 and ZrO2. An ANOVA (p<0.05)
found that the silane-treated 10%w/w TiO2 and ZrO2 had significantly higher compres-
sive strength than their untreated counterparts (p=3.94×10−06 and p=4.57×10−04 re-
spectively). Silane-treated 10%w/w TiO2 had significantly higher compressive strength
than all the cements (p<0.05) except Palacos R (p=0.50) which was found to be com-
parable. Silane-treated ZrO2 had significantly higher compressive strength than Cemex
(p=9.64×10−04), 10%w/w TiO2 (p=4.04×10−05) and 10%w/w ZrO2 (p=4.57×10−04) but
significantly worse when compared to Palacos R (p=7.45×10−04).
Figure 5.5: Average compressive strength
The bending modulus of silane-treated 10%w/w TiO2 was significantly higher than all the
other cement formulations (p<0.05), as shown in Figure 5.6(a). There was no significant
difference in modulus when using silane-treated ZrO2 over untreated ZrO2 (p=0.46), how-
ever silane-ZrO2 was found to have a significantly lower bending modulus than Palacos R
(p=0.02) and 10%w/w TiO2 (p=6.32×10−05).
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(a) Bending modulus
(b) Bending strength
Figure 5.6: Average bending properties
Figure 5.6(b) shows the bending strength for the tested bone cement formulations. Silane-
treated 10%w/w TiO2 had a significantly higher bending strength than untreated 10%w/w
TiO2 (p=2.52×10−03) and 10%w/w ZrO2 (p=0.01) and was above the minimum require-
ments of the ISO5833 standard, which was not the case with 10%w/w TiO2 cement.
Silane-treated 10%w/w ZrO2 on the other hand did not perform significantly better than
untreated ZrO2 (p=0.57) or the other cements. All formulations however were found to
be significantly lower in bending strength when compared to Palacos R (p<0.05).
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5.3.4 Fracture toughness
Figure 5.7 shows the fracture toughness of commercial cements, untreated 10%w/w TiO2
and ZrO2 and silane-treated 10%w/w TiO2 and ZrO2. The fracture toughness of 10%w/w
TiO2 was improved by the silane coating, but this was not significant (p=0.24). The silane-
treated 10%w/w TiO2 was found to be significantly better than Cemex (p=1.22×10−04)
and silane-treated 10%w/w ZrO2 (p=0.02) bone cements. Similarly, the silane-treated
10%w/w ZrO2 cement was found to be significantly better than Cemex (p=0.02). Cemex
was found to have the poorest fracture toughness properties, whilst Palacos R was found to
have significantly higher fracture toughness properties when compared to all the cements
(p<0.05).
Figure 5.7: Average fracture toughness
5.3.5 Fatigue
Figure 5.8 and Table 5.2 show the fatigue results and fatigue constants respectively for
commercial, model and novel untreated and silane-treated cements. The silane coating on
TiO2 and ZrO2 has improved the crack growth rates at ∆K=1MPam
1/2 (A coefficient),
however the change in crack growth rates over the range of ∆K tested (m coefficient)
was not improved. This is identifiable in Figure 5.8 where the fatigue plots have shifted
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(a)
(b)
Figure 5.8: Fatigue test results
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Table 5.2: Fatigue constants of commercial, model and novel silane-treated cements
A m
Correlation
coefficient
Palacos R 3.73×10−07 4.65 0.62
Cemex 5.39×10−07 5.92 0.82
Model cement 4.83×10−07 3.73 0.67
0%w/w radiopacifier 3.53×10−06 5.49 0.69
10%w/w TiO2 3.00×10−06 6.03 0.57
Silane-10%w/w TiO2 6.80×10−07 5.94 0.92
10%w/w ZrO2 6.92×10−05 6.88 0.73
Silane-10%w/w ZrO2 5.51×10−06 6.76 0.84
down to lower crack growth rates for silane-treated cements. The silane-treated cements
achieved low crack growth rates at low stress intensities and comparable crack growth
rates at higher stress intensities when compared to the model and commercial cements
as shown in Figure 5.8. Furthermore the silane treatment of the novel radiopacifiers has
achieved less variability in the crack growth rates as demonstrated by an increase in the
correlation coefficient with the Paris Law (Table 5.2). The decrease in variance of the
results is attributed to the reduction in agglomerations resulting in a more homogeneous
cement. This in turn produces more consistent results between samples.
5.3.6 Scanning electron microscopy
Figure 5.9 shows SEM images taken from the fracture surfaces of fatigue samples with
10%w/w TiO2 and ZrO2 and silane-treated 10%w/w TiO2 and ZrO2. Silane treatment
has improved the dispersion of TiO2 particles, however for silane-treated 10%w/w ZrO2
large agglomerations were still present, suggesting poor silanisation. Both silane fracture
surfaces however, were found to be rougher than the untreated TiO2 and ZrO2 fracture
surfaces demonstrating less brittle failure. Furthermore semi-circular microcracks were
found to have developed on the fracture surface of the silane-treated 10%w/w TiO2, in-
dicative of microcracks forming ahead of the crack tip. The microcracks would induce
plastic deformation ahead of the crack tip and cause the main crack to deviate or branch
out, slowing crack propagation and reducing the stress intensity at the tip of the crack.
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(a) 10%w/w TiO2 (b) 10%w/w Silane-TiO2
(c) 10%w/w ZrO2 (d) 10%w/w Silane-ZrO2
Figure 5.9: SEM images of fracture surfaces - Red arrows indicate PMMA beads, green
arrows indicate radiopacifier particle agglomerations, blue arrows indicate pores and voids
and white arrows indicate microcracks (bar=100µm)
5.4 Discussion
Silane coupling agents have been shown to enhance the bond strength and interfacial prop-
erties of implants made of titanium291,293, zirconium294, 295 and cobalt-chrome alloys134.
Silanes have also been used with PMMA containing glass fibres296, calcium chloride183,
hydroxylapatite297, silver and aluminium298. In all cases, the performance of PMMA with
the additional materials was enhanced by the use of silanes. Although the initial results
from Chapter 4 show that anatase TiO2 and yttria-stabilised ZrO2 do not improve the
properties of bone cement, the use of silanes in conjunction with the novel radiopacifier
may enhance the properties of the cement. A recent study has shown when methacry-
loxypropyltrimethoxysilane is added directly to MMA, the interfacial strength and the
hydrolysis resistance of the metal-PMMA interface is improved, however the compressive
and bending strength of the cement remain unaltered182. Similarly, the addition of silanes
to dental cements did not result in significantly enhanced properties299. In order for the
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silane to improve the mechanical properties of bone cement, it must first be applied to the
surface of the radiopacifier.
The technique used to treat the radiopacifiers was judged successful for anatase TiO2
using FTIR analysis, whilst for ZrO2 the results are equivocal due to the intensity of the
FTIR peaks and the presence of agglomerations. In both samples however, characteristic
peaks of both the radiopacifier materials and the silane were detected. Several stud-
ies have used similar treatment and analytical procedures to characterise silane-treated
surfaces293–295, 300. Other studies have used alternative methods to analyse coatings, in-
cluding X-ray photoelectron spectroscopy (XPS)295, scanning electron microscopy (SEM)
and contact-angle measurements300.
Silane treatment of the novel radiopacifiers alters the surface characteristics and allowed
the powders to be dispersed in the liquid component of the cement (MMA). When suc-
cessfully treated, the substrate surface will be covalently linked to the silane with the
organofunctional group of the silane on the outermost layer of the substrate. This group
in methacryloxypropyltrimethoxysilane is a methacrylate which renders the surface of the
substrate hydrophobic. Furthermore the interactions between the methacrylate molecules
on the outer surface of the substrate and the methacrylate molecules in MMA allowed for a
well-dispersed stable suspension to be formed. Visual inspection of the suspensions found
that the treated TiO2 dispersed more readily than the treated ZrO2. Sedimentation of the
treated substrate particles were found to occur over time due to gravity and differences
in density, however the particles could be resuspended by agitation. The ability of the
silane-treated TiO2 and ZrO2 to be suspended in MMA enhanced the dispersion of the
radiopacifier. Furthermore, interactions between the methacrylate molecules in MMA and
on the surface of the treated radiopacifiers would ensure some degree of bonding between
the treated radiopacifier particles and the polymer matrix during polymerisation.
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Overall the silane treatment did not significantly affect the setting properties of the ce-
ment. The amount of silane used and the extent of the coating on the surface of the
radiopacifier may not have been sufficient to affect the polymerisation of PMMA. The
setting time for the silane-treated 10%w/w ZrO2 cement was similar to Palacos R and the
10%w/w ZrO2 cement, further highlighting the impact of ZrO2 on the polymerisation of
bone cement.
In theory, the silane coating of the radiopacifier particles should improve the dispersion of
the particles throughout the cement and improve the adhesion between the particles and
the PMMA matrix. This was clearly the case with silane-treated TiO2 where improve-
ments in compressive strength, bending strength, bending modulus, fracture toughness
and fatigue characteristics were observed. Similar results were observed in other studies
whereby improvements in compressive and flexural properties occurred as a result of silane
use298, 301, 302. A moderate increase in toughness was observed with the silane-treated TiO2
and this agrees with results from other publications83, 173. The SEM images of the frac-
ture surface of the silane-treated TiO2 sample showed few agglomerations and rougher
fracture surfaces with semi-circular cracks. The well-dispersed TiO2 may have increased
the modulus of the cement, however, good dispersion of the radiopacifier would result in
less stress concentrations and stress risers, which initiate cracks. The dispersion of rigid
particles in the polymer matrix would also have distributed stresses away from the crack
tip, acting as a toughening mechanism. Moreover, good adhesion between the TiO2 par-
ticle and the PMMA matrix would require higher stresses to break the covalent bonds,
and cause debonding of the particle from the polymer matrix. Good adhesion would also
induce higher levels of deformation in the surrounding polymer as rigid particles do not
deform. Both mechanisms would result in a tougher, stronger material as observed in the
results.
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Although these improvements were found to occur with silane-treated TiO2 samples, this
was not the case with silane-treated ZrO2 samples. Few significant improvements were
observed as a result of silane coating ZrO2 and large agglomerations were still visible on
the fracture surfaces of the fatigue samples. By assessing the surface coatings in the FTIR
results, it is probable that the silane-treatment of ZrO2 was incomplete. Recent studies
experienced similar difficulties in achieving complete silane treatment of yttria-stabilised
and non-stabilised ZrO2
303–305. Sandblasting with silica-coated alumina prior to silane
treatment has been shown to improve the outcome of silane treatment and may offer a
solution to this problem294, 295.
5.5 Conclusions
In conclusion, the silane treatment of TiO2 is thought to have been successful, whilst
difficulties in achieving complete treatment of ZrO2 was experience. Silane treating TiO2
greatly improved the mechanical and fatigue properties of the cement and did not sig-
nificant alter the setting properties. Moreover, silane-treated TiO2 cement met all the
ISO5833 minimum requirements for acrylic cements. The use of a silane on the surface
of TiO2 enhanced the the surface characteristics of the radiopacifier, allowing it to be
dispersed effectively in MMA. This in turn would have improved the dispersion and adhe-
sion between PMMA and the radiopacifier, allowing several of the toughening mechanisms
discussed to be induced. Introducing silane-treated TiO2 into a commercial cement as a
substitute for BaSO4 or ZrO2, using industrial mixing and preparation techniques, may
result in further improvements to mechanical and fatigue properties.
The biocompatibility of the silane used has previously been questioned and although only
a small quantity is employed on the surface of each radiopacifier particle, it is essential to
study the effect this has on surrounding cells and tissues. Furthermore the use of anatase
TiO2 may yield positive results in terms of bone growth and osseointegration. The fol-
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lowing chapter focuses primarily on bone growth and the interactions between the novel
silane-treated radiopacifiers and MC3T3-E1 cells, an osteoblast precursor cell line derived
from mouse calvaria.
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Chapter 6
Biocompatibility and
osseointegration of PMMA bone
cements
6.1 Introduction
Anatase TiO2 and yttria-stabilised ZrO2 have the potential to be used as radiopacifiers
for bone cements. Improvements in the setting, mechanical, fracture toughness and fa-
tigue properties of the cement containing anatase TiO2 and yttria-stabilised ZrO2 were
not observed due to agglomerations of the radiopacifiers and poor bonding to the polymer
matrix. Consequently, a silane coating on the surface of the radiopacifier particles was
tested and significant improvements to the mechanical and fatigue properties were ob-
served. PMMA is generally considered to have little to no influence on bone growth and
the use of novel materials such as silane treated TiO2 and ZrO2 may have the potential to
enhance bone growth at the cement-bone interface. The work in this chapter assessed the
bioactivity of the novel cement formulations in terms of hydroxylapatite (HA) growth on
the surface of the cement and interactions with MC3T3-E1 cells. If demonstrated to be
functionally bioactive, bone growth at the cement-bone interface may be improved, per-
haps preventing micromotion and potentially encouraging new bone to grow into fatigue
cracks in the cement over time.
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6.1.1 Bone growth
When an implant is introduced into the body, there is an initial inflammatory response
with the arrival of phagocytes and other repair cells. The subsequent tissue response will
then determine the outcome of the implant. A toxic tissue response would cause death
to the surrounding tissue and cells. An inert response may result in the formation of
a thin protective layer around 1-3µm in thickness and if micromotion occurs, a fibrous
tissue can form, preventing any bond from forming. Bioactive materials have the ability
to evoke a positive response with the surrounding tissue, rapidly creating chemical bonds
and encouraging natural healing mechanisms. In the case of bone cements, a bioactive
material would deposit layers of bone minerals rapidly306.
Bone consists primarily of collagen fibres and crystalline salts. The two main compo-
nents of the crystalline salts deposited in bone matrix are calcium (Ca) and phosphate
(PO4), which combine to form HA crystals (Ca10[PO4]6[OH]2). These crystals have good
compressive strength whilst the collagen fibres have good tensile strength. When combined
with a degree of bonding between the collagen fibres and the crystals, a bony structure is
formed with good properties in both compression and tension.
Within bone there are also blood vessels, nerves and cells, which play a vital role in
bone remodelling, growth and healing (Figure 6.1). The main cells within bone are fibrob-
lasts, fibrocytes, osteoblasts, osteocytes, osteoclasts and osteoprogenitors. Fibroblasts
and fibrocytes are responsible for collagen formation, which enhances tensile properties.
Osteoprogenitor cells are found deeper in the periosteum and in bone marrow and differ-
entiate into osteoblasts under the influence of growth factors such as bone morphogenic
proteins (BMPs), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF)
and transforming growth factor beta (TGF-β). Osteoblasts are responsible for forming
new bone. They form the organic component of bone, osteoid, which is predominantly
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Figure 6.1: Structure of bone and its remodelling process
made of collagen. Minerals then begin to form around this collagen to form HA. Osteo-
cytes are mature osteoblasts that have become trapped in the bone matrix. Osteocytes
are sensitive to pressure, enabling bone to remodel itself in response to loads, and move
nutrients and waste through the bone matrix. Osteoclasts counterbalance the role of os-
teoblasts and are responsible for bone resorption.
Beneficial interactions between cells involved in bone remodelling and hydroxylapatite
(HA) has resulted in a variety of orthopaedic applications for HA, as detailed in a re-
view by Oonishi et al.307. Numerous studies have investigated the use of HA in bone
cement178,179, 297, 308, 309 , bone spacers and scaffolds255, 256 and as a surface coating for
implants250, 310–313. Osteoblast cells proliferate on bone-like apatite layers and form a bi-
ological matrix of natural HA and collagen, whilst consuming the apatite in the bone-like
material and later remodelling it314. This process, which occurs between artificial materi-
als and natural bone, is identical to the process that occurs naturally in bone remodelling.
HA not only induces mechanisms of natural bone growth but is also non-toxic, reduc-
ing unwanted inflammatory responses. Although successfully used in bone scaffolds and
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non-load bearing applications, recent studies have shown that incorporating HA into bone
cement may have a detrimental effect on mechanical and fatigue properties308.
The interaction between cells and the surface of an implanted material depends on a
range of material properties such as chemical composition, particle size, surface roughness
and surface energy310, 315. These properties dictate how effectively biological molecules
and cells behave on, and adsorb to, surfaces. Proteins such as vitronectin (contained in
serum which mediates osteoblast adhesion)316, fibronectin and albumin have been shown
to adsorb more rapidly onto hydrophilic surfaces with high surface energies, therefore
enhancing the rate of adhesion of specific anchorage-dependent cells (e.g. osteoblasts, fi-
broblasts and endothelial cells)317. Recent studies have shown how surface energy plays a
vital role in the efficiency of cell-material interactions, affecting both protein adsorption318
and cell attachment319. Materials with improved physical and chemical properties could
therefore enhance cell behaviour at the surface of the implant and extend its lifetime.
The surface energy of a material defines how a liquid behaves at that surface. A low
surface energy, demonstrated by a high water contact angle between the solid surface
and water, represents a hydrophobic surface. Surfaces with a high surface energy and a
low contact angle tend to be more hydrophilic. This concept is highlighted in Figure 6.2
Figure 6.2: Contact angle technique to measure surface energy or the hydropho-
bic/hydrophilic properties of a material
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which demonstrates the degree of wetting of different surface types. As previously dis-
cussed, hydrophilic surfaces tend to enhance cell interaction, adsorption and adhesion and
is also favourable for HA formation320. Negatively charged surfaces were also reported
to enhance hydroxylapatite formation321. By replacing the radiopacifier of PMMA bone
cement with a more hydrophilic and negatively charged material, there is the potential to
enhance bone growth properties.
Titanium is widely employed in orthopaedics due to its low toxicity and ability to bond to
bone. The low toxicity is due to the thin oxide layer (2-7nm)322–324 that naturally forms
when titanium is exposed to oxygen, creating TiO2, a stable and inert compound. In ad-
dition to being stable in the physiological environment, TiO2 has been found to increase
calcium ion interactions, which is important for protein and osteoblast adhesion as well
as HA formation325. In particular, the anatase crystal structure of TiO2 is speculated to
have a higher bioactivity than rutile or amorphous TiO2. This is due to the closer lattice
match with HA, higher acidity and lower surface zeta potential caused by a larger number
of hydroxyl groups on the surface. Deposition of HA on anatase at a pH of 7.4 is faster
than on the rutile form at the same pH326.
The surface energies of PMMA, BaSO4, TiO2, ZrO2 and the silane (methacryloxypropy-
ltrimethoxysilane) used in the previous chapter were obtained from published literature
and are shown in Table 6.1. From this datum it is expected that commercial bone cements
Table 6.1: Surface energies of different materials
Material Surface energy / mN/m
PMMA 39327
BaSO4 33
328
Anatase TiO2 91
185
Yttria-stabilised ZrO2 42
329
Methacryloxypropyltrimethoxysilane 34300
HA 72-95330
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containing roughly 10%w/w BaSO4 will have the lowest surface energy and thus be more
hydrophobic in nature, whereas bone cements containing anatase TiO2 will have a higher
surface energy with a lower contact angle and be more hydrophilic. It is also expected
that silane treating TiO2 and ZrO2 will reduce the surface energy of the cement when
compared to cements with untreated TiO2 and ZrO2. This is due to the hydrophobic
nature of the silane. As previously discussed in Chapter 5 the hydrolyzable group of the
silane creates a covalent bond with the oxide surface of the metal, leaving the organofunc-
tional group of the silane free to attach to the surrounding polymer. When TiO2 and
ZrO2 particles are coated with the silane, the hydrophobic organofunctional group will be
left on the surface, rendering the particle more hydrophobic. It is therefore expected that
particles that have been treated to increase hydrophobicity for dispersion and adhesion
purposes will have a lower surface energy and possibly poorer bone growth properties.
Recent studies however have shown that the silane functional groups and silanol groups
(Si-OH) can enhance apatite formation183, 311. Furthermore osteoblast-like cell behaviour
has been shown to be more dependent on surface chemistry rather than general surface
properties such as surface energy and wettability331 .
6.2 Methods
6.2.1 Surface energy determinations
Surface energy measurements were taken according to the British Standards EN828332.
Small cylindrical bone cement samples (10mm diameter, 2mm thickness) containing 10%w/w
BaSO4, TiO2, ZrO2, silane-treated TiO2 and silane-treated ZrO2 were prepared as de-
scribed in Section 2.1. The flat surfaces of the samples were sanded with a 500 grit silicon
carbide paper. Three test liquids were used in this experiment: water, methanol and
glycerol.
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2µL of the test liquid was pipetted onto the surface of the bone cement sample at a
90◦ angle and an image was taken of the profile of the droplet (perpendicular to the
surface) using a high definition digital camera. The images were then imported into ImageJ
(National Institutes of Health, Maryland, USA) and the right and left contact angles were
measured to give an average contact angle per sample (θ) as shown in Figure 6.3. The
experiment was repeated five times for each sample.
Figure 6.3: Contact angle measurements
A linear variation (y = mx + c) of Young’s equation is shown in Equation 6.1 and was used
to calculate the total surface free energy of each sample. The interfacial tension values
for the test liquids (Table 6.2) and the average contact angles for each liquid on a sample
were used in Equation 6.2 to produce y and x points. Plots for each sample were produced
and the slope and y-intercept determined using linear regression. The square of the slope
corresponds to the polar proportion of the solid body surface energy (σPS ) and the square
of the y-intercept corresponds to the disperse proportion of the solid body surface energy
(σDS ). The sum of these two proportions gives the total surface free energy of the sample
(σS), as shown in Equation 6.3.
(1 + cosθ)× σL
2
√
σPL
=
√
σPS ×
√
σPL√
σDL
+
√
σDS (6.1)
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(1 + cos)θ × σL
2
√
σDL
, x =
√
σPL√
σDL
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P
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D
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Where:
θ is the measured contact angle;
σL is the surface tension of the liquid used;
σDL is the disperse proportion of the liquid used;
σPL is the polar proportion of the liquid used;
σS is the surface tension of the sample;
σDS is the disperse proportion of the sample;
σPS is the polar proportion of the sample;
Table 6.2: Interfacial tensions of test liquids
Test
liquid
Surface tension
σL / mN/m
Disperse
proportion σDL
/ mN/m
Polar
proportion σPL
/ mN/m
Water 72.8 21.8 51.0
Methanol 22.5 18.2 4.3
Toluene 28.5 28.5 0.0
6.2.2 Hydroxylapatite growth
HA growth was determined using the ISO23317:2007 standard333. 10x10x2mm square
bone cement samples were prepared for the model cement with 10%w/w BaSO4, 10%w/w
TiO2, 10%w/w ZrO2, 10%w/w Silane treated TiO2 and 10%w/w Silane treated ZrO2 as
described in Section 2.1. Two samples for each group and time point were used (n=2,
36 samples in total). Each sample was stored in 30mL of simulated body fluid (SBF)
based on a solution developed by Kokubo et al.334 with a composition and preparation
method as specified in ISO 23317:2007. The samples and SBF were stored in a V-bottom
container at 37◦C for 1 hour, 1 week and 4 weeks. After each time point, the samples were
removed and washed twice with distilled deionised water to remove any unattached HA
precipitates. The samples were then desiccated without heat to prevent crystallisation.
The sample surface was examined by X-ray diffraction (XRD) using a Philips PW3830
X-ray generator with a PW1710 Diffractometer control (Philips Research, Eindhoven,
The Netherlands) and X’pert Industry v1.1c software (PANalytical B.V., Almelo, The
134
Chapter 6. Biocompatibility and osseointegration of PMMA bone cements
Netherlands). The scan was run between 3◦ and 50◦ (2θ) at a scan speed of 0.020◦/s.
After XRD, one sample from each group was imaged using scanning electron microscopy
(SEM) for visual inspection of apatite crystals as described in Section 2.8. The second
sample was incubated in SBF for a total of 6 weeks and imaged using SEM.
6.2.3 MC3T3-E1 cell culture
Gibco R© Minimum Essential Medium alpha (α-MEM) with nucleosides (L-Glutamine,
sodium pyruvate, lipoic acid, B12, biotin, and ascorbic acid) was purchased from Life
Technologies Ltd (Paisley, UK) and prepared according to the manufacturer’s instruc-
tions. MC3T3-E1 osteoblasts of passage 14-16 were cultured in α-MEM supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37◦C, 5% CO2.
Once confluent, the cells were trypsinized, resuspended in α-MEM and counted using a
haemocytometer.
6.2.4 Osteoblast adhesion
The ability of a cell to adhere and anchor itself to a specific surface will dictate how quickly
it will interact with the surface and carry out its intended function. The rate of osteoblast
cell adhesion is important as it will define how rapidly the cells can deposit minerals on
the surface of the material and begin forming new bone.
10mm diameter by 2mm height cylindrical bone cement samples were prepared in a simi-
lar manner to the samples used for surface energy measurements. The samples consisted
of bone cement containing 0%w/w radiopacifier (radiolucent), 10%w/w BaSO4, 10%w/w
TiO2, 10%w/w ZrO2, 10%w/w silane-treated TiO2 and 10%w/w silane-treated ZrO2. Four
samples for each test group and time point were prepared (n=4, 72 samples in total). The
cylindrical samples were sterilized by soaking in 100% ethanol for 5 minutes and allowed to
air dry under aseptic conditions. MC3T3-E1 cells were cultured as previously described.
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The cement samples were placed in a 24 well-plate and 6000 cells in 150µL of culture
medium (α-MEM) was carefully seeded directly onto the top of each sample and incu-
bated. After 4 hours each well was flooded with 750µL of medium and incubated for 1, 4
and 24 hours.
After each time point, the medium was removed from each well and the samples were
washed with phosphate buffer saline (PBS) to remove any non-adherent cells. The PBS
was then removed and the adherent cells fixed with 10%v/v neutral buffered formalin
(NBF) for 10 minutes. The NBF was removed and the samples were washed with PBS
and stained with 1%w/v toluene blue for 10 minutes after which the stain was removed
and the samples were washed twice with distilled water. The samples were left to dry and
four different areas on the surface of each sample were imaged using an Olympus IX50
light microscope (Olympus, Southend-on-Sea, UK). The number of adherent cells were
counted using ImageJ software (National Institutes of Health, Maryland, USA).
6.2.5 Osteoblast proliferation
Cell proliferation refers to the growth of a cell population. The ability of a material to in-
crease the rate of cell proliferation would be beneficial to healing processes such as the one
experienced during total joint replacements. The faster the cells reproduce and develop,
the more cells that are available to carry out specific tasks, such as developing new bone
material. Therefore, the rate of cell proliferation is a parameter that must be evaluated.
Furthermore, cell proliferation tests evaluate the number of live cells and therefore also
provide a measure of how detrimental a material or chemical is to cell activity.
10mm diameter by 2mm height cylindrical bone cement samples were also used for the
proliferation test and three samples and one control for each test group and time point
was used (n=3, 48 samples in total). The cylindrical samples were sterilized in 100%
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ethanol for 5 minutes and allowed to air dry under sterile conditions. MC3T3-E1 cells
were cultured as previously described. The cement samples were placed in a 24 well-plate
and each well was flooded with 3000 cells in 500µL of α-MEM or α-MEM medium alone
for the controls. The well plate was gently agitated to ensure an even distribution of cells
on the sample surfaces then incubated at 37◦C in 5% CO2 for 3 and 7 days, with the
medium replaced every 2 days.
After 3 and 7 days the well plates were removed from the incubator and the medium
removed from each well. The samples were then washed with PBS and moved into a
new well plate. 500µL of α-MEM and 100µL of CellTiter 96 R© AQueous One Solution
Proliferation Assay (Promega Corporation, WI, USA) was added to each well containing
samples and the plate was incubated in the dark at 37◦C in 5% CO2 for 2 hours. The
assay is composed of a tetrazolium compound (MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). MTS reacts with living cells
to produce a formazan precipitate, which can be determined at 490nm. The absorbance
values are therefore a direct measure of the number of living cells in the medium. After
2 hours, 100µL of the assay medium was moved to a 96-well plate and the absorbance
was read at 490nm using a Packard Spectracount plate reader. The absorbance of the
control samples were subtracted from the absorbance of samples with cells to account for
background colouration arising from interaction with the bone cement
6.3 Results
6.3.1 Surface Energy
Table 6.3 shows the results of the surface energy measurements. Bone cement with no ra-
diopacifier and the model cement which contains 10%w/w BaSO4 had significantly lower
surface energies than the other cements (ANOVA, p<0.05) demonstrating a more hy-
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Table 6.3: Experimental surface energies
Surface energy / mN/m
0%w/w Radiopacifier (Radiolucent) 30.6±3.8
Model cement 28.8±3.0
10%w/w TiO2 44.5±3.5
Silane 10%w/w TiO2 42.5±3.3
10%w/w ZrO2 36.7±3.8
Silane 10%w/w ZrO2 41.6±6.2
drophobic surface. The cement formulations with treated and untreated TiO2 and ZrO2
had the highest surface energies making them more hydrophilic. There was no significant
difference in surface energy as a result of silane treatment (p=0.43 for TiO2 and p=0.21
for ZrO2). Samples with 10%w/w TiO2 had a significantly higher surface energy than
samples with 10%w/w ZrO2 (p=0.02), however the difference between silane-treated TiO2
and silane-treated ZrO2 was not significant (p=0.80).
6.3.2 Hydroxylapatite growth
Figures 6.4 to 6.8 show the XRD spectra for the model, TiO2, silane TiO2, ZrO2 and
silane ZrO2 cements respectively after storage in SBF for 1 hour, 1 week and 4 weeks.
The top spectrum for each figure corresponds to peaks obtained from XRD scans of HA,
whilst the bottom spectra were obtained from XRD scans of the radiopacifier material
used in the cement samples. It is expected that if a material successfully promotes bone
growth, then full surface coverage will occur and only peaks from HA will be observed.
For materials that gradually nucleate bone minerals, it is expected that peaks from both
HA and the radiopacifier material will be present. When peaks from both HA and the
radiopacifier occur at the same position (2θ), then an overall increase in peak intensity
should be observed.
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Figure 6.4: XRD spectra of the model cement samples stored in SBF over time
Figure 6.5: XRD spectra of TiO2 samples stored in SBF over time
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Figure 6.6: XRD spectra of silane TiO2 samples stored in SBF over time
Figure 6.7: XRD spectra of ZrO2 samples stored in SBF over time
140
Chapter 6. Biocompatibility and osseointegration of PMMA bone cements
Figure 6.8: XRD spectra of silane ZrO2 samples stored in SBF over time
All XRD spectra had peaks at the same positions as the radiopacifier materials, demon-
strating the presence of the radiopacifier material on the surface of all the samples. Simi-
larly, the XRD spectra demonstrate that the anatase phase of TiO2 and the cubic phase
ZrO2 were present.
From the model cement XRD scans, it is clear that no HA growth took place on the
surface of the cement. All the peaks coincided with the BaSO4 spectrum, with the excep-
tion of one peak at 38.25◦ after 1 week in SBF. This peak did not match with those of
HA and was not present at 4 weeks, therefore the deposition of HA can be ruled out.
Bone cement containing TiO2 on the other hand demonstrated strong peaks after 4 weeks
in SBF at 11.03◦, 21.95◦, 22.83◦ and 32.33◦ which coincided with HA peaks. Peaks at
44.53◦ after 1 week and 20.48◦ after 4 weeks were shown on the XRD scans, however they
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do not match the HA peaks. The source or cause of these peaks is not understood. Bone
minerals were not detected at 1 hour and 1 week and the strongest peak for HA (31.80◦)
was not present in any of the scans, demonstrating the crystal structure of HA may not
have fully formed after 4 weeks.
Similar to TiO2, silane-treated TiO2 samples were found to have peaks at the same po-
sitions as HA after 4 weeks in SBF. These peaks occurred at 10.85◦, 16.86◦, 22.83◦ and
32.33◦. The peaks obtained by the silane TiO2 samples were not exactly the same as
those obtained with the TiO2 samples as a peak at 16.86
◦ was present but not at 21.95◦.
Similarly, there was no peak at 31.8◦.
ZrO2 and silane-treated ZrO2 had identical spectra with strong ZrO2 peaks at 30.24
◦
and 35.28◦. No other peaks were detected at 1 hour, 1 week or 4 weeks. Although XRD
may not detect very thin surface layers of HA, it can be assumed no minerals were present
on the surface of samples containing ZrO2 and silane-treated ZrO2.
Figure 6.9 shows the SEM images of the samples stored in SBF for 1 week. At 1 week there
are no discernible features on the surfaces of the model cement, ZrO2 and silane-treated
ZrO2 samples that would indicate the growth of HA crystals, however on the surface of
TiO2 and silane TiO2 at 1 week, small straight edged structures were observed.
Figure 6.10 shows samples stored in SBF for 4 weeks. After 4 weeks the surfaces of
the model, ZrO2 and silane-treated ZrO2 samples appear altered, however there were no
visible crystal formations on the surfaces. TiO2 and silane TiO2 samples after 4 weeks had
many irregular shaped structures forming on the surface. This time point coincides with
the results from the XRD scans, which show selected peaks associated with HA forming.
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(a) Model cement (b) TiO2 (c) Silane TiO2
(d) ZrO2 (e) Silane ZrO2
Figure 6.9: SEM images of the surface of samples stored in SBF for 1 week - Green arrows
indicate potential HA crystal structures on surface of samples
(a) Model cement (b) TiO2 (c) Silane TiO2
(d) ZrO2 (e) Silane ZrO2
Figure 6.10: SEM images of the surface of samples stored in SBF for 4 weeks - Green
arrows indicate potential HA crystal structures on surface of samples
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(a) TiO2 (b) Silane TiO2
Figure 6.11: SEM images of the TiO2 and Silane TiO2 samples after storage in SBF for 6
weeks - Green arrows indicate potential HA crystal structures on surface of samples
After 6 weeks in the SBF solution, clear straight edged geometrical shapes were observed on
the surfaces of TiO2 and silane TiO2 samples, indicative of crystal structures (Figure 6.11).
6.3.3 Osteoblast adhesion
Figure 6.12 shows the osteoblast adhesion at 1, 4 and 24 hours for the tested cements. At
all time points silane-TiO2 had the highest level of MC3T3-E1 cell adhesion. Cell adhe-
sion was significantly higher at 1 hour incubation compared to the other cements (p<0.05).
Figure 6.12: Osteoblast adhesion
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10%w/w TiO2 cement had significantly higher levels of cell adhesion than the model ce-
ment at 1 hour (p=4.15×10−03), whilst there were no significant differences between the
rest of the cements (p>0.05). At 4 hours however, all the cements had performed similarly
with the exception of silane-TiO2 which was found to be significantly better than the con-
trol radiolucent (0%w/w radiopacifier) cements (p=0.04). Finally at 24 hours, TiO2 and
silane-TiO2 were significantly more adherogenic than radiolucent cement (p=0.01) and the
model cement (p=0.04), whilst silane-ZrO2 performed significantly better than radiolucent
cements (p=0.04). Overall it was observed that the silane-TiO2 cements performed the
best in terms of MC3T3-E1 cell adhesion, closely followed by the 10%w/w TiO2 cement
and then the ZrO2 cements. From these initial results, the interaction between TiO2 and
MC3T3-E1 cells was found to be beneficial for cell adhesion as was the silane treatment.
Figures 6.13 to 6.18 show images of the stained cells at 1, 4 and 24 hours on the sur-
face of the different cement samples. For all cements, the cells were found to change
morphology as the incubation times increased. Initially, at 1 hour, cells were rounded and
by 24 hours the MC3T3-E1 cells began to spread and appear similar in morphology to
osteoblast cells. From the images it is clear that TiO2 containing cements had a signifi-
cantly higher number of cells adhered to the surface. Furthermore, the cells on the TiO2
containing cements were found to be more widely spread at 1 and 4 hours.
(a) 1 hour (b) 4 hours (c) 24 hours
Figure 6.13: Stained MC3T3-E1 cells on the surface of the radiolucent cement
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(a) 1 hour (b) 4 hours (c) 24 hours
Figure 6.14: Stained MC3T3-E1 cells on the surface of the model cement
(a) 1 hour (b) 4 hours (c) 24 hours
Figure 6.15: Stained MC3T3-E1 cells on the surface of the TiO2 cement
(a) 1 hour (b) 4 hours (c) 24 hours
Figure 6.16: Stained MC3T3-E1 cells on the surface of the silane TiO2 cement
(a) 1 hour (b) 4 hours (c) 24 hours
Figure 6.17: Stained MC3T3-E1 cells on the surface of the ZrO2 cement
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(a) 1 hour (b) 4 hours (c) 24 hours
Figure 6.18: Stained MC3T3-E1 cells on the surface of the silane ZrO2 cement
6.3.4 Osteoblast proliferation
The results of the proliferation test are shown in Figure 6.19. Although osteoblasts were
found to attach more readily on the surface of silane-TiO2 samples, the results for cell
proliferation demonstrates that silane treatment has a detrimental effect on MC3T3-E1
cell profileration. Absorbance values at 490nm on silane-treated samples were found to be
lower than those obtained from 10%w/w TiO2 and ZrO2 samples. Although a reduction
in cell proliferation was experienced, this was not significant for silane-TiO2 at both 3
Figure 6.19: Osteoblast proliferation
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days (p=0.29) and 7 days (p=0.27). Silane-TiO2 however was significantly worse than the
model cement on day 7 (p=0.03) and Silane-ZrO2 was significantly worse than the model
cement on days 3 (p=3.83×10−03) and 7 (p=6.34×10−03). On day 7, silane-treated ZrO2
was significantly worse than all of the cements (p<0.05). Nevertheless, the percentage
change between day 3 and 7 for proliferation was found to be 75.9% for radiolucent, 76.7%
for BaSO4, 83.0% for TiO2, 80.6% for ZrO2, 91.1% for silane-treated TiO2 and 98.8%
for silane-treated ZrO2. Therefore, although lower yields were obtained for live cells at
days 3 and 7, the percentage increase in the number of live cells were highest for cements
containing silane-treated TiO2 and ZrO2, followed by 10%w/w TiO2 and ZrO2 cements
and finally BaSO4 and radiolucent cements. This demonstrates that the radiopacifier used
can affect the rate of MC3T3-E1 cell proliferation.
6.4 Discussion
PMMA is not considered bioactive as it does not readily interact and bond with bone.74, 302, 335
This is believed to have contributed to the loosening of the implant at the cement-bone
interface and is a significant problem in total joint replacements. As discussed in the intro-
duction, cases of loosened implants were found to be accompanied by bone lysis, resorption
and macrophagic reactions139, 142. In order to prevent such biological mechanisms, there is
a need to encourage osseointegration and enhance the bone growth properties of PMMA
bone cements. Several studies have attempted to improve this aspect of bone cement
using calcium salts (CaCl2, Ca(CH3COO)2 or Ca(OH)2) with and without a silane
335,
magnesium oxide (MgO)188, apatite-wollastonite glass ceramic particles302, strontium ox-
ide (SrO)176, HA177–179, sodium fluoride (NaF)88, and rutile TiO2
180. The majority of
these studies claim to have observed improvements in bone growth properties.
As Table 6.1 demonstrated, anatase TiO2 had a surface energy similar to HA and sig-
nificantly higher than PMMA and BaSO4, whilst yttria-stabilised ZrO2 had a moderately
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higher surface energy than PMMA and BaSO4. By incorporating materials with higher
surface energies into PMMA bone cement, the overall surface energy of the cement was
increased. Higher surface energies result in a more hydrophilic surface, which is favourable
for cell adhesion and cell interactions317. It was expected that the silane coating would
significantly decrease the surface energy of the cement, however this did not occur. The
wettability of the radiopacifiers were found to influence the overall surface properties of
the cement to a greater extent than the silane treatment.
Overall it was found that bone cement containing BaSO4 or ZrO2 did not precipitate
any mineralisation on the surface of the cement when submerged in SBF over time. Bone
cement containing TiO2 and silane-TiO2 however, demonstrated some mineralisation af-
ter 4 weeks in SBF as crystals were detected by XRD and SEM imaging. This may be
linked to the increased surface energy of the cement as a result of using TiO2. The crystal
structure and surface oxides of TiO2 may also enhance the interaction with calcium ions.
Full surface coverage with minerals however, was only achieved after incubation in SBF
for more than 4 weeks, demonstrating the process of HA deposition on PMMA in vitro
requires extended incubation periods.
The morphology of the HA obtained differed from the morphology obtained in other stud-
ies. Ciobanu et al.312 found that titanium alloy, surface treated with sodium hydroxide
(NaOH) solution and heat treated, established petal rose-like HA crystals roughly 2-5µm
in size, when submerged in a supersaturated calcification solution. Wen et al.313 utilised
the same simulated body fluid (SBF) as this study and obtained similar HA morphologies
on the surface of titanium-zirconium alloys after just one day. Furthermore, at 8 and 15
days in SBF, a much denser coating of fine HA precipitates were obtained. In a different
study which precipitated HA on the surface of porous silicon, the floccules of HA obtained
were similar in morphology to the HA obtained in this study and similar peaks were
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found using XRD (≃10◦ and 32◦), however the HA precipitates were significantly smaller
( ≃100nm)336. Larger (≃200-300nm) lath-like HA particles were obtained by Mitsionis
et al.337 when precipitating HA in the presence of spherical TiO2 particles. Lath-like
particles were also obtained in this study after 4 weeks in SBF, however the particles were
much larger (10-100µm) than the HA precipitates described in the literature. The larger
sized HA crystals obtained may be due to the longer soaking periods used (up to 4 weeks)
and the surface properties of the cement inducing specific crystal sizes and morphologies
to nucleate. Although differences in the HA morphologies were found between the results
obtained and the results in the literature, the combination of scanning electron microscopy
(SEM) and X-ray diffraction (XRD) have shown the precipitates to be calcium/HA based
minerals.
All the studies discussed used scanning electron microscopy (SEM) and X-ray diffrac-
tion (XRD) techniques to characterise the HA precipitates. Other techniques that were
used in the literature include, energy-dispersive X-ray spectroscopy (EDS / EDAX)312, 313,
atomic force microscopy (AFM)336 and fourier transform infrared spectroscopy (FTIR)337.
The use of XRD and SEM techniques to characterise apatite on the surface of materials
is specified in the guidelines for the ISO 23317:2007 Standard (Implants for surgery - In
vitro evaluation for apatite-forming ability of implant materials). This standard is based
on a method developed by Kokubo et al.334 and has been used in numerous other stud-
ies247–253. This technique was deemed suitable for establishing the apatite-forming ability
of the novel materials tested, however the use of EDAX/EDS would have proved useful
in quantifying the amount of calcium deposited on the surface of the novel cement samples.
The results from the osteoblast adhesion experiments correlate well with the results ob-
tained from the HA growth experiment. Cement samples containing either treated or
untreated TiO2 were found to have higher numbers of adhered osteoblast-like cells at each
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time point when compared with other cements. The MC3T3-E1 cells on the surface of the
cement samples containing TiO2 were also found to be more spread out and less circular in
shape. Cell spreading is important in osteoblast-like cells as it is the process that follows
adhesion and precedes proliferation315.
Bone cement with silane-treated TiO2 was found to have high levels of cellular adhe-
sion after 1 hour. This may be due to the functional groups of the silane interacting with
the MC3T3-E1 cells. Recent studies have found that MC3T3-E1 osteoblast behaviour
and HA formation is enhanced by the functional groups of silanes311, 331. Similarly, the
silanol group (Si-OH) of silanes was also found to induce apatite formation183. As the
silane-treated ZrO2 did not achieve high levels of adhesion after 1 hour, it can be assumed
that either the combination of TiO2 and the silane contributed to the high adhesion rates,
or the silane treatment did not work for ZrO2 as postulated in the previous chapter.
MC3T3 cells are a strain of tissue culture cells derived from Mus musculus (house mice)
and are widely used as models for osteoblast studies as they are stated to be one of the
most convenient and physiologically-relevant systems for the study of osteoblasts338. Ex-
tracting human osteoblast cells is a complex and time consuming process, therefore the
MC3T3-E1 cell line was used. The use of MC3T3-E1 cells for assessing attachment, pro-
liferation and mineralisation on the surface of materials is well documented254–256.
The adhesion of the MC3T3-E1 cells was tested after 1, 4 and 24 hours incubation as
at these time points cell adhesion is most likely to occur. The proliferation tests were
carried out after 3 and 7 days incubation as proliferation occurs after cell adhesion and
spreading. After 3 days incubation, the majority of MC3T3-E1 cells are likely to have
adhered to the cement surface and begun to proliferate. As cells adhered most quickly
to the silane-treated TiO2 surface it was expected that at 3 days the cell proliferation for
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silane-treated TiO2 would be highest. Cell proliferation however was found to be reduced
by the presence of the silane when compared to other cement samples. The reduction in
cell proliferation was significant for silane-treated ZrO2, but not for silane-treated TiO2.
As the assay method measures the number of living cells, it is possible that the cells
on the surface of the silane-treated TiO2 cement samples attached rapidly, spread and
proliferated but died before the 3 day time point, however between 3 and 7 days incu-
bation, a significant increase in the number of living cells were detected for all cements,
demonstrating cell proliferation still took place. Furthermore the percentage increase in
the number of live cells between 3 and 7 days was found to be highest for cements con-
taining silane-treated TiO2 and ZrO2. Nevertheless, the results for cell proliferation draws
questions with regards to the biocompatibility of the silane used. Although methacry-
loxypropyltrimethoxysilane has been tested in dental and orthopaedic materials, further
biocompatibility testing is required if it is to be used in bone cements.
Overall the results from this study accord with previous publications which state that
anatase TiO2 is beneficial for bone growth in vitro and in animal studies
180, 278, 279, 325.
Further in vitro tests however are required to investigate the cytotoxicity of the silane-
coated TiO2 cements. For example, rat bone chips can be cultured on the surface of the
novel cements to investigate cell behaviour, as a study on coated titanium surfaces has
done339. Once in vitro studies prove successful, in vivo animal trials can then be un-
dertaken. Trials using similar materials have performed tests on rats180, rabbits257 and
sheep138,258.
6.5 Conclusions
Bone cement containing anatase TiO2 demonstrated good bone growth properties as a re-
sult of TiO2 increasing the overall hydrophilicity of the cement. Furthermore silane coating
the anatase TiO2 was found to achieve similar HA growth and improved cell adhesion due
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to the functional groups of the silane interacting with the osteoblast-like cells. The silane
coating however was found to have a detrimental effect on cell proliferation which raises
questions with regards to the biocompatibility of methacryloxypropyltrimethoxysilane.
Although silane coated anatase TiO2 has proven to be an effective radiopacifier with po-
tential to enhance the bone growth properties of PMMA bone cement, further cytotoxicity
testing is required before any form of in vivo testing can be considered.
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Chapter 7
Mechanical and structural changes
in commercial bone cements due to
ageing and moisture uptake
7.1 Introduction
Although there is an extensive literature on bone cement performance, few studies have
been conducted on the ageing and moisture uptake of commercial bone cements and the
effect this has on mechanical and fatigue properties over time. Bone cement fails pre-
dominantly after long-term use and the temperatures and conditions found in vivo may
contribute to this. A study investigating the degradation of bone cement is of clinical
relevance and may provide insight into how conditions experienced in vivo contribute to
cement failure.
The current published standards for acrylic-based resin cements (ISO5833:2002223 , ASTM
F451-08224) are ill-defined and do not completely address the ageing effects of physiological
conditions. In this Chapter the effects of moisture and temperature, at levels similar to
those encountered in vivo, on water uptake, mechanical, fatigue, and structural properties
were studied over time for two commercial cements.
155
Chapter 7. Ageing and moisture uptake of PMMA bone cement
7.1.1 Diffusion in polymers
Polymers have been known to undergo changes in mechanical and rheological properties
when submersed in fluid over time. The extent of these changes can be attributed to the
degree of fluid uptake, the nature of the immersion fluid, the temperature, the composi-
tion of the polymer and the duration of immersion. Typical changes include an increase
in mass and a lowering of the glass transition temperature (Tg, when a polymer changes
from a glassy to a rubbery state)340. The effects of physiological salts, body temperature
(37◦C) and fluid on the compressive strength, flexural properties, fracture toughness and
fatigue properties of bone cements however are still unclear.
Diffusion in polymers is a complex process and difficult to predict. It is known that the
diffusion of a liquid into a polymer is affected by the physical properties of the polymer
network and the interactions between the polymer and the liquid itself. A classification
method was proposed by Alfrey et al.341, whereby diffusion is classified according to the
polymer relaxation rate and liquid diffusion rate. The classifications fall into two cate-
gories, Fickian (Case I) and non-Fickian (Case II and anomalous) and can be related by
Equation 7.1 where Mt is the amount of solvent absorbed per unit area at time t, k is a
constant and n is a parameter related to the diffusion mechanism which lies between 1/2
and 1 342.
Mt = kt
n (7.1)
The majority of polymers are known to follow a Fickian uptake curve (Fick’s second
law343), particularly when the temperature is above the glass transition point (Tg) and
the polymer chains have high mobility, allowing for easy penetration of the liquid344. This
behaviour is characterised by a high polymer relaxation rate, Rrelax, and a low liquid diffu-
sion rate, Rdiff (Rrelax ≫ Rdiff ). The diffusion distance of this mechanism is proportional
to the square root of time and therefore the n parameter is 1/2. Fickian diffusion has been
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observed in polymers with plasticisers below the glass transition temperature and the lit-
erature shows a maximum value for total percentage weight change of roughly 2%50,344.
Interestingly, the diffusion into PMMA of methanol with water was found to follow Fick-
ian diffusion below the glass transition temperature as water acted as a plasticiser, which
increased chain mobility allowing for further water penetration344.
Non-Fickian diffusion is usually observed in glassy polymers below the glass transition
temperature, where the polymer chains are not mobile enough to permit diffusion of
liquids. Two non-Fickian diffusion processes can occur, case II and anomalous. These
processes differ by the rates with which the liquid diffuses into the polymer. For case
II diffusion, the rate is much higher than the polymer relaxation rate (Rdiff ≫ Rrelax),
whilst for anomalous diffusion, the rates are roughly the same (Rdiff ≃ Rrelax). For case
II diffusion, the diffusion distance is directly proportional to time so n is equal to 1 and
for anomalous diffusion, the rate is between that of Fickian diffusion and case II diffusion
so n is between 1/2 and 1 342.
Water uptake in bone cements can arise through any of these diffusion processes, however
Fickian diffusion is most likely as water may act as a plasticiser for bone cements. The
actual mechanism of water uptake in polymers varies but can arise due to fluid occupying
vacancies in the material, such as pores or voids, or by water diffusing between intermolec-
ular spaces.345 With PMMA bone cements, vacancies are created by entrapped air during
mixing and by leaching monomer. Water molecules are also small enough to diffuse into
spaces within radiopacifier agglomerations and between the polymer molecules. The latter
is more pronounced as a result of plasticisation and higher temperatures, which causes the
polymer chains to relax and increase the intermolecular spaces. Fluid can therefore diffuse
into bone cements either without any relationship to the polar molecules in the material
(free volume theory) or it can be governed by specific molecular interactions346, 347 .
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7.2 Methods
7.2.1 Materials
Cemex Isoplastic was obtained from Tecres (Sommacampagna, Italy) and Palacos R
was provided by Heraeus (Newbury, UK). Sodium chloride (≥99.9%), potassium chlo-
ride (≥99%), calcium chloride (≥99%) and sodium bicarbonate (≥99.7%) were purchased
from Fisher Scientific (Fisher Scientific UK Ltd, Loughborough, UK).
7.2.2 Ageing conditions
Cemex Isoplastic and Palacos R compression and bending samples were prepared as de-
scribed in Chapter 2. The compression test samples were weighed to an accuracy of
±0.1mg prior to ageing. Both bending and compression samples were then aged in air at
23◦C for 1, 2, 3, 7, 15 and 60 days or submerged in Ringer’s solution at 37◦C for the same
periods. The Ringer’s solution was replaced every 2 weeks. Ringer’s solution (8.6mg/mL
NaCl, 0.3mg/mL KCl and 0.33mg/mL CaCl2, buffered to a pH of 7.4 with NaHCO3
276)
was selected as it is an isotonic solution and large quantities can be easily prepared. The
solution was buffered to ensure a consistent pH throughout the experiment, as occurs in
vivo. Control samples were aged according to the ISO5833 standard223 in air for 24 hours.
7.2.3 Moisture uptake and mechanical testing
After each time point the compression test samples were removed from their medium and
the surface blotted dry with filter paper. The samples were then weighed and Equation 7.2
was used to establish the percentage change in mass. The samples were then tested in com-
pression and bending samples were tested at each time point as outlined in Sections 2.3.1
and 2.3.2 respectively.
% weight gain =
Mt −Mo
Mo
× 100 (7.2)
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Where:
Mt Weight of the sample at time t
Mo Weight of the sample at start (t=0)
7.2.4 Mathematical modelling
Three different types of diffusion can occur with PMMA bone cements (page 156). To
better understand the type of diffusion taking place, Equation 7.1 (Mt=kt
n) was applied
to moisture uptake at different time points (0-3 days and 3-60 days). As the amount of
solvent absorbed per unit area (Mt) can be indirectly measured by the change in weight of
the material, the total percentage weight change was used. Fickian and case II diffusion
equations were applied to the data and the goodness of fit was investigated using the curve
fitting toolbox in Matlab (MathWorks, Cambridge, UK), which calculated the coefficients
by minimizing the sum of squared residuals. A modification to Equation 7.1, in the form
of an additional coefficient to model leaching components from the cement was made to
better model the data obtained.
7.2.5 Fracture toughness
Fracture toughness was tested for samples aged in air for 24 hours at 23◦C and Ringer’s so-
lution for 60 days at 37◦C as described in Section 2.4 to establish differences between aged
samples and samples tested according to the ageing conditions outlined by the ISO5833
standard.
7.2.6 Fatigue testing
Four fatigue samples of each cement brand were prepared as described in Section 2.5. Two
samples were aged in air at 23◦C and the other two samples were aged in Ringer’s solution
at 37◦C for a minimum of 60 days prior to testing.
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7.2.7 Scanning electron microscopy
Scanning electron microscopy was used to analyse the fracture surfaces of fatigue samples
aged in air and Ringer’s solution.
7.2.8 Vickers hardness
Disc shaped samples were prepared and tested as described in Section 2.6 after 24 hours
ageing in air at 23◦C and 60 days ageing in Ringer’s solution at 37◦C.
7.2.9 Glass transition temperature
The glass transition temperature of samples aged in air for 24 hours and Ringer’s solution
for 60 days at 37◦C was measured as described in Section 2.7.
7.2.10 Structural changes
Structural changes were monitored by Fourier Transform Infrared Spectroscopy (FTIR)
using a Perkin Elmer Spectrum One FT-IR Spectrometer with FT-IR Spectrum software
(Perkin Elmer, Massachusetts, USA) at the Cardiff School of History, Archaeology and
Religion. Measurements were taken between 4000cm−1 and 450cm−1 with a resolution
of 4cm−1. Samples were scanned after being aged 24 hours in air at 23◦C and 60 days
in Ringer’s solution at 37◦C. The surface of aged bending samples was scanned using
attenuated total reflectance (ATR) at 6 different sections on the sample, taking 30 scans
at each section to obtain an average spectrum representative of the entire sample. To
ensure components from the Ringer’s solution did not interfere with FTIR measurements,
samples were washed with deionised water and dried prior to scanning. To obtain a
spectrum representing both the outer and inner parts of the sample a clean and sterile
file was used to remove a small cross section of the sample and 1mg of the sample was
combined and compressed with 100mg of potassium bromide (KBr) in a pestle and mortar
until a fine uniform powder was obtained. The powder was then placed in a disc shaped
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press between two stainless steel disks and subjected to a force of 10kN for 30 seconds,
followed by 100kN for 30 seconds to create discs. Two discs were prepared per sample and
30 scans per sample were carried out to obtain an accurate spectrum.
7.3 Results
7.3.1 Moisture uptake
Figure 7.1 shows the weight changes of Palacos R and Cemex aged in Ringer’s solution at
37◦C or in air over the square root of time. This type of plot was employed to demonstrate
Fickian diffusion, indicated by a linear relationship between moisture uptake and the
square root of time. Both commercial cements aged in Ringer’s solution experienced a
total weight gain of around 1.5-2% whilst samples aged in air experienced a loss in weight
of around 0.3%. The linear portions of the curves for samples aged in Ringer’s solution
occur within the first 7 days (168 hours/12.96 square root of hours), after which water
absorption continued at a slower rate. Equilibrium for both cements was reached after
Figure 7.1: Moisture uptake over time for Cemex and Palacos R in Ringer’s solution and
in air
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30 days and overall Palacos R had greatest moisture uptake at the end of the study (60
days).
7.3.2 Mathematical modelling
Figures 7.2(a) and 7.2(b) show the goodness of fit between the real datum and the datum
obtained from the models. Similarly, Tables 7.1 and 7.2 show the results of modelling
moisture uptake for Cemex and Palacos R respectively. For both cement brands the
modified Equation 7.1 (Mt = b+ kt
n) fit the data most accurately. This equation used an
additional constant (b) to represent the leaching of monomer thereby creating vacancies
for the water to diffuse into. For the first 3 days, both cements fitted a Fickian diffusion
model well (R-value≥0.95) and when using Equation 7.1 (Mt = ktn) Cemex and Palacos
R had n values of 0.526 and 0.354 respectively, signifying a close relationship to Fickian
diffusion. After 3 days however, the diffusion slowed and was no longer Fickian. The
additional coefficient did not improve the goodness of fit for both cements between 3 and
60 days in Ringer’s solution. This demonstrates the leaching monomer does not affect the
moisture uptake after 3 days in Ringer’s solution. The case II diffusion equation produced
the poorest fit for all the data modelled and therefore water absorption was considered to
be non-linear with time.
(a) Cemex (b) Palacos R
Figure 7.2: Moisture uptake data and model data for (a) Cemex and (b) Palacos R over
time in Ringer’s solution
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Table 7.1: Mathematical modelling of diffusion types to moisture uptake results for Cemex
Fickian Case II Equation 7.1
Modified
equation 7.1
Mt = kt
1/2 Mt = kt Mt = kt
n Mt = b+ kt
n
k 0.056 0.001 0.380 1.581
Entire n 0.500 1.000 2.11 0.091
curve b - - - -1.346
R-value 0.2340 -1.0631 0.9144 0.9445
k 0.126 0.017 0.114 0.031
0-3 n 0.500 1.000 0.526 0.801
days b - - - 0.162
R-value 0.9688 0.8662 0.9693 0.9992
k 0.052 0.001 0.798 0.463
3-60 n 0.500 1.000 0.100 0.137
days b - - - 0.400
R-value -0.6748 -28.7763 0.9674 0.9636
Table 7.2: Mathematical modelling of diffusion types to moisture uptake results for Palacos
R
Fickian Case II Equation 7.1
Modified
equation 7.1
Mt = kt
1/2 Mt = kt Mt = kt
n Mt = b+ kt
n
k 0.067 0.001 0.319 0.568
Entire n 0.500 1.000 0.264 0.204
curve b - - - -0.345
R-value 0.6462 -0.3002 0.9719 0.9784
k 0.123 0.016 0.217 0.132
0-3 n 0.500 1.000 0.354 0.451
days b - - - 0.095
R-value 0.9572 0.6390 0.9929 0.9961
k 0.063 0.002 0.526 0.443
3-60 n 0.500 1.000 0.191 0.208
days b - - - 0.103
R-value -0.6748 -5.3414 0.9078 0.9052
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7.3.3 Mechanical properties
Figures 7.3(a), 7.3(b) and 7.3(c) show the compression, bending modulus and bending
strength respectively for Palacos R and Cemex aged in Ringer’s solution at 37◦C and
in air. For all mechanical properties, samples aged in air had significantly higher values
compared to samples aged in Ringer’s solution after 60 days (ANOVA, p=1.98×10−03 for
Palacos R and p=9.07×10−07 for Cemex). At 24 hours, Palacos R had higher compressive
strength but as the cement cured, Cemex became stiffer and stronger in compression.
All compressive strength values were found to reach a maximum after 30 days and all
cements were found to experience a peak in mechanical properties at around 24-48 hours.
For bending strength and bending modulus it was difficult to establish subtle changes
over time due to high variance experienced between samples, caused by the presence
of pores. Nevertheless, after 60 days, Cemex samples aged in air had a significantly
higher bending modulus than samples aged in Ringer’s solution (p=0.02). There was no
significant difference in bending strength after ageing in air or Ringer’s solution after 60
days for Cemex (p=0.13) and Palacos R (p=0.18). Similarly Palacos R samples aged in
air did not have a significantly different bending modulus than samples aged in Ringer’s
solution (p=0.16).
7.3.4 Fracture toughness
From fracture toughness tests, both commercial cements experienced a significant loss
in critical stress intensity factor after ageing in Ringer’s for 60 days (p=2.63×10−03 for
Cemex and p=3.87×10−04 for Palacos R), as shown in Table 7.3.
Table 7.3: Fracture toughness of Cemex and Palacos R cements before and after ageing
in Ringer’s for 60 days
Critical stress intensity factor (KIC) / MPam
1/2
Cemex
Air 1 day 1.7±0.1
Ringer’s 60 days 1.4±0.1
Palacos R
Air 1 day 2.5±0.2
Ringer’s 60 days 1.5±0.3
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(a) Compression
(b) Bending modulus
(c) Bending strength
Figure 7.3: Changes in mechanical properties of Cemex and Palacos R over time in Ringer’s
solution and in air
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7.3.5 Fatigue testing
Figures 7.4(a) and 7.4(b) show the fatigue test results for Cemex and Palacos R re-
spectively when aged in air and in Ringer’s solution at 37◦C for 60 days. Both cements
experienced a reduction in fatigue properties as a result of ageing in Ringer’s solution.
Cemex aged in Ringer’s solution experienced increased crack growth rates for all stress
intensities, whilst Palacos R aged in Ringer’s solution experienced a lesser detrimental
effect on crack growth rates at high stress intensities. The change in crack growth rate for
Palacos R was much more severe as the stress intensity increased as shown by a steeper
slope. These results are highlighted when the Paris Law is applied to the data as shown
in Table 7.4. Cemex samples aged in Ringer’s solution experienced an increase in fatigue
constants ‘A’ and ‘m’, whilst Palacos R increased slightly in fatigue constant ‘A’ and
significantly in fatigue constant ‘m’. All fatigue samples were found to have correlation
coefficients above 0.60 when the Paris Law was applied, demonstrating a moderate to
strong positive correlation between the data and the Paris Law. Palacos R had lower
correlation coefficients when compared to Cemex, due to variations in the crack growth
rates of the samples tested.
Table 7.4: Fatigue test constants of Cemex and Palacos R cements before and after ageing
in Ringer’s for 60 days. ‘A’ is the crack growth at ∆K=1MPam1/2 and ‘m’ is the slope of
the data
A m
Correlation
coefficient
1 day air
60 days
Ringer’s
1 day air
60 days
Ringer’s
1 day air
60 days
Ringer’s
Cemex 5.39×10−07 1.29×10−05 5.92 6.20 0.82 0.86
Palacos R 3.73×10−07 7.34×10−07 4.65 7.33 0.67 0.66
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(a)
(b)
Figure 7.4: Fatigue results for (a) Cemex and (b) Palacos R over time in Ringer’s solution
and air
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7.3.6 SEM images
The fracture surfaces for samples aged in Ringer’s solution for 60 days were found to be
rougher, containing a greater amount of small cracks (Figure 7.5) Fracture surfaces for
both cements were found to have high levels of porosity before and after ageing in Ringer’s
solution.
7.3.7 Vickers hardness
Similar to fracture toughness, both commercial cements experienced a significant reduction
in hardness after ageing in Ringer’s solution at 37◦C for 60 days (p=5.53×10−06 for Cemex
and p=0.03 for Palacos R, Table 7.5).
Table 7.5: Vickers hardness of Cemex and Palacos R cements before and after ageing in
Ringer’s for 60 days
Hardness (HV30/10) / MPa
Cemex
Air 1 day 24.8±2.0
Ringer’s 60 days 19.1±2.0
Palacos R
Air 1 day 19.8±1.8
Ringer’s 60 days 17.5±2.6
7.3.8 Glass transition temperature
Table 7.6 shows the glass transition temperatures obtained by dynamic mechanical thermal
analysis for Cemex and Palacos R before and after ageing in Ringer’s solution for 60 days
at 37◦C. A significant reduction in glass transition temperature was experienced for both
Cemex (p=3.60×10−04) and Palacos R (p=7.12 ×10−04).
Table 7.6: Tg of Cemex and Palacos R cements before and after ageing in Ringer’s for 60
days
Glass transition temperature (Tg) /
◦C
Cemex
Air 1 day 127.3±1.6
Ringer’s 60 days 121.6±1.4
Palacos R
Air 1 day 126.2±3.3
Ringer’s 60 days 117.9±1.2
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(a) ×13 (b) ×70
(c) ×13 (d) ×70
(e) ×13 (f) ×70
(g) ×13 (h) ×70
Figure 7.5: SEM images of the fracture surfaces of (a-b) Cemex aged in air, (c-d) Ce-
mex aged in Ringer’s solution, (e-f) Palacos R aged in air and (g-h) Palacos R aged in
Ringer’s solution - Red arrows indicate the location of PMMA beads, green arrows indicate
radiopacifier particles, blue arrows indicate pores and white arrows indicate microcracks
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7.3.9 Structural changes
Figure 7.6 shows the FTIR spectra obtained using ATR on the surface of samples and Fig-
ure 7.7 shows the FTIR spectra obtained using KBr discs of the cross section of samples for
Cemex and Palacos R before and after ageing in Ringer’s solution. Comparing the molec-
ular structure of PMMA and the FTIR peaks obtained, characteristic bonds that form
PMMA were found to be present in the FTIR spectra. The two peaks between 2850cm−1
and 2950cm−1 represent methylene (CH2) and methyl (CH3) stretches. Sharp peaks found
at 1400cm−1 and 1450cm−1 also represent the methyl group (CH3) of PMMA. Peaks found
between 1300cm−1 and 1500cm−1 are attributed to the bending of CH molecules. The
single peak at 1730cm−1 represents a C=O stretch, the peak at 1250cm−1 represents the
C-C-O stretch, the peak at 1150cm−1 represents an O-C-C stretch and peaks between
1300cm−1 and 900cm−1 represent C-O stretches. ZrO2, the radiopacifier for Palacos R
also has peaks between 2800cm−1 and 2950cm−1, around 1450cm−1, 1370cm−1, 750cm−1
and a broad peak at 500cm−1. BaSO4, used in Cemex has two large peaks located around
1000cm−1 and 550cm−1. These peaks coincide with PMMA peaks and are assumed to be
present.
Several changes occurred to the FTIR spectra as a result of ageing. Increases in peak
intensity signify an increase in the number bonds formed and a shift in the position of
peaks demonstrates a change in one chemical bond in favour of another. It was found that
changes occurred to both cement brands after ageing for 60 days in Ringer’s solution. The
changes were only observed on ATR scans and not when using KBr discs. A decrease in
intensity of peaks located between 2850cm−1 and 2950cm−1 were observed and is char-
acteristic of a transition from unsaturated alkenes (C=C) to saturated alkanes (C-C), as
occurs in the polymerization of MMA in PMMA and also indicates the absence of unre-
acted monomer, which leaches out of the cement over time. Similarly increases in peaks
at 1730cm−1, between 900cm−1 and 1300cm−1 were found, demonstrating an increase in
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Figure 7.6: FTIR spectra using ATR of Cemex and Palacos R after ageing in air for 24
hours and Ringer’s solution for 60 days
Figure 7.7: FTIR spectra using KBr discs of Cemex and Palacos R after ageing in air for
24 hours and Ringer’s solution for 60 days
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the number of C=O and C-O bonds as the cement polymerises and forms new bonds. The
increase in peak intensity of ATR scans demonstrates the slow polymerisation of the outer
layers of the cement over 60 days after mixing.
A peak located at 3000cm−1 began to develop whilst peaks at 2800cm−1 were found
to decrease in intensity for ATR scans. This demonstrates a shift from CH stretches to
OH stretches, which signifies CH bonds are slowly being converted to OH bonds. Similarly
the peak located at 1430cm−1 and the peak located at 1060cm−1 were found to increase
in intensity for ATR scans. This supports the theory that carboxyl groups (-COOH) are
forming. These changes were only present on surface ATR scans and not KBr scans that
use a cross-section of the cement. Therefore water is thought to only penetrate a short
distance and not diffuse deep into the bulk of the cement over 60 days at 37◦C.
7.4 Discussion
The mechanism of moisture uptake and ageing in PMMA bone cements is of clinical rel-
evance as changes to the material properties over time may affect the performance of the
cement and influence the likelihood of failure.
Three processes are thought to occur simultaneously during the ageing of bone cement:
the cement polymerises further over a prolonged period of time, increasing the strength
and modulus of the cement, unreacted monomer and other components will diffuse out of
the cement and water will penetrate into the cement. Although several studies have been
conducted with regards to structural and molecular changes149, 150, 348, few have investi-
gated moisture uptake and mechanical properties as a result of ageing. Therefore, this
chapter considers moisture uptake and changes in mechanical, fatigue and structural prop-
erties using in vitro techniques in an attempt to better understand how in vivo conditions
may contribute to cement failure.
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To fully investigate how cement ages clinically, the cement must be subjected to in vivo
conditions, which would require the removal of working implants. This can only be justi-
fied when implant failure occurs. Should the implant fail, the amount of cement available
for testing would be limited and the cement would have been exposed to high stresses
in the removal process, which in turn would affect the results obtained. The mixing and
implant techniques adopted by the surgeon may also vary, influencing the properties of the
cement, measuring moisture uptake over time would be difficult and all cement samples
would have experienced different loading conditions. Therefore, for this particular study,
in vivo tests were not carried out and cement retrievals were not used. In vitro condition-
ing of pre-moulded samples was adopted with a similar temperature, moisture, pH and
salt concentration as found in vivo. Ringer’s solution contains approximately the same
concentration of Cl− ions found in body and interstitial fluids276. It allowed for individual
samples to be fully immersed and the solution to be changed regularly. Lipid solutions
have been shown to be a preferable ageing medium as they replicate the fatty conditions
found in bone marrow50, however the shelf life of lipid solutions would not suit the time
scale of this study and may have interfered with FTIR measurements.
The increase in weight over time for samples aged in Ringer’s solution was caused by
the diffusion of water into the cement309. Similar levels of moisture uptake (1.8-2%) have
been reported with other polymers50, 349. Although PMMA is a hydrophobic polymer,
studies have shown it to absorb up to 2% of its weight in water350–352. A recent study
by N’Diaye et al.353 demonstrated that PMMA swells when submerged in water. This
increase in mass may be beneficial in reducing shrinkage stresses associated with bone
cements. The commercial bone cements achieved a total moisture uptake of between
1.5% and 2.3%. Palacos R had a greater moisture uptake when compared to Cemex due
to the presence of methyl acrylate in Palacos R, which is more hydrophilic than methyl
methacrylate. Therefore, the composition of the cement plays a role in the extent of mois-
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ture uptake. For both cements, there was a linear relationship between weight change
and the square root of time for the first 7 days. Mathematical modelling demonstrated
that the initial diffusion of water into the cement follows Fickian diffusion, but only up
to 3 days in Ringer’s solution. This result is similar to a study by Grinstead et al.344
where Fickian diffusion was observed below the glass transition point of polymers as re-
sult of the plasticising effect of water. The standard deviations of the results for the
initial moisture uptake period were large, demonstrating variance in the amount of water
absorption. The variability in the levels of moisture uptake after initial immersion has
implications on the efficiency and control of antibiotic release from bone cement. The
decrease in weight experienced by samples aged in air occurred as a result of residual
monomer from the polymerisation reaction evaporating over time. Although a decrease in
weight was demonstrated for samples aged in air, the amount of MMA evaporating fluc-
tuated, with no linear correlation between change in weight and time. It can be assumed
that samples aged in Ringer’s solution also experience leaching of the residual monomer.
This is further highlighted by the improved goodness of fit for the mathematical models
using the additional coefficient for leaching monomer (b). The goodness of fit was only
improved for samples aged in Ringer’s solution up to 3 days. Between 3 and 60 days the
models were not improved when using the additional coefficient. Therefore it is thought
that the leaching monomer does not influence moisture uptake beyond 3 days immersion.
The initial diffusion of water into bone cement is thought to be governed by vacancies in
the cement, whereby leaching monomer molecules are replaced by water molecules. This
mechanism results in a dramatic increase in moisture uptake over the first 3 days, which
slows as the amount of leached monomer reduces. After the initial uptake of water, dif-
fusion between the polymer molecules is thought to take place at a lower rate, as water
molecules slowly diffuse between the polymer chains. This period of moisture uptake may
also be influenced by molecular changes in the cement and the relaxation of the polymer
chains. The plasticising effect of water may increase chain mobility, allowing for water
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to penetrate deeper into the cement. Similarly, porosity in the cement may prolong the
moisture uptake process by creating pathways for further diffusion.
When examining changes in mechanical and structural properties, it was observed that
the cement polymerised slowly over months, creating interpenetrating molecular networks,
which in turn increased the strength and modulus of the cement. The major changes in
mechanical properties occurred within the first few hours after mixing. It was also found
that samples aged in Ringer’s solution for 60 days always had poorer properties than sam-
ples aged in air for the same amount of time. This is due to water acting as a plasticiser
and inducing structural changes and degradation in the polymer matrix as described by
other authors147, 348. Samples aged in Ringer’s solution were found to reach an equilibrium
value for moisture uptake after 30 days, which coincided with the time when equilibrium
values for compression and bending properties were achieved. This would indicate changes
in mechanical properties lessen as water content reaches a maximum. Samples aged in
Ringer’s solution were also found to fail in a less brittle manner. Fatigue samples aged in
Ringer’s solution demonstrated this with rougher fracture surfaces. Schmitt et al.349 found
that long-term soaking in Ringer’s solution improves fatigue crack propagation resistance.
It was theorised that water absorption increases polymer chain mobility and enhances
crack tip blunting. This however, was not observed in this study as fracture toughness
and fatigue properties were reduced after ageing in Ringer’s solution. Degradation of the
cement as a result of ageing may have caused the observed decrease in fracture toughness
and fatigue properties.
The outermost surface of bone cement experiences the most water penetration and there-
fore is more prone to degradation and structural changes as a result of ageing in isotonic
fluid. Hardness tests on the surface of samples demonstrated that the material softened
over time when aged in Ringer’s solution. Furthermore, FTIR scans highlighted structural
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changes on the surface of samples (using ATR), but not through the bulk (cross-section)
of the cement (using KBr). The increase in intensity of peaks for ATR scans may be
attributed to molecular bonds continuously forming on the outermost layers of the ce-
ment. This is consistent with previous studies that state when bone cement is mixed,
polymerisation occurs most rapidly in the centre of the cement mass, where the most heat
is generated, whilst the outermost layers polymerise more slowly and less completely354, 355.
Polymers have been known to undergo hydrolysis when immersed in acidic conditions
at high temperatures. The acid acts as a catalyst for the reaction and under weak acidic
conditions, hydrolysis of the polymer may occur slowly over time. As OH groups were
found to form when bone cement was immersed in Ringer’s solution at 37◦C, it is possible
that hydrolysis of the ester groups of PMMA caused the change in polymeric structure.
Any localised acidic pH in the area of the implant may further accelerate this reaction
in vivo. This process results in the formation of methanol (CH3OH) and carboxylic acid
(-COOH) (as shown in Figures 7.8(a) and 7.8(b) for MMA and PMMA respectively).
This theory has been postulated by other authors and demonstrated using a variety of
techniques149, 150. Bettencourt et al.150 found changes in the wetting properties and the
(a)
(b)
Figure 7.8: Hydrolysis of ester groups in (a) MMA and (b) PMMA
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molecular structure of PMMA bone cement arising from artificial ageing using contact
angle measurements and X-ray photoelectron spectroscopy (XPS). Hughes et al.149 used
gel permeation chromatography (GPC) to demonstrate changes in molecular weight and
FTIR to demonstrate chemical changes in artificially and physiologically-aged cement.
The changes observed by Hughes and Bettencourt were similar to the results of this study.
Oonishi et al.348 also used FTIR to study structural changes of retrieved CMW1 cement
samples. CMW1 cement, however did not undergo structural changes, as experienced
with Cemex and Palacos R in this study. Structural changes in Cemex and Palacos R
were further highlighted by a reduction in the glass transition temperature. Since the
glass transition temperature is dependent upon molecular weight it can be assumed that
a reduction in the molecular weight would also have occurred as a result of ageing. These
findings correlate well with the majority of ageing studies on PMMA148–150, 340. A reduc-
tion in both these properties would result in polymer chains having greater mobility at
body temperature. This greater mobility can be attributed to scission of polymer chains,
via the hydrolysis mechanism outlined above, and would result in the cement behaving in
a more elastic and less brittle manner, as observed in the results.
Overall, moisture uptake in two commercial bone cements were found to reach a max-
imum value of roughly 2% after 30 days. The amount of moisture uptake is dependent
upon the composition of the cement. Initial water absorption is thought to occur via a
Fickian process, governed by vacancies created by the leaching monomer and entrapped
air, after which anomalous diffusion is thought to follow at a slower rate as the polymer
chains relax and increase their intermolecular spacings. Maximum saturation of water was
accompanied by a decrease in the mechanical, fatigue and fracture toughness properties.
The reduction in these properties is attributed to the structural changes that PMMA
undergoes as a result of hydrolysis over time. To prevent hydrolysis, novel hydropho-
bic materials may be incorporated in bone cement to alter surface properties. Gbureck
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et al.182 incorporated a bifunctional coupling agent into the monomer of bone cement
to successfully enhance hydrolysis resistance at the metal-polymer interface. This study
has also highlighted the limitations of the ISO5833 guidelines for testing bone cements,
which obtained significantly different results from aged cements. Physiological conditions
are known to differ greatly from those specified by the standard. Boneloc cement, which
performed to the requirements of the standard at room temperature failed clinically due
to the temperatures experienced in vivo151. Therefore there is a need to improve current
testing standards to address the effects of physiological conditions. Immersion in an iso-
tonic fluid at high temperatures (e.g. 60◦C) for a short period of time may be sufficient
to accelerate the diffusion process and thus, the ageing of the cement.
Although a variety of properties of bone cement after ageing have been investigated, there
are several limitations to this study. The samples were unloaded when aged in a basic
isotonic fluid. In vivo it is expected that the cement will be subjected to loading and
unloading regimes. It is also expected that the environment experienced in vivo is more
hostile with the cement interacting with cells, enzymes, lipid material and wear particles.
This may have a greater impact on the changes experienced in terms of molecular, mechan-
ical and crack propagation properties. A great deal of variance was noted in the bending
properties of aged cement as a result of variance between sample batches. Furthermore,
the results from the tests conducted can be influenced by factors such as porosity and the
presence of stress raisers, such as voids and agglomerations. Static tests do not replicate
the loading conditions that occur in vivo. Nevertheless, the range of in vitro tests em-
ployed, which cover properties and loading conditions relevant to in vivo circumstances,
can be used to establish baseline performance for comparative purposes.
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7.5 Conclusions
Polymers have been known to undergo time-dependant changes in mechanical and rheo-
logical properties when submerged in aqueous fluid. The extent of these changes can be
attributed to the amount of fluid uptake, the type of fluid, the surrounding temperature,
the composition of the polymer and the immersion time340. Initial diffusion of water into
PMMA bone cement was found to be Fickian and governed by the leaching of unreacted
monomer from the cement, which created vacancies for water molecules. The in vitro
ageing conditions resulted in a maximum of 2% change in weight after 30 days, which
significantly affected the properties of the commercial bone cements tested. Not only were
mechanical and fatigue properties of bone cements affected, but structural changes were
also found to occur over time. Structural changes occurred on the outermost layer of the
cement, where high levels of diffusion are thought to take place and where the cement
polymerises most slowly.
The mechanisms of moisture uptake and degradation due to ageing have been investi-
gated. The changes in mechanical and structural properties of cement as a result of
ageing may contribute to the long-term failure of PMMA bone cements.
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Chapter 8
Commercially available antibiotic-
loaded cements
8.1 Introduction
The remaining chapters of this thesis will focus on the delivery of therapeutic agents via
PMMA bone cements. The drug release, mechanical, fatigue and structural properties of
commercially available antibiotic-containing cements are explored in this chapter and the
results will be used for comparison in subsequent chapters.
8.1.1 Antibiotics
Fear of antibiotic resistance has led to a decrease in the local application of antibiotics.
Joint replacement surgery is one of the few conditions where local application remains jus-
tified. Mineralised bone tissue cannot expand and inflammation of adjacent tissue results
in reduced blood flow to the immediate area, which prevents the delivery of therapeutic
agents transported via circulatory blood, necessitating localised delivery of antibiotics.
When implanting artificial joints there is a risk of infection as the presence of a small
amount of bacteria on the surface of the implant may result in a poor surgical outcome.
Bacteria at the implant surface may become sessile by forming a biofilm. If the bacteria in
the biofilm subsequently revert to a planktonic form, infection can be induced in adjacent
tissue. Although antibiotics administered systemically (e.g. intravenously or orally) are
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able to affect planktonic bacteria in the surrounding soft tissue or bone, they are unable
to affect sessile forms of bacteria in biofilms. Therefore, a revision surgery would be re-
quired as the sessile bacteria would act as a reservoir for recurrent infections. To prevent
infections and the need for revision surgeries, it is essential to ensure the eradication of
bacteria immediately after surgery.
The concept for using bone cement as a reservoir for local antibiotic delivery was developed
in 1969 when it was observed that the acrylic monomer of bone cement was eluted from
the cement over a long period of time after setting30. The antibiotics were first introduced
into the cement in the form of a powder. This method proved to be successful and has
since been the method adopted in joint surgery.
The powdered antibiotic is incorporated between a meshwork of PMMA chains throughout
the cement and therefore, the release of the antibiotic is dependent upon the penetration of
water into the cement. As previously discussed in Chapter 7, diffusion of water into bone
cement follows a Fickian relationship and maximum uptake was achieved after roughly 2
months. Although the diffusion of water into the cement is a slow process, it has been
established that powdered antibiotics in PMMA bone cements are released within the first
few minutes up to the first 6 hours356. Furthermore, the release was found to occur from
the surface layers of the cement, with the majority of the antibiotic left inaccessible in the
bulk of the cement194, 218, 357.
Although a high burst of antibiotic in the moments directly following surgery is advanta-
geous in eliminating the majority of the bacteria present, any remaining spores or biofilms
of bacteria may lay dormant and reproduce after the initial burst of antibiotics. This in
turn may develop into an infection over time resulting in the patient requiring a revision
surgery. To overcome this problem, a delivery system is required which provides the initial
182
Chapter 8. Commercially available antibiotic-loaded cements
burst of treatment, followed by a prolonged release of the remaining antibiotic, above in-
hibitory concentrations. This must also be achieved without compromising the mechanical
and fatigue performance of the cement.
When selecting an antibiotic for use in the bone cement, the following properties are
required24:
• High solubility
• Heat stability during polymerisation
• No chemical interaction with PMMA or mediators of polymerisation
• Low effect on the mechanical strength of the cement
• Good release from cured/polymerised bone cement
An antibiotic commonly employed in PMMA bone cements is gentamicin sulphate. Gen-
tamicin is an highly hydrophilic, bactericidal, broad-spectrum antibiotic used for the treat-
ment of various Gram-positive and Gram-negative infections including pathogenic species
of Escherichia, Enterobacter, Klebsiella, Salmonella, Serratia, Shigella, Staphylococcus au-
reus, some Proteus and Pseudomonas aeruginosa. Gentamicin is also heat stable and has
low allergenicity22, however the antimicrobial efficacy of gentamicin is concentration de-
pendent and bacterial barriers and adverse effects such as nephrotoxicity and neurotoxicity
limit its daily dosage when taken systemically358. Gentamicin sulphate is incorporated in
large amounts in PMMA bone cements, roughly 1g per 40g of cement; however, only a
small percentage is released when incorporated as a powder into PMMA bone cement.
Between 2003 and 2009 in England and Wales, the number of hip replacements using
antibiotic-loaded bone cements was found to have increased from 85% to 92%. Similarly
for cemented knee replacements, the use of antibiotic-loaded bone cements increased from
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92% to 96%21. This trend demonstrates the recent popularity of antibiotic-loaded cements
and the need to prevent septic failure. The antibiotic release mechanisms are still not well
understood and the effect of adding powdered antibiotics on the mechanical and fatigue
properties of bone cements is still of concern (see Chapter 1).
In this chapter the antibiotic release and the antimicrobial efficacy of commercially avail-
able cements was investigated. Furthermore, the impact of using powdered gentamicin
sulphate on the mechanical, fatigue and structural properties of commercially available
cements, both before and after elution of the antibiotic, was assessed.
8.2 Methods
8.2.1 Materials
Cemex and Cemex Genta were obtained from Tecres (Sommacampagna, Italy), Palacos R
and Palacos R+G were provided by Heraeus (Newbury, UK) and CMW Smartset GHV
was provided by Depuy (Blackpool, UK). O-phthaldialdehyde (≥97%, HPLC), ethanol
(≥99.8%, HPLC), 2-mercaptoethanol (≥99.0%) and sodium borate (≥99.0%) were ob-
tained from Sigma Aldrich (Gillingham, UK).
8.2.2 Antibiotic release
Commercially available antibiotic-loaded cements (Cemex Genta, Palacos R+G and CMW
Smartset GHV) were prepared as described in Section 2.1. Standard Cemex and Palacos
R bone cement samples were prepared and tested to ensure leaching components of the
cement did not affect measurements of antibiotic release. Table 8.1 shows the composi-
tions of the cements tested. A high-density PTFE mould was manufactured to produce
10mm diameter by 2mm thick cylindrical samples. All samples were finished with a 250
grit silicon carbide sandpaper to the stated dimensions with a tolerance of ±0.2mm. Each
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Table 8.1: Composition of gentamicin containing bone cements
Cemex Cemex Palacos Palacos CMW
Genta R R+G
Smartset
GHV
Liquid component / g 13.30 13.30 18.78 18.80 18.88
Methyl Methacrylate / %w/w 99.10 98.20 97.98 97.87 97.50
N-N Dimethyl-p-Toluidine / %w/w 0.90 1.80 2.02 2.13 2.50
Hydroquinone / ppm 75.00 75.00 60.00 60.00 75.00
Powder Component / g 40.00 40.00 40.00 40.80 40.00
Polymethyl Methacrylate / %w/w 84.30 82.78 84.50 83.27 80.45
Barium Sulphate / %w/w 13.00 10.00 - - -
Benzoyl Peroxide / %w/w 2.70 3.00 0.50 0.50 2.00
Zirconia / %w/w - - 15.00 15.00 14.37
Gentamicin sulphate / %w/w - 4.22 - 1.23 4.22
Powder : Liquid ratio 3.01 3.01 2.13 2.17 2.11
sample weighed 0.40±0.01g and five samples for each test group was examined. Each
sample was stored in 5mL of Ringer’s solution (8.6mg/mL NaCl, 0.3mg/mL KCl and
0.33mg/mL CaCl2, buffered to a pH of 7.4 with NaHCO3
276) at 37◦C. After 6 hours, 1,
2, 3, 7, 15, 30 and 60 days the Ringer’s solution was removed and stored in the dark
at -20◦C before assaying; 5mL of fresh Ringer’s was added as replacement until the next
time point. Ringer’s solution was replaced at the selected time points in order to approach
sink conditions, a condition where the drug concentration in the eluent can be assumed
negligible in comparison to the maximum solubility of the drug.
The solutions were thawed overnight at room temperature in the dark and the concentra-
tion of gentamicin was determined using an o-phthaldialdehyde (PHT) method developed
by Sampath et al.359 and Zhang et al.360, whereby a PHT reagent reacts with the amino
groups of gentamicin sulphate to yield measurable fluorogenic products. The reagent
was prepared by adding 2.5g of o-phthaldialdehyde, 62.5mL of ethanol and 3mL of 2-
mercaptoethanol to 560mL of 0.04M sodium borate solution in distilled water. The PHT
reagent was stored in an amber glass bottle in the dark for 24 hours prior to use.
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Twelve calibration solutions with gentamicin concentrations from 0µg/mL to 100µg/mL in
Ringer’s solution were prepared for the calibration curve. 1mL of the calibration solution
was added to 1mL PHT reagent and 1mL isopropanol and left for 40 minutes to react.
The absorbance was then measured at 340nm using a Hitachi U-1900 spectrophotometer
(Hitachi High-Technologies Europe GmbH, Mannheim, Germany) and a linear relation-
ship between concentration and absorbance was produced. 1mL of the sample eluate was
mixed with 1mL PHT reagent and 1mL isopropanol and left for 40 minutes to react and
its absorbance compared against the calibration graph, in order to determine the con-
centration of gentamicin sulphate released by the samples at each time point. Average
gentamicin concentrations for each time point were calculated from the 5 samples and the
cumulative gentamicin release was calculated over 60 days.
Gentamicin release was also calculated as the cumulative release of gentamicin sulphate as
a percentage of the theoretical maximum amount of gentamicin sulphate in each sample
(Equation 8.1).
Percentage release =
Rc × 5
Gs
× 100 (8.1)
Where:
Rc is the experimental cumulative gentamicin sulphate release in µg/mL
Gs is the amount of gentamicin sulphate in 0.4g of cement in µg
8.2.3 Mathematical modelling
Mathematical models were applied to the antibiotic release data for the commercial bone
cements to better understand release kinetics. In the equations described, Rt is the total
percentage gentamicin sulphate released, t is the time period, n is an exponential function
and k is a diffusion related constant. Equation 8.2 was developed by Korsmeyer et al.361
who stated drug release was exponentially related to time.
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Rt = kt
n (8.2)
Higuchi et al.362 proposed Equation 8.3, whereby the release of drugs is dependent upon
Fickian diffusion of water into the material.
Rt = kt
1/2 (8.3)
Equation 8.4 is associated with a Noyes-Whitney dissolution process363. The Noyes-
Whitney dissolution process states that the dissolution rate of a solid is dependent on
its diffusion coefficient, the surface area of the solid, the concentration at the boundary
layer and the length of the boundary layer.
Rt = k[1− exp(−nt)] (8.4)
Equation 8.5 is an expanded version of Korsmeyer’s work developed by Lindner and Lip-
pold which takes into account an additional coefficient (b) to represent the initial burst of
antibiotics from the surface of the cement364. The additional coefficient was added to the
Higuchi and Noyes-Whitney equations (Equations 8.3 and 8.4) and applied to the release
data.
Rt = b+ kt
n (8.5)
All models were applied to the data using the curve fitting toolbox in Matlab (MathWorks,
Cambridge, UK), which calculates the coefficients by minimizing the sum of squared resid-
uals.
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8.2.4 Agar diffusion assay
10mm diameter by 2mm thick cylindrical bone cement samples were prepared as previ-
ously described. Tryptone soya agar (TSA) was prepared by dissolving 40g of tryptone
soy agar medium in one litre of distilled water. The solution was boiled for one minute
then sterilized in an autoclave at 121◦C for 15 minutes. The solution was allowed to cool
to 45-50◦C before being dispensed into Petri dishes (9cm diameter). The Petri dishes were
cooled to room temperature then stored at 8-15◦C until use.
Staphylococcus aureus (S. aureus) was cultured in tryptic soy broth (TSB) for 18-24 hours
at 37◦C. A sterile cotton swab was used to spread the inoculum across the TSA Petri dish.
The Petri dish was turned by 60◦ and the process was repeated to ensure complete surface
coverage. A 10µg gentamicin disc was placed on the Petri dish as a control and pressure
was applied to the top of the disc to ensure full surface contact. The dish was divided
into segments and the bone cement samples were placed well separated on the agar, in the
same manner. The Petri dish was then incubated at 37◦C for 18-24 hours, after which, the
zones of inhibition around the samples and gentamicin disc were measured. Images of the
zones of inhibition were taken and measured using ImageJ software (National Institutes
of Health, Maryland, USA). The zones of inhibition were measured as the radius of the
zone minus the radius of the sample. Two measurements for each zone of inhibition were
taken, perpendicular to one another. The experiment was repeated in triplicate (n=3).
Observations on the appearance of the bacterial cultures and the zones of inhibition were
also made.
8.2.5 Mechanical properties
Compression and bending samples of Cemex Genta, CMW Smartset GHV and Palacos
R+G were prepared and tested as described in Sections 2.3.1 and 2.3.2. Samples were
tested after 24 hours in air and after ageing in Ringer’s solution at 37◦C for 60 days, with
188
Chapter 8. Commercially available antibiotic-loaded cements
the Ringer’s solution changed every 2 weeks. Results for Cemex and Palacos R cement
were previously reported in Chapter 7.
8.2.6 Fracture toughness
Fracture toughness values for Cemex Genta, Palacos R+G and CMW Smartset GHV were
obtained according to Section 2.4 for samples aged in both air for 24 hours and in Ringer’s
solution at 37◦C for 60 days. Results for Cemex and Palacos R cement were previously
obtained in Chapter 7.
8.2.7 Fatigue testing
Fatigue test samples were prepared and tested as described in Section 2.5. Results were
obtained for samples aged in air for 24 hours and after ageing in Ringer’s solution at 37◦C
for 60 days, with the Ringer’s solution changed every 2 weeks. Results for Cemex and
Palacos R cement were previously obtained in Chapter 7.
8.2.8 SEM images
SEM images of the fracture surfaces of the fatigue test samples were taken as described in
Section 2.8. Higher magnification SEM images of the cement powders were prepared to
study differences in particle morphology, and SEM images of the surfaces following release
of the antibiotic into Ringer’s solution for 60 days were compared with fresh samples.
Cemex and Palacos R fatigue and powder images were taken from Chapter 7.
8.2.9 Vickers hardness
Hardness values for Cemex Genta, Palacos R+G and CMW Smartset GHV were obtained
as described in Section 2.6 for samples aged in air for 24 hours and Ringer’s solution at
37◦C for 60 days, with the Ringer’s solution changed every 2 weeks. Values for hardness
for Cemex and Palacos R were taken from Chapter 7.
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8.2.10 Glass transition temperature
The glass transition temperature (Tg) of Cemex Genta, Palacos R+G and CMW Smartset
GHV were obtained for samples aged in air for 24 hours and Ringer’s solution at 37◦C for
60 days, with the Ringer’s solution changed every 2 weeks, as described in Section 2.7.
Cemex and Palacos R Tg values were taken from Chapter 7.
8.3 Results
8.3.1 Antibiotic release
Figure 8.1 shows the calibration graph obtained using the PHT assay method for vary-
ing concentrations of gentamicin sulphate in Ringer’s solution. A good correlation was
obtained (R-value of 0.9987) and the standard deviations were acceptable. It was noted
that at concentrations approaching 100µg/mL, the standard deviations of the absorbance
values increased resulting in reduced linearity between absorbance and gentamicin sul-
phate concentration. This technique was deemed accurate for absorbance values below 1.6
(gentamicin sulphate concentrations of up to 90µg/mL).
Figure 8.1: Calibration curve for the PHT assay of gentamicin sulphate
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For Cemex and Palacos R bone cements the PHT assay resulted in absorbance values of
0±0.005 for all time points, demonstrating that leached materials from the cement samples
did not react with the PHT reagent and thereby compromise the assay. Figure 8.2 (a) and
(b) shows the cumulative antibiotic release over 72 and 1440 hours (60 days) respectively
for commercially available antibiotic cements. The dashed lines represent the maximum
concentration which might be obtained if all the gentamicin sulphate in the cement sample
had been released. The standard deviations of the assay were found to be below ±7µg/mL,
demonstrating low variance in release between samples and acceptable accuracy within the
assay technique. It was noted that standard deviations were largest for the initial time
points. All cements experienced a burst of gentamicin sulphate release within the first 72
hours. The majority of the release was found to occur within the first 6 hours, after which
the rate of release decreased. After 720 hours, the release of gentamicin sulphate was
found to have reached a maximum with limited further release over the next 720 hours.
Overall Palacos R+G achieved significantly higher antibiotic release than Cemex Genta
(ANOVA, p=2.24×10−04) and CMW Smartset (p=4.63×10−05), which released roughly
half the amount of gentamicin sulphate.
Figure 8.3 shows the total percentage of gentamicin sulphate released from the commercial
cements. Cemex Genta and CMW smartset released only approximately 1.5% of its total
gentamicin sulphate content after 72 hours and 3% after 1440 hours incubation. As both
cements have 1g of gentamicin sulphate per 40g of cement powder, this would result in
roughly 15mg of antibiotic being released after 72 hours and 30mg over the course of 1440
hours from a single dose of cement. Palacos R+G obtained a much higher percentage
release of approximately 6% after 72 hours and 9% after 1440 hours. As Palacos R+G has
0.5g of gentamicin sulphate per 40g of cement powder, this would result in roughly 30mg
of antibiotic being released over 72 hours and 45mg over 1440 hours.
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(a) Gentamicin release over 72 hours
(b) Gentamicin release over 1440 hours
Figure 8.2: Cumulative antibiotic release from Cemex Genta, CMW Smartset GHV and
Palacos R+G bone cement
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(a) Percentage gentamicin release over 72 hours
(b) Percentage gentamicin release over 1440 hours
Figure 8.3: Cumulative percentage release from Cemex Genta, CMW Smartset GHV and
Palacos R+G bone cement
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8.3.2 Mathematical modelling
Table 8.2 shows the coefficient values that most accurately model the experimental antibi-
otic release data using the Korsmeyer-Peppas model, the Higuchi model and the Noyes-
Whitney model for each cement. The table also shows the goodness of fit (R-value)
between the experimental data and the models for each cement brand. The Korsmeyer-
Peppas model was found to best model the antibiotic release for all three commercially
available bone cements. The Higuchi model was found to have the poorest fit with the
experimental data as the antibiotic release was not controlled by a single process alone.
The n coefficient obtained using the Korsmeyer-Peppas model was found to be less than
0.5 for all three cements, demonstrating the antibiotic release was not governed by Fickian
diffusion alone, however this may be as a consequence of the method employed. This is
further highlighted by the poor correlation between the Higuchi model and the experimen-
tal data. The Noyes-Whitney model was found to have a moderate fit, demonstrating the
possibility of dissolution based processes taking place during gentamicin sulphate release
from PMMA bone cements.
Table 8.2: Mathematical modelling of antibiotic release for Cemex Genta, CMW Smartset
and Palacos R+G
Korsmeyer Higuchi Noyes-Whitney
Rt = kt
n Rt = kt
1/2 Rt =
k[1− exp(−nt)]
Cemex Genta
k 0.507 0.094 2.397
n 0.240 0.500 0.015
R-value 0.9783 0.3655 0.8505
CMW smartset
k 0.552 0.100 2.343
n 0.237 0.500 0.020
R-value 0.9726 0.3320 0.9151
Palacos R+G
k 2.421 0.696 7.827
n 0.284 0.500 0.011
R-value 0.9559 -0.4704 0.8204
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Table 8.3 shows the coefficient and correlation values obtained when an additional co-
efficient (b) was added to the Korsmeyer-Peppas model (as developed by Lindner and
Lippold364), the Higuchi model and Noyes-Whitney model for each cement to represent
the burst-type release of gentamicin sulphate from the surface of the cements. The good-
ness of fit between the experimental data and the expanded models were all improved
by the additional coefficient. The expanded Korsmeyer-Peppas model produced the most
accurate model, followed by the expanded Noyes-Whitney model and then the expanded
Higuchi model. The improved fit of the expanded Higuchi model demonstrates a burst
type release of gentamicin from the surface of the cement, followed by a much slower
release, controlled by diffusion into the cement. For both the expanded Noyes-Whitney
and the expanded Higuchi models, the burst coefficient was positive. For the expanded
Korsmeyer-Peppas model however, the coefficient was negative and the reason for this is
not understood.
Table 8.3: Mathematical modelling of antibiotic release for Cemex Genta, CMW Smartset
and Palacos R+G using the additional coefficient
Expanded
Korsmeyer
Expanded
Higuchi
Expanded
Noyes-Whitney
Rt = b+ kt
n Rt = b+ kt
1/2 Rt =
b+ k[1− exp(−nt)]
k 4.687 0.058 1.874
Cemex n 0.065 0.500 0.006
Genta b -4.700 0.844 0.734
R-value 0.9988 0.9012 0.9602
k 6.333 0.061 1.998
CMW n 0.054 0.500 0.007
Smartset b -6.367 0.917 0.733
R-value 0.9955 0.8919 0.9582
k 24.487 0.160 5.541
Palacos n 0.039 0.500 0.010
R+G b -23.426 3.764 2.744
R-value 0.9885 0.8337 0.9570
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Figure 8.4 shows the goodness of fit between the experimental data and the values obtained
using the mathematical models. As previously discussed, for all three commercial cements
the Higuchi model demonstrated the poorest fit. The expanded Korsmeyer-Peppas model
demonstrated the best fit for all three models. All models were found to be improved
by the additional coefficient representing a burst of gentamicin sulphate release from the
surface of the cement.
8.3.3 Agar diffusion assay
Good surface coverage of S. aureus was achieved on the agar plates using the technique
described. Figure 8.5 shows the average zones of inhibition obtained for commercially
available bone cements using a method based on the Kirby-Bauer agar diffusion assay.
Susceptibility of strains may be defined as those with a zone of inhibition greater than
2mm 365.
Consistent zones were obtained for the 10µg gentamicin discs, demonstrating the strain
of S. aureus used was susceptible to gentamicin sulphate. The standard deviations for
each 10µg gentamicin disc was small, reflecting the symmetrically circular zones obtained.
Furthermore, the samples produced zones of similar diameter, demonstrating a consistent
amount of gentamicin sulphate was released.
The commercial bone cements without gentamicin sulphate (Cemex and Palacos R) did
not produce zones of inhibition and therefore showed no antimicrobial properties. Cemex
Genta gave large zones of inhibition, however the results were not consistent as one of the
samples was found to have a significantly smaller zone of inhibition. The standard devia-
tions for each sample was small, demonstrating even diffusion of gentamicin sulphate from
the surface of the sample. Palacos R+G had one of the largest zones of inhibition, however
there were significant differences between samples. The standard deviation obtained from
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(a) Cemex Genta
(b) CMW Smartset
(c) Palacos R+G
Figure 8.4: Antibiotic release models for (a) Cemex Genta, (b) CMW Smartset and (c)
Palacos R+G
197
Chapter 8. Commercially available antibiotic-loaded cements
Figure 8.5: Average zones of inhibition for commercially available cements
one of the sample was particularly large due to an irregular-shaped zone. Overall, Palacos
R+G produced substantially variable zones of inhibition. CMW was found to be the most
consistent cement, obtaining similar zones to the 10µg gentamicin discs with acceptable
standard deviations and minimum variation between samples.
Figure 8.6 shows images of the zones of inhibition obtained for the commercially available
cements and the 10µg gentamicin control disc. As discussed, even release of gentamicin
sulphate was obtained for the 10µg gentamicin discs and CMW bone cement. There were
no zones of inhibition for commercial cements without antibiotic. Cemex Genta produced
a slightly oval shaped zone and Palacos R+G demonstrated poor antimicrobial efficacy
for two of the samples tested.
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(a) (b) (c) (d) (e) (f)
(g) (h) (i) (j) (k) (l)
(m) (n) (o) (p) (q) (r)
Figure 8.6: Zones of inhibition for (a-c) 10µg discs, (d-f) Cemex, (g-i) Cemex Genta, (j-l)
Palacos R, (m-o) Palacos R+G and (p-r) CMW
8.3.4 Mechanical properties
The mechanical properties of the commercially available cements before and after age-
ing in Ringer’s solution for 60 days are shown in Table 8.4. All of the cements tested
experienced a significant reduction in compressive strength (p<0.05), with the excep-
tion of Cemex bone cement, which demonstrated a significant increase (p=0.01). There
was no significant difference between Cemex and Cemex Genta at 24 hours air exposure
(p=0.09), however after 60 days in Ringer’s solution, Cemex was found to be significantly
stronger in compression when compared to Cemex Genta (p=6.07×10−05). After 24 hours
air exposure, the addition of gentamicin sulphate to Palacos R significantly reduced the
compressive strength of the cement (p=2.74×10−03). After 60 days in Ringer’s solution
however, there was no significant difference between Palacos R and Palacos R+G (p=0.15).
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Table 8.4: Mechanical properties of commercially available cements before and after ageing
in Ringer’s for 60 days
Compressive
strength (σc) /
MPa
Bending
modulus (Eb) /
MPa
Bending
strength (B) /
MPa
Cemex
Air 1 day 85.2±4.2 3080±204 46.0±6.5
Ringer’s 60 days 92.7±2.5 2540±92 37.6±0.2
Cemex Air 1 day 89.7±2.1 3160±128 49.1±3.6
Genta Ringer’s 60 days 81.9±1.9 2840±80 50.4±3.8
Palacos R
Air 1 day 104.6±2.6 3460±97 73.4±2.9
Ringer’s 60 days 75.5±5.7 3180±80 69.4±0.6
Palacos R+G
Air 1 day 95.7±3.3 3110±110 66.6±2.4
Ringer’s 60 days 80.3±3.3 2790±155 50.4±7.0
CMW Air 1 day 85.8±2.6 3290±264 68.7±4.3
Smartset Ringer’s 60 days 80.7±4.0 2080±225 48.3±4.5
In terms of bending modulus, all cements experienced a significant reduction as a result
of ageing in Ringer’s solution for 60 days (p<0.05). There was no significant difference
after 24 hours between the bending moduli of Cemex and Cemex Genta (p=0.53). After
ageing in Ringer’s solution, Cemex Genta was found to have significantly higher bending
modulus (p=7.92×10−03). With Palacos cement, the addition of gentamicin sulphate sig-
nificantly reduced the bending modulus at both 24 hours in air (p=2.41×10−03) and 60
days in Ringer’s solution (p=0.02).
Palacos R+G, CMW and Cemex cement were found to have significantly reduced bending
strength after ageing in Ringer’s solution for 60 days (p=1.27×10−03, p=1.18×10−04 and
p=0.02 respectively), whilst there was no significant difference for the other cements as a
result of ageing in Ringer’s solution (p=0.14 for Palacos R and p=0.62 for Cemex Genta).
There was no significant difference in bending strength between Cemex and Cemex Genta
at 24 hours (p=0.42). After 60 days in Ringer’s solution however, Cemex Genta was found
to be significantly stronger than Cemex cement (p=6.34×10−03). For Palacos cement, the
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addition of gentamicin sulphate was found to significantly reduce the bending strength at
both 24 hours in air (p=8.06×10−03) and 60 days in Ringer’s solution (p=0.01).
8.3.5 Fracture toughness
The fracture toughness of Cemex, Palacos R and CMW were found to be significantly
reduced (p=2.62×10−03, p=3.87×10−03 and p=2.23×10−03 respectively) as a result of
ageing in Ringer’s solution for 60 days, as shown in Table 8.5. After 24 hours in air, the
addition of gentamicin sulphate did not significantly affect the fracture toughness (p=0.30
for Cemex and p=0.81 for Palacos). After 60 days in Ringer’s solution, the fracture
toughness of the cements with gentamicin sulphate were found to be significantly higher
over their antibiotic-free counterparts (p=3.78×10−04 for Cemex and p=8.31×10−04 for
Palacos).
Table 8.5: Fracture toughness of commercially available cements before and after ageing
in Ringer’s for 60 days
Critical stress intensity factor
(KIC) / MPam
1/2
Cemex
Air 1 day 1.7±0.1
Ringer’s 60 days 1.4±0.1
Cemex Genta
Air 1 day 1.6±0.1
Ringer’s 60 days 1.8±0.1
Palacos R
Air 1 day 2.5±0.2
Ringer’s 60 days 1.5±0.3
Palacos R+G
Air 1 day 2.5±0.1
Ringer’s 60 days 2.4±0.2
CMW Smartset Air 1 day 2.2±0.1
GHV Ringer’s 60 days 1.8±0.1
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8.3.6 Fatigue testing
Figure 8.7 shows the fatigue results obtained for antibiotic-loaded and unloaded cements
after ageing in air. The crack growth rates were found to be higher for cements with
gentamicin sulphate when compared to cements without gentamicin sulphate.
Figure 8.7: Fatigue results from commercially available antibiotic-loaded and unloaded
bone cements
The fatigue results obtained for antibiotic-loaded cements after ageing in Ringer’s solution
for a minimum of 60 days are shown in Figure 8.8. No distinguishable differences were
observed in terms of crack growth rates as a result of ageing in Ringer’s solution for 60
days.
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Figure 8.8: Fatigue results from commercially available antibiotic-loaded bone cements
before and after ageing in Ringer’s at 37◦C in Ringer’s solution
Table 8.6 shows the fatigue constants obtained when the Paris Law was applied to the
experimental data. CMW Smartset GHV aged in air for 24 hours performed the poorest
with very high crack growth rates at high stress intensities, whilst Palacos R+G was found
to perform the best in terms of fatigue crack propagation. In terms of crack growth rate
at ∆K=1MPam1/2, the ‘A’ coefficient, there was a reduction for Cemex, Cemex Genta
and Palacos R as a result of ageing in Ringer’s solution, whilst there was an increase for
Palacos R+G and CMW. The addition of gentamicin sulphate to Cemex and Palacos R
cements was found to increase the ‘A’ coefficient at both 24 hours in air and 60 days in
Ringer’s solution.
The slope of the plot (‘m’ coefficient), which represents the change in crack growth rate
as stress intensity increases, was found to increase for all the cements (except CMW) as a
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Table 8.6: Fatigue test constants of commercially available cements before and after ageing
in Ringer’s for 60 days. ‘A’ is the crack growth at ∆K=1MPam1/2 and ‘m’ is the slope of
the data
A m
Correlation
coefficient
1 day air
60 days
Ringer’s
1 day air
60 days
Ringer’s
1 day air
60 days
Ringer’s
Cemex 5.39×10−07 1.29×10−05 5.92 6.20 0.82 0.86
Cemex Genta 7.17×10−05 1.64×10−04 6.99 7.42 0.89 0.79
Palacos R 3.73×10−07 7.34×10−07 4.65 7.33 0.67 0.66
Palacos R+G 2.62×10−06 1.13×10−06 5.01 5.18 0.81 0.74
CMW
Smartset
GHV
1.39×10−04 2.49×10−06 11.71 6.95 0.86 0.88
result of ageing in Ringer’s solution. Furthermore, the ‘m’ coefficient was found to increase
as a consequence of using gentamicin sulphate in Cemex and Palacos R after 24 hours in
air. Similarly, after 60 days in Ringer’s solution, the addition of gentamicin sulphate to
Cemex cement resulted in an increase in the ‘m’ coefficient. The correlation coefficient for
all cements was acceptable (≥0.66), demonstrating a moderate correlation between the
experimental datum and the applied Paris Law. It was observed however, that the corre-
lation coefficient for Cemex Genta and Palacos R+G was reduced after ageing in Ringer’s
solution, demonstrating high variability in crack growth rates for stress intensities tested.
8.3.7 SEM images
Figures 8.9 to 8.11 show the SEM images of the fatigue fracture surfaces. All cements
were found to have pores due to entrapped air during the mixing process. As discussed in
Chapter 7, all cements were found to have a rougher fracture surface as a result of ageing
in Ringer’s solution. Samples with gentamicin sulphate were found to have significantly
more pores than samples without and the pores were found to be irregular in shape and
204
Chapter 8. Commercially available antibiotic-loaded cements
(a) Air ×13 (b) Air ×70
(c) Ringer’s ×13 (d) Ringer’s ×70
(e) Air ×13 (f) Air ×70
(g) Ringer’s ×13 (h) Ringer’s ×70
Figure 8.9: Fracture surfaces of fatigue samples aged in air and Ringer’s solution for (a-
d) Cemex and (e-h) Cemex Genta - Red arrows indicate the location of PMMA beads,
green arrows indicate radiopacifier particles, blue arrows indicate pores and white arrows
indicate microcracks. Magnification at ×13 and ×70.
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(a) Air ×13 (b) Air ×70
(c) Ringer’s ×13 (d) Ringer’s ×70
(e) Air ×13 (f) Air ×70
(g) Ringer’s ×13 (h) Ringer’s ×70
Figure 8.10: Fracture surfaces of fatigue samples aged in air and Ringer’s solution for (a-d)
Palacos R and (e-h) Palacos R+G - Red arrows indicate the location of PMMA beads,
green arrows indicate radiopacifier particles, blue arrows indicate pores and white arrows
indicate microcracks. Magnification at ×13 and ×70.
206
Chapter 8. Commercially available antibiotic-loaded cements
(a) Air ×13 (b) Air ×70
(c) Ringer’s ×13 (d) Ringer’s ×70
Figure 8.11: Fracture surfaces of fatigue samples aged in air and Ringer’s solution for
(a-d) CMW Smartset GHV - Red arrows indicate the location of PMMA beads, green
arrows indicate radiopacifier particles, blue arrows indicate pores and white arrows indicate
microcracks. Magnification at ×13 and ×70.
size, ranging from 10-200µm in length. Closer examination of the fracture surfaces of Ce-
mex Genta and CMW Smartset GHV cements prior to ageing in Ringer’s solution found
very small (10µm) round beads of gentamicin sulphate. After ageing, in Ringer’s solution,
a high number of 10µm pores were found on the fracture surfaces of Cemex Genta and
CMW Smartset GHV cements.
The SEM images of the antibiotic release assay samples are shown in Figures 8.12 to
8.14. The surface roughness of all samples were similar due to polishing with the same
grade silicon carbide paper. All cements prior to incubation were found to have few to no
pores on the surface of the sample. Similarly, after 1440 hours incubation, the samples
without gentamicin sulphate were found to have few to no pores. Samples with gentamicin
sulphate however, had significantly higher levels of porosity on the surface of the cement
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(a) 0 hours ×13 (b) 0 hours ×70
(c) 1440 hours ×13 (d) 1440 hours ×70
(e) 0 hours ×13 (f) 0 hours ×70
(g) 1440 hours ×13 (h) 1440 hours ×70
Figure 8.12: Surfaces of antibiotic release samples at 0 hours and after 1440 hours (60 days)
in Ringer’s solution for (a-d) Cemex and (e-h) Cemex Genta - Red arrows indicate PMMA
beads, green arrows indicate radiopacifier particles and blue arrows indicate gentamicin
sulphate particles or pores created by the release of gentamicin sulphate. Magnification
at ×13 and ×70.
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(a) 0 hours ×13 (b) 0 hours ×70
(c) 1440 hours ×13 (d) 1440 hours ×70
(e) 0 hours ×13 (f) 0 hours ×70
(g) 1440 hours ×13 (h) 1440 hours ×70
Figure 8.13: Surfaces of antibiotic release samples at 0 hours and after 1440 hours (60 days)
in Ringer’s solution for (a-d) Palacos R and (e-h) Palacos R+G - Green arrows indicate
radiopacifier particles, blue arrows indicate gentamicin sulphate particles or pores created
by the release of gentamicin sulphate. Magnification at ×13 and ×70.
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(a) 0 hours ×13 (b) 0 hours ×70
(c) 1440 hours ×13 (d) 1440 hours ×70
Figure 8.14: Surfaces of antibiotic release samples at (a-b) 0 hours and (c-d) after 1440
hours (60 days) in Ringer’s solution for CMW Smartset GHV - Red arrows indicate PMMA
beads and blue arrows indicate gentamicin sulphate particles or pores created by the release
of gentamicin sulphate. Magnification at ×13 and ×70.
after incubation. Furthermore, the pores were found to be irregular in shape and ranging
from 50-200µm in length. The increased porosity was not caused by entrapped air during
mixing or the removal of PMMA beads.
The powder component of the cements tested is illustrated in Figure 8.15. Cemex ce-
ments were found to have a more fused powder morphology, whilst Palacos and CMW
cements had clear individual PMMA beads with sizes ranging from 10µm to 100µm. The
remainder of the powder component consisted of smaller radiopacifier particles and gen-
tamicin sulphate particles. Cemex Genta and CMW were found to have similar gentamicin
sulphate morphologies in the form of small (≃10µm) beads. Palacos R+G was found to
have irregular shaped crystalline (5-20µm) gentamicin sulphate particles.
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(a) ×226 (b) ×226
(c) ×226 (d) ×226
(e) ×226
Figure 8.15: SEM images of the powder component of (a)Cemex, (b) Cemex Genta, (c)
Palacos R, (d) Palacos R+G and (e) (c) CMW Smartset GHV - Red arrows indicate
PMMA beads, green arrows indicate radiopacifier particles and white arrows indicate
gentamicin sulphate particles
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8.3.8 Vickers hardness
All samples were found to have a reduced hardness value after ageing in Ringer’s solution
for 60 days (Table 8.7). The reduction was found to be significant for Cemex, Palacos R
and Palacos R+G (p=5.53×10−06, p=0.03 and p=9.21×10−04 respectively). There was
no significant difference in hardness as a result of adding gentamicin sulphate to Cemex
cement (p=0.92 after ageing in air and p=0.08 after ageing in Ringer’s solution for 60 days).
Similarly, the hardness of Palacos cement was not affected by gentamicin sulphate when
tested after ageing in air (p=0.23), however after ageing in Ringer’s solution, the hardness
of Palacos was significantly reduced by the addition of gentamicin sulphate (p=0.02).
Table 8.7: Vickers hardness of commercially available cements before and after ageing in
Ringer’s for 60 days
Hardness (HV30/10) / MPa
Cemex
Air 1 day 24.8±2.0
Ringer’s 60 days 19.1±2.0
Cemex Genta
Air 1 day 24.6±5.0
Ringer’s 60 days 21.3±3.3
Palacos R
Air 1 day 19.8±1.8
Ringer’s 60 days 17.5±2.6
Palacos R+G
Air 1 day 18.7±1.8
Ringer’s 60 days 14.4±3.0
CMW Smartset
Air 1 day 21.7±0.9
Ringer’s 60 days 20.2±2.2
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8.3.9 Glass transition temperature
All samples, with the exception of Palacos R+G were found to have a significantly lower
glass transition temperatures as a result of incubation in Ringer’s solution for 60 days,
as shown in Table 8.8 (p<0.05). The addition of gentamicin sulphate to Palacos R was
found to significantly reduce the glass transition temperature of the cement when tested
after 24 hours in air (p=1.18×10−04).
Table 8.8: Tg of commercially available cements before and after ageing in Ringer’s for 60
days
Glass transition temperature
(Tg) /
◦C
Cemex
Air 1 day 127.3±1.6
Ringer’s 60 days 121.6±1.4
Cemex Genta
Air 1 day 128.5±3.8
Ringer’s 60 days 121.1±1.9
Palacos R
Air 1 day 126.2±3.3
Ringer’s 60 days 117.9±1.2
Palacos R+G
Air 1 day 115.4±1.2
Ringer’s 60 days 117.6±1.5
CMW Smartset GHV
Air 1 day 121.9±7.3
Ringer’s 60 days 109.9±0.8
8.4 Discussion
The use of gentamicin sulphate in PMMA bone cement as a local drug delivery system is
growing in popularity due to its success in preventing post-operative infections. It is dis-
puted however, whether the use of powdered gentamicin sulphate has a detrimental effect
on the performance of PMMA. Furthermore, concern has been raised with regards to the
growing number of antibiotic resistant bacteria present in patients with antibiotic-loaded
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cements. The work in this chapter has investigated the antibiotic release, the antimicrobial
activity and the mechanical and fatigue properties of three commercially available cements.
The PHT assay used in this study was found to be an accurate and useful measure for
establishing release profiles of antibiotic-loaded cements, allowing for multiple samples to
be tested quickly and easily. This method was not affected by materials leached from the
cement. A static release test was performed, as used by Dunne et al.194; this was unlike
the dynamic elution tests used by other authors197,356, which involves continuous mixing.
The advantage of the static method was that it allowed for multiple samples from each
test group to be tested over extended periods of time, however, this method does not
replicate the continuous circulation of blood as occurs in vivo and concentration barriers
affecting the release of the antibiotic are known to occur in static release tests. In this
experiment however, the replacement of Ringer’s solution reduced the long-term build up
of concentration barriers. Furthermore, immersion of samples in 5mL of fluid ensured sink
conditions were maintained, as the antibiotic concentrations obtained can be considered
negligible in comparison to the maximum solubility of gentamicin sulphate (50mg/mL).
The standard deviations for the first time points of the release assay were found to be
large due to the uncontrolled release of gentamicin sulphate from the surface of the ce-
ment. This result agrees with previous publications, whereby a burst of antibiotic re-
lease from the surface layers of the cement samples was experienced within the first 6
hours194, 218, 356, 357. This poses significant problems in vivo as any bacteria unaffected
by the initial release of antibiotic may cause infections at a later time. Palacos R+G
was found to release significantly more gentamicin sulphate than the other cements, even
though the formulation contains half the amount of gentamicin sulphate. The enhanced
release may be attributed to the composition of the cement encouraging certain release
mechanisms or the morphology of the gentamicin sulphate used.
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A maximum of 10% of the total amount of gentamicin sulphate incorporated was released
over 60 days, leaving the majority of the antibiotic entrapped in the bulk of the cement. A
maximum of 50mg of gentamicin sulphate was released over the 60 day incubation period.
This dosage is locally administered and is a much more efficient treatment method as
systemic treatment requires significantly higher doses due to poor uptake (3-6mg/kg body
weight for children, adolescents and adults with normal renal function). Although local
delivery is more effective in preventing implant infection, a greater and more prolonged
release of antibiotic would reduce the likelihood of bacterial activity.
The in vitro release concentrations obtained are expected to differ from concentrations
found in vivo. Nevertheless, the experiment has highlighted key information on the type of
release expected to occur in vivo. A recent study has shown that the minimum inhibitory
concentration (MIC) of gentamicin for S. aureus strains isolated from orthopaedic im-
plants was 16-32µg/mL366 . Although the initial release of antibiotics from the commercial
cements tested were found to be above the MIC, low sub-inhibitory levels were found to
occur over prolonged periods of time after the initial burst of antibiotic. Subjecting bacte-
ria to levels of antibiotic below the MIC has been shown to contribute to the development
of resistant strains366, 367. Furthermore, studies have found gentamicin resistant bacteria
to be present post-operatively when gentamicin-loaded cements were used368, 369. There is
therefore a need for prolonged release of antibiotics from bone cement, maintained above
minimum inhibitory levels in order to prevent infections and the formation of resistant
bacteria.
Results from the mathematical models demonstrated that antibiotic release from bone
cements was not governed by diffusion alone. Previous studies have postulated that water
cannot diffuse into glassy polymers such as PMMA below the Tg, rather, water penetrates
the cement through voids and cracks on the surface370, 371. The results from Chapter 7
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however, have shown that a certain degree of diffusion takes place. The additional burst
coefficient improved the accuracy of all the models as it accounts for the initial release of
antibiotics from the surface of the cement. After the initial surface release, water may pen-
etrate the cement via pores and to a certain extent diffusion through the polymer chains,
releasing more gentamicin from layers below the surface, but at a slower rate. This finding
agrees with other authors who have hypothesised that initial water penetration may create
channels by which gentamicin may elute out towards the surface of the cement197. These
theories also provide an explanation for the goodness of fit of the Noyes-Whitney disso-
lution model. The expanded Korsemeyer-Peppas model developed by Lindner et al.364,
which states that antibiotic release is governed by release from the surface of the cement
and is exponentially related to time, was found to most accurately model the antibiotic
release for all the cements. Other studies have shown that the Khun and Wilson model372,
which combines all three factors discussed (surface release, dissolution and diffusion), pro-
vides a good fit for antibiotic release from bone cements. An extensive review has been
conducted by Lewis et al.373 highlighting the different release models proposed in the
literature.
Recent studies have shown that the rate of drug release from bone cement is affected
by the mixing technique employed due to the varying porosities obtained203, 204. The sam-
ples tested were all prepared in a similar manner with the same surface roughness and
few surface pores was detected prior to the release assay. Furthermore, cements without
gentamicin were found to have no pores after incubation. Therefore, it is hypothesised
that the antibiotic release from the surface of the cement creates pores, which allows water
to diffuse further into the cement through subsequent pore generation.
From the antimicrobial assays, it was found that the strain of S. aureus used was sus-
ceptible to gentamicin sulphate. The 10µg control discs produced consistent zones of inhi-
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bition, demonstrating the validity of the assay. Cements without antibiotics were found to
have no antimicrobial properties, highlighting the need for a therapeutic delivery system in
PMMA bone cement. The use of 1g of powdered gentamicin sulphate per 40g of cement for
Cemex Genta and CMW and 0.5g per 40g of cement for Palacos R+G produced moderate
antimicrobial activity. Cemex Genta and Palacos R+G samples were found to produce
irregular shaped zones and a high level of variation between samples. This is likely due to
the poor dispersion of gentamicin sulphate on the surface of the cement, which results in
an uneven diffusion of antibiotic through the agar, creating irregular shaped zones. Similar
studies have also shown gentamicin sulphate to agglomerate in PMMA bone cement194.
This is due to incompatibilities in terms of hydrophobicity/hydrophilicity between PMMA
and gentamicin sulphate resulting in an heterogeneous system with multiple phases.
Although Palacos R+G was found to achieve the best antibiotic release in Ringer’s solu-
tion, it did not consistently perform as well on agar against bacteria. In agar diffusion
tests, the gentamicin diffuses from surface layers of the cement into the agar and creates
a zone in which bacterial growth is inhibited. This is an effective test as it demonstrates
the efficacy of the delivery system against bacteria commonly found in orthopaedic infec-
tions. In vivo the cement is assumed to be in direct contact with bone tissue and the
diffusion test has shown that poor dispersion of antibiotics on the surface of the cement
may not fully inhibit bacteria dispersed around the implant. As zone size is a function of
the diffusion rate through the agar, the potency of the antibiotic and the growth of the
bacteria, smaller inhibition zones do not always imply less inhibitory action. This tech-
nique therefore, can only been used for qualitative purposes. Similar techniques have been
used in other studies to assess the antimicrobial activity of different antibiotics in bone
cement216,374. The ability of the antibiotic-loaded cements to prevent biofilm formation is
another index of its efficacy. Previous studies have shown that using powdered gentamicin
sulphate in PMMA bone cement does not prevent the formation of biofilms194, 198, 214, 216.
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In terms of mechanical properties and glass transition temperature, the use of powdered
gentamicin sulphate did not affect Cemex bone cement, however a reduction was observed
when antibiotic was employed in Palacos cement. When testing hardness and fracture
toughness, both cements were not affected by the addition of gentamicin sulphate powder.
Therefore, the impact of using gentamicin sulphate powder is thought to be dependent
upon the cement composition and the type of test performed. The lack of conclusive
results from static tests accords with the view of Dunne et al.194 who stated “antibiotic
does not play an active role in the mechanical performance of the cement when it is being
statically loaded within its elastic region”.
Ageing in Ringer’s solution for 60 days resulted in the elution of powdered gentamicin
sulphate from the commercial cements and as a consequence of this, a reduction was ob-
served in the majority of the properties tested. What is known from studies reported
in Chapter 7, however, is that aged cements experience a change in static properties re-
gardless of the presence of gentamicin sulphate. Nevertheless, increased porosity due to
antibiotic elution can contribute to reductions in mechanical properties. In similar studies,
the addition of supplementary amounts of gentamicin was found to decrease the mechan-
ical and fatigue properties of PMMA bone cements194, 196, 202, 375–377. This was linked to
agglomerations of gentamicin sulphate when more than 0.5g of gentamicin sulphate per
40g of cement was used, which resulted in large pores after elution.
When testing fatigue crack propagation, the results demonstrated that the addition of
gentamicin sulphate powder increased the crack growth rates for all the cement brands
tested. After antibiotic elution, the fatigue crack propagation was not significantly differ-
ent most probably because the greatest proportion of the antibiotic had not been released.
Nevertheless increased porosity was observed in cements with powdered gentamicin sul-
phate, and this may ultimately have a detrimental effect on the performance of the cement.
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A higher number of pores were found on the surfaces of gentamicin sulphate containing
samples used in the release assay. This agrees with the hypothesis that initial antibiotic
release creates porosity on the surface of samples, which then allows further penetration
of water into the cement. The porosity observed is also thought to create stress concen-
trations upon loading, which weakens the cement.
The morphology of the gentamicin sulphate powder in the cements tested was found to be
different. The gentamicin sulphate in Palacos R+G was seen to have a more crystalline
and irregular shape whilst CMW and Cemex Genta had smaller rounded particles of gen-
tamicin sulphate. The shape and size of the antibiotic particle has been known to play a
vital role on the dose and duration of the release378. Antibiotics in the form of crystalline
particles have been shown to dissolve more readily from the surface of the cement and ob-
tain better release profiles than fine powders379. It is likely that the gentamicin sulphate
powder selected for use in Palacos R+G along with the porosity of the cement contributed
to the overall enhanced antibiotic release when compared to CMW and Cemex Genta.
8.5 Conclusions
The majority of the gentamicin sulphate release was found to occur within the first 6 hours
and only a low percentage (<10%) of the total antibiotic was released. This may lead to re-
sistant bacteria forming as sub-inhibitory levels become established after this early phase.
Mathematical modelling of the cement demonstrated that release occurred as a result of
gentamicin sulphate release from the surface of the cement, followed by porosity driven
mechanisms, as confirmed by SEM images. Poor dispersion of antibiotic at the surface of
the cement possibly resulted in poor uniformity of antimicrobial activity. Furthermore,
the properties of the cements were found to be altered by the use of powdered gentamicin
sulphate, particularly in terms of fatigue crack propagation.
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Although the use of powdered gentamicin sulphate in PMMA bone cements has been
successful in reducing the rate of infections in joint replacement surgery, post-operative
infections are still known to occur. Different antibiotics such as ciprofloxacin and van-
comycin may be used, which have been shown to be more active against bacteria366, how-
ever the limitations of using powdered antibiotics in bone cement, such as poor dispersion
and altered mechanical and fatigue properties, are still expected to be present regardless
of the therapeutic agent used. Therefore, there is a need for a novel delivery system in
PMMA bone cements, which will not affect the mechanical and fatigue properties and
will ensure a prolonged release of antibiotic at inhibitory levels. In addition, improved
dispersion of the antibiotic is required to ensure adequate distribution of activity at the
surface of the implant. Having established these requirements, the subsequent chapters
focus on the development and testing of a novel drug delivery system for PMMA bone
cements.
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Incorporating a liposomal drug
delivery system
9.1 Introduction
Commercially available bone cements with powdered gentamicin sulphate have limitations
associated with antimicrobial efficacy, the release of antibiotics, mechanical performance
and fatigue properties. Attempts to overcome these problems include the use of gentam-
icin solution206–209, alternative therapeutic agents210–218 and silver nanoparticles219–221.
Some of these attempts have met with moderate success, however poor mechanical and
antimicrobial properties still limit these novel formulations. To overcome these limitations,
a novel approach to drug delivery in bone cement was considered. In this delivery system,
liposomes encapsulating a therapeutic agent, were dispersed in PMMA bone cement in an
attempt to improve the pharmacokinetic, mechanical and fatigue properties of antibiotic-
loaded bone cements. This chapter describes the development of this novel approach and
how the stability and dispersion of the system was tested.
9.1.1 Liposomes
Liposomes are vesicles consisting of a bilayer of lipid molecules which usually enclose an
aqueous solution (Figure 9.1)380. Although an hydrophobic preparation can also be en-
trapped. These vesicles, usually composed of phospholipids, were discovered in 1965 when
it was found that lipids dispersed in water spontaneously to form large multilamellar vesi-
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Figure 9.1: Liposome vesicle
cles381. Depending on the preparation technique, liposome vesicles can range from tens
of nanometres to tens of microns in diameter. The lamellarity of the liposomes can also
vary, as can the quantity of material entrapped within the aqueous compartment and lipid
bilayer. Liposomes were originally used as models for the lipid bilayer portion of cell mem-
branes381. Liposomes can thus be designed to mimic the behaviour of natural membranes,
whilst also being degradable in a similar manner, making them an ideal vehicle for medical
applications.
The most frequent use of liposome formulations has been to improve the solubility of ther-
apeutic agents. Pharmacologically active agents used in liposomes include antineoplastic
and antimicrobial drugs, chelating agents, steroids, vaccines and genetic materials382. Li-
posomes are able to remain within the circulatory system for increased lengths of time and
have been known to accumulate at sites of disease or inflammation, increasing the bioavail-
ability of the therapeutic agents383–386. The lipid bilayer encapsulating the therapeutic
agent protects active compounds from biological degradation, leading to an enhancement
in therapeutic potency and also reduce the cytotoxicity of certain drugs387. As the lipid
vesicle can encapsulate both an aqueous and an hydrophobic solution, a combination of
different therapeutic agents can be employed for specific treatments. These advantages
along with the proven safety and efficacy of liposomes have made them an attractive can-
didate for a drug delivery system in the medical field, particularly in the areas of drug
targeting and immune modulation.
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Phospholipids
Phospholipids are molecules which form the major structural components of cell mem-
branes380. They are naturally occurring, biodegradable, non-toxic and generally consist of
two hydrophobic fatty acid chains connected to a hydrophilic polar headgroup as shown
in Figure 9.2388, 389. The hydrophilic polar headgroup is linked to two hydrophobic acyl
hydrocarbon chains by a glycerol molecule, resulting in an amphiphatic molecule. Phos-
pholipids are generally not soluble in aqueous environments as they tend to aggregate
and migrate to surfaces. This arises as a result of the hydrophobic fatty acid chains
orientating away from water, creating a bilayer sheet with the hydrophilic heads in the
aqueous solution and the fatty acid chains protruding into a hydrophobic region, often
air. This minimises the interaction between the aqueous solution and the long fatty acid
chains. This capability can be exploited however and when the bilayer sheets fold onto
themselves, they may create liposome vesicles. Figure 9.3 shows the variety of lamellar
structures created when phospholipid bilayers create liposome vesicles.
Figure 9.2: Phospholipid structure
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Figure 9.3: Lamellar structures
Liposome charge
A commonly used phospholid is phosphatidyl choline (PC, also known as lecithin), which
can be derived from both natural and synthetic sources. PC can be extracted from egg
yolk, soya beans and less readily from bovine heart and spinal cord tissue. PC is frequently
employed in formulations due to its low cost relative to other phospholipids, its neutral
charge and its chemical inertness. Although the headgroup of PC is positively charged, the
negative charge of the phosphate molecule at the phosphatidyl moiety neutralizes the over-
all charge. This overall neutrality is also seen with phosphatidylethanolamine (Table 9.1).
More generally however, and as a result of the phosphate molecule in phospholipids, the
majority of phospholipids with neutral and negatively charged headgroups are considered
negatively charged overall (e.g. phosphatidylserine, phosphatidylglycerol, phosphatidic
acid and phosphatidylinositol).
By altering the polar headgroup of the phospholipid (as shown in Table 9.1), different
surface charges thus can be adopted, which may be advantageous to applications such as
drug targeting or inducing mineralisation. Recent studies have used phospholipids as a
coating material for implants and have shown that phosphatidyl serine (PS) is an effective
lipid for promoting calcification both in vitro and in vivo247, 254, 257. The surface charge
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Table 9.1: Naturally occurring phospholipids
Fatty acid chain Headgroup Common Name Abbreviation
(Phosphatidyl-)
choline PC
ethanolamine PE
serine PS
glycerol PG
acid PA
inositol PI
of the liposome also affects its stability as lack of surface charge can increase aggrega-
tion390. In vivo however, neutral and positively charged liposomes and those containing
phosphatidylcholine were found to be most stable; whilst negatively charged liposomes
were less so, binding to higher amounts of protein in the blood391.
Liposomes can be created from a mixture of phospholipids. For example, Santin et al.247
used phosphatidylcholine, phosphatidylserine and cholesterol liposomes at a molar ra-
tion of 7:2:1 to test the calcium-binding potential of phospholipids for implant coatings.
Phosphatidylinositol was also tested by replacing phosphatidylserine in the same study.
Certain lipids exist which do not have phosphatidyl moieties and can also be employed
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in liposome mixtures. The overall charge of these molecules is governed mainly by the
charge on the hydrophilic head group. This has allowed for the manufacture of synthetic
cationic (positively charged) liposomes, which have gained recent interest in gene deliv-
ery due to the negatively charged genetic material binding with the positively charged
liposome by electrostatic interactions. Examples of cationic liposomes include DOTAP
(1,2-dioleoyloxy-3-(trimethylammonio) propane), DOTMA (N-(2,3- (dioleoyloxy)propyl-
N,N,N-trimethyl ammonium), DODAc (dioctadecyldimethylammonium chloride), DM-
RIE (1,2-dimyristoyloxypropyl-3-dimethyl-hydroxyethyl ammonium), DOSPA (2,3-dioleoy-
loxy-N-(2 (sperminecarboxamide) ethyl) -N,N-dimethyl-1-propananninium) and DOGS
(dioctadecylamidoglycylspermine).
Phase transition temperature
The phase transition temperature (Tc), the temperature at which the phospholipid changes
from a gel phase to a liquid phase, is important as high Tc liposomes result in a less fluid
bilayer at physiological temperatures, which is less likely to leak the encapsulated content.
Furthermore, high Tc lipids have been shown to have a lower level of uptake by phagocytic
cells386. The use of sterol lipids, such as cholesterol, in liposomes has been shown to
increase the Tc and in higher concentrations, completely eliminate the phase transition,
resulting in a decrease in membrane fluidity, increased stability and less likelihood of
leakage. Heating above the Tc of the phospholipids during manufacture of liposomes is
required in order to form vesicles.
Liposome size
Liposomes vary in size ranging from 0.025 to 2.5µm 387; such liposomes can vary in
the number of bilayers. In general, liposomes are classified into one of four categories:
small unilamellar vesicles (SUV, <100nm), large unilamellar vesicles (LUV, >100nm),
multilamellar vesicles (MLV, >100nm) and multivesicular vesicles (MVV, >100nm)387.
226
Chapter 9. Incorporating a liposomal drug delivery system
SUVs consist of a single bilayer and are homogeneous in size. Due to their small dimen-
sions, there tends to be excessively high stresses on the bilayer of SUVs which makes them
thermodynamically unstable and susceptible to aggregation and fusion392. Furthermore,
the low aqueous volume to liquid ratio (0.2-1.5 l/mole lipid) results in limited encapsula-
tion of material, particularly macromolecules. SUVs do, however, have a long circulation
half-life387.
LUVs also consist of a single bilayer, however due to its larger size and high aqueous
volume to lipid ratio (7 l/mole lipid), they have a much higher encapsulation efficiency
and high capture rate of macromolecules. The single bilayer allows for high volumes of
hydrophilic drugs to be encapsulated387. The larger size also results in increased stability
due to lower stresses associated with the longer curvature of the vesicle.
MLVs consist of more than one bilayer and tend to be larger in size than SUVs and LUVs.
The multiple bilayers tend to favour encapsulation of hydrophobic materials. MLVs have
a moderate aqueous volume to lipid ratio (1-4 l/mole of lipid)387. The larger size results in
a more stable liposome with a long shelf-life, but this size does make MLVs more suscep-
tible to phagocytic uptake. MVVs are similar to MLVs, however consist of a large vesicle
encapsulating several smaller vesicles as shown in Figure 9.3. This type of vesicle usually
forms in the initial stages of liposome preparation prior to forming SUVs, as discussed
later in this chapter.
In order to maximise the accumulation of liposomal drugs at disease sites, homogeneous
vesicles with diameters between 70-150nm are usually employed393. Vesicles of this size are
small enough to circulate without becoming trapped in tissue microvasculature, but also
small enough to penetrate through pores and gaps in the vascular endothelium associated
with areas of inflammation394, 395. This size range has good therapeutic carrying capabili-
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ties, with acceptable encapsulation efficiencies and the liposomes are small enough to pass
through sterilizing filters without damage or loss of contents. Furthermore, liposomes of
this size range are generally considered to be stable in suspension. Although larger lipo-
somes are also considered stable, sedimentation of the suspension has been known to occur
over time, resulting in a shorter usable shelf-life.
9.1.2 Preparation of liposomes
The preparation method largely dictates the size, structure, dispersity and shelf-life of
liposomal systems. Therefore, the following factors must be taken into account when
establishing a method for liposome manufacture:
• The physical chemistry of the material being encapsulated and the lipid composition.
• The toxicity and concentration of the encapsulated material.
• The medium in which the liposome vesicles are being dispersed.
• The size, stability, dispersion and shelf-life requirements.
• The target area, required dosage and release rate.
• Reproducibility and clinical applicability.
Liposomes created by low shear sonication tend to produce MLVs, whilst high shear son-
ication tends to produce SUVs. Sonicated liposomes have a wide size distribution and as
sonication can be detrimental to the structure of certain therapeutic agents, they are less
preferred in delivery systems380. For more uniformly sized liposomes that can encapsulate
therapeutic agents, extrusion or the Mozafari method is generally used, however this usu-
ally results in unilamellar vesicles being formed. A simplified classification of preparation
methods is shown in Figure 9.4.
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Figure 9.4: Classification of liposome preparation methods (FRV - Freeze/rehydrated
vesicles)380 .
The method of preparation has a significant effect on the encapsulation efficiency of the
liposome. Preparation methods can be classified into two categories according to the
method of loading therapeutic agents: these are known as passive and active loading
methods. Passive loading involves introducing the drugs before or during the manufactur-
ing process of the liposome, whilst active loading involves loading therapeutic agents into
pre-formed liposomes.
Passive loading can be classified further into mechanical dispersion methods (i.e. soni-
cation, membrane extrusion), solvent dispersion methods (i.e. ethanol injection, reverse
phase evaporation) and detergent removal methods (i.e. dialysis, column chromatogra-
phy)380. Although passive loading methods, such as the thin-film hydration technique,
are simple, they are associated with a relatively poor encapsulation efficiency (5-15%).
Other techniques, such as freeze drying, have been shown to improve encapsulation effi-
ciency, however these methods can also alter the size distribution of the suspension396.
Active loading creates a concentration gradient to force materials through the bilayer and
into preformed liposomes. This method is associated with higher encapsulation efficiencies
(up to 90%) and usually involves the use of pH gradients to encapsulate materials397.
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9.1.3 Liposomes in PMMA bone cements
Despite their long availability, liposomal drug delivery systems are still being developed
and optimised for a variety of medical applications. A recent literature search has found
little mention of using liposomes in polymeric materials for medical application. The main
anticipated issues with using liposomes in bone cements include: incompatibilities with
the hydrophobic and aqueous systems comprising the cement ingredients; the high setting
temperature of bone cements; the dispersion of the liposomes in the cement; the release
of the liposome vesicles from the cement; the bioavailability of any entrapped agents; and
the effect of included liposomes on the mechanical and fatigue properties of bone cement.
The work in the next two chapters is designed to investigate the stability and dispersion
of liposomes in PMMA bone cement, the delivery of an antibiotic from bone cement using
liposomes, and their effect on mechanical, fatigue and structural properties.
9.1.4 Surfactants
Liposomes intended to encapsulate a water-soluble antibiotic are generally formed in an
aqueous suspension, which is incompatible with the hydrophobic MMA and PMMA that
makes up bone cement. Freeze drying or lyophilizing methods can be used to turn lipo-
somes into a powder which might more readily be incorporated into the powder component
of bone cements. Lyophilizing however, is a complex, time consuming and costly process
and although the process improves encapsulation efficiency, the liposome bilayer is broken
and reformed, altering the size of the liposomes. This results in less control over the size
distribution of the final suspension. A more favourable option, and certainly one which in
principle offers enhanced dispersion, is to incorporate liposomes into the non-polar liquid
component of bone cement (MMA). This difference in polarity between the two liquids,
however, will result in phase separation and loss of stability.
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When mixing an aqueous liposomal suspension with MMA, a water-in-oil mixture is cre-
ated, whereby charged water molecules attract each other and MMA molecules with no
charge attract each other creating two separate phases. This was found to occur when
gentamicin sulphate solution was added to bone cement and resulted in poor mechanical
properties206, 207. The use of emulsifiers to prevent phase separation has been tested with
gentamicin sulphate solution in bone cement, however a reduction in mechanical proper-
ties was still found to occur208. Therefore, it is proposed that liposomes will be formulated
in the presence of a surfactant, whilst also minimising the aqueous volume by pelleting
the liposomes.
When selecting an appropriate surfactant for use in a bone cement, two main consid-
erations must be borne in mind; the surfactant must be non-toxic and it must be able
to overcome the forces separating the two phases in order to create a stable emulsion.
Surfactants tend to be amphiphilic, like liposomes, and usually consist of a solubilizing
hydrophilic “head” group and a hydrophobic “tail” group as shown in Figure 9.5. Surfac-
tants are classified by the charge contained within the hydrophilic head group. The four
basic classifications are shown in Table 9.2.
Figure 9.5: Surfactant structure
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Table 9.2: Classification of surfactants
Classification Head group charge Example head groups
Anionic Negatively charged
Carboxyl (RCOO−M+), sulphonate
(RSO−3 M
+), sulphate (ROSO−3 M
+) or
phosphate (ROPO−3 M
+)
Cationic Positively charged
Quaternary ammonium halides (R4N
+X−), pH
dependent primary, secondary or tertiary
amines
Nonionic
No charge (but contains highly
polar groups)
Polyethylene (R-OCH2CH2O), aliphatic
alcohols (-OH)
Amphoteric
Contains positively and negatively
charged groups
Amino acids (NH+3 CHRCOO
−), sulphobetaines
(RN+(CH3)2CH2CH2SO
+
3
Nonionic surfactants generally tend to be less toxic and more biocompatible than other
surfactants. As a result of this, nonionic block copolymers are extensively used in thera-
peutic delivery systems. Another advantage of nonionic block copolymers is that they work
via steric repulsion instead of electrostatic stabilization as most surfactants do. With elec-
trostatic stabilization (Figure 9.6(a)), components are added to the solution which change
the overall charge of the system and allows for a stable and well dispersed colloid. This
method may affect the structure and stability of the liposome as surfactant ions have been
known to react with lipid molecules and therefore electrostatic stabilization may not be
suitable for this application. Steric repulsion occurs when polymers are added to a system
and adsorb on the surface of particles (Figure 9.6(b)). These polymer chains increase
the distance between those particles and render van der Waals forces too weak to cause
agglomeration.
(a) Electrostatic (b) Steric
Figure 9.6: Different stabilization systems398
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Figure 9.7: Pluronic structure
A particular nonionic surfactant group of interest is the range of polyethylene oxide-
polypropylene oxide-polyethylene oxide triblock copolymers (PEO-PPO-PEO), otherwise
known under the trade names of Poloxamer and Pluronic. These surfactants are composed
of two hydrophilic polyethylene oxide (PEO) chains joined together by a hydrophobic
polypropylene oxide (PPO) chain (Figure 9.7). The differences in chemical structure and
polarity between the two chains creates an hydrophobic/hydrophilic balance which can be
used to address the polarity differences between water and methyl methacrylate (MMA).
For the Pluronics the nomenclature used can be a useful shorthand for the structure:
the first letter provides information on its physical form at room temperature (L is liq-
uid, P is paste and F is flake or solid), the first digit (or first two digits if the number is
three digits long) multiplied by 300 gives the approximate molecular weight of the PPO
component and the last digit multiplied by ten gives the percentage of PEO content. For
example, Pluronic L31 is a liquid at room temperature, its PPO component has a molec-
ular weight of 900g/mol and a PEO content of 10%. From this information and knowing
the molecular weight of one chain of PPO is 58g/mol and one chain of PEO is 44g/mol,
with the OH and O portions having a combined molecular weight of 18g/mol, the number
of PEO and PPO chains can be be calculated and the structure of the Pluronic deduced.
Table 9.3 shows different Pluronic products and their calculated structures.
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Table 9.3: Structure of different Pluronics
Pluronic
Mw of
PPO /
g/mol
% PEO
content
Mw of
PEO /
g/mol
Average
Mw /
g/mol
Number
of PPO
chains
Number
of PEO
chains
HLB
HLB
group
L31 900 10 110 1100 15 2 4.5 3 to 6
L43 1200 30 555 1850 21 12 12 8 to 12
L44 1200 40 880 2200 21 20 16 15 to 18
L61 1800 10 200 2000 31 4 3 3 to 6
L62 1800 20 472 2360 31 10 7 7 to 9
L64 1800 40 1160 2900 31 26 15* 13 to 15
P65 1800 50 1700 3400 31 38 17* 15 to 18
F68 1800 80 6720 8400 31 152 29* n/a
P84 3200 40 1680 4200 55 38 14* 13 to 15
P104 3000 40 2360 5900 52 53 12 to 18* 15 to 18
P123 3600 30 1725 5750 62 39 7 to 12* 8 to 12
F127 3600 70 8820 12600 62 200 22* n/a
Note: n/a - not applicable as calculated HLB outside of HLB group ranges * - HLB values obtained experimentally
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To narrow the selection for this particular application, Pluronics with a working temper-
ature range between 0◦C and 100◦C were selected as they are capable of withstanding
the high exothermic curing temperatures of bone cement and long term use in vivo. A
semi-empirical scale for selecting an appropriate surfactant can also be used. The scale
was originally developed by Griffin et al.399, 400 and is known as the hydrophilic-lipophilic
balance (HLB). The HLB is based on the relative percentage of hydrophilic to hydrophobic
components in the surfactant molecule. Table 9.4 shows HLB ranges and their specific
applications. Griffin’s technique to calculate the HLB value was quite laborious and re-
quired several trial and error steps, therefore the process was altered by Davies et al.401,
allowing a surfactant’s HLB number to be calculated directly from its chemical formula.
The improved method uses Equation 9.1 and empirically determined values for organic
groups. Studies have shown HLB values calculated using this method agree with values
obtained experimentally398,402.
Table 9.4: HLB values and their application
HLB Range Application
3-6 water-in-oil emulsifier
7-9 wetting agent
8-12 oil-in-water emulsifier
13-15 detergent
15-18 solubilizer
HLB = 7 + Σ(Hydrophilic group no.)− Σ(Hydrophobic group no.) (9.1)
By using Table 9.5, each ethylene oxide (EO) unit has a calculated HLB of 0.33 and each
propylene oxide (PO) unit has an HLB of -0.15. Using the estimated number of units
in each chain, as shown in Table 9.3, the calculated HLB values for EO and PO and
Equation 9.1, the HLB values for the Pluronics were determined. Pluronic L31 and L61
have HLB values of 5 and 4 respectively, making them suitable for oil-in-water emulsions
such as incorporating an aqueous liposome solution into MMA. Furthermore, these values
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Table 9.5: HLB values for component groups
Group HLB Number Group HLB Number
Hydrophilic Hydrophobic
-SO4Na
+ 38.7 -CH- 0.475
-COO− 21.2 -CH2- 0.475
-COOK 21.1 -CH3 0.475
-COONa 19.1 =CH- 0.475
-N (tertiary amine) 9.4 -CF2- 0.87
Ester (sorbitan ring) 6.8 -CF3 0.87
Ester (free) 2.4
-COOH 2.1 Derived
-OH (free) 1.9 -CH2-CH2-O 0.33
-O- 1.3 -CH2-CH2-CH2-O- 0.15
OH- (sorbitan ring) 0.5
agree with experimental data (HLB of 1-7 for both)398, 402. These calculations however, as
described by Davies et al.401, are not accurate for large molecules with more than 20 PEO
units as the different parts of the same molecule act virtually independently. Therefore,
for Pluronics with more than 20 PEO units, experimental methods are required.
The precise mechanism by which the Pluronics and the liposome vesicles interact is un-
known and the literature on this subject is limited. It can be speculated however, that
the hydrophilic PEO chains will orientate themselves to the outer hydrophilic polar heads
of the liposome vesicle, leaving the hydrophobic PPO chains free to interact with the hy-
drophobic non-polar MMA. This structure is shown in Figure 9.8. Due to the limitations
Figure 9.8: Liposome-Pluronic structure
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of the available imaging techniques, the structural integrity of the liposome-Pluronic ar-
rangement will be difficult to observe as Pluronic chains tend to be smaller than 5nm.
Therefore, the functional stability of the liposome-Pluronic structures in MMA was inves-
tigated instead, in terms of sedimentation rate, dispersion and ability to withstand high
temperatures.
9.2 Methods
9.2.1 Materials
Phosphatidyl choline (PC) from egg yolk (≥99.0%), cholesterol (C, ≥99.0%), uranyl ac-
etate (≥98.0%) and Pluronics L31, L61, F68 and F127 were purchased from Sigma Aldrich
(Gillingham, UK). Chloroform (HPLC grade) was purchased from Fisher Scientific (Fisher
Scientific UK Ltd, Loughborough, UK). Pluronics L43, L44, L62, L64, P65, P84, P104,
P123 were provided by BASF (BASF Corporation, Connecticut, USA). TopFluor choles-
terol was purchased from INstruchemie (INstruchemie BV, Delfzijl, Netherlands)
9.2.2 Liposome preparation
Liposomes containing phosphatidyl serine (PS) were to be used due to that lipid’s calcu-
logenic potential as described in the literature247, 254, 257 , however charge incompatibilities
between PS and gentamicin sulphate used in the next chapter, resulted in an unstable li-
posome bilayer. Thus, a neutral liposome (phosphatidylcholine (PC) and cholesterol (C))
was used.
PC and C were weighed and combined in a ratio of 7:1 respectively and added to a 50mL
round-bottom flask. 5mL of chloroform was added to the flask and the suspension was vor-
texed until the lipids dissolved. The flask was attached to a rotary evaporator with a water
bath set at 60◦C (above Tc of PC) with a vacuum pump and rotation set to 1 revolution
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per second. Once all the chloroform had evaporated and a thin film of lipids had formed,
deionised water heated to 60◦C was added and the flask vortex mixed to create a suspen-
sion of liposome vesicles at a concentration of 5mg/mL. The lipid suspension was held at
60◦C for 30 minutes for the liposomes to form. The suspension was extruded 10 times
under nitrogen pressure (8 bars maximum) using a Lipex extruder (Northern Lipids Inc.,
British Columbia, Canada) vertically through a 400nm polycarbonate membrane (What-
man, UK) followed by further extrusion 10 times using a 100nm polycarbonate membrane.
The average liposome diameter was measured by laser diffraction using a Beckman Coulter
N4 PLUS particle size analyzer (Beckman Coulter Ltd, High Wycombe, UK) to ensure
an average 100nm diameter liposome suspension was obtained. 2%w/w of Pluronic (L31,
L43, L44, L61, L62, L64, P65, F68, P84, P104, P123 or F127) was added to the liposome
suspension after extrusion. This concentration was selected as this is below the critical
micelle concentration (CMC) of the Pluronics, which is the concentration above which
surfactant micelles form. The liposome-Pluronic suspension was centrifuged at 100,000g
(25,000 RPM) for 1 hour at 4◦C using a Beckman Optima LE-80K centrifuge (Beckman
Coulter Ltd., High Wycombe, UK) with a SW28 rotor to create a pellet in order to
minimize the amount of water in the final cement mixture.
9.2.3 Liposome diameter
PC:C liposomes without Pluronics were prepared as described and centrifuged to produce
a 10mg pellet. The pellet was resuspended in 10mL of deionised water and vortexed.
The liposome diameters were measured by laser diffraction using a Beckman Coulter N4
PLUS particle size analyzer (Beckman Coulter Ltd, High Wycombe, UK), to ensure the
liposomes were not damaged or altered during the centrifugation process.
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10mg PC:C liposome pellets with and without Pluronics were prepared as described and
resuspended in 10mL of MMA by the process of titruration, followed by vortexing. The
liposome diameters in MMA were measured by laser diffraction.
9.2.4 Sedimentation rate
The sedimentation rate was established by measuring the absorption at 420nm of the
liposome-Pluronic suspension in MMA over time using an Hitachi U-1900 spectropho-
tometer (Hitachi High-Technologies Europe GmbH, Mannheim, Germany) against a MMA
blank. The suspensions were agitated initially and placed in the spectrophotometer, where
the suspension was allowed to stand undisturbed over a period of one hour whilst absorp-
tion readings were taken.
9.2.5 Transmission electron microscopy
Transmission electron microscopy (TEM) was used to image the dispersion of liposomes in
MMA and water. PC:C liposomes and PC:C liposomes with L61 Pluronic were prepared
as described and mixed at a volumetric ratio of 1:1 with 4%w/v aqueous uranyl acetate
and left for 60 minutes. The liposomes were then pelleted as described and resuspended
in 10mL of water or MMA. The suspension was further diluted at a 10%v/v concentration
and a 10µL droplet of the dilute suspension was added to a Formvar carbon film on a
400 mesh Nickel grid (EM Systems Support Ltd., Macclesfield, UK) and allowed to dry
in air. MMA alone was also dried on a grid as a control. The grids were observed using
a Philips CM12 TEM (Philips Research, Eindhoven, Netherlands) operating at 80kV.
Images were recorded using an SIS MegaView III digital camera (Olympus Soft Imaging
Solutions GmbH, Mu¨nster, Germany).
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9.2.6 Temperature stability tests
To ensure the liposome-Pluronic systems are capable of withstanding the high setting
temperatures of PMMA bone cements, samples were heated in water and in a dry state
at 80◦C for 10 minutes. The liposome-Pluronic system was not tested in MMA since this
would polymerise under these conditions making characterisation difficult. This particu-
lar temperature and time period was selected as a likely worst case scenario for setting
temperature and time for bone cements in order to test the robustness of the liposome-
Pluronic system.
5mg/mL liposome suspensions with and without Pluronics (L31, L43 or L61) were pre-
pared as described and diluted to 1mg/mL. A small hole was drilled through the top of
a 1.5mL Eppendorf tube. 1mL of the 1mg/mL liposome suspension was pipetted into
the Eppendorf. A K-wire thermocouple was cleaned and sterilized by washing with 70%
ethanol and air dried. The thermocouple was placed into the liposome suspension through
the hole in the Eppendorf and connected to a temperature monitor. The Eppendorf was
placed in an oven at 80◦C and the temperature was monitored. Once the temperature
reached 80◦C, the Eppendorf was left in the oven for 10 minutes then removed and al-
lowed to cool. The average diameter of the liposome suspension was measured by laser
diffraction. The experiment was repeated in triplicate.
For the dry state, 0.1mL of the 1mg/mL liposome suspension with and without Pluronics
(L31, L43 or L61) was allowed to dry at room temperature in a 96-well plate. The plate
was placed in a oven at 80◦C, with the temperature monitored using a sterile K-wire ther-
mocouple within the well. Once the temperature inside the well reached 80◦C, the plate
was left in the oven for 10 minutes then removed and allowed to cool. Each dry sample
was resuspended in 0.1mL of freshly deionised water and the diameter of the liposomes
was measured by laser diffraction. The experiment was repeated in triplicate.
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9.2.7 Fluorescence microscopy
To assess the dispersion of the liposomes in a commercial cement, 100mg of liposomal
material was suspended in water at a concentration of 5mg/mL, as described. Fluorescent
TopFluor Cholesterol (FC, 23-(dipyrrometheneboron difluoride)-24-norcholesterol, INstru-
chemie BV, Delfzijl, Netherlands) was used to substitute for a portion of the cholesterol
component to give a ratio of 7:0.9:0.1 of PC:C:FC. The fluorescent liposome suspension
was sized using laser diffraction to ensure 100nm liposomes were formed. 1mL of the
suspension was diluted in 4mL of distilled deionised water to obtain a concentration of
1mg/mL and fluorescent images were taken for observation. The remaining 5mg/mL lipo-
somal suspension was divided into four aliquots of 4mL. 2%w/w of Pluronic L31, L43 or
L61 was added to three of the aliquots and the suspension was pelleted as previously de-
scribed. Similarly, the remaining 4mL aliquot of 5mg/mL liposomal suspension alone was
pelleted. The four pellets were individually resuspended in 2mL of the liquid component
of Palacos R (MMA). This was mixed with 4g of the Palacos R powder as described in
Section 2.1. The cement was compressed between two glass slides to create a thin sample
capable of transmitting light. All cement samples were inspected under a light microscope
for pores and transparency and stored in the dark until observed using an Olympus IX50
fluorescent microscope. A green filter (495-570nm) was used to excite the fluorescent lipids
and images of the emitted red fluorescence were taken.
9.3 Results
9.3.1 Liposome diameter
The average diameter of the PC:C liposomes in water prior to extrusion was 588.4±
242.9nm. After sequential extrusion through a 400nm and then 100nm polycarbon-
ate membrane, the average diameter reduced to 100.3±18.50nm. The addition of the
Pluronics after extrusion did not significantly alter the average diameters of the liposomes
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(L31=107.9±27.8nm, L43=105.6±20.5nm and L61=100.9±29.5nm). The centrifugation
process did not to affect the liposome size as the average diameter of the PC:C liposomes
after centrifugation and resuspension in water was 110.5±16.33nm.
Table 9.6 shows the average liposome size after centrifugation and resuspension in MMA
for suspensions with and without Pluronics. The diameters of all liposome suspensions in
MMA were larger when compared to measurements in water. The accuracy of the laser
diffraction technique was also found to be reduced when taking measurements in MMA.
This may be due to liposomes aggregating or reforming in the MMA or due to laser diffrac-
tion being an unsuitable technique for particle size measurements in MMA. Regardless of
this, liposomes with L31, L43 and L61 were found to produce the smallest liposomes with
the narrowest size distributions.
Table 9.6: Particle size of liposomes with Pluronics in MMA
Size / nm
PC:C 870±400
PC:C L31 380±180
PC:C L43 390±150
PC:C L44 1580±120
PC:C L61 450±200
PC:C L62 2000±860
PC:C L64 1080±520
PC:C F68 1100±490
PC:C P84 840±370
PC:C P104 920±440
PC:C P123 750±250
PC:C F127 6160±2860
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9.3.2 Sedimentation rate
Figure 9.9 shows the absorbance at 420nm over one hour for liposome pellets resuspended
in MMA with and without Pluronics. All suspensions had an initial absorbance value
between 1.8 and 2.5. All samples were stable for up to 120 seconds, after which period
the liposomes, with exception of L31, L43 and L61, aggregated and sedimented rapidly.
After 2400 seconds, only three liposome-Pluronic combinations remained fully suspended
(L31, L43 and L61), whilst the remainder of the suspensions were unstable. Sedimented
samples were characterised by a white solid at the bottom of the cuvette, whilst suspended
samples were found to range from visually clear to slightly cloudy in appearance.
Figure 9.9: Sedimentation rate of liposomes with different Pluronics in MMA
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9.3.3 Transmission electron microscopy
Figure 9.10 shows TEM images of pelleted PC:C liposome suspensions in water and MMA
with and without L61 Pluronic. In all images, Pluronic micelles, which are usually 2-
10nm in diameter, were not observed403. Pelleted PC:C liposomes resuspended in water
had some aggregations present with sizes ranging from 400nm up to 2µm, however the
majority of the liposomes dispersed were between 80 and 200nm in diameter. When PC:C
liposomes with L61 Pluronic were pelleted and resuspended in water, the liposomes aggre-
gated, forming large agglomerations of liposomes ranging from 200nm to several microns.
(a) (b)
(c) (d)
Figure 9.10: TEM images of PC:C liposomes in (a) water, (b) water with L61, (c) MMA
and (d) MMA with L61 (Bar=1µm)
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Similarly, pelleted PC:C liposomes resuspended in MMA agglomerated, however within
the agglomerations, the individual liposomes were intact, with diameters ranging from 60
to 200nm. When PC:C liposomes with L61 Pluronic were pelleted and resuspended in
MMA, the liposomes were well dispersed, with intact bilayers and diameters ranging from
50 to 200nm.
Figure 9.11 shows pelleted PC:C liposomes with L61 Pluronic that have been resuspended
in MMA. Few agglomerations are observed and the liposomes are well dispersed with
diameters ranging from 50 to 200nm.
Figure 9.11: TEM of dispersed liposomes with L61 in MMA (Bar=2µm)
9.3.4 Temperature stability tests
Table 9.7 shows the average liposomal diameters for liposome suspensions with and without
Pluronics heated to 80◦C in a wet and dry state. Initially all liposomes were approximately
100nm in diameter when suspended at 23◦C in water. When heated to 80◦C for 10 minutes,
the changes were not significant (ANOVA, p<0.05). When dried at room temperature,
heated to 80◦C for 10 minutes and resuspended, all suspensions increased significantly in
size with large standard deviations and size distributions.
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Table 9.7: Particle size of liposomes before and after heating in a wet and dry state
Size /nm
PC:C
23◦C 100.3±18.5
80◦C wet 101.6±16.5
80◦C dry 540.8±241.8
PC:C L31
23◦C 107.9±27.8
80◦C wet 113.5±27.6
80◦C dry 706.1±328.2
PC:C L43
23◦C 105.6±20.5
80◦C wet 111.0±23.9
80◦C dry 597.4±270.9
PC:C L61
23◦C 100.9±29.5
80◦C wet 95.8±15.6
80◦C dry 979.9±455.3
9.3.5 Fluorescence microscopy
Figure 9.12 shows the fluorescence microscopy images of fluorescent PC:C:FC liposomes
in water and pelleted fluorescent PC:C:FC liposomes with and without Pluronics in Pala-
cos R cement. The liposomes with fluorescent TopFluor cholesterol emitted detectable
(a) Water (b) Palacos R (c) Palacos R L31
(d) Palacos R L43 (e) Palacos R L61
Figure 9.12: Fluorescent microscopy images of liposomes (a) in water, (b) in Palacos R,
(c) in Palacos R with L31, (d) in Palacos R with L43 and (e) in Palacos R with L61
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levels of fluorescence. Although well dispersed in water, the red fluorescent liposomes
were significantly larger when compared to measurements obtained using laser diffraction
methods. Fluorescence was observed for all fluorescent liposomes in Palacos R samples;
although all appeared greater than 100nm in size. For liposomes in Palacos R without
Pluronics, large agglomerations were observed up to 100µm in size. In contrast, for lipo-
somes with Pluronics L31, L43 and L61 in Palacos R, the fluorescent images were found
to be significantly smaller and well dispersed throughout the cement sample.
9.4 Discussion
Liposomes have been extensively used as pharmaceutical carriers in recent years due to
their unique ability to encapsulate both hydrophobic and hydrophilic therapeutic agents.
Liposomes can: protect these drugs from external conditions; reduce the cytotoxicity of
therapeutic agents; be functionalized with ligands to target specific cells and tissues; and,
be coated with inert biocompatible polymers such as PEO to stabilize and prolong the
circulation half-life in vivo. Liposomes can also be manufactured to desired formulations
in terms of composition, size, surface charge, combination of encapsulated therapeutic
agents and other properties383–385.
Prior to extrusion, the liposomes formed by the thin-film hydration technique were large
with a wide size distribution. After extrusion through a 100nm polycarbonate membrane,
a uniform suspension of 100nm liposomes with a small size distribution was obtained. By
using the extrusion technique, liposome size can be controlled according to the membrane
pore size, making it an ideal technique for consistent delivery of therapeutic agents.
The addition of Pluronics to the surface of the liposomes did not affect the bilayer as
liposomes were intact and roughly 100nm in size. If disruption of the bilayer had oc-
curred, the liposomes would have been likely to reform to the state prior to extrusion,
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with diameters of several hundred nanometres. These findings agree with studies using
liposomes and Pluronics in an aqueous solution404–406. Although, small changes to the
liposome diameter occurred as a result of using Pluronics, these changes were not signifi-
cant and Pluronic chains are too small (≤5nm) to be detected by laser diffraction methods.
When a high centrifugal force was applied to the liposomes to obtain a pellet, the bi-
layer was still found to remain intact and the diameters and distributions were found
to be unchanged from the original suspension, as established by laser diffraction and
TEM. Furthermore, the pelleted liposomes were easily resuspended in water by agitation
or vortexing. Centrifugation of liposomes does however, reduce the final yield of liposo-
mal material after resuspension. Smaller liposomes (≤50nm) may remain suspended after
centrifugation and are therefore lost when the supernatant is discarded. The final concen-
tration of the pelleted liposomes cannot therefore be accurately deduced.
When resuspending the liposome pellets in MMA, not all combinations of Pluronic pro-
duced stable suspensions. Visually, the unstable suspensions in MMA were characterised
by a cloudy appearance with large lipid agglomerations, which were found to rapidly sed-
iment. The stability of these suspensions was not improved by increased agitation or
vortexing. As a consequence of this, sizing using laser diffraction was difficult and the
applicability of the technique was significantly reduced, particularly as measurement in
non-polar, polymeric liquids, such as MMA, are not usually conducted. Furthermore, laser
diffraction measurements assume the particles being measured are spherical and the tech-
nique cannot provide information on the shape and morphology of the measured particle.
Laser diffraction however, was able to demonstrate that Pluronic L31, L43 and L61 treat-
ment created the smallest (<500nm) liposome diameters, whilst the other Pluronics pro-
duced much larger sizes with wide size distributions. As the stability of liposomes in MMA
has not been previously studied, two possible explanations for these results are presented.
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Firstly, the liposome bilayer may be disrupted in MMA due to the hydrophobic nature
of the liquid, causing the liposomes to reorientate themselves to minimise hydrophilic-
hydrophobic interactions. This would result in the formation of larger liposomes such
as those experienced prior to extrusion and the hydrophobic fatty acid chains would be
orientated outwards, resulting in the encapsulated therapeutic agents being released. The
second possible explanation for the increase in liposome diameters in MMA is as a result of
agglomeration through hydrophile-hydrophile attraction in the hydrophobic MMA. L31,
L43 and L61 were found to reduce agglomeration supposedly by creating a hydrophobic
layer of PPO chains around the liposomes with consequential steric repulsion. This com-
bined with the low resolution, sensitivity and accuracy of laser diffraction measurements
in MMA resulted in much larger diameters being estimated.
The sedimentation measurements agree with the agglomeration hypothesis as all liposome-
Pluronic combinations were found to sediment over time, with the exception of Pluronics
L31, L43, L61, which produced a stable suspension. All initial absorbance values were
found to be around 2.0, demonstrating at the start of the experiment around 99% of the
light at 420nm was absorbed by the sample due to the presence of suspended lipid material
in the MMA. Although the majority of the Pluronic treated liposomes did not sediment in
the first few minutes, the stability of the system over extended periods of time is important
as it will dictate the shelf-life of the product. For the majority of the suspensions with
Pluronics, agitation was sufficient to temporarily resuspend the sedimented lipid material.
This is important as agitation of the suspension can be carried out by the surgeon prior
to mixing the cement. Ultimately, the most important parameter is the dispersion of the
liposomes in the MMA as this will govern the release and the uniformity of mechanical
and the fatigue properties of the cement.
To investigate the structure and morphology of the liposomes, TEM imaging was used.
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The method developed to image the liposomes using TEM was successful. Negative stain-
ing of the liposomes by adding uranyl acetate prior to centrifugation proved to be the
most effective method; staining after centrifugation did not produce clear images.
The TEM images show that the liposome structure is intact after centrifugation and re-
suspension in water, again demonstrating that the high centrifugal forces did not disrupt
the lipid bilayer. No Pluronic micelles were observed as the Pluronic was used below its
CMC.
Pluronic L61 was detrimental to the dispersion of the liposome pellet in water most prob-
ably due to Pluronic L61 being predominantly hydrophobic (longer PPO chains than PEO
chains). Furthermore, the proposed arrangement between the liposome and the Pluronic
would result in the hydrophobic PPO chains facing outwards. This would result in a more
hydrophobic liposome surface, which in an aqueous solution would cause the liposomes
to aggregate. Agglomerations were also observed when the pelleted liposomes were sus-
pended in MMA without Pluronics. This is likely due to the orientation of the liposome
hydrophilic outer layer causing aggregation in the non-polar, hydrophobic MMA. From
the TEM images however, it was clear that the liposomes remained intact, with average
diameters of roughly 100nm, when suspended in MMA. This supports the agglomeration
hypothesis as opposed to the disruption, reorientation and formation of larger liposomes.
Furthermore, this demonstrates that laser diffraction in MMA measured the size of the
agglomerations and not the diameter of the individual liposomes. When using Pluronic
L61, the liposomes were well dispersed in MMA. Therefore, the TEM images demonstrated
that Pluronics can be used to effectively disperse liposomes in MMA. It is proposed that
the Pluronics increase the surface hydrophobicity of the liposomes by adsorbing on the
outermost surface of the phospholipid head groups.
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In terms of stability at high temperatures, the liposome formulation used was found to
be stable at 80◦C for 10 minutes when in an aqueous suspension. When dried and heated
however, the bilayer may have disassociated and the liposomes were then found to reform
into multilamellar vesicles. Studies on lyophilizing and drying liposomes have found that
the use of cryopreservatives, such as sugar molecules, to replace the water molecules at
the bilayer during drying, maintains the bilayer structure and therefore, the liposome size
and entrapped contents380. The use of sucrose to preserve the liposomes during drying
provides an additional method for reducing the water content in the final cement mixture.
Lyophilizing liposomes could not be undertaken in this study. Nevertheless, as the results
have shown, pelleting of liposomes by centrifugation has maintained the liposomal struc-
ture and when incorporated within the setting cement, the liposome structure is assumed
to remain intact due to the surrounding cement matrix.
Sizing by fluorescence microscopy differed from the measurements obtained by TEM and
laser diffraction. This is attributed to the distortion of the emitted fluorescent light source
as it travels through the medium (water or PMMA) before it is detected by the microscope.
Futhermore, as a large number of liposomes are present throughout the cross-section of
a sample, the focal plane cannot detect all the fluorescent sources. As the focal plane is
moved away from a fluorescent source, a “halo” is formed, which becomes larger and more
diffuse, as observed for fluorescent liposomes in water. Therefore, the fluorescent images
only provide qualitative results and TEM images have confirmed the size of the liposomes
in MMA. Nevertheless, fluorescence microscopy was found to be an effective technique to
demonstrate the dispersion of liposomes in PMMA.
In the absence of Pluronics, the fluorescent liposomes were found to aggregate in the
cement, resulting in large fluorescent patches. Fluorescent liposomes with Pluronics L31,
L43 and L61 were found to produce much smaller foci of fluorescence, which were well
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dispersed, demonstrating the effectiveness of these Pluronics in dispersing the liposomes
throughout the cement.
Generally Pluronic block copolymers were found effective in dispersing liposomes in non-
aqueous environments. Not all Pluronics were found to be suitable for dispersing liposomes
in MMA. Pluronics L31, L43, L61 were found to produce the most favourable results. This
agrees with the HLB scale for Pluronics L31 and L61, which have HLB values between 3
and 6 and are therefore suitable as water-in-oil emulsifiers. Pluronic L43 however, which is
considered an oil-in-water emulsifier, with an HLB value of 12, was also found to perform
well for this application. This demonstrates that the HLB scale can only be used as a
guide for selecting surfactants. When comparing the properties of Pluronics L31, L43 and
L61, they were all found to have molecular weights less than or equal 2000 and be more
hydrophobic in nature with higher PPO than PEO content. This agrees with the theory
that the Pluronics increase the hydrophobicity of the liposome system in order to improve
the dispersion.
Referring back to the proposed liposome-Pluronic structure (Figure 9.8), the presence
of long PPO chains may ‘block’ the attachment sites for additional Pluronics. Similarly,
long PEO chains may cause the attached Pluronics to extend farther from the surface of
the liposome and shield the surface from the approach of additional Pluronics. It also
offers the suggestion that there may be some steric hindrance occurring on the liposome
surface when either or both PPO and PEO chains are lengthy.
The use of liposomes with block copolymers has been investigated by several authors407, 408.
Such an arrangement has been shown to reduce the systemic toxicity of drugs, such as pa-
clitaxel, when used as a hydrogel409. Melittin liposomes, surface modified with Pluronics
were shown to exhibit enhanced bioavailability, effective anticancer activity and reduced
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side effects compared with melittin solution406. Furthermore, the use of polymers in con-
junction with liposomes is well documented, particularly for cancer treatments385, 387, 410.
Nevertheless, these systems employed polymers in order to enhance liposomal dispersion
and circulation characteristics in an aqueous phase and previous thought has not been
given to apply such systems to disperse liposomes in non-aqueous environments. The in-
teractions between block copolymers and liposomes are not well understood. Kostarelos
et al.404,405 proposed a specific orientation of the Pluronic on the surface of the liposome,
whereby the hydrophobic PPO chain is in contact with the hydrophilic outer surface of the
liposome, leaving the PEO chains to interact with the aqueous solution. Although plausi-
ble, this system would not improve the dispersion of the liposomes in MMA. Furthermore,
the interactions between PPO and the hydrophilic head groups of lipids are unfavourable.
Kostarelos et al.405 also proposed incorporating the Pluronics into the bilayer structure
during the preparation process. This would result in the PPO chains located inside the
lipid bilayer and the PEO chains in either the aqueous compartment of the liposome or
outside of the liposome. This proposed structure would not alter the hydrophobicity on
the surface of the liposome and therefore, would not alter the dispersion of liposomes in
MMA. Furthermore, Pluronic molecules not incorporated in the bilayer would be free to
attach on the surface of the liposome, resulting in both systems being present, with little
control over the liposome-Pluronic arrangement. This method was attempted in the early
stages of this study, however due to the above reasons was not felt sufficiently controlled
to pursue further.
The proposed attachment between the PEO chains of the Pluronic molecule and the
surface of the liposome is not a covalent bond but is considered to be a weak physical
adsorption, governed mainly by van der Waals forces. Therefore, the attachment itself is
not permanent, however data in this thesis has shown that interactions between certain
Pluronic molecules and liposomes is sustained sufficiently to improve dispersion proper-
253
Chapter 9. Incorporating a liposomal drug delivery system
ties. The use of Pluronics adsorbed on the surface of liposomes provides a convenient and
cost-effective method for altering surface characteristics in order to improve dispersion
properties.
Although, the stability of liposomes in MMA with specific Pluronics has been shown to
be acceptable in the short term, further studies are required to assess long-term stability.
This is vital as it will establish the shelf-life of the potential product and its viability as a
drug delivery system for PMMA bone cements.
9.5 Conclusions
A uniform suspension of 100nm liposomes with a small size distribution was obtained by
the method of thin-film hydration and extrusion. The size and morphology of the lipo-
somes were not altered by the addition of Pluronics or by centrifugation. Furthermore, the
liposomes were found to withstand the high setting temperature of PMMA bone cement
unless previously dried. Pluronics are required to ensure stable suspensions of liposomes
in MMA; without the addition of Pluronics, liposomes were found to agglomerate and sed-
iment. Optimal activity was obtained from Pluronics with a molecular weight of less than
2000 and a larger hydrophobic portion (e.g. such as L31, L43 and L61); other Pluronics
could not produce the required stability and dispersion of liposomes in MMA. It is hypoth-
esised that the PEO chains of the Pluronic adsorb onto the surface of the liposome and
the PPO chains are left on the outermost layer to interact with the medium. This results
in a hydrophobic outer layer, which allows the liposomes to be dispersed in non-polar,
hydrophobic liquids, such as MMA.
In conclusion, a novel method for incorporating liposomes in bone cement, using Pluronic
block copolymers, has been developed. Such a combination of liposomes with certain
Pluronics was found to achieve good stability and dispersion in a commercially available
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cement (Palacos R). Liposomes encapsulating therapeutic agents, such as gentamicin sul-
phate, can now be incorporated into commercial cements to study the antibiotic release
and antimicrobial properties. The results can then be compared with the findings from
Chapter 8 for commercially available antibiotic cements, which use powdered gentamicin
sulphate. Similarly, the effect of the novel therapeutic delivery system on mechanical and
fatigue properties must be investigated to ensure the novel system is suitable for PMMA
bone cements.
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Chapter 10
Release characteristics of liposomal
bone cements and their mechanical,
fatigue and structural properties
10.1 Introduction
Liposomes have been successfully incorporated into a commercially available bone cement
(Palacos R) as discussed in the previous chapter. Having established the stability and
dispersion of the liposomes in PMMA bone cement, this chapter investigates the release,
antimicrobial, mechanical, fatigue and structural properties of the novel liposomal system
with encapsulated gentamicin sulphate. Furthermore, the results obtained are compared
with data from Chapter 8 for commercially available antibiotic-loaded cements.
Previous studies have investigated the use of aminoglycoside antibiotics, such as gen-
tamicin sulphate, encapsulated in liposomes. It was found that liposomes significantly
increase the therapeutic index of gentamicin sulphate when administered as free particles
directly into the circulation due to improved pharmacokinetics and pharmacodynamics411.
The use of liposomes was also found to enhance the accumulation of therapeutic agents
at the site of infection384,412. Furthermore, encapsulated gentamicin was found to have a
longer circulation half-life than free gentamicin in mouse and rat studies413.
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As a result of incompatibilities between aqueous liposomes and hydrophobic materials,
such as PMMA, little research has been conducted on using liposomes in bone cement.
A recent study was published however, which incorporated a powdered form of liposomal
amphotericin B (AmBisome) into the powder component of Simplex P bone cement414.
This technique differs from the one developed in Chapter 9 as there is no attempt to
overcome the incompatibilities discussed and the results and findings obtained in this
thesis remain novel.
10.2 Methods
10.2.1 Materials
Phosphatidyl choline (PC) from egg yolk (≥99%), cholesterol (C, ≥99%) and gentamicin
sulphate (≥590µg gentamicin base per mg) were purchased from Sigma Aldrich (Sigma-
Aldrich Company Ltd., Gillingham, UK). Chloroform (HPLC grade) was purchased from
Fisher Scientific (Fisher Scientific UK Ltd, Loughborough, UK). Palacos R cement was
provided by Heraeus (Heraeus Medical Ltd., Newbury, UK).
10.2.2 Liposome preparation
A similar method for liposome preparation was undertaken as described in Chapter 9.
175mg of PC and 25mg of C were weighed and added to a 50mL round bottom flask.
5mL of chloroform was added to the flask and the suspension was vortexed until the lipids
dissolved.
The flask was attached to a rotary evaporator with a water bath set at 60◦C (above
Tc of PC) with a vacuum pump and rotation set to 1 revolution per second. Once the
chloroform had evaporated and a thin film of lipids had formed, 40mL of 5mg/mL gentam-
icin sulphate solution, heated to 60◦C, was added and the flask vortex mixed to create a
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suspension of liposome vesicles with a concentration of 5mg/mL. The liposome suspension
was held at 60◦C for 30 minutes for the liposomes to form. The suspension was extruded 10
times under nitrogen pressure (8 bars maximum) using a Lipex extruder (Northern Lipids
Inc., British Columbia, Canada) vertically through a 400nm polycarbonate membrane
(Whatman, UK) followed by further extrusion 10 times through a 100nm polycarbonate
membrane. A Beckman Coulter N4 PLUS particle size analyzer was used to ensure 100nm
diameter liposomes were produced. 2%w/w of L31 Pluronic was added and the solution
was centrifuged at 100,000g (25,000 RPM) for 1 hour at 4◦C using a Beckman Optima LE-
80K centrifuge with a SW28 rotor to create a pellet. The 200mg pellet was resuspended
in 20mL of the liquid component of Palacos R (MMA) by a process of titruration using a
glass mortar and pestle followed by vortexing. The method was repeated for L43 and L61
Pluronics.
10.2.3 Antibiotic release
Palacos R bone cement containing 200mg of liposomal gentamicin sulphate (with Pluronics
L31, L43 or L61) per 40g of cement (herein referred as liposomal Palacos R) was prepared
and tested as outlined in Section 8.2.2. The same time points (6 hours, 1, 2, 3, 7, 15, 30
and 60 days) were used to allow for comparison with commercial cements. The amount
of gentamicin sulphate used in the liposomal cements was 1/5th of the amount that is
in Cemex Genta and 2/5ths of the amount that is in Palacos R+G (see Table 8.1 in
Chapter 8). The results for gentamicin sulphate release from Palacos R+G, Cemex Genta
and CMW were taken from previous chapters.
10.2.4 Mathematical modelling
Mathematical models were applied to the antibiotic release data for the liposomal Palacos
R cements as described in Section 8.2.3. The Higuchi, Korsmeyer-Peppas and Noyes-
Whitney models were applied to the data as were the expanded versions, which use an
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additional coefficient to represent the burst of release of gentamicin sulphate from the
surface of the cement.
10.2.5 Agar diffusion assay
Liposomal Palacos R cement samples were prepared as described above and tested against
S. aureus as described in Section 8.2.4. The results for Palacos R+G were taken from
previous chapters.
10.2.6 Mechanical testing
Compression and bending samples of liposomal Palacos R were prepared and tested after
24 hours in air at 23◦C and 60 days in Ringer’s solution at 37◦C, with the Ringer’s solution
changed every 2 weeks, as described in Sections 2.3.1 and 2.3.2. The results for Palacos
R and Palacos R+G were taken from previous chapters.
10.2.7 Fracture toughness
Fracture toughness values for the liposomal Palacos R samples were obtained as described
in Section 2.4 for samples aged in air for 24 hours at 23◦C and Ringer’s solution at 37◦C
for 60 days, with the Ringer’s solution changed every 2 weeks. The results for Palacos R
and Palacos R+G were taken from previous chapters.
10.2.8 Fatigue testing
Fatigue test samples of liposomal Palacos R cements were prepared and tested as described
in Section 2.5 for samples aged in air for 24 hours at 23◦C and Ringer’s solution at 37◦C
for 60 days, with the Ringer’s solution changed every 2 weeks. The results for Palacos R
and Palacos R+G were taken from previous chapters.
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10.2.9 SEM images
SEM images of the fracture surface of the fatigue test samples were taken as described in
Section 2.8. SEM images of the surfaces of release samples after 0 hours and 60 days in
Ringer’s solution at 37◦C were taken and SEM images for Palacos R and Palacos R+G
were taken from previous chapters.
10.2.10 Vickers hardness
Vickers hardness was determined as described in Section 2.6 for liposomal Palacos R
samples aged in air for 24 hours at 23◦C and Ringer’s solution at 37◦C for 60 days, with
the Ringer’s solution changed every 2 weeks. Hardness values for Palacos R and Palacos
R+G were taken from previous chapters.
10.2.11 Glass transition temperature
The glass transition temperature of liposomal Palacos R samples were obtained for samples
aged in air for 24 hours at 37◦C and Ringer’s solution at 37◦C for 60 days as described in
Section 2.7.
10.2.12 Structural changes
The molecular structure of the liposomal Palacos R cement containing Pluronic L61
was studied by Fourier Transform Infrared Spectroscopy (FTIR) using a Perkin Elmer
Spectrum One FT-IR Spectrometer with FT-IR Spectrum software (Perkin Elmer, Mas-
sachusetts, USA). Attenuated total reflectance (ATR) measurements were taken of Palacos
R, Palacos R+G and the liposomal Palacos R with L61 pluronic. Measurements were taken
between 4000cm−1 and 450cm−1 with a resolution of 4cm−1. 30 scans at 6 different sec-
tions of each sample were taken to obtain average spectra. Samples were scanned after 24
hours in air at 23◦C.
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10.3 Results
Liposomal Palacos R cements will be referred to individually as Palacos R L31, Palacos
R L43 and Palacos R L61 for the explanation of results.
10.3.1 Antibiotic release
Figure 10.1 shows the cumulative release of gentamicin sulphate from Cemex Genta, CMW,
Palacos R+G and the liposomal Palacos R cements over 72 and 1440 hours. All three li-
posomal Palacos R cements released similar amounts of gentamicin sulphate at all time
points. At 6 and 24 hours the liposomal Palacos R cements released similar concentrations
of gentamicin sulphate as Cemex Genta and CMW (creating concentrations ≃10µg/mL),
which was much lower than the initial burst of gentamicin sulphate from Palacos R+G (cre-
ating concentrations ≃25µg/mL). At 72 hours, the liposomal Palacos R cements released
gentamicin sulphate, which created concentrations of roughly 45µg/mL in the surrounding
Ringer’s solution, whilst Palacos R+G achieved a concentration of 59µg/mL and Cemex
Genta and CMW a concentration 30µg/mL. When assessing the release for the first 72
hours for the liposomal Palacos R cements, a linear release was obtained with a constant
release of roughly 10µg/mL at each time point. Furthermore, the standard deviations ex-
perienced for all liposomal Palacos R cements within the first 72 hours were smaller than
those experienced by the commercial cements with powdered gentamicin. After 360 hours,
the cumulative gentamicin sulphate concentration obtained from the liposomal Palacos R
cements were similar to Palacos R+G (85-90µg/mL), which was significantly higher than
Cemex Genta and CMW (55-60µg/mL).
In terms of total percentage release (Figure 10.2), the liposomal Palacos R cements per-
formed significantly better than the commercial cements. At 6 hours, a similar percentage
release was experienced by Palacos R+G and the liposomal Palacos R cements (≃2.7%),
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(a) Release after 72 hours
(b) Release after 1440 hours
Figure 10.1: Cumulative gentamicin sulphate release from commercial cements and lipo-
somal Palacos R samples
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(a) Percentage release after 72 hours
(b) Percentage release after 1440 hours
Figure 10.2: Cumulative percentage release of gentamicin sulphate from commercial ce-
ments and liposomal Palacos R samples
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however after this time point the liposomal Palacos R cements achieved much higher per-
centages. At 72 hours, the liposomal Palacos R released 11-12% of the total gentamicin
sulphate used, whilst Palacos R+G released roughly 6% and Cemex Genta and CMW
released 1.4-1.7%. This would result in roughly 24mg of antibiotic being released per 40g
of cement for the liposomal Palacos R cements compared to 30mg for Palacos R+G and
15mg for Cemex Genta and CMW. After 1440 hours, the liposomal Palacos R cements
released 21-22%, whilst Palacos R+G, Cemex Genta and CMW released 8.9%, 2.8% and
3.0%. This would result in 44mg for the liposomal Palacos R cements, 45mg for Palacos
R+G and 30mg for Cemex Genta and CMW per 40g of PMMA bone cement, which is
equivalent to one dose of cement, over the course of 1440 hours.
10.3.2 Mathematical modelling
Figure 10.3 shows the goodness of fit for the mathematical models compared to the experi-
mental data obtained from liposomal Palacos R cements with Pluronics L31, L43 and L61.
The expanded Noyes-Whitney and the expanded Korsmeyer-Peppas models were found
to most accurately model the gentamicin sulphate release from the liposomal Palacos R
cements, whilst the Higuchi and the expanded Higuchi equations modelled the release least
accurately.
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(a) L31
(b) L43
(c) L61
Figure 10.3: Antibiotic release models for liposomal Palacos R with (a) L31, (b) L43 and
(c) L61
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The results from the mathematical modelling of the gentamicin sulphate release from
liposomal Palacos R is shown in Table 10.1. The Noyes-Whitney dissolution model fits
the experimental release data for the liposomal Palacos R cements the best. This is
contrary to the results obtained when modelling the commercial antibiotic cements, where
the Korsmeyer-Peppas model produced the most accurate model. The exponential (n) and
the diffusion (k) coefficients obtained for the Korsemeyer-Peppas models on the liposomal
Palacos R cements were similar to the coefficients obtained from the commercial antibiotic
cements. Although the Higuchi equation poorly modelled the data for the liposomal
Palacos R cements, the goodness of fit (R-values) was greater than when the model was
applied to the commercial antibiotic cements. The coefficient and goodness of fit values
were similar for all liposomal Palacos R cements.
Table 10.1: Mathematical modelling of antibiotic release for liposomal Palacos R
Korsmeyer Higuchi Noyes-Whitney
Rt = kt
n Rt = kt
1/2 Rt =
k[1− exp(−nt)]
Palacos R L31
k 3.142 0.716 19.070
n 0.273 0.500 0.012
R-value 0.9345 0.5828 0.9555
Palacos R L43
k 3.039 0.743 20.072
n 0.284 0.500 0.011
R-value 0.9396 0.6420 0.9559
Palacos R L61
k 2.861 0.6959 18.746
n 0.284 0.500 0.011
R-value 0.9187 0.6242 0.9716
Table 10.2 shows the results from the mathematical modelling of the liposomal Palacos
R when using the additional coefficient with the Korsmeyer-Peppas, Higuchi and Noyes-
Whitney models. The additional coefficient improved the goodness of fit for all the mod-
els. The additional coefficient also resulted in the expanded Korsmeyer-Peppas and the
expanded Noyes-Whitney models having similar R-values. The ‘b’ coefficient was found
to be positive for the expanded Noyes-Whitney and Higuchi models and negative for the
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expanded Korsmeyer-Peppas models, as occured with the commercial antibiotic cements.
The coefficient and goodness of fit values were similar for all three liposomal Palacos R
cements.
Table 10.2: Mathematical modelling of antibiotic release for liposomal Palacos R samples
using the additional coefficient
Expanded
Korsmeyer
Expanded
Higuchi
Expanded
Noyes-Whitney
Rt = b+ kt
n Rt = b+ kt
1/2 Rt =
b+ k[1 − exp(−nt)]
k 56.050 0.496 16.930
Palacos R n 0.051 0.500 0.008
L31 b -58.930 5.224 2.698
R-value 0.9855 0.8483 0.9761
k 48.389 0.531 17.830
Palacos R n 0.060 0.500 0.007
L43 b -51.675 5.045 2.938
R-value 0.9857 0.8612 0.9796
k 74.105 0.498 17.324
Palacos R n 0.040 0.500 0.009
L61 b -77.852 4.700 1.736
R-value 0.9797 0.8334 0.9803
10.3.3 Agar diffusion
Figures 10.4 and 10.5 show the zones of inhibition obtained for the 10µg gentamicin discs,
Palacos R+G and the liposomal Palacos R cements with Pluronics L31, L43 and L61. As
described in Chapter 8, Palacos R+G had poorly consistent antimicrobial properties, with
irregular shaped zones and significant differences between samples. The liposomal Palacos
cement samples however produced regular, circular zones of similar sizes. Furthermore,
the standard deviations were found to be small, as were the differences between samples
in each group. The use of different Pluronics did not significantly affect the size and shape
of the zone of inhibition produced. The zones obtained for the 10µg gentamicin control
disc were also consistent, with similar sizes and shapes obtained for all three discs.
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Figure 10.4: Average zones of inhibition for Palacos R+G and the liposomal Palacos R
cements
(a) (b) (c) (d) (e) (f)
(g) (h) (i)
(j) (k) (l) (m) (n) (o)
Figure 10.5: Zones of inhibition for the (a-c) 10µg discs, (d-f) Palacos R+G and the
liposomal Palacos R cements with L31 (g-i), L43 (j-l) and L61 (m-o) Pluronics
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10.3.4 Mechanical properties
The mechanical properties of Palacos R, Palacos R+G and the liposomal Palacos R bone
cements with Pluronics L31, L43 and L61 are shown in Table 10.3. At 24 hours in air, all
liposomal Palacos R samples were significantly worse in compression than Palacos R and
Palacos R+G (ANOVA, p<0.05). There were no significant differences between the differ-
ent Pluronics in terms of compressive strength for the liposomal Palacos R cements after
1 day (p>0.05). After 60 days in Ringer’s solution, Palacos R L31 and L43 were signifi-
cantly stronger than Palacos R (p=1.09×10−04 for Palacos R L31 and p=0.01 for Palacos
R L43) and Palacos R+G (p=2.13×10−05 for Palacos R L31 and p=0.03 for Palacos R
L43). There was no significant difference between Palacos R L61 and Palacos R/R+G
(p=0.16 and p=1.00 respectively). After 60 days in Ringer’s solution, there were signif-
icant differences in terms of compressive strength between all three liposomal Palacos R
cements (p=8.35×10−07), with L31 being the strongest, followed by L43 and L61 cements.
The liposomal Palacos R cements increased in compressive strength after storage for 60
days in Ringer’s solution (L31 and L43 significantly - p=2.90×10−05 and p=8.14×10−04
Table 10.3: Mechanical properties of commercial and liposomal Palacos R bone cements
before and after storage in Ringer’s solution for 60 days
Compressive
strength (σc) /
MPa
Bending
modulus (Eb) /
MPa
Bending
strength (B) /
MPa
Palacos R
Air 1 day 104.6±2.6 3460±97 73.4±2.9
Ringer’s 60 days 75.5±5.7 3180±80 69.4±0.6
Palacos R+G
Air 1 day 95.7±3.3 3110±110 66.6±2.4
Ringer’s 60 days 80.3±3.3 2790±155 50.4±7.0
Palacos R L31
Air 1 day 80.8±3.4 3200±61 79.0±3.9
Ringer’s 60 days 99.6±3.6 2640±212 68.7±6.4
Palacos R L43
Air 1 day 77.4±2.4 3330±181 73.0±4.3
Ringer’s 60 days 84.7±1.5 2590±214 65.3±7.0
Palacos R L61
Air 1 day 78.2±1.5 3270±137 74.1±3.4
Ringer’s 60 days 80.3±3.5 2780±87 70.3±6.8
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respectively), whilst Palacos R and Palacos R+G were found to decrease significantly in
compressive strength (p=2.19×10−05 and p=1.18×10−04 respectively).
In terms of bending modulus, at 24 hours in air and 60 days in Ringer’s solution, there
were no significant differences between the different Pluronics of the liposomal Palacos R
cements (p=0.79 for air and p=0.97 for Ringer’s solution). The bending modulus of Pala-
cos R L31 was significantly lower than Palacos R (p=1.70×10−03), whilst there were no
significant differences between Palacos R and Palacos R L43 (p=0.23) and L61 (p=0.05)
at 24 hours. There were no significant differences in bending modulus at 24 hours and
60 days in Ringer’s solution between the liposomal Palacos cements and Palacos R+G
(p=0.11 for air and p=0.27 for Ringer’s solution). After 60 days in Ringer’s solution how-
ever, all the liposomal Palacos R cements were found to have significantly lower bending
modulus than Palacos R (p<0.05). All the cements experienced a significant reduction in
bending modulus as result of storage in Ringer’s solution for 60 days (p<0.05).
After 24 hours in air and 60 days in Ringer’s solution, there were no significant differences
in bending strength between Palacos R and the liposomal Palacos R cements (p=0.09
for air and p=0.68 for Ringer’s solution). When compared to Palacos R+G however, the
liposomal Palacos R cements were found to have significantly higher bending strengths
at both 24 hours (p<0.05) and 60 days (p<0.05). There were no significant differences
between the three liposomal Palacos R cements under both storage conditions (p=0.08 for
air and p=0.66 for Ringer’s solution). Storage in Ringer’s solution was found to signifi-
cantly decrease the bending strength of all cements, except Palacos L43 (p=0.09) and L61
(p=0.30). It was observed that not all liposomal Palacos R bending samples fractured.
Some samples were loaded past the elastic limit of the material and brittle fracture did
not occur. The sample plastically deformed to a point where insufficient contact with the
rollers did not allow further loading.
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All liposomal Palacos R cements were above the ISO5833 minimum requirements for com-
pressive strength (70MPa), bending modulus (1800MPa) and bending strength (50MPa).
10.3.5 Fracture toughness
Table 10.4 shows the fracture toughness of Palacos R, Palacos R+G and the liposomal
Palacos R bone cements with Pluronics L31, L43 and L61. The liposomal Palacos R
cements were found to be significantly higher (by approximately 20%) than Palacos R
and Palacos R+G at 24 hours in air and 60 days in Ringer’s solution (p<0.05). Palacos
R was found to be significantly reduced in toughness as a result of ageing in Ringer’s
solution (p=3.87×10−04), whilst Palacos R+G and the liposomal Palacos R cements were
not significantly different (p>0.05).
Table 10.4: Fracture toughness of commercial and liposomal bone cements before and
after storage in Ringer’s solution for 60 days
Critical stress intensity factor
(KIC) / MPam
1/2
Palacos R
Air 1 day 2.46±0.19
Ringer’s 60 days 1.50±0.31
Palacos R+G
Air 1 day 2.49±0.13
Ringer’s 60 days 2.35±0.19
Palacos R L31
Air 1 day 3.04±0.27
Ringer’s 60 days 2.94±0.21
Palacos R L43
Air 1 day 2.86±0.18
Ringer’s 60 days 2.85±0.35
Palacos R L61
Air 1 day 2.92±0.24
Ringer’s 60 days 2.83±0.09
10.3.6 Fatigue testing
Figure 10.6 shows the fatigue results for commercial Palacos R, Palacos R+G and the
liposomal Palacos R cements after storage in air. All three liposomal Palacos R cements
performed similarly in terms of crack growth rates. Lower crack growth rates were ob-
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Figure 10.6: Fatigue results from commercial and liposomal Palacos R bone cement after
storage in air
Figure 10.7: Fatigue results from commercial and liposomal bone cement after storage in
Ringer’s solution at 37◦C in Ringer’s solution
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tained for the liposomal Palacos R cements when compared to both Palacos R and Palacos
R+G. Furthermore, low crack growth rates could not be achieved under low stress inten-
sities with the liposomal Palacos R cements.
Figure 10.7 shows the fatigue results for commercial Palacos R, Palacos R+G and the
liposomal Palacos R cements after storage in Ringer’s solution at 37◦C for a minimum of
60 days. The crack growth rates for the liposomal Palacos R bone cements were increased
as a result of storage in Ringer’s solution for 60 days. The crack growth rates for the
liposomal Palacos R cements were similar to Palacos R and lower than Palacos R+G.
The three liposomal Palacos R cements obtained similar crack growth rates for the stress
intensities tested.
The constants obtained when the Paris Law was applied to the fatigue data is shown in
Table 10.5 for Palacos R, Palacos R+G and the liposomal Palacos R cements with Pluron-
ics L31, L43 and L61. As previously described, the crack growth rates at 1MPam1/2 (‘A’
Table 10.5: Fatigue test constants of commercial and liposomal Palacos R bone cement
before and after storage in Ringer’s solution for 60 days
A m
Correlation
coefficient
1 day air
60 days
Ringer’s
1 day air
60 days
Ringer’s
1 day air
60 days
Ringer’s
Palacos R 3.73×10−07 7.34×10−07 4.65 7.33 0.67 0.66
Palacos R+G 2.62×10−06 1.13×10−06 5.01 5.18 0.81 0.74
Palacos R
L31
8.50×10−08 2.75×10−07 5.39 5.30 0.72 0.80
Palacos R
L43
2.68×10−08 1.64×10−07 4.85 3.90 0.61 0.75
Palacos R
L61
4.45×10−08 1.63×10−07 6.47 2.94 0.72 0.75
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coefficient) for the liposomal Palacos R cements were lower than the other cements. This
is demonstrated for samples aged for 1 day in air and 60 days in Ringer’s solution. Storage
in Ringer’s solution increased the crack growth rates for all cements, except Palacos R+G,
which remained unchanged.
The slope of the plots (‘m’ coefficient) for the liposomal Palacos R cements were greater
than the slope for Palacos R after 1 day in air. Similarly for Palacos R L31 and L61, the
slopes were greater than Palacos R+G. After 60 days in Ringer’s solution, the slopes of
Palacos R L43 and L61 were significantly lower than those obtained by Palacos R and
Palacos R+G, whilst the slope for Palacos R L31 remained unchanged. Furthermore,
the ‘m’ coefficient of the liposomal Palacos R cements were not worsened by storage in
Ringer’s solution for 60 days, as experienced with the other cements.
10.3.7 SEM images
SEM images of the fracture surfaces of the fatigue samples are shown in Figures 10.8 to
10.10. All cements were found to have pores present after storage in air for 1 day and
Ringer’s solution for 60 days. Air entrapped during mixing and removal of PMMA beads
during fracture may have caused the porosity of the fracture surface. When tested in
air, the liposomal Palacos R cements were found to have smaller sized pores (20-50µm),
whilst Palacos R and Palacos R+G had larger pores (50-100µm). After storage in Ringer’s
solution for 60 days, all fracture surfaces were found to have large 50-100µm pores. Closer
inspection of the liposomal Palacos R cements found small well-dispersed pores (<10µm)
throughout the fracture surface. Rough fracture surfaces were also observed for the li-
posomal Palacos R cements aged in air and Ringer’s solution, indicating a non-brittle
fracture.
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(a) Air ×13 (b) Air ×70
(c) Ringer’s ×13 (d) Ringer’s ×70
(e) Air ×13 (f) Air ×70
(g) Ringer’s ×13 (h) Ringer’s ×70
Figure 10.8: Fracture surfaces of fatigue samples aged in air and Ringer’s solution for (a-d)
Palacos R and (e-h) Palacos R+G - Red arrows indicate the location of PMMA beads,
green arrows indicate radiopacifier particles, blue arrows indicate pores and white arrows
indicate microcracks.
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(a) Air ×13 (b) Air ×70
(c) Ringer’s ×13 (d) Ringer’s ×70
(e) Air ×13 (f) Air ×70
(g) Ringer’s ×13 (h) Ringer’s ×70
Figure 10.9: Fracture surfaces of fatigue samples aged in air and Ringer’s solution for (a-d)
liposomal Palacos R with L31 and (e-h) L43 - Red arrows indicate the location of PMMA
beads, green arrows indicate radiopacifier particles and blue arrows indicate pores.
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(a) Air ×13 (b) Air ×70
(c) Ringer’s ×13 (d) Ringer’s ×70
Figure 10.10: Fracture surfaces of fatigue samples aged in (a-b) air and (c-d) Ringer’s
solution for liposomal Palacos R with L61 - Red arrows indicate the location of PMMA
beads, green arrows indicate radiopacifier particles and blue arrows indicate pores.
SEM images of the surface of the antibiotic release samples (Figures 10.11 to 10.13) demon-
strated that the liposomal Palacos R cements did not have large pores both before or after
storage in Ringer’s solution for 60 days, whilst Palacos R+G had 50-200µm pores on
the surface of the cement. Closer examination of the surface of the liposomal Palacos R
cements found small well-dispersed pores (<10µm) as found in the fracture surfaces.
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(a) 0 hours ×13 (b) 0 hours ×70
(c) 1440 hours ×13 (d) 1440 hours ×70
(e) 0 hours ×13 (f) 0 hours ×70
(g) 1440 hours ×13 (h) 1440 hours ×70
Figure 10.11: Surfaces of antibiotic release samples after 0 and 1440 hours (60 days) in
Ringer’s solution for (a-d) Palacos R and (e-h) Palacos R+G - Green arrows indicate
radiopacifier particles and blue arrows indicate gentamicin sulphate particles or pores
created by the release of gentamicin sulphate.
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(a) 0 hours ×13 (b) 0 hours ×70
(c) 1440 hours ×13 (d) 1440 hours ×70
(e) 0 hours ×13 (f) 0 hours ×70
(g) 1440 hours ×13 (h) 1440 hours ×70
Figure 10.12: Surfaces of antibiotic release samples after 0 and 1440 hours (60 days) in
Ringer’s solution for (a-d) liposomal Palacos R with L31 and (e-h) L43 - Green arrows
indicate radiopacifier particles and blue arrows indicate gentamicin sulphate particles or
pores created by the release of gentamicin sulphate.
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(a) 0 hours ×13 (b) 0 hours ×70
(c) 1440 hours ×13 (d) 1440 hours ×70
Figure 10.13: Surfaces of antibiotic release samples after (a-b) 0 hours and (c-d) 1440
hours (60 days) in Ringer’s solution for liposomal Palacos R with L61 - Green arrows
indicate radiopacifier particles and blue arrows indicate gentamicin sulphate particles or
pores created by the release of gentamicin sulphate.
10.3.8 Vickers hardness
The hardness values for Palacos R, Palacos R+G and the liposomal Palacos R cements
before and after storage in Ringer’s solution for 60 days are shown in Table 10.6. All three
liposomal Palacos R cements had significantly (ANOVA, p<0.05) higher hardness values
than Palacos R and Palacos R+G after storage in air and Ringer’s solution (p<0.05).
Ageing in Ringer’s solution for 60 days did not significantly reduce the hardness of the
liposomal Palacos R cements (p>0.05). All three liposomal Palacos R cements had sim-
ilar hardness values (not significantly different, p=0.28 for air and p=0.28 for Ringer’s
solution).
281
Chapter 10. Liposomal bone cement
Table 10.6: Vickers hardness of commercially available antibiotic-loaded cements and li-
posomal Palacos R before and after storage in Ringer’s solution for 60 days
Hardness (HV30/10) / MPa
Palacos R
Air 1 day 19.76±1.84
Ringer’s 60 days 17.47±2.58
Palacos R+G
Air 1 day 18.74±1.80
Ringer’s 60 days 14.35±3.01
Palacos R L31
Air 1 day 26.55±3.22
Ringer’s 60 days 23.77±2.77
Palacos R L43
Air 1 day 25.92±1.93
Ringer’s 60 days 23.54±3.39
Palacos R L61
Air 1 day 28.10±3.76
Ringer’s 60 days 25.41±2.06
10.3.9 Glass transition temperature
Table 10.7 shows the Tg values for Palacos R, Palacos R+G and the liposomal Palacos
R cements before and after storage in Ringer’s solution for 60 days. After 1 day in air
and 60 days in Ringer’s solution, all three liposomal Palacos R cements had similar Tg
values (not significantly different, p=0.52 for air and p=0.13 for Ringer’s solution). After
1 day in air, Palacos R had significantly higher Tg value than Palacos R L43 (p=0.03), but
not significantly higher than L31 (p=0.08) and L61 (p=0.10). After 60 days in Ringer’s
solution, Palacos R L31 and L43 had significantly higher Tg values than Palacos R (p=0.03
and p=2.49×10−03 respectively), whilst L61 was not significantly different (p=0.09). The
liposomal Palacos R samples at 1 day in air had significantly higher Tg values than Palacos
R+G (p<0.05). Similarly, at 60 days in Ringer’s solution, Palacos L31 and L43 had
significantly higher Tg values than Palacos R+G (p=0.03 and p=2.63×10−03 respectively).
All the cements, with the exception of Palacos R L43, experienced a drop in Tg as a result
of storage in Ringer’s solution for 60 days.
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Table 10.7: Tg of commercially available antibiotic-loaded cements and liposomal Palacos
R before and after storage in Ringer’s solution for 60 days
Glass transition temperature
(Tg) /
◦C
Palacos R
Air 1 day 126.17±3.25
Ringer’s 60 days 117.90±1.23
Palacos R+G
Air 1 day 115.44±1.16
Ringer’s 60 days 117.58±1.50
Palacos R L31
Air 1 day 122.68±2.24
Ringer’s 60 days 119.86±1.18
Palacos R L43
Air 1 day 121.78±2.10
Ringer’s 60 days 121.52±1.40
Palacos R L61
Air 1 day 123.20±1.36
Ringer’s 60 days 119.74±1.69
10.3.10 Structural changes
Figure 10.14 shows the FTIR spectra obtained by ATR measurements for Palacos R,
Palacos R+G and Palacos R L61. Peaks, from PMMA molecules were found for all
samples. These include methylene (CH2) and methyl (CH3) peaks between 2850cm
−1
and 2950cm−1, at 1400cm−1 and at 1450cm−1; the C=O stretch at 1730cm−1; the C-
C-O stretch at 1250cm−1; the O-C-C stretch at 1150cm−1 and C-O stretches between
1300cm−1 and 900cm−1. For Palacos R+G, the peaks around 2900cm−1 were different,
with the primary peak at 2850cm−1 being suppressed, when compared to Palacos R L61
and Palacos R. Small peaks were present in both Palacos R+G and the liposomal Palacos
R cements, which represent gentamicin sulphate, however peaks for liposomal and Pluronic
materials were not detected potentially due to very small concentrations being present in
the cement. The gentamicin sulphate peaks were located at roughly 1050cm−1, 1540cm−1,
3000cm−1 and as broad peaks around 3400cm−1. The strongest peaks for gentamicin
sulphate located at 2340cm−1 and 2360 cm−1 however, were not detected. This may
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Figure 10.14: FTIR spectrum of Palacos R, Palacos R+G and liposomal Palacos R using
ATR
be due to the infra-red signals obtained from PMMA being much stronger than those
obtained from gentamicin sulphate. Overall, few differences were detected between the
cements, demonstrating similar molecular structures.
10.4 Discussion
Commercially available antibiotic-loaded cements, such as Palacos R+G, employ large
amounts of gentamicin sulphate powder to achieve therapeutic levels of release (from 0.5-
1g per 40g of cement). Although these cements have reduced infection rates in cemented
joint replacements, there are several limitations associated with this delivery system. A
large dose of the antibiotic is released in an uncontrolled manner from the surface of the
cement within the first 6 hours, after which, lower, possibly sub-inhibitory levels, are re-
leased over prolonged periods of time. This may enable the formation of resistant bacteria.
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Although large amounts of gentamicin sulphate are incorporated in commercial cements,
only a small percentage of this is released, leaving the majority of the antibiotic unused
in the bulk of the cement. Large amounts of powdered gentamicin in bone cements has
been shown to affect mechanical and fatigue properties in previous studies194–196,200, with
no beneficial influence on the formation of biofilms198, 199 . Furthermore, the results from
Chapter 8 has shown poor dispersion of gentamicin sulphate in bone cement to result
in poor antimicrobial activity. With this in mind, there is an opportunity to improve
antibiotic-loaded cements.
Liposomes have been extensively used in medicine as drug delivery devices for the treat-
ment of infections and cancers. Liposomes have also been used in opthalmology, pain
management and vaccinations385, 387, 410 . Various therapeutic agents have been employed
within liposomes, including antimicrobial and antineoplastic therapeutic agents, chelat-
ing agents, steroids, vaccines and genetic materials382. The majority of these liposomal
systems are administered as an aqueous suspension and there is little evidence of use in
polymers or non-aqueous environments. Nevertheless, the results from this chapter and
Chapter 9 demonstrate that liposomes with an encapsulated antibiotic can be effectively
dispersed in PMMA bone cement using certain Pluronics (L31, L43 and L61). All three
Pluronics gave similar results in terms of antibiotic release, antimicrobial efficacy and me-
chanical, fatigue and material properties as a result of good dispersion throughout the
cement.
For the liposomal Palacos R cements, there was a small initial burst of gentamicin sulphate
released from the surface of the cement as these surface liposomes came into contact with
water. The initial burst of gentamicin sulphate was lower than the commercial cements
however, as significantly less gentamicin sulphate was employed and fewer agglomerations
were present on the surface. This resulted in a more linear, gradual and prolonged release
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of antibiotic. The SEM images of the release samples confirm this as the commercial ce-
ments had randomly located large pores caused by the release of surface agglomerations
of gentamicin sulphate, whilst the liposomal Palacos R cements had much smaller well-
dispersed pores. The presence of small well-dispersed pores would allow for the controlled
diffusion of water through the outer layers of the cement. This in turn would allow water
to penetrate the antibiotic below the surface of the cement, resulting in a more gradual
and controlled release. Large random pores caused by agglomerations of gentamicin sul-
phate powder would result in a less controlled release as water penetration into the cement
would be less uniform. The standard deviations for the liposomal Palacos R cements were
also smaller, demonstrating consistency between the samples tested over the early time
points. Commercial cements on the other hand demonstrated large standard deviations
due to different levels of antibiotic being released from each sample.
After 360 hours, the release from the liposomal Palacos R cements was equal to that
of Palacos R+G, despite there being 60% less gentamicin sulphate in the liposomal Pala-
cos R cements. This resulted in a much higher percentage release (11-12% at 72 hours
and 21-22% at 1440 hours), more than double that of Palacos R+G and 7 times greater
than Cemex Genta and CMW cements. The high release from Palacos cements may be
attributed to the cement composition and therefore a limitation of this study is that com-
parisons with Cemex Genta and CMW cements cannot be accurately performed. It is
possible that the gentamicin sulphate release from the liposomal system would differ when
used in other cement brands, although improvements would be expected.
Similar amounts of gentamicin sulphate were released from the liposomal Palacos R ce-
ments and Palacos R+G, however the liposomal system demonstrated much higher effi-
ciency compared to cements with powdered gentamicin sulphate. A recent study using
liposomal amphotericin B in Simplex P bone cement obtained similar results, whereby
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cement with liposomal amphotericin B achieved higher levels of release than cement with
amphotericin B deoxycholate414 . Furthermore, the release was also speculated to be re-
lated to diffusion from pores in the cement.
The PHT assay was deemed sufficiently accurate and reproducible for assessing the re-
lease of gentamicin sulphate from PMMA bone cements between concentrations of 0 and
100µg/mL, as discussed in Chapter 8. Should a finer resolution and greater sensitivity to
detect lower concentrations of release be required, high-performance liquid chromatogra-
phy (HPLC) can be employed as used by Dunne et al.194. Static release tests were carried
out to compare the release from liposomal Palacos R cements with the release results from
Chapter 8 for commercial cements. Although dynamic elution tests would more accurately
replicate in vivo conditions, the static release test used provides basic information on the
release of gentamicin sulphate as a result of water penetration and therefore, mathemat-
ical modelling is simplified as fewer parameters need to be considered. Results obtained
using dyamic elution techniques however, may be different as the cement is subjected to a
continuous circulation of medium, which may encourage degradation of the cement, allow-
ing for increased water penetration and antibiotic release. Although Ringer’s solution at
37◦C replicated similar temperatures, pH and salt concentrations found in vivo, the vis-
cosity of the solution differs from blood, which is increased due to the presence of plasma
and particles, such as red blood cells. In vivo therefore, the penetration of blood into
the cement may differ from that of Ringer’s solution, resulting in different release rates.
Therefore, this in vitro investigation can be used to compare the performance of different
therapeutic delivery systems, but cannot be used to quantitatively determine antibiotic
tissue and fluid concentrations in vivo.
As discussed in Chapter 9, centrifugation of liposomes may not harvest all the lipid ma-
terial for inclusion in the MMA, but calculations on gentamicin content have assumed
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that all the liposomes were incorporated in cement. Furthermore, a high encapsulation
efficiency (nearing 100%) of gentamicin sulphate was also assumed, however studies have
shown the encapsulation efficiency of gentamicin sulphate in liposomes to range from 5
to 40%415, 416. Therefore, the efficiency of gentamicin sulphate release from the liposomal
Palacos R cement is thought to be significantly higher than the calculated results.
The high efficiency of delivery from the liposomal system may be attributed to the re-
lease mechanisms taking place. Equations for antibiotic release were used in an attempt
to establish this mechanism. Although the equations used were simple, it was possible
to establish the dominant release mechanism in the cements tested, although it is likely
that a combination of mechanisms are occurring during the release of gentamicin sul-
phate. Therefore, combining the release equations may provide a more accurate model, as
demonstrated by Khun and Wilson372. The results from the mathematical models have
highlighted differences between the liposomal Palacos R cements and the commercial ce-
ments. The Noyes-Whitney equation was found to model the release data for the liposomal
cements most effectively, whilst the Korsemeyer-Peppas equation best suited the commer-
cial cements (Chapter 8). Furthermore, the Higuchi model was also more accurate for
the liposomal Palacos R cements, demonstrating a closer relationship to Fickian diffusion.
The use of an additional coefficient improved the goodness of fit for all the models accom-
modating the initial burst of gentamicin sulphate released from the surface of the cement.
Interestingly, the burst coefficient improved the models for the commercial cements to a
greater extent than the liposomal Palacos R cements. Overall, the expanded Korsmeyer-
Peppas and expanded Noyes-Whitney models best suited the gentamicin sulphate release
from the liposomal Palacos R cements, demonstrating the release was exponentially re-
lated to time and governed by concentration and surface area dependent processes.
The agar diffusion test demonstrated good bioavailability of the encapsulated gentamicin
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sulphate in the liposomal Palacos R cements as reproducible zones of inhibition against S.
aureus were obtained, consistent in both size and shape between all the liposomal Palacos
R samples. Good dispersion of the liposomes on the surface layers of cement would result
in an even diffusion of gentamicin sulphate through the agar, creating consistent zones of
inhibition. It can be concluded, therefore, that the liposomal system would most likely in-
hibit bacteria in all regions of the cement, unlike commercial products which were found to
have inconsistent zones of inhibition due to an uneven distribution of gentamicin sulphate.
The efficacy of the liposomal system was only tested against one strain of bacteria as a
bioindicator. The ability of liposomes to encapsulate a combination of antibiotics could
widen the antimicrobial spectrum of the cement without altering the release properties.
Although the liposomal Palacos R cements were found to have good release and antimi-
crobial properties, a reduction in compressive strength was experienced. It is thought that
the liposomes are more easily deformed than rigid gentamicin sulphate particles and the
presence of well-dispersed 100nm liposomes would result in a more porous cement, mak-
ing the liposomal Palacos R cements weak in compression. The reduction in compressive
strength may also be attributed to the presence of water. The presence of water has been
shown to decrease the polymerisation induction period of methyl methacrylate417. The
induction period for free radical polymerisation reactions is the time required for complete
consumption of the inhibitor (hydroquinone in the case of bone cement). Although water
did not alter the polymerisation of MMA in the study, a shorter induction period may
have implications on the mechanical properties of the cement. A study using lyophilized
liposomes in bone cement also demonstrated a reduction in compressive strength414, there-
fore, the presence of small quantities of water is unlikely to have caused the reduction.
After storage in Ringer’s solution, the compressive strength of the liposomal Palacos R
cements increased, whilst the compressive strength of Palacos R and Palacos R+G de-
creased. This may be due to the liposomal Palacos R cements setting slowly over 60 days
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or the plasticisation effect of water not affecting the liposomal Palacos R cements. This
suggests that the liposomal cements may perform better in terms of compressive strength
in vivo.
The bending modulus of the liposomal Palacos R cement was not significantly different
from Palacos R+G and all the cements experienced a reduction in modulus due to storage
in Ringer’s solution as a result of plasticisation and hydrolysis of PMMA as discussed in
Chapter 7. The bending modulus of the liposomal Palacos R cement was significantly
lower than Palacos R after 60 days in Ringer’s solution due to the gentamicin sulphate
being released, resulting in a more porous cement.
Improvements in bending strength were observed for the liposomal Palacos R cement
when compared to Palacos R+G. This is due to the even dispersion of the liposomes
which contrasts with the weakening effect of agglomerations of powdered gentamicin sul-
phate. No improvements in bending strength were observed when compared to Palacos R.
The compression and bending tests were carried out according to the ISO5833 standard,
which all cements must undergo prior to approval for medical application. The liposomal
Palacos R cements were found to exceed the ISO5833 minimum requirements for compres-
sion and bending properties, demonstrating the novel delivery system in Palacos cement
is suitable as an acrylic cement for orthopaedics.
After the release of gentamicin sulphate from the liposomal Palacos R cements, small
well-dispersed pores were observed in the SEM images. It has been hypothesised that
small dispersed pores may be beneficial to mechanical and fatigue properties by dispers-
ing energy ahead of the crack tip, as well as blunting the crack tip418. Small pores are
also thought to reduce polymerisation shrinkage, reducing the likelihood of residual stress-
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induced cracks61. It is postulated that the sub-micron pores and liposomes in the liposomal
Palacos R cements behave similar to small rubber particles, inducing toughening mech-
anisms. Rubber particles have been shown to improve the fracture toughness of bone
cement through plastic deformation, crack deviation and craze formation166–168. As dis-
cussed in Chapter 3, crazes are considered load bearing cracks with highly drawn fibrils
spanning the crack. This provides support against loads and delays failure. Although craz-
ing is usually a precursor to brittle failure, the highly drawn fibrils require considerable
plastic deformation and energy to form, therefore enhancing the fracture toughness of the
material. Rubber particles used in brittle polymers have been shown to increase fracture
toughness by increased craze density419–422. Under high strain rates, shear yielding is in-
duced by cavitation of the rubber particles, whilst at low strain rates, matrix deformation
and crack deviation is induced169. It is hypothesised that the liposomes and pores behave
in a similar manner. This theory may offer an explanation for the reduced compressive
strength of the liposomal Palacos R cements, as the compression test was conducted at a
strain rate of 20mm/min, causing cavitation, whilst bending was conducted at 5mm/min,
which induced matrix deformation, crack deviation and crazing. Furthermore, rubber par-
ticles have also been shown to reduce the modulus of materials, as experienced with the
liposomal Palacos R cements423.
The theory of rubber-like toughening in the liposomal Palacos R cements is further corrob-
orated by the fact that fracture toughness and fatigue crack propagation were improved
by the use of well-dispersed liposomes. The fracture surfaces were found to be rougher in
the liposomal Palacos R cements, demonstrating non-brittle fracture. Furthermore, the
fracture toughness was not significantly reduced by ageing in Ringer’s solution.
Tests on the structure of liposomal Palacos R cements demonstrate that liposomes do
not affect the molecular structure of the cement, however the hardness of the cement was
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significantly increased by the addition of liposomes. As the yield stress of a material is
roughly three times the hardness value, it is expected that the yield stress of the lipo-
somal Palacos R cements would also be significantly higher than Palacos R/R+G. The
glass transition temperature was also affected, however at temperatures well below the Tg
of the cements (e.g. in vivo temperatures of 37◦C), it is expected that the slight change
will not be detrimental to the mechanical properties as fatigue testing at 37◦C was not
detrimental to crack growth rates. The ISO5833 standard used for mechanical testing
does not specify required testing temperatures. Nevertheless, testing at this temperature
would ensure the changes in Tg experienced do not significantly affect the compression
and bending properties of the liposomal Palacos R cements. Furthermore, creep testing
would provide useful information on the rate of deformation that the novel cement is likely
to undergo in vivo.
10.5 Conclusions
Liposomes have been successfully incorporated into a commercial PMMA bone cement
(Palacos R) and with the exception of compressive strength, the commercial cement
properties were not adversely affected. Furthermore, all cement properties were above
the ISO5833 minimum requirements for acrylic resin cements and the presence of well-
dispersed liposomes throughout the cement improved the bending, fracture toughness,
fatigue and hardness properties of the commercial cement. It is speculated that the im-
provement in crack growth resistance is caused by the dispersed liposomes inducing rubber
toughening mechanisms, such as crazing, crack deviation and matrix deformation. The
novel drug delivery system demonstrated enhanced dispersion of antibiotics when com-
pared to the current powdered antibiotic system. This resulted in a more controlled,
gradual and prolonged release of gentamicin sulphate; enhanced antimicrobial properties
and higher efficiency, requiring less gentamicin sulphate to achieve therapeutic levels of
release. The mechanism of release was found to be altered as it is speculated that the
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dispersed liposomes allowed water to penetrate and diffuse below the surface of cement in
a controlled manner.
Although the initial results are promising, it is essential to study the long-term stabil-
ity of liposomes in MMA to establish the shelf-life of the system. The behaviour and
integrity of the liposomes in the cement will have implications on the therapeutic index
and circulation times in vivo and therefore, must be investigated. The system must also be
optimised in terms of the antibiotics used; the size and composition of the liposomes; the
encapsulation efficiency and the use of other preparation methods, such as lyophilization,
to ensure optimum release, antimicrobial, mechanical and fatigue properties in vivo.
In conclusion, the release of liposomal therapeutic agents from PMMA bone cement may
play a vital role in reducing infection rates in cemented joint replacements. The ability
of liposomes to deliver a diverse range of therapeutic agents combined with the technol-
ogy to disperse liposomes in methacrylate-based materials and potentially other polymeric
materials has a wide range of applications.
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Discussion
The failure rate of recently implanted cemented joint replacements has been shown to be
roughly 10% after 15 years74. With an ageing population on the increase, implant failure,
which requires revision surgery, may have considerable consequences for the health care
services. Furthermore, the increase in life expectancy requires better implants, which are
more resistant to loading, biological responses and the biological environment in order
to preserve the quality of life of patients. Although PMMA bone cement is known to
fail predominantly as a result of aseptic loosening21, the mechanisms behind this are not
fully understood. Understanding cement failure and how it behaves in vivo over time is
essential for developing future formulations.
Several studies have investigated the ageing of PMMA bone cements. These studies how-
ever, were limited to investigating changes in surface properties, molecular weight and
chemical structure as a result of ageing149, 150, 348 . The impact of physiological ageing
on important parameters, such as moisture uptake and mechanical and fatigue proper-
ties were not studied. In this study, two commercial cements with different compositions
were aged in vitro to investigate changes in these properties that may occur due to body
temperature, pH, moisture uptake and physiological salts over time. Storage in Ringer’s
solution at 37◦C had a significant impact on the compression, bending, fracture toughness
and fatigue properties of the cement. Changes to these properties were attributed to a 2%
increase in weight, caused by moisture uptake as a result of Fickian diffusion of water into
the cement. As postulated by Hughes et al.149 and Bettencourt et al.150, the penetration
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of water into the cement is thought to cause polymeric chain scission by hydrolysis of the
ester groups of PMMA. This would increase chain mobility, decrease mechanical properties
and cause changes to the molecular structure of the cement, as observed in the results.
High variability in the results were observed however, due to variation in the prepara-
tion techniques creating inhomogeneities in the samples. Preparation techniques that are
capable of producing homogeneous samples in a controlled and reproducible manner are
required to improve the precision of the results. X-ray imaging or porosimetry measure-
ments may also be employed to determine the presence of pores or agglomerations, which
may affect results, prior to ageing and testing. Furthermore, in vivo conditions could be
more accurately replicated, for example, by using blood as opposed to Ringer’s solution.
Therefore, the results obtained cannot quantitatively predict the changes that will occur
in vivo. Nevertheless, qualitative data has been obtained and demonstrates that physio-
logical ageing of PMMA bone cement is a potential contributor to in vivo failure. This
study also highlights the limitations of using ISO standards to establish the suitability of
cement formulations. The ISO5833 standard for acrylic resin cement does not consider the
implications of cement ageing, which may influence the clinical success of the cemented
implant. An example of this is Boneloc cement (Biomet Inc., Indiana, USA), which met
the minimum requirements set by the standard, however resulted in unacceptably high
levels of clinical failure due to in vivo temperatures inducing changes in mechanical prop-
erties151. Therefore, testing of novel cement formulations after ageing is recommended to
prevent undesirable clinical outcomes.
A review of the literature has highlighted limitations of the current cement formulations
and other potential contributors to failure. A widely disputed contributor is the radiopaci-
fier employed in PMMA bone cement. Previous studies have demonstrated that radiopaci-
fiers influence the mechanical and fatigue properties of commercial cements35,66, 82, 91–95.
The majority of studies testing novel radiopacifiers however, had a different composition
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from the commercial cements being used for comparison180, 188. Therefore, an accurate
comparison between the novel cements and the commercial cements could not be made.
With this in mind, a model cement was developed to investigate the effect of using differ-
ent radiopacifier materials, on the properties of bone cement. Two cement brands, Cemex
(Tecres, Sommacampagna, Italy) and Palacos R (Heraeus, Newbury, UK), were used as a
baseline due to their distinctly different properties and compositions. The model cement
was designed to have intermediate properties between the two commercial cements in an
attempt to represent a generic PMMA bone cement. Thus, changes in the properties of the
model cement when formulated with different radiopacifiers could be compared with the
model cement and would be as a direct result of changes in the radiopacifier. This method
was also considered to be more effective than attempting to replace the radiopacifier in
commercial cements, as removing the radiopacifier from a pre-blended cement would be
difficult to achieve. The complete removal of the radiopacifier material cannot be guaran-
teed and the method of removal may affect some cement properties.
Anatase TiO2 and yttria-stabilised ZrO2 are materials commonly employed to improve
the properties of composites. Although similar materials have been tested in PMMA
bone cement, the development of a model cement has allowed the effect of using anatase
TiO2 and yttria-stabilised ZrO2 over conventional radiopacifiers to be determined. All
radiopacifiers were found to be suitable for PMMA bone cement, however, there were no
significant improvements in using anatase TiO2 or yttria-stabilised ZrO2 over BaSO4. All
the radiopacifiers tested demonstrated a similar problem in that the radiopacifier particles
were found to agglomerate in the cement due to the hydrophilic nature of the material
when surrounded by hydrophobic PMMA. These results agree with previous studies, which
have demonstrated that the agglomerating nature of radiopacifiers is detrimental to the
performance of PMMA bone cements35, 91, 92, 95.
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To overcome the incompatibilities between PMMA and the radiopacifier particles, a methacry-
late based silane was used to alter the surface characteristics to improve the dispersion
and adhesion of the radiopacifiers to the polymer matrix. The silane treatment proved
to be successful for anatase TiO2, which demonstrated significant improvements in me-
chanical properties. Furthermore, the unique surface properties of anatase TiO2 and the
silane were found to improve the bone growth properties of PMMA bone cement. The
biocompatibility of the silane was questioned however, as cell proliferation was adversely
influenced by the presence of the coating. Further tests would be required to fully establish
the viability of this technology for PMMA bone cement. Tests using bone chips on the
surface of the cement, as employed by Schuler et al.339, would more accurately replicate
the conditions found at the cement-bone interface and provide vital information on the
performance in vivo. Furthermore, changes in surface properties of the cement as a result
of using the novel radiopacifiers may have implications on the moisture uptake and ageing
of the cement. Therefore, a limitation of this study is that the long-term performance of
the cement was not assessed. Nevertheless, silane-treated anatase TiO2 has been shown
to be a suitable radiopacifier for PMMA bone cement, demonstrating improvements in
mechanical and bone growth properties. As PMMA is generally considered bioinert in
terms of bone growth, improvements in the osseointegrative properties of PMMA bone
cement may play a vital role in reducing loosening at the cement-bone interface.
Infected joint replacements account for only a small percentage of failed implants. Nev-
ertheless, post-surgical infections are difficult to treat and are therefore a serious problem
with severe implications for patient outcomes and survival rates. Bacteria on the surface
of the implant are not easily eliminated and may act as a reservoir for recurring infections.
Furthermore, systemic antibiotics are not effective in reaching and treating the affected
area due to limited blood flow. The use of bone cement as a local delivery system for
antibiotics is a popular solution to this problem, with the number of surgeons opting to
298
Chapter 11. Discussion
use commercially available antibiotic-loaded cements increasing. The current system how-
ever, which utilises powdered gentamicin sulphate, was found to have several limitations.
Poor dispersion and agglomerations of the powdered gentamicin sulphate resulted in poor
release profiles, with a burst of antibiotic release occurring from surface agglomerations
in an uncontrolled manner. This results in large, irregular, randomly located pores on
the surface of the cement, which altered the mechanical and fatigue properties of the ce-
ment. Furthermore, the majority of the antibiotic release occurs within the first 6 hours,
after which sub-inhibitory levels are maintained, which may encourage the formation of
resistant bacteria. Although large quantities of gentamicin sulphate are incorporated into
the cement (0.5-1g of gentamicin sulphate per 40g of cement), only a small percentage
of this is released. These findings strongly agree with the results from other studies and
show that the limitations are related to the type of system, as opposed to the antibiotic
used194–197,200.
Given these shortcomings, a delivery system, using liposomes as a therapeutic carrier,
was developed for PMMA bone cements. A novel method for dispersing hydrophilic li-
posomes in a hydrophobic liquid using biocompatible block copolymers was developed to
overcome incompatibilities between the two systems. The dispersion of sub-micron lipo-
somes improved the bending, fracture toughness, fatigue and hardness properties of the
commercial cement and maintained other properties meeting the ISO standard require-
ments both before and after ageing. Improved antimicrobial performance was observed
and the release of gentamicin sulphate from the liposomal cement was more controlled,
gradual and prolonged when compared to the powdered antibiotic system.
Overall, the results for the liposomal cement are encouraging and have demonstrated that
the liposomal delivery system performs well in a methacrylate-based polymer. A benefit
of this technology, is that it does not alter the surgical procedure and therefore, additional
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training is not required to mix and apply the liposomal cement. A cost analysis however,
is necessary to determine the economical viability of implementing and manufacturing this
technology on an industrial scale. Other methacrylate-based medical devices, which may
benefit from this technology include: dental materials; screw fixation in bone; bone cavity
and skull defect fillers; and materials used for vertebral stabilisation424.
The advantages associated with liposomes, such as the ability to incorporate a combination
of therapeutic agents, improved delivery control and the ability to regulate the size and
composition, may allow optimisation of the system and further enhance the performance
of liposomal bone cements. This flexibility increases the range of applications for this tech-
nology. For example, triclosan may be encapsulated in liposomes and incorporated into
dental cements. Bone growth factors or strontium may be encapsulated in liposomes to en-
hance the bone growth of orthopaedic cements or spacers. Bone growth properties may be
further enhanced as liposomes composed of certain phospholipids (e.g. phosphatidylserine
and phosphatydilinositol) have demonstrated calciotropic properties247, 254, 257.
The use of liposomes outside of methacrylate-based materials would further widen the
applicability of the technology. If liposomes can be dispersed in other hydrophobic poly-
meric materials using Pluronics, then the technology can be applied to other medical
devices, such as catheters or biodegradable implants, to deliver therapeutic agents and
prevent infections. Furthermore, the release of liposomes from polymeric systems may
allow for the local delivery of therapeutic agents, such as cytotoxic antineoplastic drugs
used in cancer treatments, closer to the site requiring treatment. For a comprehensive list
of the liposome-therapeutic combinations, which have been clinically approved and are
currently undergoing clinical trials, refer to Tables 11.1 and 11.2385,387, 410 . Light-sensitive
liposomes may also be incorporated into polymeric systems to control the release of en-
capsulated materials by light activation, closer to the disease site. Radiopaque liquids,
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such as iodine-based liquids, may be encapsulated in liposomes and dispersed in polymers
to provide radiopacity limiting the potentially toxic effects of using liquid radiopacifiers.
Similarly, metal particles, such as those used in magnetic liposomes for magnetic reso-
nance imaging (MRI), may be encapsulated in liposomes to produce radiopacity without
the undesirable effects associated with using powdered radiopacifiers.
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Table 11.1: Clinically approved liposomal-based therapeutics
Trade
Name
Company
Liposome
Composition
Liposome
Charge
Therapeutic
Therapeutic
Type
Form/Shelf-life Indication
Abelcet Enzon, Cephalon
DMPC and DMPG
(7:3 molar ratio)
Negative Amphoterecin B
Polyene
antimycotics
Suspension/24
months
Fungal infections
AmBisome
Gilead Sciences,
NeXstar
HSPC, DSPG and
cholesterol (2:0.8:1
molar ratio)
Negative Amphoterecin B
Polyene
antimycotics
Powder/36
months
Fungal and protozoal
infections
Amphotec Sequus Cholesteryl sulfate Negative Amphotericin B
Polyene
antimycotics
Powder/24
months
Fungal infections
DepoCyt
SkyePharma,
Napp
DOPC, DPPG,
Cholesterol and
Triolein (7:1:11:1 molar
ratio)
Negative Cytarabine Antineoplastics
Suspension/18
months
Malignant lymphomatous
meningitis
DaunoXome
Gilead Sciences,
NeXstar, Galen
DSPC and cholesterol
(2:1 molar ratio)
Neutral Daunorubicin citrate Antineoplastics
Emulsion/12
months
HIV-related Kaposis sarcoma
Myocet Zeneus, Cephalon
EPC and cholesterol
(55:45 molar ratio)
Neutral
Doxorubicin
hydrochloride
Antineoplastics
Powder/18
months
Combination therapy with
cyclophosphamide in
metastatic breast cancer
Epaxal
Berna Biotech,
Janssen-Cilag
DOPC and DOPE Neutral
Inactivated hepatitis A
virus (haemagglutinin)
Vaccine
Suspension/36
months
Hepatitis A
Inflexal V
Berna Biotech,
Janssen-Cilag
DOPC and DOPE Neutral
Influenza virus surface
antigens
(haemagglutinin and
neuraminidase)
Vaccine
Suspension/12
months
Influenza
DepoDur
SkyePharma,
Endo
DOPC, DPPG,
cholesterol, Triolein
(7:1:11:1 molar ratio)
Negative
Morphine sulphate
pentahydrate
Analgesic
Suspension/24
months
Postsurgical analgesia
Visudyne QLT, Novartis
EPG and DMPC (3:5
molar ratio)
Neutral Verteporfin
Photosensitizing
agent
Powder/48
months
Age-related macular
degeneration, pathologic
myopia, ocular histoplasmis
Doxil/Caelyx
Ortho Biotech,
Schering-Plough,
Seqqus,
Janssen-Cilag
HSPC, cholesterol and
PEG 200-DSPE
(56:39:5 molar ratio)
Neutral
Doxorubicin
hydrochloride
Antineoplastics
Suspension/20
months
HIV-related Kaposis
sarcoma, metastatic breast
cancer, metastatic ovarian
cancer and prostate cancer
Estrasorb Novavax HSPC Neutral Estradiol hemihydrate Hormone
Emulsion/36
months
Menopausal therapy
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Table 11.2: Liposomal-based therapeutics in clinical trials
Trade
Name
Company
Liposome
Composition
Liposome
Charge
Therapeutic
Therapeutic
Type
Indication
LEP-ETU NeoPharm
DOPC, cholesterol
and cariolipin (90:5:5
molar ratio)
Negative Paclitaxel
Mitotic
inhibitor
Ovarian, breast, lung
cancer
LEM-ETU NeoPharm
DOPC, cholesterol
and cariolipin (90:5:5
molar ratio)
Negative Mitoxantrone Antineoplastics
Leukemia, breast,
stomach, liver, ovarian
cancers
EndoTAG-1 Medigene
DOTAP, DOPC and
paclitaxel (50:43:3
molar ratio)
Positive Paclitaxel
Mitotic
inhibitor
Anti-angiogenic
properties, breast cancer,
pancreatic cancer
Arikace Insmed
DPPC and
cholesterol
Neutral Amikacin
Aminoglycoside
antibiotic
Lung infection
Marqibo
Talon
therapeutics
Egg sphingomyelin
and cholesterol
(55:45 molar ratio)
Negative Vincristine
Mitotic
inhibitor
Metastatic malignant
uveal melanoma
ThermoDox Celsion
DPPC, MSPC and
PEG 200-DSPE
(90:10:4 molar ratio)
Neutral
Doxorubicin
hydrochloride
Antineoplastics
Non-resectable
hepatocellular carcinoma
Atragen Aronex
DMPC and soybean
oil
Neutral Tretinoin Antineoplastics
Acute promyelocytic
leukemia,
hormone-refractory
prostate cancer
T4N5
liposome
lotion
AGI Dermatics Unknown -
Bacteriphage T4
endonuclease 5
Bacteriphage/
Enzyme
Xeroderma pigmentosum
Liposomal
Grb-2
Bio-Path Unknown -
Grb2 antisense,
oligodeoxynucelotide
Synthetic DNA
Acute myeloid leukemia,
chronic myelogenous
leukemia, acute
lymphoblastic leukemia
Nyotran Aronex
DMPC, DMPG and
cholesterol
Negative Nystatin
Polyene
antimycotics
Systemic fungal infections
LE-SN38
NeoPharm,
Insys
Therapeutics
DOPC, cholesterol
and cardiolipin
Negative SN-38 Metabolite
Metastatic colorectal
cancer
Aroplatin Antigenics DMPC and DMPG Negative Cisplatin Antineoplastics
Metastatic colorectal
cancer
Liprostin Endovasc Unknown - Prostaglandin E1 Antiulcerative Peripheral vascular disease
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Stimuvax Merck KGaA
Monophosphoryl
lipid A, cholesterol,
DMPG and DPPC
Negative BLP25 lipopeptide Vaccine
Cancer vaccine for
multiple myeloma
developed encephalitis
SPI-077 Sequus
SHPC, cholesterol,
DSPE-PEG
Neutral Cisplatin Antineoplastics
Head and neck cancer,
lung cancer
Lipoplatin Regulon
SPC, DPPG,
cholesterol and
mPEG 2000-DSPE
Negative Cisplatin Antineoplastics
Pancreatic cancer, head
and neck cancer,
mesothelioma, breast and
gastric cancer,
non-squamous
non-small-cell lung cancer
S-CKD602 Alza
DPSC and
DSPE-PEG (95:5
molar ratio)
Neutral Camptothecin
Drug
intermediate
Recurrent and progressive
carcinoma of the uterine
cervix
OSI-211
OSI Pharma-
ceuticals
HSPC, cholerstol
(2:1 molar ratio)
Neutral Lurtotecan Anti-histamine
Ovarian cancer, head and
neck cancer
INX-0125 Inex
Egg sphingomyelin
and cholesterol
(55:45 molar ratio)
Neutral Vinorelbine
Mitotic
inhibitor
Advanced solid tumors
INX-0076 Inex
Egg sphingomyelin
and cholesterol
(55:45 molar ratio)
Neutral Topoitecan Antineoplastics Advanced solid tumors
Liposome-
Annamycin
Callisto DSPC and DSPG Negative Annamycin
Anthracycline
antibiotic
Acute lymphocytic
leukemia
SLIT
Cisplatin
Transave
DPPC and
cholesterol
Neutral Cisplatin Antineoplastics Cancer treatments
AeroLEF
Delex
Therapeutics
EPC/SPC,
cholesterol
Neutral Fentanyl Analgesic Pain treatment
Onco TCS Inex, Enzon DSPC, cholesterol Neutral Vincristine sulfate
Antineoplastic
Agents
Cancer treatments
Allovectin-7 Vical DMRIE and DOPE Positive HLA-B7 plasmid Gene
Gene therapy of
metastatic cancers
Annamycin Aronex
DMPC, DPPC,
DMPG, Sterylamine
(SA), cholesterol
Negative Annamycin
Anthracycline
antibiotic
Breast cancer
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12.1 Conclusions
The recent evolution of biomaterials has resulted in biological sciences representing an
equally important contribution to that of materials science and engineering in laying the
foundations for effective medical devices. Furthermore, advances in technology have in-
creased the sophistication with which biomaterials are designed and have permitted the
development of materials with increasingly complex functions. In spite of this, PMMA
bone cements have experienced few improvements since first being introduced into or-
thopaedics in the late 1950s. Failure of cemented implants still remains an issue and with
an ageing demographic, there is a clear need to improve current cement formulations in
an attempt to reduce failure rates. Nevertheless, PMMA bone cement remains one of the
most reliable methods for implant fixation and plays a vital role in the treatment of severe
joint conditions, such as osteoarthritis.
The main purpose of this research programme was to develop novel formulations of PMMA
bone cement, which may contribute to preventing failure. In order to achieve this, it was
necessary to gain an understanding of the properties and characteristics of PMMA bone
cement, why it fails and what has been done in an attempt to prevent failure. A good
understanding of the different test methods used to determine the properties of PMMA
was also required and knowledge of the principles behind the test methods allowed for a
critical assessment of the results.
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Previous studies have demonstrated clear changes in chemical and molecular properties
as a result of ageing, however little is known about the moisture uptake of PMMA bone
cement and the effect this may have on mechanical and fatigue properties. This study
found that significant changes to the mechanical and fatigue properties were experienced
when cement was aged in vitro, in partially simulated in vivo conditions. The reduc-
tion in properties was found to coincide with the time when maximum moisture uptake
was achieved. The mechanism by which water diffuses into the cement was hypothe-
sised and the structural ageing and degradation of bone cement was found to agree with
those postulated by other authors. This study has highlighted the need for more accurate
standards of testing, which fully address the effects of physiological ageing over extended
periods of time. Furthermore, this study has significant implications on how bone cement
is thought to behave in vivo over time and provides insight into a potential cause of failure.
Another contributor to the early failure of PMMA bone cement has been linked to the
radiopacifier material used. In order to study the effect of different radiopacifier materials
on the properties of PMMA bone cement, a different approach was required. A model
cement was developed with intermediate properties between two distinctly different com-
mercial cements. This allowed novel radiopacifier materials to be tested and the direct
impact of those materials to be deduced. Silane-treated anatase TiO2 was found to be
a suitable radiopacifier material, demonstrating good mechanical and fatigue properties
and improved bone growth properties. The improvement in bone growth may help prevent
loosening at the cement-bone interface and therefore, reduce the number of failed implants.
Powdered antibiotic in PMMA bone cement is currently used in an attempt to reduce
surgical infections and is a technique that is growing in popularity. Nevertheless, previous
studies have hypothesized that powdered antibiotic is detrimental to the performance of
PMMA bone cement and performs poorly in terms of antibiotic release and in prevent-
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ing bacterial growth. This study has established suitable test methods for determining
the release and antimicrobial properties of antibiotic-loaded bone cements. Furthermore,
these methods have highlighted the limitations of using powdered antibiotic in PMMA
bone cements.
Having established the inability of the current delivery system to achieve acceptable release
and antimicrobial activity without adversely affecting mechanical and fatigue properties,
a novel delivery system was developed. The system combined two materials widely em-
ployed in drug delivery systems: block copolymers and lipids. The specific combination
and arrangement of the two materials allowed for the dispersal of hydrophilic liposomes
in a hydrophobic environment in a completely novel way. Sub-micron liposomes were
dispersed in PMMA bone cement, which in turn improved the release, antimicrobial, me-
chanical and fatigue properties of the commercial cement. This novel system achieved
controlled delivery of gentamicin from PMMA bone cement without adversely affecting
mechanical performance. This in turn will not only contribute to reducing infection rates,
but has broader implications since the technology has the potential to be incorporated in a
variety of materials and therefore, may find applicability in a wide range of medical devices.
In conclusion, this study set out to develop novel techniques to help prevent the failure of
cemented joint replacements. In doing so, an understanding of the science behind PMMA
bone cement, the potential causes of failure, methods of testing the different properties of
PMMA bone cement, and techniques to prevent failure have been established. There was
a contribution to the existing knowledge on cement failure and two novel techniques were
developed, which may aid in preventing cement failure in vivo. Recent advances in technol-
ogy have highlighted the need for cross-disciplinary collaborations, such as this one, and
have created opportunities to improve biomaterials using novel approaches. Advancing
knowledge in this particular field of science is of paramount importance as improvements
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will not only lessen the burden on health care services, but will also contribute to improving
patient outcomes and a higher quality of life.
12.2 Further work
The work carried out in this study has produced novel techniques and has contributed to
the existing body of knowledge and as a result, a series of further questions have emerged
from this. The following experiments have been deemed outside the scope and time frame
of this study, but they may form the basis for potential future research.
Although silane treated anatase TiO2 demonstrated encouraging mechanical, fatigue and
bone growth properties, the biocompatibility of the particular silane employed has been
questioned. A series of in vitro experiments investigating the toxicity of the silane on
tissues and cells would clarify the clinical applicability of the technology. Should the out-
come of such experiments be favourable, animal trials may then be justifiable to assess
the extent of osseointegration.
The ageing experiments have provided useful information on the nature of PMMA and
showed the moisture uptake was sufficient for the release of therapeutic agents. The
experiment however, did not establish the depth of penetration of water, an important
parameter, which will dictate the release characteristics of therapeutic agents from bone
cement. Additionally, such an experiment may offer further information on the extent of
degradation expected to occur in vivo over time. A potential method of studying fluid
penetration in PMMA bone cement may involve the use of dyes, such a methylene blue,
or spectroscopic and optical measurement techniques.
The development of the liposomal delivery system has created exciting possibilities for
the delivery of therapeutic agents from bone cement. The delivery system however, still
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requires development to ensure optimum drug release, and further improvements to me-
chanical and fatigue properties. Further, the composition of the liposome vesicles may play
a significant role in cellular and tissue interactions in vivo. For example, the use of phos-
phatidylserine and phosphatidylinositol lipids have demonstrated calciotropic properties
when employed as coatings for metallic implants247, 254, 257. The use of these phospholipids
may encourage osseointegration of bone cement and advanced experiments may involve
studying gene expression in osteoblast and osteoblast precursor cells in the presence of the
phospholipids. Similarly, the delivery of osteogenic materials, such bone growth factors,
using the liposomal delivery system may offer a unique and novel approach to enhance the
bone growth properties of PMMA bone cement.
Another promising and exciting aspect of the liposomal delivery system is its potential to
deliver a combination of antibiotics to achieve a synergistic effect. Agar diffusion tests,
double-disk synergy tests or the checkerboard method would be simple, yet effective meth-
ods to evaluate synergy between antibiotics against known bacterial strains. Synergistic
combinations could then be employed in bone cement using the liposomal delivery system
and the release and inhibition of bacterial strains could be studied. Furthermore, there
is the possibility of performing these tests against clinical isolates from infected joint re-
placements, obtained through clinical collaborators. Investigating the efficacy of the novel
delivery system in preventing biofilms is also of great interest as a solution to this problem
in joint replacements is yet to be discovered.
Successful implementation of the liposomal delivery system would require industrial scale
production methods. Batch production methods to obtain large quantities of materials
may alter the properties of the final product and therefore careful consideration and inves-
tigation of the processes are required. Similarly, the method of mixing the bone cement,
as previously discussed, alters the porosity of the polymerised product. This in turn may
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affect the release characteristics of the liposomal cement and therefore, further work in
this area is necessary.
The final experimental work that is of great interest is the wider applicability of the lipo-
somal delivery system in various biomaterials. Having enhanced the properties of PMMA
bone cement, the use of such a technology may be advantageous to other biomaterials,
such as restorative dental materials or catheters. Although this is merely speculative, it
is worthwhile investigating and may create further opportunities for future research and
collaborations.
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